## Cigna

## Section III. Prior Authorizations and Concurrent Review

Section III. Prior Authorizations and Concurrent Review %		
2. Total Number of Authorizations Requested (Prospective and Concurrent) (Total of A, B, C, D & F)	25312	N/A
3. Reauthorization Requests (ongoing care) - Approved	2434	84.2%
4. Reauthorization Requests (ongoing care) - Denied	456	15.8%
A. Total Reauthorization Requests	2890	100%
5. Standard Requests Approved - not extended	16879	84.8%
6. Standard Requests Denied - not extended	3031	15.2%
B. Total Standard Requests - not extended	19910	100%
7. Extended Reviews (Outside Consultation) Approved	0	
8. Extended Reviews (Outside Consultation) Denied	0	
C. Total Extended Reviews (Outside Consultation)	0	
9. Extended Reviews (Additional Information Requested) Approved	258	70.5%
10. Extended Reviews (Additional Information Requested) Denied	108	29.5%
D. Total Extended Reviews (Additional Information Requested)	366	100%
11. Standard Prior Authorization Determinations Approved After Appeal (Denial overturned) (Includes items 6, 8, & 10 above)	34	23.6%
12. Standard Prior Authorization Determinations Denied After Appeal (Denial upheld) (Includes items 6, 8, & 10 above)	110	76.4%
E. Total Appeals of Standard Denied Prior Authorization Requests	144	100%
13. Expedited Reviews Approved	1905	88.8%
14. Expedited Reviews Denied	241	11.2%
F. Total Expedited (urgent) Requests	2146	100%
15. Expedited Prior Authorization Determinations Approved After Appeal (Denial overturned)	43	24.2%
16. Expedited Prior Authorization Determinations Approved After Appeal (Denial upheld)	135	75.8%
G. Total Appeals of Expedited Denied Prior Authorization Requests	178	100%
17-a. Standard Request Average Approval Time (Days) (Includes Totals B, C, and D above)	4	N/A
17-b. Standard Request Median Approval Time (Days) (Includes Totals B, C, and D above)	4.23	N/A
18-a. Expedited Review Average Approval Time (Hours)	96	N/A
18-b. Expedited Review Median Approval Time (Hours)	5	N/A
19-a. Concurrent Care (Reauthorization) Request Average Approval Time (Days)	0.06	N/A
19-b. Concurrent Care (Reauthorization) Request Median Approval Time (Days)	1	N/A
20. Prior authorization requests for chiropractic services	0	N/A

## Section VII: List All Items and Services That Required Prior Authorization

CPT	
Code	Description of Item or Service
11920	Tattooing To Correct Color Defects; 6.0 Sq Cm/<
11921	Tattooing To Correct Color Defects; 6.1-20.0 Sq Cm
11950	Subq Injection, Filling Matl; 1 Cc/<
11951	Subq Injection, Filling Matl; 1.1 To 5.0 Cc
11952	Subq Injection, Filling Matl; 5.1 To 10.0 Cc
11954	Subq Injection, Filling Matl; > 10.0 Cc
	Adjacent Tissue Transfer, Forehead/Cheeks/Chin/Mouth/Neck/Axillae/Genitalia/Hands/Feet;
14040	10 Sq Cm/<
	Adjacent Tissue Transfer,
14041	Forehead/Cheeks/Chin/Mouth/Neck/Axillae/Genitalia/Hands/Feet;10.1-30.0sqcm
14060	Adjacent Tissue Transfer/Rearrangement, Eyelids/Nose/Ears/Lips; Defect 10 Sq Cm/<
14061	Adjacent Tissue Transfer/Rearrangement, Eyelids/Nose/Ears/Lips; Defect 10.1-30.0 Sq Cm
15150	Tissue cultured skin autograft, trunk, arms, legs; first 25 sq cm or less
45455	Tissue cultured skin autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands,
15155	feet, and/or multiple digits; first 25 sq cm or less
15271	Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area
15271	Application of skin substitute graft to trunk, arms, legs, total wound surface area greater than
	or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and
15273	children
	Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia,
	hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or
15275	less wound surface area
	Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia,
45077	hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq
15277	cm; first 100 sq cm wound surface area, or 1% of body area of infants and children
15756	Free muscle or myocutaneous flap with microvascular anastomosis Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms,
15771	and/or legs; 50 cc or less injectate
13771	Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck,
15773	ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate
15775	Punch Graft, Hair Transplant; 1-15 Punch Grafts
15776	Punch Graft, Hair Transplant; > 15 Punch Grafts
	Implantation of biologic implant (eg, acellular dermal matrix) for soft tissue reinforcement (ie,
15777	breast, trunk) (List separately in addition to code for primary procedure)
15780	Dermabrasion; Total Face
15781	Dermabrasion; Segmental, Face
15782	Dermabrasion; Regional, Other Than Face
15783	Dermabrasion; Superficial, Any Site
15786	Abrasion; Single Lesion
15788	Chemical Peel, Facial; Epidermal
15789	Chemical Peel, Facial; Dermal
15792	Chemical Peel, Nonfacial; Epidermal

15793	Chemical Peel, Nonfacial; Dermal
15819	Cervicoplasty
15820	Blepharoplasty Lower Eyelid
15821	Blepharoplasty, Lower Eyelid; W/Extensive Herniated Fat Pad
15822	Blepharoplasty, Upper Eyelid
15823	Blepharoplasty, Upper Eyelid; W/Excessive Skin Weighting Down Lid
15824	Rhytidectomy; Forehead
15825 15826	Rhytidectomy; Neck W/Platysmal Tightening (Platysmal Flap, P-Flap) Rhytidectomy; Glabellar Frown Lines
15828	Rhytidectomy; Cheek, Chin, & Neck
15829	Rhytidectomy; Superficial Musculoaponeurotic System (Smas) Flap
15830	Excision, excessive skin and subcutaneous tissue (incluedes lipectomy, abdomen, infraumbilical panniculectomy
15832	Excision, excessive skin and subcutaneous tissue (includes lipectomy); thigh
15833	Excision, excessive skin and subcutaneous tissue (includes lipectomy); leg
15834	Excision, excessive skin and subcutaneous tissue (includes lipectomy); hip
15835	Excision, excessive skin and subcutaneous tissue (includes lipectomy); http://www.accessive.skin.and.subcutaneous.tissue (includes lipectomy); buttock
15836	Excision, excessive skin and subcutaneous tissue (includes lipectomy); arm
15837	Excision, excessive skin and subcutaneous tissue (includes lipectomy); forearm or hand
15838	Excision, excessive skin and subcutaneous tissue (includes lipectomy); submental fat pad
15839	Excision, excessive skin and subcutaneous tissue (includes lipectomy); submentarial pad
15840	Graft, Facial Nerve Paralysis; Free Fascia Graft (W/Obtaining Fascia)
15841	Graft, Facial Nerve Paralysis; Free Muscle Graft (W/Obtaining Faseia)
15842	Graft, Facial Nerve Paralysis; Free Muscle Flap, Microsurgical Technique
15845	Graft, Facial Nerve Paralysis; Regional Muscle Transfer
15876	Suction Assisted Lipectomy; Head & Neck
15877	Suction Assisted Lipectomy; Trunk
15878	Suction Assisted Lipectomy; Upper Extremity
15879	Suction Assisted Lipectomy; Lower Extremity
17106	Destruction, Cutaneous Vascular Proliferative Lesions; < 10 Sq Cm
17107	Destruction, Cutaneous Vascular Proliferative Lesions; 10.0-50.0 Sq Cm
17108	Destruction, Cutaneous Vascular Proliferative Lesions; > 50.0 Sq Cm
17380	Electrolysis epilation, each 30 minutes
19105	Ablation, cryosurgical, of fibroadenoma, including ultrasound guidance, each fibroadenoma
10100	Placement of radiotherapy afterloading expandable catheter (single or multichannel) into the
	breast for interstitial radioelement application following partial mastectomy, includes imaging
19296	guidance; on date separate from partial mastectomy
	Placement of radiotherapy after loading brachytherapy catheters (multiple tube and button
	type) into the breast for interstitial radioelement application following (at the time of or
19298	subsequent to) partial mastectomy, includes imaging guidance
19300	Mastectomy for gynecomastia
19303	Mastectomy , simple, complete
19316	Mastopexy
19318	Breast reduction

19325	Breast augmentation with implant
19328	Removal of intact breast implant
19330	Removal of ruptured breast implant, including implant contents (eg, saline, silicone gel)
19340	Insertion of breast implant on same day of mastectomy (ie, immediate)
19342	Insertion or replacement of breast implant on separate day from mastectomy
19350	Nipple/Areola Reconstruction
19355	Correction, Inverted Nipples
19357	Tissue expander placement in breast reconstruction, including subsequent expansion(s)
19361	Breast reconstruction; with latissimus dorsi flap
19364	Breast reconstruction; with free flap (eg, fTRAM, DIEP, SIEA, GAP flap)
19366	Breast reconstruction with other technique
19367	Breast reconstruction; with single-pedicled transverse rectus abdominis myocutaneous (TRAM) flap
19368	Breast reconstruction; with single-pedicled transverse rectus abdominis myocutaneous (TRAM) flap, requiring separate microvascular anastomosis (supercharging)
19369	Breast reconstruction; with bipedicled transverse rectus abdominis myocutaneous (TRAM) flap
19380	Revision of reconstructed breast (eg, significant removal of tissue, re-advancement and/or re- inset of flaps in autologous reconstruction or significant capsular revision combined with soft tissue excision in implant-based reconstruction)
19396	Preparation, Moulage, Custom Breast Implant
20555	Placement of needles or catheters into muscle and/or soft tissue for subsequent interstitial radioelement application (at the time of or subsequent to the procedure)
20560	Needle insertion(s) without injection(s); 1 or 2 muscle(s)
20561	Needle insertion(s) without injection(s); 3 or more muscles
20605	Arthrocentesis, Aspiration &/Or Injection; Intermediate Joint/Bursa
20606	Arthrocentesis, aspiration and/or injection, intermediate joint or bursa (eg, temporomandibular, acromioclavicular, wrist, elbow or ankle, olecranon bursa); with ultrasound guidance, with permanent recording and reporting
20930	Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure)
20931	Allograft, structural, for spine surgery only (List separately in addition to code for primary procedure)
20932	Allograft, includes templating, cutting, placement and internal fixation, when performed; osteoarticular, including articular surface and contiguous bone (List separately in addition to code for primary procedure)
20933	Allograft, includes templating, cutting, placement and internal fixation, when performed; hemicortical intercalary, partial (ie, hemicylindrical) (List separately in addition to code for primary procedure)
20934	Allograft, includes templating, cutting, placement and internal fixation, when performed; intercalary, complete (ie, cylindrical) (List separately in addition to code for primary procedure)
20936	Autograft for spine surgery only (includes harvesting the graft); local (eg, ribs, spinous process, or laminar fragments
20937	Autograft for spine surgery only (includes harvesting the graft); morselized (through separate skin or fascial incision)

	Autograft for spine surgery only (includes harvesting the graft); structural, bicortical or
	tricortical (through separate skin or fascial incision) (List separately in addition to code for
20938	primary procedure)
20000	Bone marrow aspiration for bone grafting, spine surgery only, through separate skin or fascial
20939	incision (List separately in addition to code for primary procedure)
20974	Electrical Stimulation To Aid Bone Healing; Noninvasive (Nonoperative)
20979	Low Intensity Ultrasound Stimulation To Aid Bone Healing; Noninvasive
20070	Ablation, Bone Tumor(s) Radiofrequency, Percutaneous, Including Computed Tomographic
20982	Guidance
	Ablation therapy for reduction or eradication of 1 or more bone tumors (eg, metastasis)
	including adjacent soft tissue when involved by tumor extension, percutaneous, including
20983	imaging guidance when performed; cryoablation
21010	Arthrotomy, Temporomandibular Joint
21050	Condylectomy, Temporomandibular Joint (Sep Proc)
21060	Meniscectomy, Partial/Complete, Temporomandibular Joint (Sep Proc)
	Manipulation of temporomandibular joint(s) (TMJ), therapeutic, requiring an anesthesia service
21073	(ie, general or monitored anesthesia care)
21083	Impression & Custom Preparation; Palatal Lift Prosthesis
21086	Impression & Custom Preparation; Auricular Prosthesis
21087	Impression & Custom Preparation; Nasal Prosthesis
21110	Application, Interdental Fixation Device, Non-Fx/Dislocation, W/Removal
21116	Injection Proc, Temporomandibular Joint Arthrography
21120	Genioplasty; Augmentation (Autograft, Allograft, Prosthetic Matl)
21121	Genioplasty; Sliding Osteotomy, Single Piece
	Genioplasty; sliding osteotomies, 2 or more osteotomies (eg, wedge excision or bone wedge
21122	reversal for asymmetrical chin)
21123	Genioplasty; Sliding, Augmentation W/Interpositional Bone Grafts W/Obtaining Autograft
21125	Augmentation, Mandibular Body/Angle; Prosthetic Matl
	Augmentation, Mandibular Body/Angle; W/Bone Graft/Onlay/Interpositional W/Obtaining
21127	Autograft
21137	Reduction Forehead; Contouring Only
21138	Reduction Forehead; Contouring/Prosthesis/Bone Graft W/Obtaining Autograft
21139	Reduction Forehead; Contouring & Setback, Anterior Frontal Sinus Wall
21141	Reconstruction Midface, Lefort I; 1 Piece, W/O Bone Graft
	Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone
21142	graft
	Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction,
21143	without bone graft
21145	Reconstruction Midface, Lefort I; 1 Piece, W/Bone Grafts
	Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, requiring
21146	bone grafts (includes obtaining autografts) (eg, ungrafted unilateral alveolar cleft)
	Reconstruction midface, LeFort I; 3 or more pieces, segment movement in any direction,
21147	requiring bone grafts (includes obtaining autografts) (eg, ungrafted bilateral alveolar cleft or multiple osteotomies)
21147	Reconstruction Midface, Lefort Ii; Anterior Intrusion
21130	

21151	Reconstruction Midface, Lefort Ii; W/Bone Grafts
21154	Reconstruction Midface, Lefort lii, W/Bone Grafts; W/O Lefort I
21155	Reconstruction Midface, Lefort Iii, W/Bone Grafts; W/Lefort I
21159	Reconstruction Midface, Lefort Iii, (Extra/Intracranial), W/Bone Grafts, W/O Lefort I
21160	Reconstruction Midface, Lefort lii, (Extra/Intracranial), W/Bone Grafts, W/Lefort I
21172	Reconstruction Superior-Lateral Orbital Rim & Lower Forehead
21175	Reconstruction, Bifrontal, Superior-Lateral Orbital Rims & Lower Forehead
21179	Reconstruction, Majority, Forehead & Supraorbital Rims; W/Grafts (Allograft/Prosthetic)
21180	Reconstruction, Majority, Forehead & Supraorbital Rims; W/Autograft
	Reconstruction, Orbit/Forehead/Nasoethmoid, Following Excision, Benign Tumor, Graft < 40
21182	Sq Cm
	Reconstruction, Orbit/Forehead/Nasoethmiod, Following Excision, Benign Tumor, Graft 40-80
21183	Sq Cm
01104	Reconstruction, Orbit/Forehead/Nasoethmoid, Following Excision, Benign Tumor, Graft > 80
21184	Sq Cm
21188	Reconstruction, Midface, Osteotomies (Non-Lefort Type), W/Grafts, W/Obtaining Autografts
21193	Reconstruction, Mandibular Rami, Horizontal, Vertical, "C"/"L" Osteotomy; W/O Bone Graft
21194	Reconstruction, Mandibular Rami, Horizontal, Vertical, "C"/"L" Osteotomy; W/Bone Graft
21195	Reconstruction, Mandibular Rami &/Or Body, Sagittal Split; W/O Int Rigid Fixation
21196	Reconstruction, Mandibular Rami &/Or Body, Sagittal Split; W/Int Rigid Fixation
21198	Osteotomy, Mandible, Segmental
21199	Osteotomy, Mandible, Segmental; W/Genioglossus Advancement
21206	Osteotomy, Maxilla, Segmental
21208	Osteoplasty, Facial Bones; Augmentation (Autograft, Allograft/Prosthetic Implant)
21209	Osteoplasty, Facial Bones; Reduction
21210	Graft, Bone; Nasal, Maxillary/Malar Areas (Includes Obtaining Graft)
21215	Graft, Bone; Mandible (Includes Obtaining Graft)
21230	Graft; Rib Cartilage, Autogenous, Face/Chin/Nose/Ear (Includes Obtaining Graft)
21235	Graft; Ear Cartilage, Autogenous, Nose/Ear (Includes Obtaining Graft)
21240	Arthroplasty, Temporomandibular Joint, W/Wo Autograft (Includes Obtaining Graft)
21242	Arthroplasty, Temporomandibular Joint, W/Allograft
21243	Arthroplasty, Temporomandibular Joint, W/Prosthetic Joint Replacement
21244	Reconstruction, Mandible, Extraoral, W/Transosteal Bone Plate
21245	Reconstruction, Mandible/Maxilla, Subperiosteal Implant; Partial
21246	Reconstruction, Mandible/Maxilla, Subperiosteal Implant; Complete
21247	Reconstruction, Mandibular Condyle W/Bone & Cartilage Autografts
	Reconstruction, Zygomatic Arch/Glenoid Fossa W/Bone & Cartilage (Includes Obtaining
21255	Autografts)
21256	Reconstruction, Orbit W/Osteotomies & Bone Grafts (Includes Obtaining Autografts)
21270	Malar Augmentation, Prosthetic Matl
21275	Secondary Revision, Orbitocraniofacial Reconstruction
21685	Hyoid Myotomy and Suspension
21740	Reconstructive Repair, Pectus Excavatum/Carinatum; Open

	Reconstructive Repair, Pectus Excavatum/Carinatum; Minimal Invasive Approach, W/O
21742	Thoracoscopy
	Reconstructive Repair, Pectus Excavatum/Carinatum; Minimal Invasive Approach,
21743	W/Thoracoscopy
	Open treatment of rib fracture(s) with internal fixation, includes thoracoscopic visualization
21811	when performed, unilateral; 1-3 ribs
	Open treatment of rib fracture(s) with internal fixation, includes thoracoscopic visualization
21812	when performed, unilateral; 4-6 ribs
	Open treatment of rib fracture(s) with internal fixation, includes thoracoscopic visualization
21813	when performed, unilateral; 7 or more ribs
	Osteotomy of spine, posterior or posterolateral approach, 3 columns, 1 vertebral segment (eg,
22206	pedicle/vertebral body subtraction); thoracic
	Osteotomy of spine, posterior or posterolateral approach, 3 columns, 1 vertebral segment (eg,
22207	pedicle/vertebral body subtraction); lumbar
	Osteotomy of spine, posterior or posterolateral approach, 3 columns, 1 vertebral segment (eg,
00000	pedicle/vertebral body subtraction); each additional vertebral segment (List separately in
22208	addition to code for primary procedure)
22210	Osteotomy of spine, posterior or posterolateral approach, 1 vertebral segment; cervical
22212	Osteotomy of spine, posterior or posterolateral approach, 1 vertebral segment; thoracic
22214	Osteotomy of spine, posterior or posterolateral approach, 1 vertebral segment; lumbar
22216	Osteotomy, Spine, Posterior/Posterolateral Approach, 1 Vertebral Segment; Add'l Segment
	Osteotomy of spine, including discectomy, anterior approach, single vertebral segment;
22220	cervical
00000	Osteotomy of spine, including discectomy, anterior approach, single vertebral segment;
22222	thoracic
22224	Osteotomy of spine, including discectomy, anterior approach, single vertebral segment; lumbar
22224	Osteotomy of spine, including discectomy, anterior approach, single vertebral segment; each
22226	additional vertebral segment (List separately in addition to code for primary procedure)
22505	Manipulation, Spine, Requiring Anesthesia, Any Region
22000	Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body,
22510	unilateral or bilateral injection, inclusive of all imaging guidance; cervicothoracic
22010	Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body,
22511	unilateral or bilateral injection, inclusive of all imaging guidance; lumbosacral
	Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body,
	unilateral or bilateral injection, inclusive of all imaging guidance; each additional
	cervicothoracic or lumbosacral vertebral body (List separately in addition to code for primary
22512	procedure)
	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone
	biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 vertebral body,
22513	unilateral or bilateral cannulation, inclusive of all imaging guidance; thoracic
	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone
	biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 vertebral body,
22514	unilateral or bilateral cannulation, inclusive of all imaging guidance; lumbar
00545	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone
22515	biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 vertebral body,

oracic Dr
)r
)r
or
or
al
without
C2
C2,
erspace
erspace
erspace
erspace
to code
omy,
ied, L5-
00, 20
eral
al
to
to
ditional

	Arthrodesis, combined posterior or posterolateral technique with posterior interbody
	technique including laminectomy and/or discectomy sufficient to prepare interspace (other
22633	than for decompression), single interspace, lumbar;
	Arthrodesis, combined posterior or posterolateral technique with posterior interbody
	technique including laminectomy and/or discectomy sufficient to prepare interspace (other
	than for decompression), single interspace, lumbar; each additional interspace (List
22634	separately in addition to code for primary procedure)
22800	Arthrodesis, posterior, for spinal deformity, with or without cast; up to 6 vertebral segments
22802	Arthrodesis, posterior, for spinal deformity, with or without cast; 7 to 12 vertebral segments
	Arthrodesis, posterior, for spinal deformity, with or without cast; 13 or more vertebral
22804	segments
22808	Arthrodesis, anterior, for spinal deformity, with or without cast; 2 to 3 vertebral segments
22810	Arthrodesis, anterior, for spinal deformity, with or without cast; 4 to 7 vertebral segments
22812	Arthrodesis, anterior, for spinal deformity, with or without cast; 8 or more vertebral segments
22818	Kyphectomy, Exposure Of Spine & Resection Vertebral Segments; 1-2 Segs
22819	Kyphectomy, Exposure Of Spine & Resection Vertebral Segments; 3 / More
22830	Exploration of Spinal Fusion
	Anterior thoracic vertebral body tethering, including thoracoscopy, when performed; up to 7
22836	vertebral segments
	Anterior thoracic vertebral body tethering, including thoracoscopy, when performed; 8 or more
22837	vertebral segments
	Revision (eg, augmentation, division of tether), replacement, or removal of thoracic vertebral
22838	body tethering, including thoracoscopy, when performed
	Posterior non-segmental instrumentation (eg, Harrington rod technique, pedicle fixation across 1 interspace, atlantoaxial transarticular screw fixation, sublaminar wiring at C1, facet
22840	screw fixation) (List separately in addition to code for primary procedure)
22040	Internal spinal fixation by wiring of spinous processes (List separately in addition to code for
22841	primary procedure)
	Posterior segmental instrumentation (eg, pedicle fixation, dual rods with multiple hooks and
	sublaminar wires); 3 to 6 vertebral segments (List separately in addition to code for primary
22842	procedure)
	Posterior segmental instrumentation (eg, pedicle fixation, dual rods with multiple hooks and
	sublaminar wires); 7 to 12 vertebral segments (List separately in addition to code for primary
22843	procedure)
	Posterior segmental instrumentation (eg, pedicle fixation, dual rods with multiple hooks and
22044	sublaminar wires); 13 or more vertebral segments (List separately in addition to code for
22844	primary procedure) Anterior instrumentation; 2 to 3 vertebral segments (List separately in addition to code for
22845	primary procedure)
22040	Anterior instrumentation; 4 to 7 vertebral segments (List separately in addition to code for
22846	primary procedure)
	Anterior instrumentation; 8 or more vertebral segments (List separately in addition to code for
22847	primary procedure)
	Pelvic fixation (attachment of caudal end of instrumentation to pelvic bony structures) other
22848	than sacrum (List separately in addition to code for primary procedure)
22849	Reinsertion, Spinal Fixation Device

22852	Removal, Posterior Segmental Instrumentation
	Insertion of interbody biomechanical device(s) (eg, synthetic cage, mesh) with integral anterior
	instrumentation for device anchoring (eg, screws, flanges), when performed, to intervertebral
	disc space in conjunction with interbody arthrodesis, each interspace (List separately in
22853	addition to code for primary procedure)
	Insertion of intervertebral biomechanical device(s) (eg, synthetic cage, mesh) with integral
	anterior instrumentation for device anchoring (eg, screws, flanges), when performed, to
	vertebral corpectomy(ies) (vertebral body resection, partial or complete) defect, in
00054	conjunction with interbody arthrodesis, each contiguous defect (List separately in addition to
22854	code for primary procedure)
	Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and
22856	microdissection); single interspace, cervical
22000	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare
22857	interspace (other than for decompression); single interspace, lumbar
	Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate
22858	preparation (includes osteophytectomy for nerve root or spinal cord decompres
	Insertion of intervertebral biomechanical device(s) (eg, synthetic cage, mesh,
	methlmethacrylate) to intervertebral disc space or verebral body defect without interbody
22859	arthro
	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare
	interspace (other than for decompression); second interspace, lumbar (List separately in
22860	addition to code for primary procedure)
22861	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical
22001	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach,
22862	single interspace; lumbar
	Removal of total disc arthroplasty (artificial disc), anterior approach, single interspace;
22864	cervical
22865	Removal of total disc arthroplasty (artificial disc), anterior approach, single interspace; lumbar
	Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion,
22867	including image guidance when performed, with open decompression, lumbar; single level
	Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion,
	including image guidance when performed, with open decompression, lumbar; second level
22868	(List separately in addition to code for primary procedure)
22960	Insertion of interlaminar/interspinous process stabilization/distraction device, without open
22869	decompression or fusion, including image guidance when performed, lumbar; single level Insertion of interlaminar/interspinous process stabilization/distraction device, without open
	decompression or fusion, including image guidance when performed, lumbar; second level
22870	(List separately in addition to code for primary procedure)
23105	Arthrotomy; Glenohumeral Joint, W/Synovectomy, W/Wo Bx
23107	Arthrotomy, Glenohumeral Joint, W/Exploration, W/Wo Loose/Fb Removal
23120	Claviculectomy; Partial
23130	Acromioplasty/Acromionectomy, Partial, W/Wo Coracoacromial Ligament Release
23410	Repair, Ruptured Musculotendinous Cuff, Open; Acute
23412	Repair, Ruptured Musculotendinous Cuff; Chronic
20412	

23415	Coracoacromial Ligament Release, W/Wo Acromioplasty
23420	Reconstruction, Complete Shoulder (Rotator) Cuff Avulsion, Chronic (Includes Acromioplasty)
23430	Tenodesis, Long Tendon, Biceps
23440	Resection/Transplantation, Long Tendon, Biceps
23450	Capsulorrhaphy, Anterior; Putti-Platt Proc/Magnuson Type Operation
23455	Capsulorrhaphy, Anterior; W/Labral Repair
23460	Capsulorrhaphy, Anterior, Any Type; W/Bone Block
23462	Capsulorrhaphy, Anterior, Any Type; W/Coracoid Process Transfer
23465	Capsulorrhaphy, Glenohumeral Joint, Posterior, W/Wo Bone Block
23466	Capsulorrhaphy, Glenohumeral Joint, Any Type Multi-Directional Instability
23470	Arthroplasty, Glenohumeral Joint; Hemiarthroplasty
23472	Arthroplasty, Glenohumeral Joint; Total Shoulder
	Revision of total shoulder arthroplasty, including allograft when performed; humeral or glenoid
23473	component
	Revision of total shoulder arthroplasty, including allograft when performed; humeral and
23474	glenoid component
	Manipulation W/Anesthesia, Shoulder Joint, W/Application Of Fixation Apparatus (Excl
23700	Dislocation)
24300	Manipulation, Elbow, Under Anesthesia
25259	Manipulation, Wrist, Under Anesthesia
26340	Manipulation, Finger Joint, Under Anesthesia, Each Joint
07000	Injection procedure for sacroiliac joint, anesthetic/steroid, with image guidance (fluoroscopy
27096	or CT) including arthrography when performed
27120	Acetabuloplasty;
27122	Acetabuloplasty; Resection, Femoral Head
27125	Hemiarthroplasty, Hip, Partial
27130	Arthroplasty, Acetabular/Proximal Femoral Prosthetic Replacement, W/Wo Autograft/Allograft
27132	Conversion, Previous Hip Surgery To Total Hip Arthroplasty, W/Wo Autograft/Allograft
27134	Revision, Total Hip Arthroplasty; Both Components, W/Wo Autograft/Allograft
27137	Revision, Total Hip Arthroplasty; Acetabular Component Only, W/Wo Autograft/Allograft
27138	Revision, Total Hip Arthroplasty; Femoral Component Only, W/Wo Allograft
27275	Manipulation, Hip Joint, Requiring General Anesthesia
	Arthrodesis, sacroiliac joint, percutaneous or minimally invasive (indirect visualization), with image guidance, includes obtaining bone graft when performed, and placement of
27279	transfixation device
27279	Arthrotomy, Knee; W/Joint Exploration, Bx/Removal, Loose/Fb
27331	Arthrotomy, W/Excision, Semilunar Cartilage (Meniscectomy) Knee; Medial/Lateral
27332	Arthrotomy, W/Excision, Semilunar Cartilage (Meniscectomy) Knee; Medial & Lateral
27334	Arthrotomy, W/Synovectomy Knee; Anterior/Posterior
27334	Arthrotomy, W/Synovectomy Knee; Anterior & Posterior W/Popliteal Area
27335	Excision, Synovial Cyst, Popliteal Space
27343	Arthrotomy W/Meniscus Repair, Knee
27403	Repair, Primary, Torn Ligament &/Or Capsule, Knee; Collateral
27405	Repair, Primary, Torn Ligament &/Or Capsule, Knee; Cruciate
2/40/	הביאמו, רוווומוץ, וטווו בוצמוווכות מיטו טמיטונל, גוופל, טועטמנל

27409	Repair, Primary, Torn Ligament &/Or Capsule, Knee; Collateral & Cruciate Ligaments
27412	Autologous Chondrocyte Implantation, Knee
27415	Rep Ligaments Knee+pes Anserin Tran
27416	Osteochondral autograft(s), knee, open (eg, mosaicplasty) (includes harvesting of autograft(s)
27425	Lateral Retinacular Release Open
27427	Ligamentous Reconstruction (Augmentation), Knee; Extra-Articular
27428	Ligamentous Reconstruction (Augmentation), Knee; Intra-Articular, (Open)
27429	Ligamentous Reconstruction (Augmentation), Knee; Intra-Articular, (Open) & Extra-Articular
27437	Arthroplasty, Patella; W/O Prosthesis
27438	Arthroplasty, Patella; W/Prosthesis
27440	Arthroplasty, Knee, Tibial Plateau
27441	Arthroplasty, Knee, Tibial Plateau; W/Debridement & Partial Synovectomy
27442	Arthroplasty, Femoral Condyles/Tibial Plateau(S), Knee
	Arthroplasty, Femoral Condyles/Tibial Plateau(S), Knee; W/Debridement & Partial
27443	Synovectomy
27445	Arthroplasty, Knee, Hinge Prosthesis
27446	Arthroplasty, Knee, Condyle & Plateau; Medial/Lateral Compartment
	Arthroplasty, Knee, Condyle & Plateau; Medial & Lateral Compartments, W/Wo Patella
27447	Resurfacing
27486	Revision, Total Knee Arthroplasty, W/Wo Allograft; 1 Component
27487	Revision, Total Knee Arthroplasty; Femoral & Entire Tibial Component
27488	Removal, Knee Prosthesis, Methylmethacrylate W/Wo Spacer Insertion
27570	Manipulation, Knee Joint Under General Anesthesia
27702	Arthroplasty, Ankle; W/Implant (Total Ankle)
27703	Arthroplasty, Ankle; Revision, Total Ankle
27704	Removal, Ankle Implant
27860	Manipulation, Ankle Under General Anesthesia
27870	Arthrodesis, Ankle, Open
28110	Ostectomy, Partial Excision, 5th Metatarsal Head (Bunionette) (Sep Proc)
28285	Correction, Hammertoe
28286	Correction, Cock-Up Fifth Toe, W/Plastic Skin Closure
00000	Hallux rigidus correction with cheilectomy, debridement and capsular release of the first
28289	metatarsophalangeal joint; without implant
28291	Hallux rigidus correction with cheilectomy, debridement and capsular release of the first metatarsophalangeal joint with implant
20291	Correction, hallux valgus with bunionectomy, with sesamoidectomy when performed; with
28292	resection of proximal phalanx base, when performed, any method
20202	Correction, hallux valgus with bunionectomy, with sesamoidectomy when performed; with
28295	proximal metatarsal osteotomy, any method
	Correction, hallux valgus with bunionectomy, with sesamoidectomy when performed; with
28296	distal metatarsal osteotomy, any method
	Correction, hallux valgus with bunionectomy, with sesamoidectomy when performed; with first
28297	metatarsal and medial cuneiform joint arthrodesis, any method

	Correction, hallux valgus with bunionectomy, with sesamoidectomy when performed; with
28298	proximal phalanx osteotomy, any method
	Correction, hallux valgus with bunionectomy, with sesamoidectomy when performed; with
28299	double osteotomy, any method
28306	Osteotomy, Metatarsal, W/Wo Lengthening/Shortening/Ang Correction; 1st Metatarsal
	Osteotomy, Metatarsal, W/Wo Lengthening/Shortening/Ang Correction; 1st Metatarsal
28307	W/Autograft
	Osteotomy, Metatarsal, W/Wo Lengthening/Shortening/Ang Correction; Not 1st Metatarsal,
28308	Each
28310	Osteotomy, Shortening, Angular/Rotational Correction; Proximal Phalanx, 1st Toe (Sep Proc)
28312	Osteotomy, Shortening, Angular/Rotational Correction; Other Phalanges, Any Toe
28315	Sesamoidectomy, 1st Toe (Sep Proc)
28446	Open osteochondral autograft, talus (includes obtaining grafts)
28750	Arthrodesis, Great Toe; Metatarsophalangeal Joint
	Extracorporeal shock wave, high energy, performed by a physician or other qualified health
	care professional, requiring anesthesia other than local, including ultrasound guidance,
28890	involving the plantar fascia
29800	Arthroscopy, Temporomandibular Joint, Dx W/Wo Synovial Bx (Sep Proc)
29804	Arthroscopy, Temporomandibular Joint, Surgical
29805	Arthroscopy, shoulder, diagnostic, with or without synovial biopsy (separate procedure)
29806	Arthroscopy, shoulder, surgical; capsulorrhaphy
29807	Arthroscopy, shoulder, surgical; repair of SLAP lesion
29819	Arthroscopy, shoulder, surgical; with removal of loose body or foreign body
29820	Arthroscopy, shoulder, surgical; synovectomy, partial
29821	Arthroscopy, shoulder, surgical; synovectomy, complete
	Arthroscopy, shoulder, surgical; debridement, limited, 1 or 2 discrete structures (eg, humeral
	bone, humeral articular cartilage, glenoid bone, glenoid articular cartilage, biceps tendon,
29822	biceps anchor complex, labrum, articular capsule, articular side of the rotator cuff, bursal side of the rotator cuff, subacromial bursa, foreign body[ies])
29022	Arthroscopy, shoulder, surgical; debridement, extensive, 3 or more discrete structures (eg,
	humeral bone, humeral articular cartilage, glenoid bone, glenoid articular cartilage, biceps
	tendon, biceps anchor complex, labrum, articular capsule, articular side of the rotator cuff,
29823	bursal side of the rotator cuff, subacromial bursa, foreign body[ies])
	Arthroscopy, shoulder, surgical; distal claviculectomy including distal articular surface
29824	(Mumford procedure)
	Arthroscopy, shoulder, surgical; with lysis and resection of adhesions, with or without
29825	manipulation
	Arthroscopy, shoulder, surgical; decompression of subacromial space with partial
	acromioplasty, with coracoacromial ligament (ie, arch) release, when performed (List
29826	separately in addition to code for primary procedure)
29827	Arthroscopy, shoulder, surgical; with rotator cuff repair
29828	Arthroscopy, shoulder, surgical; biceps tenodesis
29860	Arthroscopy, Hip, Dx W/Wo Synovial Bx (Sep Proc)
29861	Arthroscopy, Hip, Surgical; W/Removal, Loose/Foreign Body
29862	Arthroscopy, Hip, Surgical; W/Chondroplasty/Arthroplasty, &/Or Resection, Labrum

29863	Arthroscopy, Hip, Surgical; W/Synovectomy
	Arthroscopy, knee, surgical; osteochondral autograft(s) (eg, mosaicplasty) (includes
29866	harvesting of the autograft[s])
29867	Arthroscopy, Knee, Surgical; Osteochondral Allograft (Eg, Mosaicplasty)
	Arthroscopy, Knee, Surgical; Meniscal Transplantation (Includes Arthrotomy For Meniscal
29868	Insertion), Medial Or Lateral
29870	Arthroscopy, Knee, Dx, W/Wo Synovial Bx (Sep Proc)
29871	Arthroscopy, Knee, Surgical; Infection, Lavage & Drainage
29873	Arthroscopy, Knee, Surgical; W/Lateral Release
29874	Arthroscopy, Knee, Surgical; Removal, Loose/Fb
29875	Arthroscopy, Knee, Surgical; Synovectomy, Limited (Sep Proc)
	Arthroscopy, knee, surgical; synovectomy, major, 2 or more compartments (eg, medial or
29876	lateral)
29877	Arthroscopy, Knee, Surgical; Debridement/Shaving, Articular Cartilage (Chondroplasty)
00070	Arthroscopy, Knee, Surgical; Abrasion Arthroplasty (W/Chondroplasty)/Multiple
29879	Drilling/Microfx
	Arthroscopy, knee, surgical; with meniscectomy (medial AND lateral, including any meniscal shaving) including debridement/shaving of articular cartilage (chondroplasty), same or
29880	separate compartment(s), when performed
20000	Arthroscopy, knee, surgical; with meniscectomy (medial OR lateral, including any meniscal
	shaving) including debridement/shaving of articular cartilage (chondroplasty), same or
29881	separate compartment(s), when performed
29882	Arthroscopy, Knee, Surgical; W/Meniscus Repair, Medial/Lateral
29883	Arthroscopy, Knee, Surgical; W/Meniscus Repair, Medial & Lateral
29884	Arthroscopy, Knee, Surgical; W/Lysis, Adhesions, W/Wo Manipulation (Sep Proc)
	Arthroscopy, Knee, Surgical; Drill, Osteochondritis Dissecans W/Bone Graft, W/Wo Int/Ext
29885	Fixation
29886	Arthroscopy, Knee, Surgical; Drilling, Intact Osteochondritis Dissecans Lesion
29887	Arthroscopy, Knee, Surgical; Drilling, Intact Osteochondritis Dissecans Lesion W/Int Fixation
29888	Arthroscopically Aided Anterior Cruciate Ligament Repair/Augmentation/Reconstruction
29889	Arthroscopically Aided Posterior Cruciate Ligament Repair/Augmentation/Reconstruction
29892	Arthroscopically Aided Repair, Osteochondritis/Talar Dome Fx/Tibial Plafond Fx
29914	Arthroscopy, hip, surgical; with femoroplasty (ie, treatment of cam lesion)
29915	Arthroscopy, subtalar joint, surgical; with acetabuloplasty (ie, treatment of pincer lesion)
29916	Arthroscopy, hip, surgical; with labral repair
30117	Excision/Destruction, Intranasal Lesion; Int Approach
30120	Excision/Surgical Planing, Skin, Nose, Rhinophyma
30400	Rhinoplasty, Primary; Lateral & Alar Cartilages &/Or Elevation, Nasal Tip
	Rhinoplasty, Primary; Complete, Ext Parts W/Bony Pyramid, Lat & Alar Cartilages &/Or Elev
30410	Nasal Tip
30420	Rhinoplasty, Primary; W/Major Septal Repair
30430	Rhinoplasty, Secondary; Minor Revision (Small Amount, Nasal Tip Work)
30435	Rhinoplasty, Secondary; Intermediate Revision (Bony Work W/Osteotomies)
30450	Rhinoplasty, Secondary; Major Revision (Nasal Tip Work & Osteotomies)
30468	Repair of nasal valve collapse with subcutaneous/submucosal lateral wall implant(s)

	Repair of nasal valve collapse with low energy, temperature-controlled (ie, radiofrequency)
30469	subcutaneous/submucosal remodeling
	Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal
31242	nerve
31243	Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve
31525	LARYNGOSCOPY W/WO TRACHEOSCOPY DX EXCEPT NEWBORN
	Laryngoscopy, flexible; with injection(s) for augmentation (eg, percutaneous, transoral),
31574	unilateral
	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with
31643	placement of catheter(s) for intracavitary radioelement application
	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with
31660	bronchial thermoplasty, 1 lobe
	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with
31661	bronchial thermoplasty, 2 or more lobes
00704	Thoracic target(s) delineation for stereotactic body radiation therapy (SRS/SBRT), (photon or
32701	particle beam), entire course of treatment
32850	Donor pneumonectomy(s) (including cold preservation), from cadaver donor
32851	Lung Transplant, Single; W/O Cardiopulmonary Bypass
32852	Lung Transplant, Single; W/Cardiopulmonary Bypass
32853	Lung Transplant, Double (Bilat Sequential/En Bloc); W/O Cardiopulmonary Bypass
32854	Lung Transplant, Double (Bilat Sequential/En Bloc); W/Cardiopulmonary Bypass
32855	Backbench Standard Preparation Of Cadaver Donor Lung Allograft; Unilateral
32856	Backbench Standard Preparation Of Cadaver Donor Lung Allograft; Bilateral
	Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura
22004	or chest wall when involved by tumor extension, percutaneous, including imaging guidance
32994	when performed, unilateral; cryoablation Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura
	or chest wall when involved by tumor extension, percutaneous, including imaging guidance
32998	when performed, unilateral; radiofrequency
33140	Transmyocardial Laser Revascularization, By Thoracotomy
00110	Insertion of epicardial electrodes(s); open incision (eg, thoracotomy, median sternotomy,
33202	subxiphoid approach)
33203	endoscopic approach (eg, thoracoscopy, pericardioscopy)
33206	Insertion of new or replacement of permanent pacemaker with transvenous electrode(s); atrial
	Insertion of new or replacement of permanent pacemaker with transvenous electrode(s);
33207	ventricular
	Insertion of new or replacement of permanent pacemaker with transvenous electrode(s); atrial
33208	and ventricular
33212	Insertion of pacemaker pulse generator only; with existing single lead
33213	Insertion of pacemaker pulse generator only; with existing dual leads
33214	Repositioning, Previously Implanted Transvenous Electrode/Pacing Cardiovert-Defib Electrode
	Repositioning of Previously Implanted Transvenous Pacemaker or Pacing Cardioverter-
33215	Defibrillator Electrode
33216	Insertion of a single transvenous electrode, permanent pacemaker or cardioverter-defibrillator
33217	Insertion of 2 transvenous electrodes, permanent pacemaker or cardioverter-defibrillator

	Repair of single transvenous electrode, permanent pacemaker or pacing cardioverter-
33218	defibrillator
	Repair of 2 transvenous electrodes for permanent pacemaker or pacing cardioverter-
33220	defibrillator
33222	Relocation of skin pocket for pacemaker
	Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, with
	attachment to previously placed pacemaker or implantable defibrillator pulse generator
33224	(including revision of pocket, removal, insertion, and/or replacement of existing generator)
	Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of
	insertion of implantable defibrillator or pacemaker pulse generator (eg, for upgrade to dual
33225	chamber system) (List separately in addition to code for primary procedure)
	Repositioning of previously implanted cardiac venous system (left ventricular) electrode
33226	(including removal, insertion and/or replacement of existing generator)
	Removal Of Permanent Pacemaker Pulse Generator With Replacement Of Pacemaker Pulse
33227	Generator; Single Lead System
22220	Removal Of Permanent Pacemaker Pulse Generator With Replacement Of Pacemaker Pulse
33228	Generator; Dual Lead System Removal Of Permanent Pacemaker Pulse Generator With Replacement Of Pacemaker Pulse
33229	Generator; Multiple Lead System
33230	
33230	Insertion Of Pacing Cardioverter-Defibrillator Pulse Generator Only; With Existing Dual Leads Insertion Of Pacing Cardioverter-Defibrillator Pulse Generator Only; With Existing Multiple
33231	Leads
33233	Removal of permanent pacemaker pulse generator only
33233	Removal, Transvenous Pacemaker Electrode(S); Single Lead System, Atrial/Ventricular
33234	Removal, Transvenous Pacemaker Electrode(S), Single Lead System, Athat Ventricular
33240	Insertion of pacing cardioverter-defibrillator pulse generator only; with existing single lead Insertion or replacement of permanent pacing cardioverter-defibrillator system with
33249	transvenous lead(s), single or dual chamber
00240	Removal Of Pacing Cardioverter-Defibrillator Pulse Generator With Replacement Of Pacing
33263	Cardioverter-Defibrillator Pulse Generator; Dual Lead System
	Removal Of Pacing Cardioverter-Defibrillator Pulse Generator With Replacement Of Pacing
33264	Cardioverter-Defibrillator Pulse Generator; Multiple Lead System
	Exclusion of left atrial appendage, open, any method (eg, excision, isolation via stapling,
33267	oversewing, ligation, plication, clip)
	Exclusion of left atrial appendage, thoracoscopic, any method (eg, excision, isolation via
33269	stapling, oversewing, ligation, plication, clip)
	Insertion or replacement of permanent subcutaneous implantable defibrillator system, with
	subcutaneous electrode, including defibrillation threshold evaluation, induction of arrhythmia,
	evaluation of sensing for arrhythmia termination, and programming or reprogramming of
33270	sensing or therapeutic parameters, when performed
33271	Insertion of subcutaneous implantable defibrillator electrode
	Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular,
22074	including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral
33274	venography) and device evaluation (eg, interrogation or programming), when performed

guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography), when 33275 performed Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with 33276 diagnostic mode activation, when performed Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to 33277 code for primary procedure) Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and 33278 lead(s) Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing 33279 lead(s) only Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only 33281 Repositioning of phrenic nerve stimulator transvenous lead(s) 33285 Insertion, subcutaneous cardiac rhythm monitor, including programming Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous 33288 stimulation or sensing lead(s) Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and 33280 interpretation 33240 interpretation 33340 interpretation 33341 intergretation 33340 interpretation 33342 3342 3344 3344 3344 3344 3344 33		Transactheter removal of normanent leadless pacemaker, right ventricular, including imaging
33275         performed           Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation, when performed           Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to 33277         code for primary procedure)           Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and lead(s)           Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) only           Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only           3281         Repositioning of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator           Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator           Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)           32280         Interpretation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, righ		Transcatheter removal of permanent leadless pacemaker, right ventricular, including imaging
Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation, when performed           Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to code for primary procedure)           Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and lead(s)           Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) only           Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only           32281         Repositioning of phrenic nerve stimulator transvenous lead(s)           32281         insertion, subcutaneous cardiac rhythm monitor, including programming           Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator           Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed;           3288         stimulation or sensing lead(s)           Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the esnor, right heart catheterization, and pul	22275	
including vessel catheterization, all imaging guidance, and pulse generator initial analysis with 33276 diagnostic mode activation, when performed Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to 33277 code for primary procedure) Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and 13278 lead(s) Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing 123279 lead(s) only Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only 33281 Repositioning of phrenic nerve stimulator transvenous lead(s) 33285 Insertion, subcutaneous cardiac rhythm monitor, including programming Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous 33288 stimulation or sensing lead(s) Transcatheter implantation of wireless pulmonary artery pressure sensor, right heart catheterization, selective pulmonary catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery 3364 paproach Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral arte	33275	
33276       diagnostic mode activation, when performed         Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to         33277       code for primary procedure)         Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and tead(s)         Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing tead(s) only         Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only         33281       Repositioning of phrenic nerve stimulator transvenous lead(s)         33281       Removal and replacement of phrenic nerve stimulator, including programming         Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator         Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous         33281       Insertion, subcutaneous cardiac rhythm monitor, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator         Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse s		
Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to code for primary procedure)           Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and lead(s)           Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing           3279         lead(s)           Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing           3280         and interrogation and programming, when performed; pulse generator only           3281         Repositioning of phrenic nerve stimulator transvenous lead(s)           32825         Insertion, subcutaneous cardiac rhythm monitor, including programming           Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator           Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed           Percutaneous transcatheter closur	00070	
33277       code for primary procedure)         Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and         33278       lead(s)         Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing         33279       lead(s) only         Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only         33281       Repositioning of phrenic nerve stimulator transvenous lead(s)         332825       Insertion, subcutaneous cardiac rhythm monitor, including programming         Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator         Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)         33288       stimulation or sensing lead(s)         Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitorig, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and 33289         Interpretation       Percutaneous transcatheter closure of the left atrial appendage with en	33276	
Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and lead(s)           Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) only           Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only           33281         Repositioning of phrenic nerve stimulator transvenous lead(s)           33285         Insertion, subcutaneous cardiac rhythm monitor, including programming           Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator           Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator           Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)           Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation           33289         Interpretation of pulse replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approach		
and interrogation and programming, when performed; system, including pulse generator and lead(s)3278Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) onlyRemoval of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only32280and interrogation and programming, when performed; pulse generator only3281Repositioning of phrenic nerve stimulator transvenous lead(s)32825Insertion, subcutaneous cardiac rhythm monitor, including programming Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator3288Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)3288stimulation or sensing lead(s)3289Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and atrial appendage angiography, when performed3280Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation33340Interpretation	33277	
33278lead(s)33278Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing 3327933279Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only33280Removal of phrenic nerve stimulator transvenous lead(s)33281Repositioning of phrenic nerve stimulator transvenous lead(s)33285Insertion, subcutaneous cardiac rhythm monitor, including programming Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)3288stimulation or sensing lead(s)Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and atrial appendage angiography, when performedPercutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach33361femoral artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic va		
Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) only           Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only           33280         and interrogation and programming, when performed; pulse generator only           33281         Repositioning of phrenic nerve stimulator transvenous lead(s)           33285         Insertion, subcutaneous cardiac rhythm monitor, including programming           Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator           Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)           Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed           Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation           Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; pen femoral	00070	
and interrogation and programming, when performed; transvenous stimulation or sensing33279lead(s) onlyRemoval of phrenic nerve stimulator, including vessel catheterization, all imaging guidance,33280and interrogation and programming, when performed; pulse generator only33281Repositioning of phrenic nerve stimulator transvenous lead(s)33285Insertion, subcutaneous cardiac rhythm monitor, including programmingRemoval and replacement of phrenic nerve stimulator, including vessel catheterization, allimaging guidance, and interrogation and programming, when performed; pulse generatorRemoval and replacement of phrenic nerve stimulator, including vessel catheterization, allimaging guidance, and interrogation and programming, when performed; transvenous33288stimulation or sensing lead(s)Transcatheter implantation of wireless pulmonary artery pressure sensor for long-termhemodynamic monitoring, including deployment and calibration of the sensor, right heartcatheterization, selective pulmonary catheterization, radiological supervision and33289interpretation, and pulmonary artery angiography, when performedPercutaneous transcatheter closure of the left atrial appendage with endocardial implant,including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, leftatrial appendage angiography, when performed, and radiological supervision and33340interpretationTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery33361femoral artery approachTranscatheter aortic valve r	33278	
33279lead(s) onlyRemoval of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only33280Repositioning of phrenic nerve stimulator transvenous lead(s)33281Repositioning of phrenic nerve stimulator transvenous lead(s)33285Insertion, subcutaneous cardiac rhythm monitor, including programmingRemoval and replacement of phrenic nerve stimulator, including vessel catheterization, all33287imaging guidance, and interrogation and programming, when performed; pulse generatorRemoval and replacement of phrenic nerve stimulator, including vessel catheterization, allimaging guidance, and interrogation and programming, when performed; transvenous33288stimulation or sensing lead(s)Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performedPercutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation33240Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery approach33361Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach33362approachTranscatheter aortic valve replacement (TA		
Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only           33280         Repositioning of phrenic nerve stimulator transvenous lead(s)           33285         Insertion, subcutaneous cardiac rhythm monitor, including programming           Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator           Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)           33288         Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed           Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation           Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery approach           Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach           Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approach           Transc		
33280and interrogation and programming, when performed; pulse generator only33281Repositioning of phrenic nerve stimulator transvenous lead(s)33285Insertion, subcutaneous cardiac rhythm monitor, including programmingRemoval and replacement of phrenic nerve stimulator, including vessel catheterization, all33287imaging guidance, and interrogation and programming, when performed; pulse generatorRemoval and replacement of phrenic nerve stimulator, including vessel catheterization, allimaging guidance, and interrogation and programming, when performed; transvenous33288stimulation or sensing lead(s)Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary artery angiography, when performedPercutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation33340interpretationTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approach	33279	
33281Repositioning of phrenic nerve stimulator transvenous lead(s)33285Insertion, subcutaneous cardiac rhythm monitor, including programming33285Insertion, subcutaneous cardiac rhythm monitor, including vessel catheterization, all33287imaging guidance, and interrogation and programming, when performed; pulse generator33288Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all33287imaging guidance, and interrogation and programming, when performed; transvenous33288stimulation or sensing lead(s)33288Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed9Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation33340Interpretation33341Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approach3362Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach3363Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach3364approach		
33285Insertion, subcutaneous cardiac rhythm monitor, including programming33285Insertion, subcutaneous cardiac rhythm monitor, including programming33287Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all33287imaging guidance, and interrogation and programming, when performed; pulse generator33288Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all33288imaging guidance, and interrogation and programming, when performed; transvenous33288stimulation or sensing lead(s)Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performedPercutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation33360Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach33363approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach33364approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approach		
Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all33287imaging guidance, and interrogation and programming, when performed; pulse generatorRemoval and replacement of phrenic nerve stimulator, including vessel catheterization, allimaging guidance, and interrogation and programming, when performed; transvenous33288stimulation or sensing lead(s)Transcatheter implantation of wireless pulmonary artery pressure sensor for long-termhemodynamic monitoring, including deployment and calibration of the sensor, right heartcatheterization, selective pulmonary catheterization, radiological supervision and33289interpretation, and pulmonary artery angiography, when performedPercutaneous transcatheter closure of the left atrial appendage with endocardial implant,including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, leftatrial appendage angiography, when performed, and radiological supervision and33340interpretationTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous3361femoral artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery3363approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery3364approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery3364approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery <td< td=""><td>33281</td><td>Repositioning of phrenic nerve stimulator transvenous lead(s)</td></td<>	33281	Repositioning of phrenic nerve stimulator transvenous lead(s)
33287imaging guidance, and interrogation and programming, when performed; pulse generatorRemoval and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)33288Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed8Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation33340Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approach3362Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach3363approach3364Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approach	33285	
Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)33288Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed3289Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation33340Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery approach3363Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery a3363 approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery a3363 approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery a3363 approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with pro		Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all
imaging guidance, and interrogation and programming, when performed; transvenous33288stimulation or sensing lead(s)Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performedPercutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation33340interpretationTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach3363approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach3364approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approach3364approach	33287	imaging guidance, and interrogation and programming, when performed; pulse generator
33288stimulation or sensing lead(s)Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed32289Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation33340Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery approach33362approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach33364approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approach		Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all
Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed33289Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation33340Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery approach33363approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach33364approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approach33364approach		imaging guidance, and interrogation and programming, when performed; transvenous
hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed32289Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation33340interpretation33361Femoral artery approach33362Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery approach33363approach33364Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approach	33288	stimulation or sensing lead(s)
catheterization, selective pulmonary catheterization, radiological supervision and33289interpretation, and pulmonary artery angiography, when performedPercutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation33340interpretationTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery approach33363approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery a3363 		Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term
33289interpretation, and pulmonary artery angiography, when performedPercutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation33340interpretationTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery approach33363approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery a3363 approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery a33363 approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery a3364 approach		hemodynamic monitoring, including deployment and calibration of the sensor, right heart
Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation33340interpretationTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery approach33362approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery a3363 approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery a3363 approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery a3364 approach		catheterization, selective pulmonary catheterization, radiological supervision and
including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation33340interpretationTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery approach33362approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery a3363 approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery a336433364approach	33289	interpretation, and pulmonary artery angiography, when performed
atrial appendage angiography, when performed, and radiological supervision and interpretation33340interpretationTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery approach33362approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery a336333363approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approach33364approach		
33340interpretation33340Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous33361femoral artery approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery33362approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery33363approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery33363approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery33364approach		including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left
Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous         33361       femoral artery approach         Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery         33362       approach         Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery         33363       approach         Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery         33363       approach         Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery         33364       approach		atrial appendage angiography, when performed, and radiological supervision and
33361       femoral artery approach         Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery         33362       approach         Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery         33363       approach         Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery         33364       approach	33340	interpretation
Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery         33362       approach         Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery         33363       approach         Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery         33363       approach         Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery         33364       approach		Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous
33362       approach         Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery         33363       approach         Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery         33364       approach	33361	femoral artery approach
Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery         33363       approach         Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery         33364       approach		Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery
33363approachTranscatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery33364approach	33362	approach
Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery           33364         approach		Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery
33364 approach	33363	approach
		Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery
	33364	approach
Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; transaortic		Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; transaortic
33365 approach (eg, median sternotomy, mediastinotomy)	33365	
Transcatheter aortic valve replacement (tavr/tavi) with prosthetic valve; transapical exposure		Transcatheter aortic valve replacement (tavr/tavi) with prosthetic valve; transapical exposure
33366 (eg, left thoracotomy)	33366	(eg, left thoracotomy)
Transcatheter mitral valve repair, percutaneous approach, including transseptal puncture		Transcatheter mitral valve repair, percutaneous approach, including transseptal puncture
33418 when performed; initial prosthesis	33418	when performed; initial prosthesis
Transcatheter pulmonary valve implantation, percutaneous approach, including pre-stenting		
33477 of the valve delivery site, when performed	33477	of the valve delivery site, when performed

	Surgical ventricular restoration procedure, includes prosthetic patch, when performed (eg,
33548	ventricular remodeling, SVR, SAVER, Dor procedures)
33927	Implantation of a total replacement heart system (artificial heart) with recipient cardiectomy
33928	Removal and replacement of total replacement heart system (artificial heart)
33930	Donor Cardiectomy-Pneumonectomy, W/Preparation & Maintenance, Allograft
33933	Backbench Standard Preparation Of Cadaver Donor Heart/Lung Allograft
33935	Heart-Lung Transplant W/Recipient Cardiectomy-Pneumonectomy
33940	Donor Cardiectomy, W/Preparation & Maintenance, Allograft
33944	Backbench Standard Preparation Of Cadaver Donor Heart Allograft
33945	Heart Transplant, W/Wo Recipient Cardiectomy
33975	Insertion, Ventricular Assist Device; Extracorporeal, Single Ventricle
33976	Insertion, Ventricular Assist Device; Extracorporeal, Biventricular
33979	Insertion, Ventricular Assist Device, Extracorporeat, Diventricular Insertion, Ventricular Assist Device, Implantable Intracorporeal, Single Ventricle
33979	Replacement of extracorporeal ventricular assist device, single or biventricular, pump(s),
33981	single or each pump
00001	Replacement of ventricular assist device pump(s); implantable intracorporeal, single ventricle,
33982	without cardiopulmonary bypass
	Replacement of ventricular assist device pump(s); implantable intracorporeal, single ventricle,
33983	with cardiopulmonary bypass
	Insertion of ventricular assist device, percutaneous, including radiological supervision and
33990	interpretation; left heart, arterial access only
	Insertion of ventricular assist device, percutaneous, including radiological supervision and
33991	interpretation; left heart, both arterial and venous access, with transseptal puncture
	Repositioning of percutaneous right or left heart ventricular assist device with imaging
33993	guidance at separate and distinct session from insertion
00005	Insertion of ventricular assist device, percutaneous, including radiological supervision and
33995	interpretation; right heart, venous access only
	Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; single
36465	incompetent extremity truncal vein (eg, great saphenous vein, accessory saphenous vein)
30403	Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to
	guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; multiple
36466	incompetent truncal veins (eg, great saphenous vein, accessory saphenous vein), same leg
36468	Injection(s) of sclerosant for spider veins (telangiectasia), limb or trunk
36470	Injection of sclerosant; single incompetent vein (other than telangiectasia)
36471	Injection of sclerosant; multiple incompetent veins (other than telangiectasia), same leg
00471	Endovenous ablation therapy of incompetent veins (other than total glocalsia), sufficiency guidance
36473	and monitoring, percutaneous, mechanochemical; first vein treated
	Endovenous Ablation Therapy Of Incompetent Vein, Extremity, Percutaneous, Radiofrequency;
36475	First Vein Treated
	Endovenous Ablation Therapy Of Incompetent Vein, Extremity, Percutaneous, Laser; First Vein
36478	Treated
	Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a
	chemical adhesive (eg, cyanoacrylate) remote from the access site, inclusive of all imaging
36482	guidance and monitoring, percutaneous; first vein treated
36511	Therapeutic Apheresis; White Blood Cells

36512	Therapeutic Apheresis; Red Blood Cells
36513	Therapeutic Apheresis; Platelets
36514	Therapeutic Apheresis; Plasma Pheresis
36516	Therapeutic apheresis; with extracorporeal immunoadsorption, selective adsorption or selective filtration and plasma reinfusion
37220	Revascularization, endovascular, open or percutaneous, iliac artery, unilateral, initial vessel; with transluminal angioplasty
37221	Revascularization, endovascular, open or percutaneous, iliac artery, unilateral, initial vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed
37222	Revascularization, endovascular, open or percutaneous, iliac artery, each additional ipsilateral iliac vessel; with transluminal angioplasty (List separately in addition to code for primary procedure)
37223	Revascularization, endovascular, open or percutaneous, iliac artery, each additional ipsilateral iliac vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)
37224	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal angioplasty
37225	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with atherectomy, includes angioplasty within the same vessel, when performed
37226	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed
37227	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal stent placement(s) and atherectomy, includes angioplasty within the same vessel, when performed
37228	Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal angioplasty
37229	Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with atherectomy, includes angioplasty within the same vessel, when performed
37230	Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed
37231	Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal stent placement(s) and atherectomy, includes angioplasty within the same vessel, when performed
37232	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with transluminal angioplasty (List separately in addition to code for primary procedure)
37233	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with atherectomy, includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)
37234	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)
37235	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with transluminal stent placement(s) and atherectomy, includes

	angian lactury within the same vessel, when performed (List separately in addition to code for
	angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)
	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation,
	intraprocedural roadmapping, and imaging guidance necessary to complete the intervention;
	venous, other than hemorrhage (eg, congenital or acquired venous malformations, venous and
	capillary hemangiomas, varices, varicoceles)
	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation,
	intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor (eg, congenital or acquired arterial malformations,
	arteriovenous malformations, arteriovenous fistulas, aneurysms, pseudoaneurysms)
	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation,
	intraprocedural roadmapping, and imaging guidance necessary to complete the intervention;
	for tumors, organ ischemia, or infarction
	Management, Recipient Hematopoietic Progenitor Cell Donor Search & Cell Acquisition
	Blood-Derived Hematopoietic Progenitor Cell Harvesting, Transplantation/Collection;
38205	Allogenic
	Blood-Derived Hematopoietic Progenitor Cell Harvesting, Transplantation/Collection;
38206	Autologous
	Transplant Preparation, Hematopoietic Progenitor Cells; Cryopreservation & Storage
	Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest,
	without washing, per donor
	Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest,
	with washing, per donor Transplant Prep, Hematopoietic Progenitor Cells; Specfc Cell Deplet W/In Harvest, T-Cell
	Deplete
38211	Transplant Preparation, Hematopoietic Progenitor Cells; Tumor Cell Deplete
38212	Transplant Preparation, Hematopoietic Progenitor Cells; Red Blood Cell Removal
38213	Transplant Preparation, Hematopoietic Progenitor Cells; Platelet Depletion
38214	Transplant Preparation, Hematopoietic Progenitor Cells; Plasma (Volume) Depletion
38215	Transplant Prep, Hematoiepotic Progenitor Cells; Cell Conc, Plasma/Mononuclear/Buffy Coat
38230	Bone marrow harvesting for transplantation; allogeneic
38232	Bone Marrow Harvesting For Transplantation; Autologous
38240	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor
38241	Hematopoietic progenitor cell (HPC); autologous transplantation
38242	Allogeneic lymphocyte infusions
38243	Hematopoietic progenitor cell (HPC); HPC boost
	Placement of needles, catheters, or other device(s) into the head and/or neck region
41019	(percutaneous, transoral, or transn
	Tongue base suspension, permanent suture technique
41530	Submucosal ablation of the tongue base, radiofrequency, 1 or more sites, per session
42145	Palatopharyngoplasty
43192	Esophagoscopy, rigid, transoral; with directed submucosal injection(s), any substance
43201	Esophagoscopy, flexible, transoral; with directed submucosal injection(s), any substance
	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed

	Esophagoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s)
43229	(includes pre- and post-dilation and guide wire passage, when performed)
	Esophagogastroduodenoscopy, flexible, transoral; with dilation of esophagus with balloon (30
43233	mm diameter or larger) (includes fluoroscopic guidance, when performed)
	Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of
43235	specimen(s) by brushing or washing, when performed (separate procedure)
	Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any
43236	substance
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple
	Esophagogastroduodenoscopy, flexible, transoral; with insertion of intraluminal tube or
43241	catheter
	Esophagogastroduodenoscopy, flexible, transoral; with injection sclerosis of
43243	esophageal/gastric varices
100.11	Esophagogastroduodenoscopy, flexible, transoral; with band ligation of esophageal/gastric
43244	varices
400.45	Esophagogastroduodenoscopy, flexible, transoral; with dilation of gastric/duodenal
43245	stricture(s) (eg, balloon, bougie) Esophagogastroduodenoscopy, flexible, transoral; with directed placement of percutaneous
43246	gastrostomy tube
43240	Esophagogastroduodenoscopy, flexible, transoral; with removal of foreign body
43247	Esophagogastroduodenoscopy, flexible, transoral; with insertion of guide wire followed by
43248	passage of dilator(s) through esophagus over guide wire
40240	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic balloon dilation of
43249	esophagus (less than 30 mm diameter)
	Esophagogastroduodenoscopy, flexible, transoral; with removal of tumor(s), polyp(s), or other
43250	lesion(s) by hot biopsy forceps or bipolar cautery
	Esophagogastroduodenoscopy, flexible, transoral; with removal of tumor(s), polyp(s), or other
43251	lesion(s) by snare technique
43254	Esophagogastroduodenoscopy, flexible, transoral; with endoscopic mucosal resection
43255	Esophagogastroduodenoscopy, flexible, transoral; with control of bleeding, any method
	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the
	muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal
43257	reflux disease
10000	Esophagogastroduodenoscopy, flexible, transoral; with placement of endoscopic stent
43266	(includes pre- and post-dilation and guide wire passage, when performed)
42070	Esophagogastroduodenoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other
43270	lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)
43280	Laparoscopy, Surgical, Esophagogastric Fundoplasty
43281	Laparoscopy, surgical, repair of paraesophageal hernia, includes fundoplasty, when performed; without implantation of me
40201	Laparoscopy, surgical, repair of paraesophageal hernia, includes fundoplasty, when
43282	performed; with implantation of mesh
	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter
43284	augmentation device (i.e., magnetic band), including cruroplasty when performed.
43285	Removal of esophageal sphincter augmentation device

43290	Esophagogastroduodenoscopy, flexible, transoral; with deployment of intragastric bariatric balloon
43291	Esophagogastroduodenoscopy, flexible, transoral; with removal of intragastric bariatric balloon(s)
43497	Lower esophageal myotomy, transoral (ie, peroral endoscopic myotomy [POEM])
43631	Gastrectomy, Partial, Distal; W/Gastroduodenostomy
43632	Gastrectomy, Partial, Distal; W/Gastrojejunostomy
43633	Gastrectomy, Partial, Distal; W/Roux-En-Y Reconstruction
	Laparoscopy, Surg, Gastric Restrictive Procedure; W Gastric Bypass And Roux-En-Y
43644	Gastroenterostomy (Roux Limb <= 150 Cm)
	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine
43645	reconstruction to limit absorption
	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive
43770	device (eg, gastric band and subcutaneous port components)
	Laparoscopy, surgical, gastric restrictive procedure; revision of adjustable gastric restrictive
43771	device component only
	Laparoscopy, surgical, gastric restrictive procedure; removal of adjustable gastric restrictive
43772	device component only
	Laparoscopy, surgical, gastric restrictive procedure; removal and replacement of adjustable
43773	gastric restrictive device component only
	Laparoscopy, surgical, gastric restrictive procedure; removal of adjustable gastric restrictive
43774	device and subcutaneous port components
	Laparoscopy, surgical, gastric restrictive procedure; longitudinal gastrectomy (ie, sleeve
43775	gastrectomy)
43842	Gastric Restrictive Proc, W/O Gastric Bypass, Morbid Obesity; Vertical-Banded Gastroplasty
100.10	Gastric Restrictve Proc, W/O Gastric Bypass, Morbid Obesity; Non-Vertical-Banded
43843	Gastroplasty
43845	Gastric Stapling Morbid Obesity
400.40	Gastric Restrictve Procedre, W/Gastric Bypass, Morbd Obsty; W/Short Limb Roux-En-Y
43846	Gastroenterostmy
43847	Gastric Restrictive Proc, W/Gastric Bypass, Morbid Obesity; W/Small Bowel Reconstruction
420.40	Revision, open, of gastric restrictive procedure for morbid obesity, other than adjustable
43848	gastric restrictive device (separate procedure)
43886	Gastric restrictive procedure, open; revision of subcutaneous port component only
43887	Gastric restrictive procedure, open; removal of subcutaneous port component only
42000	Gastric restrictive procedure, open; removal and replacement of subcutaneous port
43888	component only
43999	Unlisted Proc, Stomach
44132	Donor Enterectomy, Open, W/Prep & Maintenance, Allograft; Cadaver Donor
44133	Donor Enterectomy, Open With Prep & Maintenance, Allograft; Partial, Living Donor
44135	Intestinal Allotransplantation; From Cadaver Donor
44136	Intestinal Allotransplantation; From Living Donor
44715	Backbench Standard Preparation Of Cadaver Or Living Donor Intestine Allograft
	Backbench Reconstruction Of Cadaver Or Living Donor Intestine Allograft; Venous
44720	Anastomosis, Each

	Backbench Reconstruction Of Cadaver Or Living Donor Intestine Allograft; Arterial
44721	Anastomosis, Each
45560	Repair, Rectocele (Sep Proc)
46505	Chemodenervation of internal anal sphincter
	Anoscopy; diagnostic, with high-resolution magnification (HRA) (eg, colposcope, operating
	microscope) and chemical agent enhancement, including collection of specimen(s) by
46601	brushing or washing, when performed
	Anoscopy; with high-resolution magnification (HRA) (eg, colposcope, operating microscope)
46607	and chemical agent enhancement, with biopsy, single or multiple
46707	Repair of anorectal fistula with plug (eg, porcine small intestine submucosa [SIS])
400.40	Hemorrhoidectomy, internal, by transanal hemorrhoidal dearterialization, 2 or more
46948	hemorrhoid columns/groups, including ultrasound guidance, with mucopexy, when performed
47133	Donor Hepatectomy, W/Preparation & Maintenance, Allograft; Cadaver Donor
47135	Liver Allotransplantation; Orthotopic, Partial/Whole, Cadaver/Living Donor, Any Age
474.40	Donor Hepatectomy, with Preparation and Maintenance of Allograft, Living Donor; Left Lateral
47140	Segment Only Donor Hepatectomy, with Preparation and Maintenance of Allograft, Living Donor; Total Left
47141	Lobectomy
4/141	Donor Hepatectomy, with Preparation and Maintenance of Allograft, Living Donor; Total Right
47142	Lobectomy
	Backbench Standard Preparation Of Cadaver Donor Whole Liver Graft; Without Trisegment Or
47143	Lobe Split
	Backbench standard preparation of cadaver donor whole liver graft prior to allotransplantation,
	including cholecystectomy, if necessary, and dissection and removal of surrounding soft
	tissues to prepare the vena cava, portal vein, hepatic artery, and common bile duct for
	implantation; with trisegment split of whole liver graft into 2 partial liver grafts (ie, left lateral
47144	segment [segments II and III] and right trisegment [segments I and IV through VIII])
	Backbench standard preparation of cadaver donor whole liver graft prior to allotransplantation,
	including cholecystectomy, if necessary, and dissection and removal of surrounding soft
	tissues to prepare the vena cava, portal vein, hepatic artery, and common bile duct for
47145	implantation; with lobe split of whole liver graft into 2 partial liver grafts (ie, left lobe [segments ]
47145	II, III, and IV] and right lobe [segments I and V through VIII]) Backbench Reconstruction Of Cadaver Or Living Donor Liver Graft Prior To Allotransplantation;
47146	Venous Anastomosis, Each
., 140	Backbench Reconstruction Of Cadaver Or Living Donor Liver Graft Prior To Allotransplantation;
47147	Arterial Anastomosis, Each
48160	Pancreatectomy, Total/Subtotal W/Autologous Transplantation Pancreas/Pancreatic Islets
48550	Donor Pancreatectomy, W/Prep & Maintenance, Cadaver Donor, W/Wo Duodenal Segment
48551	Backbench Standard Preparation Of Cadaver Donor Pancreas Allograft
	Backbench Reconstruction Of Cadaver Donor Pancreas Allograft Prior To Transplantation,
48552	Venous Anastomosis, Each
48554	Transplantation, Pancreatic Allograft
48556	Removal, Transplanted Pancreatic Allograft
49906	Free Omental Flap W/Microvascular Anastomosis
	Ablation, open, 1 or more renal mass lesion(s), cryosurgical, including intraoperative
50250	ultrasound guidance and monitoring, if performed

50300	Donor Nephrectomy; Cadaver Donor, Unilat/Bilat W/Prep & Maintenance, Allograft
50320	Donor Nephrectomy, Open, Living Donor W/O Allograft Preparation & Maintenance
50323	Backbench Standard Preparation Of Cadaver Donor Renal Allograft
50325	Backbench Standard Preparation Of Living Donor Renal Allograft (Open Or Laparoscopic)
	Backbench Reconstruction Of Cadaver Or Living Donor Renal Allograft Prior To
50327	Transplantation; Venous Anastomosis, Each
	Backbench Reconstruction Of Cadaver Or Living Donor Renal Allograft Prior To
50328	Transplantation; Arterial Anastomosis, Each
	Backbench Reconstruction Of Cadaver Or Living Donor Renal Allograft Prior To
50329	Transplantation; Ureteral Anastomosis, Each
50340	Recipient Nephrectomy (Sep Proc)
50360	Renal Allotransplantation, Implantation, Graft; W/O Donor & Recipient Nephrectomy
50365	Renal Allotransplantation, Implantation, Graft; W/Recipient Nephrectomy
50370	Removal, Transplanted Renal Allograft
	Laparoscopy, surgical; ablation of renal mass lesion(s), including intraoperative ultrasound
50542	guidance and monitoring, when performed
50547	Laparoscopy, Surgical; Donor Nephrectomy, Living Donor W/O Allograft Prep & Maintenance
50592	Ablation, 1 or more renal tumor(s), percutaneous, unilateral, radiofrequency
50593	Ablation, renal tumor(s), unilateral, presutaneous cryotherapy
51715	Endoscopic Injection, Implant Matl Into Submucosal Tissues, Urethra &/Or Bladder Neck
	Insertion, Inflatable Urethra/Bladder Neck Sphincter, W/Placement Pump &/Or Reservoir &
53445	Cuff
53446	Removal, Inflatable Urethral/Bladder Neck Sphincter W/Pump/Reservoir/Cuff
53447	Removal & Replacement, Inflatable Sphincter W/Pump, Reservoir, Cuff, Same Session
53448	Remov & Replace Inflatable Sphincter W/Pump/Reservoir/Cuff, Infected, W/Irrig & Debride
53449	Repair, Inflatable Urethral/Bladder Neck Sphincter Device, Incl Pump/Reservoir/Cuff
	Periurethral transperineal adjustable balloon continence device; bilateral insertion, including
53451	cystourethroscopy and imaging guidance
50 (50	Periurethral transperineal adjustable balloon continence device; unilateral insertion, including
53452	cystourethroscopy and imaging guidance
53453	Periurethral transperineal adjustable balloon continence device; removal, each balloon
50454	Periurethral transperineal adjustable balloon continence device; percutaneous adjustment of
53454	balloon(s) fluid volume
53850	Transurethral Destruction, Prostate Tissue; Microwave Thermotherapy
53852	Transurethral Destruction, Prostate Tissue; Radiofrequency Thermotherapy
53860	Transurethral radiofrequency micro-remodeling of the female bladder neck and proximal urethra for stress urinary incontinence
54125	Amputation, Penis; Complete
54360	Plastic Operation, Penis To Correct Angulation
54400	Insertion, Penile Prosthesis; Non-Inflatable (Seni-Rigid)
54401	Insertion, Penile Prosthesis; Inflatable (Self-Contained)
54405	Insertion, (Multi-Component) Inflatable Penile Prosthesis
54440	Plastic Operation, Penis, Injury
54520	Orchiectomy, Simple, W/Wo Prosthesis, Scrotal/Inguinal Approach

54660	Insertion, Testicular Prosthesis (Sep Proc)
54690	Laparoscopy, Surgical; Orchiectomy
55180	Scrotoplasty; Complicated
	Biopsies, prostate, needle, transperineal, stereotactic template guided saturation sampling,
55706	including imaging guidance
55860	Exposure, Prostate, Any Approach, Radiation Insertion
	Exposure, Prostate, Any Approach, Radiation Insertion; W/Lymph Node Bx (Limited Pelvic
55862	Lymphadenect)
55865	Exposure, Prostate, Any Approach, Radiation Insertion; W/Bilat Pelvic Lymphadenectomy
55873	Cryosurgical ablation of the prostate (includes ultrasonic guidance and monitoring)
	Transperineal placement of biodegradable material, peri-prostatic, single or multiple
55874	injection(s), including image guidance, when performed
	Transperineal placement of needles or catheters into prostate for interstitial radioelement
55875	application, with or without cystoscopy
55920	Placement of needles or catheters into pelvic organs and/or genitalia (except prostate) for
	subsequent interstitial radioelement application
56625	Vulvectomy Simple; Complete
56800	Plastic Repair, Introitus
56805	Clitoroplasty, Intersex State
56810	Perineoplasty, Repair, Perineum, Nonobstetrical (Sep Proc)
57110	Vaginectomy, Complete Removal, Vaginal Wall
57155	Insertion of uterine tandem and/or vaginal ovoids for clinical brachytherapy
57156	Insertion of a vaginal radiation afterloading apparatus for clinical brachytherapy
57240	Anterior colporrhaphy, repair of cystocele with or without repair of urethrocele, including cystourethroscopy, when performed
57250	Posterior Colporrhaphy, Repair, Rectocele W/Wo Perineorrhaphy
57260	Combined anteroposterior colporrhaphy, including cystourethroscopy, when performed
37200	Combined anteroposterior colporrhaphy, including cystourethroscopy, when performed; with
57265	enterocele repair
57268	Repair, Enterocele, Vaginal Approach (Sep Proc)
57270	Repair, Enterocele, Abdominal Approach (Sep Proc)
57280	Colpopexy, Abdominal Approach
57282	Sacrospinous Ligament Fixation, Prolapse, Vagina
57283	Colpopexy, Vaginal; Intra-Peritoneal Approach (Uterosacral, Levator Myorrhaphy)
07200	Paravaginal defect repair (including repair of cystocele, if performed); open abdominal
57284	approach
57285	Paravaginal defect repair (including repair of cystocele, if performed) ;vaginal approach
57291	Construction, Artificial Vagina; W/O Graft
57292	Construction, Artificial Vagina; W/Graft
57295	Revision (including removal) of prosthetic vaginal graft, vaginal approach
57296	Revision (including removal) of prosthetic vaginal graft; open abdominal approach
57335	Vaginoplasty, Intersex State
57423	Paravaginal defect repair (including repair of cystocele, if performed), laparoscopic approach
57425	Laparoscopy, Surgical, Colpopexy (Suspension of Vaginal Apex)
5/425	Laparoscopy, Surgical, Colpopexy (Suspension of Vaginal Apex)

58150	Total Abdominal Hysterectomy W/Wo Removal Tube(S)/Ovary(S)
	Vaginal hysterectomy, for uterus greater than 250 g; with colpo-urethrocystopexy (Marshall-
58293	Marchetti-Krantz type, Pereyra type) with or without endoscopic control
58346	Insertion, Heyman Capsules, Clinical Brachytherapy
	Laparoscopy, Surg, W/Vaginal Hysterectomy, Uterus 250gms/<; W/Removal, Tube(S) &/Or
58552	Ovary(S)
	Laparoscopy, Surg, W/Vaginal Hysterectomy, Uterus >250gms; W/Remove Tube(S) &/Or
58554	Ovary(S)
58570	Laparoscopy, surgical, with total hysterectomy, for uterus 250 g or less
	Laparoscopy, surgical, with total hysterectomy, for uterus 250g or less; with removal of tube(s)
58571	and/or ovary (s)
58572	Laparoscopy; surgical, with total hysterectomy, for uterus greater than 250 g
	Laparoscopy; surgical, with total hysterectomy, for uterus greater than 250 g, with removal of
58573	tube(s) and/or ovary (s)
	Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and
58580	monitoring, radiofrequency
	Laparoscopy, surgical, ablation of uterine fibroid(s) including intraoperative ultrasound
58674	guidance and monitoring, radiofrequency.
59076	Fetal Shunt Placement, Including Ultrasound Guidance
	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with
61736	magnetic resonance imaging guidance, when performed; single trajectory for 1 simple lesion
	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with
	magnetic resonance imaging guidance, when performed; multiple trajectories for multiple or
61737	complex lesion(s)
61790	Creation, Lesion, Stereotactic, Percutaneous, Neurolytic Agent; Gasserian Ganglion
61791	Creation, Lesion, Stereotactic, Percutaneous, Neurolytic Agent; Trigeminal Medullary Tract
	Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 simple cranial
61796	lesion
0.1700	Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 complex cranial
61798	lesion
61850	Twist Drill/Burr Hole(S), Implantation, Neurostimulator Electrodes, Cortical
61860	Craniectomy/Craniotomy, Implantation, Neurostimulator Electrodes, Cerebral, Cortical
01000	Burr Hole Craniotomy with Implantation of Subcortical Electrode Array, wo Intraop
61863	Microelectrode Recording; First Array
01007	Burr Hole Craniotomy with Implantation of Subcortical Electrode Array, w Intraop
61867	Microelectrode Recording; First Array
C100E	Subq Placement Cranial Neurostimulator Pulse Generator/Receiver; W/Connection Sngle
61885	Electrod Array Suba Placement Cranial Neurostimulator Pulse Concreter/Paceiver: W//Connection 2+
61886	Subq Placement Cranial Neurostimulator Pulse Generator/Receiver; W/Connection 2+ Electrode Arrays
01000	Insertion of skull-mounted cranial neurostimulator pulse generator or receiver, including
	craniectomy or craniotomy, when performed, with direct or inductive coupling, with
61889	connection to depth and/or cortical strip electrode array(s)
01000	Revision or replacement of skull-mounted cranial neurostimulator pulse generator or receiver
61891	with connection to depth and/or cortical strip electrode array(s)
01001	

	Lysis, Perq, Epidural Adhesions, Solution Injection/Mechanical W/Radiologic Localization; 2
62263	Days/>
62264	Lysis, Perq Epidural Adhesions, Solution Injection/Mechanical W/Radiologic Localization; 1 Day
	Injection/Infusion Neurolytic Substance, W/Wo Therapeutic Substance; Epidural
62281	Cervical/Thoracic
62282	Injection/Infusion Neurolytic Substance; Epidural, Lumbar/Caudal
	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, any
	method utilizing needle based technique to remove disc material under fluoroscopic imaging
62287	or other form of indirect visualization, with discography and/or epidural injection(s) at the treated level(s), when performed, single or multiple levels, lumbar
62290	Injection, Diskography, Each Level; Lumbar
62291	Injection, Diskography, Each Level; Cervical/Thoracic
02201	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid,
	steroid, other solution), not including neurolytic substances, including needle or catheter
	placement, interlaminar epidural or subarachnoid, cervical or thoracic; without imaging
62320	guidance
	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid,
	steroid, other solution), not including neurolytic substances, including needle or catheter
00004	placement, interlaminar epidural or subarachnoid, cervical or thoracic; with imaging guidance
62321	(ie, fluoroscopy or CT)
	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter
	placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging
62322	guidance
	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid,
	steroid, other solution), not including neurolytic substances, including needle or catheter
	placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging
62323	guidance (ie, fluoroscopy or CT)
	Endoscopic decompression of spinal cord, nerve root(s), including laminotomy, partial
	facetectomy, foraminotomy, discectomy and/or excision of herniated intervertebral disc, 1
62380	interspace, lumbar
	Laminectomy with exploration and/or decompression of spinal cord and/or cauda equina, without facetectomy, foraminotomy or discectomy (eg, spinal stenosis), 1 or 2 vertebral
63001	segments; cervical
63003	Laminectomy, W/O Facetectomy/Foraminotomy/Diskectomy, 1/2 Segments; Thoracic
63005	Laminectomy W/O Facetectomy/Foraminotomy/Diskectomy, 1/2 Segments; Lumbar
63012	Laminectomy W/Removal, Abnormal Facets, Lumbar
63015	Laminectomy W/O Facetectomy/Foraminotomy/Diskectomy, > 2 Segments; Cervical
63016	Laminectomy W/O Facetectomy/Foraminotomy/Diskectomy, > 2 Segments; Thoracic
63017	Laminectomy W/O Facetectomy/Foraminotomy/Diskectomy, > 2 Segments; Lumbar
	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial
	facetectomy, foraminotomy and/or excision of herniated intervertebral disc; 1 interspace,
63020	cervical

	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial
	facetectomy, foraminotomy and/or excision of herniated intervertebral disc; 1 interspace,
63030	lumbar
	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial
	facetectomy, foraminotomy and/or excision of herniated intervertebral disc; each additional
63035	interspace, cervical or lumbar (List separately in addition to code for primary procedure)
	Laminotomy W/Partl Facetectmy/Foramnotmy/Herniated Diskect, Re-Exploratn, Sngle
63040	Interspc; Cervical
	Laminotomy W/Partl Facetectomy/Foraminotomy/Herniated Diskect, Re-Explor, Sngle
63042	Interspc; Lumbar
	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial
	facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration,
63043	single interspace; each additional cervical interspace (List separately in addition to code for primary procedure)
00040	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial
	facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration,
	single interspace; each additional lumbar interspace (List separately in addition to code for
63044	primary procedure)
	Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of
	spinal cord, cauda equina and/or nerve root[s], [eg, spinal or lateral recess stenosis]), single
63045	vertebral segment; cervical
	Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of
	spinal cord, cauda equina and/or nerve root[s], [eg, spinal or lateral recess stenosis]), single
63046	vertebral segment; thoracic
	Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of
63047	spinal cord, cauda equina and/or nerve root[s], [eg, spinal or lateral recess stenosis]), single vertebral segment; lumbar
00047	Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of
	spinal cord, cauda equina and/or nerve root[s], [eg, spinal or lateral recess stenosis]), single
	vertebral segment; each additional vertebral segment, cervical, thoracic, or lumbar (List
63048	separately in addition to code for primary procedure)
	Laminoplasty, Cervical, With Decompression Of The Spinal Cord, Two Or More Vertebral
63050	Segments;
	Laminoplasty, Cerv, W Decompression Of Spinal Cord, 2 Or > Verteb Segments; W
63051	Reconstruction Of Posterior Bony Elements
62050	Laminectomy, facetectomy, or foraminotomy (unilateral or bilateral with decompression of
63052	spinal cord, cauda equina and/or nerve root[s] [eg, spinal or lateral recess stenosis] Laminectomy, facetectomy, or foraminotomy (unilateral or bilateral with decompression of
63053	spinal cord, cauda equina and/or nerve root[s] [eg, spinal or lateral recess stenosis]
63055	Transpedicular Approach, 1 Segment; Thoracic
63056	Transpedicular Approach, 1 Segment; Lumbar (Transfacet/Lateral Extraforaminal)
63057	Transpedicular Approach, Add'l Segment; Thoracic/Lumbar
63075	Diskectomy, Anterior; Cervical, 1 Interspace
63076	Diskectomy, Anterior; Cervical, Add'l Interspace
63081	Vertebral Corpectomy, Anterior; Cervical, 1 Segment
63082	Vertebral Corpectomy, Anterior; Cervical, Add'l Segment
00002	Torrestat oupportanty, Antonoi, Col Mout, Aut roognon

63085 63086 63087 63088	Vertebral Corpectomy, Transthoracic; Thoracic, 1 Segment
63087	
	Vertebral Corpectomy, Thoracolumbar, Lower Thoracic/Lumbar; 1 Segment
03000	
	Vertebral Corpectomy, Transperitoneal/Retroperitoneal, Lower Thoracic/Lumbar/Sacral; 1
63090	
63091	
00001	Vertebral Corpectomy, Lateral Extracavitary Approach w Decompression of Spinal Cord/Nerve
63101	
	Vertebral Corpectomy, Lateral Extracavitary Approach w Decompression of Spinal Cord/Nerve
63102	
	Vertebral Corpectomy, Lateral Extracavitary Approach w Decompression Spinal Cord/Nerve
63103	Rts; Thoracic/Lumbar, ea addl Seg
	Laminectomy and section of dentate ligaments, with or without dural graft, cervical; 1 or 2
63180	5
	Laminectomy and section of dentate ligaments, with or without dural graft, cervical; more than
63182	
63185	
63190	
63191	
63194	Laminectomy with cordotomy, with section of 1 spinothalamic tract, 1 stage; cervical
63196	
63198	Laminectomy with cordotomy with section of both spinothalamic tracts, 2 stages within 14 days; cervical
63200	Laminectomy, W/Release, Tethered Spinal Cord, Lumbar
63250	
63252	
63265	
63267	
63270	Laminectomy, Excision, Intraspinal Lesion Other Than Neoplasm, Intradural; Cervical
63287	
63287 63290	
63290	
63290 63300	Vertebral Corpectomy, 1 Segment: Extradural, Thoracic, Transthoracic Approach
63290 63300 63301	Vertebral Corpectomy, 1 Segment; Extradural, Thoracic, Transthoracic Approach Vertebral Corpectomy, 1 Segment; Extradural, Thoracic, Thoracolumbar Approach
63290 63300	Vertebral Corpectomy, 1 Segment; Extradural, Thoracic, Thoracolumbar Approach
63290 63300 63301	Vertebral Corpectomy, 1 Segment; Extradural, Thoracic, Thoracolumbar Approach Vertebral Corpectomy, 1 Segment; Extradural, Lumbar/Sacral,
63250 63252 63265 63270 63270 63275 63275 63280 63280 63282 63285	Laminectomy, Excision/Occlusion, Avm, Spinal Cord; Cervical Laminectomy, Excision/Occlusion, Avm, Spinal Cord; Thoracolumbar Laminectomy, Excision, Non-Neoplastic Lesion, Extradural; Cervical Laminectomy, Excision, Non-Neoplastic Lesion, Extradural; Lumbar Laminectomy, Excision, Intraspinal Lesion Other Than Neoplasm, Intradural; Cervical Laminectomy, Excision, Intraspinal Lesion Other Than Neoplasm, Intradural; Lumbar Laminectomy, Bx/Excision, Intraspinal Neoplasm; Extradural, Cervical Laminectomy, Bx/Excision, Intraspinal Neoplasm; Extradural, Cervical Laminectomy, Bx/Excision, Intraspinal Neoplasm; Extradural, Lumbar Laminectomy, Bx/Excision, Intraspinal Neoplasm; Intradural, Extramedullary, Cervical Laminectomy, Bx/Excision, Intraspinal Neoplasm; Intradural, Intramedullary, Cervical Laminectomy, Bx/Excision, Intraspinal Neoplasm; Intradural, Intramedullary, Thoracolumbar Laminectomy, Bx/Excision, Intraspinal Neoplasm; Intradural, Intramedullary, Thoracolumbar Laminectomy, Bx/Excision, Intraspinal Neoplasm; Extradural-Intradural Lesion, Any Level Vertebral Corpectomy, 1 Segment; Extradural, Cervical

63305	Vertebral Corpectomy, 1 Segment; Intradural, Thoracic, Transthoracic Approach
63306	Vertebral Corpectomy, 1 Segment; Intradural, Thoracic, Thoracolumbar Approach
	Vertebral Corpectomy, 1 Segment; Intradural, Lumbar/Sacral, Transperitoneal/Retroperitoneal
63307	Approach
63308	Vertebral Corpectomy, Add'l Segment
63620	Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 spinal lesion
63650	Percutaneous Implantation, Neurostimulator Electrode Array, Epidural
63655	Laminectomy, Implantation, Neurostimulator Electrodes, Plate/Paddle, Epidural
	Revision including replacement, when performed, of spinal neurostimulator electrode
63663	percutaneous array(s), including fluoroscopy, when performed
	Revision including replacement, when performed, of spinal neurostimulator electrode
	plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when
63664	performed
	Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring
63685	pocket creation and connection between electrode array and pulse generator or receiver
00000	Revision or removal of implanted spinal neurostimulator pulse generator or receiver, with
63688	detachable connection to electrode array
64405	Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve Injection(s), anesthetic agent(s) and/or steroid; brachial plexus, including imaging guidance,
64415	when performed
04415	Injection(s), anesthetic agent(s) and/or steroid; axillary nerve, including imaging guidance,
64417	when performed
04417	Injection(s), anesthetic agent(s) and/or steroid; femoral nerve, including imaging guidance,
64447	when performed
64450	Injection(s), anesthetic agent(s) and/or steroid; other peripheral nerve or branch
	Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging
64454	guidance, when performed
	Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging
64479	guidance (fluoroscopy or CT), cervical or thoracic, single level
	Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging
	guidance (fluoroscopy or CT), cervical or thoracic, each additional level (List separately in
64480	
	Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging
64483	guidance (fluoroscopy or CT), lumbar or sacral, single level
	Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging
64484	guidance (fluoroscopy or CT), lumbar or sacral, each additional level (List separately in addition to code for primary procedure)
04404	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or
	nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic;
64490	single level
	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or
	nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic;
64491	second level (List separately in addition to code for primary procedure)
	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or
	nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic;
64492	third and any additional level(s) (List separately in addition to code for primary procedure)

	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or
04400	nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single
64493	level
	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or
04404	nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral;
64494	second level (List separately in addition to code for primary procedure)
	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or
04405	nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; third
64495	and any additional level(s) (List separately in addition to code for primary procedure)
64505	Injection, Anesthetic Agent; Sphenopalatine Ganglion
64510	Injection, Anesthetic Agent; Stellate Ganglion (Cervical Sympathetic)
64520	Injection, Anesthetic Agent; Lumbar/Thoracic (Paravertebral Sympathetic)
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve
	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes
64555	sacral nerve)
	Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal
64561	placement) including image guidance, if performed
	Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes
64566	programming
	Open implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and
64568	pulse generator
	Revision or replacement of cranial nerve (eg, vagus nerve) neurostimulator electrode array,
64569	including connection to existing pulse generator
0.4575	Open implantation of neurostimulator electrode array; peripheral nerve (excludes sacral
64575	nerve)
64591	Open implantation of neurostimulator electrode array; sacral nerve (transforaminal
64581	placement)
64582	Open implantation of hypoglossal nerve neurostimulator array, pulse generator, and distal
	respiratory sensor electrode or electrode array
64585	Revision or removal of peripheral neurostimulator electrode array
	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or
64590	receiver, requiring pocket creation and connection between electrode array and pulse
04590	generator or receiver
64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array
04090	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated
	neurostimulator, including imaging guidance, when performed; each additional electrode array
64597	(List separately in addition to code for primary procedure)
64600	Destruction, Neurolytic, Trigeminal Nerve; Supraorbital/Infraorbital/Mental/Inferior Alveolar
64605	Destruction, Neurolytic, Trigeminal Nerve; 2nd & 3rd Division
64610	
04010	Destruction, Neurolytic, Trigeminal Nerve; 2nd & 3rd Division W/Radiologic Monitoring
64624	Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed
64624	Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (ie,
64625	fluoroscopy or computed tomography)
04023	

	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2
64628	vertebral bodies, lumbar or sacral
0.020	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each
	additional vertebral body, lumbar or sacral (List separately in addition to code for primary
64629	procedure)
	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance
64633	(fluoroscopy or CT); cervical or thoracic, single facet joint
	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance
	(fluoroscopy or CT); cervical or thoracic, each additional facet joint (List separately in addition
64634	to code for primary procedure)
0.4005	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance
64635	(fluoroscopy or CT); lumbar or sacral, single facet joint
	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance
64636	(fluoroscopy or CT); lumbar or sacral, each additional facet joint (List separately in addition to code for primary procedure)
64640	Destruction, Neurolytic; Other Peripheral Nerve/Branch
64642	Chemodenervation of one extremity; 1-4 muscle(s)
	Chemodenervation of one extremity; 5 or more muscle(s)
64644	
64646	Chemodenervation of trunk muscle(s); 1-5 muscle(s)
64647	Chemodenervation of trunk muscle(s); 6 or more muscle(s)
64650	Chemodenervation of eccrine glands; both axillae
64653	Chemodenervation of eccrine glands; other area(s) (eg, scalp, face, neck), per day
64716	Neuroplasty &/Or Transposition; Cranial Nerve (Specify)
64722	Decompression; Unspecified Nerve(S) (Specify)
64732	Transection/Avulsion; Supraorbital Nerve
64734	Transection/Avulsion; Infraorbital Nerve
64736	Transection/Avulsion; Mental Nerve
64738	Transection/Avulsion; Inferior Alveolar Nerve, Osteotomy
64740	Transection/Avulsion; Lingual Nerve
64742	Transection/Avulsion; Facial Nerve, Differential/Complete
64744	Transection/Avulsion; Greater Occipital Nerve
64771	Transection/Avulsion, Other Cranial Nerve, Extradural
64772	Transection/Avulsion, Other Spinal Nerve, Extradural
64864	Suture, Facial Nerve; Extracranial
64865	Suture, Facial Nerve; Infratemporal, W/Wo Grafting
64866	Anastomosis; Facial-Spinal Accessory
64868	Anastomosis; Facial-Hypoglossal
65756	Keratoplasty (corneal transplant); endothelial
65778	Placement of amniotic membrane on the ocular surface; without sutures
65779	Placement of amniotic membrane on the ocular surface; single layer, sutured
65780	Ocular surface reconstruction; amniotic membrane transplantation, multiple layers
	Transluminal dilation of aqueous outflow canal (eg, canaloplasty); without retention of device
66174	or stent
	Transluminal dilation of aqueous outflow canal (eg, canaloplasty); with retention of device or
66175	stent

	Insertion of anterior segment aqueous drainage device, without extraocular reservoir, external
66183	approach
	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage
	procedure), manual or mechanical technique (eg, irrigation and aspiration or
	phacoemulsification), complex, requiring devices or techniques not generally used in routine
	cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary
	posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage;
	with insertion of intraocular (eg, trabecular meshwork, supraciliary, suprachoroidal) anterior
66989	segment aqueous drainage device, without extraocular reservoir, internal approach, one or more
	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage
	procedure), manual or mechanical technique (eg, irrigation and aspiration or
	phacoemulsification); with insertion of intraocular (eg, trabecular meshwork, supraciliary,
	suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir,
66991	internal approach, one or more
67027	Implant, Intravitreal Drug Delivery System W/Removal, Vitreous
07040	Destruction of localized lesion of retina (eg, macular edema, tumors), 1 or more sessions;
67218	radiation by implantation of source (includes removal of source) Destruction of localized lesion of choroid (eg, choroidal neovascularization); photocoagulation
67220	(eg, laser), 1 or more sessions
67900	Repair, Brow Ptosis, (Supraciliary/Mid-Forehead/Coronal Approach)
07000	Repair of blepharoptosis; frontalis muscle technique with suture or other material (eg, banked
67901	fascia)
	Repair of blepharoptosis; frontalis muscle technique with autologous fascial sling (includes
67902	obtaining fascia)
67903	Repair, Blepharoptosis; (Tarso) Levator Resection/Advancement, Int Approach
67904	Repair, Blepharoptosis; (Tarso) Levator Resection/Advancement, Ext Approach
67906	Repair, Blepharoptosis; Superior Rectus W/Fascial Sling
67908	Repair, Blepharoptosis; Conjunctivo-Tarso-Muller's Muscle-Levator Resection
69090	Ear Piercing
69300	Otoplasty, Protruding Ear, W/Wo Size Reduction
00710	Implantation/Replacement, Electromagnetic Bone Conduction Hearing Device, Temporal
69710	Bone
00714	
hu/1/	Implantation, osseointegrated implant, skull; with percutaneous attachment to external
69714 69715	speech processor
69714 69715	speech processor Implantation, Osseointegrated Implant, Temporal Bone; W/Mastoidectomy
	speech processor Implantation, Osseointegrated Implant, Temporal Bone; W/Mastoidectomy Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to
69715	speech processor Implantation, Osseointegrated Implant, Temporal Bone; W/Mastoidectomy Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or resulting in removal of less than 100 sq
	speech processor Implantation, Osseointegrated Implant, Temporal Bone; W/Mastoidectomy Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to
69715	speech processor Implantation, Osseointegrated Implant, Temporal Bone; W/Mastoidectomy Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or resulting in removal of less than 100 sq mm surface area of bone deep to the outer cranial cortex
69715 69716	speech processorImplantation, Osseointegrated Implant, Temporal Bone; W/MastoidectomyImplantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or resulting in removal of less than 100 sq mm surface area of bone deep to the outer cranial cortexReplacement (including removal of existing device), osseointegrated implant, skull; with
69715 69716 69717	speech processor Implantation, Osseointegrated Implant, Temporal Bone; W/Mastoidectomy Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or resulting in removal of less than 100 sq mm surface area of bone deep to the outer cranial cortex Replacement (including removal of existing device), osseointegrated implant, skull; with percutaneous attachment to external speech processor Replacement, Osseointegrated Implant, Temporal Bone; W/Mastoidectomy Replacement (including removal of existing device), osseointegrated implant, skull; with
69715 69716 69717	speech processor Implantation, Osseointegrated Implant, Temporal Bone; W/Mastoidectomy Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or resulting in removal of less than 100 sq mm surface area of bone deep to the outer cranial cortex Replacement (including removal of existing device), osseointegrated implant, skull; with percutaneous attachment to external speech processor Replacement, Osseointegrated Implant, Temporal Bone; W/Mastoidectomy Replacement (including removal of existing device), osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or
69715 69716 69717	speech processor Implantation, Osseointegrated Implant, Temporal Bone; W/Mastoidectomy Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or resulting in removal of less than 100 sq mm surface area of bone deep to the outer cranial cortex Replacement (including removal of existing device), osseointegrated implant, skull; with percutaneous attachment to external speech processor Replacement, Osseointegrated Implant, Temporal Bone; W/Mastoidectomy Replacement (including removal of existing device), osseointegrated implant, skull; with

	Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to
	external speech processor, outside of the mastoid and resulting in removal of greater than or
69729	equal to 100 sq mm surface area of bone deep to the outer cranial cortex
00720	Replacement (including removal of existing device), osseointegrated implant, skull; with
	magnetic transcutaneous attachment to external speech processor, outside the mastoid and
	involving a bony defect greater than or equal to 100 sq mm surface area of bone deep to the
69730	outer cranial cortex
69930	Cochlear Device Implantation, W/Wo Mastoidectomy
69955	Total Facial Nerve Decompression &/Or Repair, (May Include Graft)
70336	Mri, Temporomandibular Joints
70450	Ct Scan, Head/Brain; W/O Contrast Matl
70460	Ct Scan, Head/Brain; W/Contrast Matl(S)
70470	Ct Scan, Head/Brain; W/O Contrast, Then W/Contrast
70480	Ct Scan, Orbit/Sella/Posterior Fossa/Outer, Middle, Inner Ear; W/O Contrast
70481	Ct Scan, Orbit/Sella/Posterior Fossa/ Outer, Middle, Inner Ear; W/Contrast
70482	Ct Scan, Orbit/Sella/Posterior Fossa/ Outer, Middle, Inner Ear; W/O Contrast, Then W/Contrast
70486	Ct Scan, Maxillofacial Area; W/O Contrast Matl
70487	Ct Scan, Maxillofacial Area; W/Contrast Matl(S)
70488	Ct Scan, Maxillofacial Area; W/O Contrast, Then W/Contrast & Further Sections
70490	Ct Scan, Soft Tissue Neck; W/O Contrast Matl
70491	Ct Scan, Soft Tissue Neck; W/Contrast Matl(S)
70492	Ct Scan, Neck Tissue; W/O Contrast, Then W/Contrast & Further Sections
	Computed tomographic angiography, head, with contrast material(s), including noncontrast
70496	images, if performed, and image postprocessing
	Computed tomographic angiography, neck, with contrast material(s), including noncontrast
70498	images, if performed, and image postprocessing
70540	Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s)
70542	Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; with contrast material(s)
	Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast
70543	material(s), followed by contrast material(s) and further sequences
70544	Mra, Head; W/O Contrast Matl(S)
70545	Mra, Head; W/Contrast Matl(S)
70546	Mra, Head; W/O Contrast Matl(S), Followed By Contrast Matl(S) & Further Sequences
70547	Mra, Neck; W/O Contrast Matl(S)
70548	Mra, Neck; W/Contrast Matl(S)
70549	Mra, Neck; W/O Contrast Matl(S), Followed By Contrast Matl(S) & Further Sequences
70551	Mri, Brain; W/O Contrast
70552	Mri, Brain; W/Contrast
70553	Mri, Brain; W/O Contrast, Then W/Contrast & Further Sequences
	Magnetic resonance imaging, brain, functional MRI; including test selection and administration
	of repetitive body part movement and/or visual stimulation, not requiring physician or
70554	psychologist administration
70555	Magnetic resonance imaging, brain, functional MRI; requiring physician or psychologist
70555	administration of entire neurofunctional testing
71250	Computed tomography, thorax, diagnostic; without contrast material

71260	Computed tomography, thorax, diagnostic; with contrast material(s)
/ 1200	Computed tomography, thorax, diagnostic; without contrast material, followed by contrast
71270	material(s) and further sections
	Computed tomography, thorax, low dose for lung cancer screening, without contrast
71271	material(s)
	Computed tomographic angiography, chest (noncoronary), with contrast material(s), including
71275	noncontrast images, if performed, and image postprocessing
71550	Mri, Chest; W/O Contrast Matl(S)
71551	Mri, Chest; W/Contrast Matl(S)
71552	Mri, Chest; W/O Contrast Matl(S), Followed By Contrast Matl(S) & Further Sequences
71555	Mra, Chest (Exclude Myocardium), W/Wo Contrast Matl(S)
72125	Ct Scan, Cervical Spine; W/O Contrast
72126	Ct Scan, Cervical Spine; W/Contrast
72127	Ct Scan, Cervical Spine; W/O Contrast, Then W/Contrast & Further Sections
72128	Computed tomography, thoracic spine; without contrast material
72129	Cat,Thoracic Spine;w/Contrst Materl,18-2
72130	Ct Scan, Thoracic Spine; W/O Contrast, Then W/Contrast & Further Sections
72131	Ct Scan, Lumbar Spine; W/O Contrast
72132	Ct Scan, Lumbar Spine; W/Contrast
72133	Ct Scan, Lumbar Spine; W/O Contrast, Then W/Contrast & Further Sections
72141	Mri, Cervical Spine; W/O Contrast
72142	Mri, Cervical Spine; W/Contrast
72146	Mri, Thoracic Spine; W/O Contrast
72147	Mri, Thoracic Spine; W/Contrast
72148	Mri, Lumbar Spine; W/O Contrast
72149	Mri, Lumbar Spine; W/Contrast
72156	Mri, Spine W/O Contrast, Then W/Contrast; Cervical
72157	Mri, Spine W/O Contrast, Then W/Contrast; Thoracic
72158	Mri, Spine W/O Contrast, Then W/Contrast; Lumbar
72159	Mra, Spine W/Wo Contrast
	Computed tomographic angiography, pelvis, with contrast material(s), including noncontrast
72191	images, if performed, and image postprocessing
72192	Ct Scan, Pelvis; W/O Contrast
72193	Ct Scan, Pelvis; W/Contrast
72194	Ct Scan, Pelvis; W/O Contrast, Then W/Contrast & Further Sections
72195	Mri, Pelvis; W/O Contrast Matl(S)
72196	Mri, Pelvis; W/Contrast Matl(S)
72197	Mri, Pelvis; W/O Contrast Matl(S), Followed By Contrast Matl(S) & Further Sequences
72198	Mra, Pelvis, W/Wo Contrast
72285	Discography, cervical or thoracic, radiological supervision and interpretation
72295	Discography, lumbar, radiological supervision and interpretation
73200	Ct Scan, Upper Extremity; W/O Contrast
73201	Ct Scan, Upper Extremity; W/Contrast
73202	Ct Scan, Upper Extremity; W/O Contrast, Then W/Contrast & Further Sections

	Computed tomographic angiography, upper extremity, with contrast material(s), including
73206	noncontrast images, if performed
73218	Mri, Upper Extremity, Other Than Joint; W/O Contrast Matl(S)
73219	Mri, Upper Extremity, Other Than Joint; W/Contrast Matl(S)
	Magnetic resonance (eg, proton) imaging, upper extremity, other than joint; without contrast
73220	material(s), followed by contrast material(s) and further sequences
73221	Mri, Any Joint, Upper Extremity; W/O Contrast Matl(S)
73222	Mri, Any Joint, Upper Extremity; W/Contrast Matl(S)
	Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast
73223	material(s), followed by contrast material(s) and further sequences
73225	Mra, Upper Extremity, W/Wo Contrast
73700	Ct Scan, Lower Extremity; W/O Contrast
73701	Ct Scan, Lower Extremity; W/Contrast
73702	Ct Scan, Lower Extremity; W/O Contrast, Then W/Contrast & Further Sections
	Computed tomographic angiography, lower extremity, with contrast material(s), including
73706	noncontrast images, if performed
73718	Mri, Lower Extremity Other Than Joint; W/O Contrast Matl(S)
73719	Mri, Lower Extremity Other Than Joint; W/Contrast Matl(S)
	Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast
73720	material(s), followed by contrast material(s) and further sequences
73721	Mri, Any Joint, Lower Extremity; W/O Contrast Matl
73722	Mri, Any Joint, Lower Extremity; W/Contrast Matl(S)
	Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast
73723	material(s), followed by contrast material(s) and further sequences
73725	Mra, Lower Extremity, W/Wo Contrast
74150	Ct Scan, Abdomen; W/O Contrast
74160	Computed tomography, abdomen; with contrast material(s)
74170	Ct Scan, Abdomen; W/O Contrast, Then W/Contrast & Further Sections
	Computed Tomographic Angiography, Abdomen And Pelvis, With Contrast Material(S),
74174	Including Noncontrast Images, If Performed, And Image Postprocessing
	Computed tomographic angiography, abdomen, with contrast material(s), including
74175	noncontrast images, if performed, and image postprocessing
74176	Computed tomography, abdomen and pelvis; without contrast material
74177	Computed tomography, abdomen and pelvis; with contrast material(s)
7.4.50	Computed tomography, abdomen and pelvis; without contrast material in one or both body
74178	regions, followed by contrast material(s) and further sections in one or both body regions
74181	Mri, Abdomen; W/O Contrast Matl(S)
74182	Mri, Abdomen; W/Contrast Matl(S)
74183	Mri, Abdomen; W/O Contrast Matl(S) Followed By Contrast Matl(S) & Further Sequences
74185	Mra, Abdomen, W/Wo Contrast
	Computed tomographic (CT) colonography, diagnostic, including image postprocessing;
74261	without contrast material
74000	Computed tomographic (CT) colonography, diagnostic, including image postprocessing; with
74262	contrast material(s) including non-contrast images, if performed
74263	Computed tomographic (CT) colonography, screening, including image postprocessing

	Magnetic recommend (or proton) imaging fotal including placental and material polyio
74712	Magnetic resonance (eg, proton) imaging, fetal, including placental and maternal pelvic imaging when performed; single of first gestation
75557	Cardiac magnetic resonance imaging for morphology and function without contrast material;
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Cardiac magnetic resonance imaging for morphology and function without contrast material;
75559	with stress imaging
	Cardiac magnetic resonance imaging for morphology and function without contrast
75561	material(s), followed by contrast material(s) and further sequences;
	Cardiac magnetic resonance imaging for morphology and function without contrast
75563	material(s), followed by contrast material(s) and further sequences; with stress imaging
	Computed tomography, heart, without contrast material, with quantitative evaluation of
75571	coronary calcium
	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and
75570	morphology (including 3D image postprocessing, assessment of cardiac function, and
75572	evaluation of venous structures, if performed) Computed tomography, heart, with contrast material, for evaluation of cardiac structure and
	morphology in the setting of congenital heart disease (including 3D image postprocessing,
	assessment of left ventricular [LV] cardiac function, right ventricular [RV] structure and
75573	function and evaluation of vascular structures, if performed)
	Computed tomographic angiography, heart, coronary arteries and bypass grafts (when
	present), with contrast material, including 3D image postprocessing (including evaluation of
	cardiac structure and morphology, assessment of cardiac function, and evaluation of venous
75574	structures, if performed)
	Noninvasive estimate of coronary fractional flow reserve (FFR) derived from augmentative
	software analysis of the data set from a coronary computed tomography angiography, with
75580	interpretation and report by a physician or other qualified health care professional
	Computed tomographic angiography, abdominal aorta and bilateral iliofemoral lower extremity
75635	runoff, with contrast material(s), including noncontrast images, if performed, and image postprocessing
76120	Cineradiography/Videoradiology, Except Where Specifically Included
70120	3D rendering with interpretation and reporting of computed tomography, magnetic resonance
	imaging, ultrasound, or other tomographic modality with image postprocessing under
76376	concurrent supervision; not requiring image postprocessing on an independent workstation
	3D rendering with interpretation and reporting of computed tomography, magnetic resonance
	imaging, ultrasound, or other tomographic modality with image postprocessing under
76377	concurrent supervision; requiring image postprocessing on an independent workstation
76390	Mr Spectroscopy
76391	Magnetic resonance (eg, vibration) elastography
76873	Echography, Transrectal; Prostate Volume Study, Brachytherapy Planning
76965	Us Guided, Interstitial Radioelement Application
77014	Computed tomography guidance for placement of radiation therapy fields
77046	Magnetic resonance imaging, breast, without contrast material; unilateral
77047	Magnetic resonance imaging, breast, without contrast material; bilateral
	Magnetic resonance imaging, breast, without and with contrast material(s), including
	computer-aided detection (CAD real-time lesion detection, characterization and
77048	pharmacokinetic analysis), when performed; unilateral

	Magnetic resonance imaging, breast, without and with contrast material(s), including
	computer-aided detection (CAD real-time lesion detection, characterization and
77049	pharmacokinetic analysis), when performed; bilateral
	Computed tomography, bone mineral density study, 1 or more sites; axial skeleton (eg, hips,
77078	pelvis, spine)
77084	Magnetic resonance (eg, proton) imaging, bone marrow blood supply
77295	3-dimensional radiotherapy plan, including dose-volume histograms
77301	Intensity Modulated Radiotherapy Plan W/Dose Volume Histograms
	Brachytherapy isodose plan; simple (calculation[s] made from 1 to 4 sources, or remote
77316	afterloading brachytherapy, 1 channel), includes basic dosimetry calculation(s)
	Brachytherapy isodose plan; intermediate (calculation[s] made from 5 to 10 sources, or
77317	remote afterloading brachytherapy, 2-12 channels), includes basic dosimetry calculation(s)
	Brachytherapy isodose plan; complex (calculation[s] made from over 10 sources, or remote
77318	afterloading brachytherapy, over 12 channels), includes basic dosimetry calculation(s)
	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design
77338	and construction per IMRT
77370	Special Medical Radiation Physics Consultation
	Radiation treatment delivery, stereotactic radiosurgery (SRS), complete course of treatment of
77371	cranial lesion(s) consisting of 1 session; multi-source Cobalt 60 based
77070	Radiation treatment delivery, stereotactic radiosurgery (SRS), complete course of treatment of
77372	cranial lesion(s) consisting of 1 session; linear accelerator based
77070	Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions,
77373	including image guidance, entire course not to exceed 5 fractions Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when
77385	performed; simple
77000	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when
77386	performed; complex
	Guidance for localization of target volume for delivery of radiation treatment, includes
77387	intrafraction tracking, when performed
77402	Radiation treatment delivery, => 1 MeV; simple
77407	Radiation treatment delivery, => 1 MeV; intermediate
77412	Radiation treatment delivery, => 1 MeV; complex
	High energy neutron radiation treatment delivery, 1 or more isocenter(s) with coplanar or non-
77423	coplanar geometry with blocking and/or wedge, and/or compensator(s)
77424	Intraoperative Radiation Treatment Delivery, X-Ray, Single Treatment Session
77425	Intraoperative Radiation Treatment Delivery, Electrons, Single Treatment Session
	Stereotactic radiation treatment management of cranial lesion(s) (complete course of
77432	treatment consisting of 1 session)
	Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or
77435	more lesions, including image guidance, entire course not to exceed 5 fractions
77469	Intraoperative Radiation Treatment Management
	Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or
77470	endocavitary irradiation)
77520	Proton Treatment Delivery; Simple W/O Compensation
77522	Proton Treatment Delivery; Simple W/Compensation
77523	Proton Treatment Delivery; Intermediate

77525	Proton Treatment Delivery; Complex
77761	Intracavitary Radiation Source Application; Simple
77762	Intracavitary Radiation Source Application; Intermediate
77763	Intracavitary Radiation Source Application; Complex
	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy,
77770	includes basic dosimetry, when performed; 1 channel
	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy,
77771	includes basic dosimetry, when performed; 2-12 channels
77772	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy,
77778	includes basic dosimetry, when performed; over 12 channels Interstitial Radioelement Application; Complex
77790	Supervision, Handling, Loading, Radiation Source
///90	Myocardial imaging, positron emission tomography (PET), metabolic evaluation study
	(including ventricular wall motion[s] and/or ejection fraction[s], when performed), single study;
78429	with concurrently acquired computed tomography transmission scan
	Myocardial imaging, positron emission tomography (PET), perfusion study (including
	ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or
	stress (exercise or pharmacologic), with concurrently acquired computed tomography
78430	transmission scan
	Myocardial imaging, positron emission tomography (PET), perfusion study (including
	ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest and stress (exercise or pharmacologic), with concurrently acquired computed tomography
78431	transmission scan
	Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic
	evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when
78432	performed), dual radiotracer (eg, myocardial viability);
	Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic
	evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when
78433	performed), dual radiotracer (eg, myocardial viability); with concurrently acquired computed tomography transmission scan
70433	Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction,
	qualitative or quantitative wall motion, ejection fraction by first pass or gated technique,
	additional quantification, when performed); single study, at rest or stress (exercise or
78451	pharmacologic)
	Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction,
	qualitative or quantitative wall motion, ejection fraction by first pass or gated technique,
70450	additional quantification, when performed); multiple studies, at rest and/or stress (exercise or
78452	pharmacologic) and/or redistribution and/or rest reinjection Myocardial perfusion imaging, planar (including qualitative or quantitative wall motion,
	ejection fraction by first pass or gated technique, additional quantification, when performed);
78453	single study, at rest or stress (exercise or pharmacologic)
	Myocardial perfusion imaging, planar (including qualitative or quantitative wall motion,
	ejection fraction by first pass or gated technique, additional quantification, when performed);
	multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or
78454	rest reinjection
70450	Myocardial imaging, positron emission tomography (PET), metabolic evaluation study
78459	(including ventricular wall motion[s] and/or ejection fraction[s], when performed), single study;

78466	Myocardial Imaging, Infarct Avid, Planar; Qualitative/Quantitative
78468	
-	Myocardial Imaging, Infarct Avid, Planar; W/Ejection Fraction, 1st Pass Technique
78469	Myocardial Imaging, Infarct Avid, Planar; Tomographic Spect W/Wo Quantification
78472	Cardiac Blood Pool Imaging, Gated Equilibrium; Planar, Single Study, Rest/Stress
78473	Cardiac Blood Pool Imaging, Gated Equilibrium; Planar, Multiple Studies, Rest/Stress
70.404	Cardiac Blood Pool Imaging, Planar, 1st Pass; Single Study & Ejection Fraction W/Wo
78481	Quantification
	Cardiac blood pool imaging (planar), first pass technique; multiple studies, at rest and with
78483	stress (exercise and/or pharmacologic), wall motion study plus ejection fraction, with or without quantification
/6463	
	Myocardial imaging, positron emission tomography (PET), perfusion study (including
78491	ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or stress (exercise or pharmacologic)
70491	Myocardial imaging, positron emission tomography (PET), perfusion study (including
	ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest
78492	and stress (exercise or pharmacologic)
70452	Cardiac Blood Pool Imaging, Gated Equilibrium, Rest, Spect, & Ejection Fraction W/Wo
78494	Quantification
78608	Brain Imaging, Positron Emission Tomography (Pet); Metabolic Evaluation
78609	Brain Imaging, Positron Emission Tomography (Pet); Perfusion Evaluation
,	Radiopharmaceutical localization of tumor, inflammatory process or distribution of
	radiopharmaceutical agent(s) (includes vascular flow and blood pool imaging, when
78803	performed)
78811	Positron emission tomography (PET) imaging; limited area (eg, chest, head/neck)
78812	Positron emission tomography (PET) imaging; skull base to mid-thigh
78813	Positron emission tomography (PET) imaging; whole body
	Positron emission tomography (PET) with concurrently acquired computed tomography (CT)
	for attenuation correction and anatomical localization imaging; limited area (eg, chest,
78814	head/neck)
	Positron emission tomography (PET) with concurrently acquired computed tomography (CT)
78815	for attenuation correction and anatomical localization imaging; skull base to mid-thigh
	Positron emission tomography (PET) with concurrently acquired computed tomography (CT)
78816	for attenuation correction and anatomical localization imaging; whole body
79101	Radiopharmaceutical Therapy, By Intravenous Administration
79403	Radiopharmaceutical Therapy, Radiolabeled Monoclonal Antibody By Intravenous Infusion
	IDH1 (isocitrate dehydrogenase 1 [NADP+], soluble) (eg, glioma), common variants (eg,
81120	R132H, R132C)
	IDH2 (isocitrate dehydrogenase 2 [NADP+], mitochondrial) (eg, glioma), common variants (eg,
81121	R140W, R172M)
01101	DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy) deletion analysis, and
81161	duplication analysis, if performed
	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg,
01100	hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full
81162	duplication/deletion analysis (ie, detection of large gene rearrangements)
01100	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg,
81163	hereditary breast and ovarian cancer) gene analysis; full sequence analysis

<ul> <li>brich (BrCAL, DNA repair associated), BrCAZ (DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (e, 44etection of large gene rearrangements)</li> <li>BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis</li> <li>BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)</li> <li>BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis (ie, detection of large gene rearrangements)</li> <li>ARE1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib tyrosine kinase inhibitor resistance), gene analysis, variants in the kinase domain</li> <li>AFE2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2</li> <li>(FRAXE)) gene analysis; characterization of alleles (eg, expanded) alleles</li> <li>AFE2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2</li> <li>(FRAXE)] gene analysis; characterization of alleles (eg, expanded) alse and methylation status)</li> <li>AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X</li> <li>chromosome inactivation) gene analysis; known familial variant</li> <li>ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted</li> <li>sequence</li> <li>ATXN1 (atraxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles</li> <li>ATXN2 (ataxin 3) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles</li> <li>ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnorm</li></ul>		BBCA1 (BBCA1, DNA repair appariated), BBCA2 (BBCA2, DNA repair appariated) (or
81164         detection of large gene rearrangements)           BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene           81165         analysis; full sequence analysis           BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene           analysis; full equication/deletion analysis (ie, detection of large gene rearrangements)           BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene           81167         analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)           ABL 1 (ABL proto-oncogene 1, non-receptor tyrosine kinase (eg, acquired imatinib tyrosine           81170         kinase inhibitor resistance), gene analysis, variants in the kinase domain           AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2           811712         [FFAXE]) gene analysis; evaluation to detect abnormal (eg, expanded size and methylation status)           AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X           81173         chromosome inactivation) gene analysis; thul gene sequence           AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X           81174         chromosome inactivation) gene analysis; thus gene analysis; targeted           81175         sequence           AK (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X		BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg,
BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene           analysis; full sequence analysis           BRCA2 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene           analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)           BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene           analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)           ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib tyrosine           kinase inhibitor resistance), gene analysis, variants in the kinase domain           AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2           [FRAXE]) gene analysis; valuation to detect abnormal (eg, expanded) alleles           AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2           [FRAXE]) gene analysis; characterization of alleles (eg, expanded) alleles           AFF2 (ALF transcription along bubbar muscular atrophy, Kennedy disease, X           chromosome inactivation) gene analysis; full gene sequence           AR (androgen receptor) (eg, spinal and bubbar muscular atrophy, Kennedy disease, X           chromosome inactivation) gene analysis; known familial variant           ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted	01104	
81165         analysis; full sequence analysis           BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)           BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)           ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib tyrosine kinase inhibitor resistance), gene analysis; variants in the kinase domain           AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2           81172         [FRAXE]) gene analysis; characterization of alteles (eg, expanded) alteles           AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2           81173         chromosome inactivation) gene analysis; full gene sequence           AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X           81174         chromosome inactivation) gene analysis; full gene sequence           AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X           81174         chromosome inactivation) gene analysis; full gene sequence           AK11 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted           sequence         atxN11 (atrophin 1) (eg, spinoccerebellar ataxia) gene analysis, evaluation to de	81164	
BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)           BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)           ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib tyrosine kinase inhibitor resistance), gene analysis, variants in the kinase domain           AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2           81170         [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded 3ze and methylation status) AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2           81171         [FRAXE]) gene analysis; scharacterization of alleles (eg, expanded size and methylation status) AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; knul gene sequence           AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; knuw familial variant           ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomoncytic leukemia), gene analysis; targeted sequence analysis (eg, exon 12)           ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles           ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles	01105	
81166         analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)           BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene           81167         analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)           ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib tyrosine           81170         kinase inhibitor resistance), gene analysis, variants in the kinase domain           AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2           81171         [FRAXE]) gene analysis; characterization of alleles (eg, expanded) alleles           AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2           81173         chromosome inactivation gene analysis; full gene sequence           AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X           81174         chromosome inactivation) gene analysis; full gene sequence           ASL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted           81176         sequence analysis (eg, exon 12)           ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis; targeted           81177         detect abnormal (eg, expanded) alleles           ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation	81165	
BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene           81167         analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)           ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib tyrosine           81170         kinase inhibitor resistance), gene analysis, variants in the kinase domain           AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2           81171         [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles           AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2           81172         [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)           AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X           81173         chromosome inactivation) gene analysis; thull gene sequence           AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X           81174         chromosome inactivation) gene analysis; thu transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; full gene           81175         sequence           ASL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; evaluation to           81176         sequence		
81167       analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)         ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imathib tyrosine         81170       kinase inhibitor resistance), gene analysis, variants in the kinase domain         AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2         81171       [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles         AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2         81172       [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         81173       chromosome inactivation) gene analysis; full gene sequence         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         81174       chromosome inactivation) gene analysis; full gene sequence         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         sequence       ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; evaluation to detect abnormal (eg, expanded) alleles         ATXN1 (atrophin 1) (eg, dentatorubral-pablidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expande	81166	
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib tyrosine         81170       kinase inhibitor resistance), gene analysis, variants in the kinase domain         AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2         81171       [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles         AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2         81172       [FRAXE]) gene analysis; characterization of alleles (eg, expanded) size and methylation status)         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         81173       chromosome inactivation) gene analysis; thul gene sequence         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         81174       chromosome inactivation) gene analysis; thul gene sequence         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         81174       chromosome inactivation) gene analysis; known familial variant         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; trugted         81175       sequence analysis (eg, exon 12)         ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, e		
81170       kinase inhibitor resistance), gene analysis, variants in the kinase domain         AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2         81171       [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles         AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2         [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         81173       chromosome inactivation) gene analysis; thull gene sequence         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         81174       chromosome inactivation) gene analysis; thull gene sequence         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         81175       sequence         ATXN1 (atditional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         81175       sequence         ATXN1 (ataditional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         81175       sequence         ATXN1 (ataditional sex combs like 1, transcriptional regulator) (	81167	
AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2         81171       [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles         AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2         81172       [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         chromosome inactivation) gene analysis; klugene sequence         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         chromosome inactivation) gene analysis; known familial variant         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         81176       sequence         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         81176       sequence analysis (eg, exon 12)         ATN1 (atrophin 1) (eg, dentatorubrat-pallidoluysian atrophy) gene analysis, evaluation to         81177       expanded) alleles         ATN1 (atrain 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATNA (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles		
81171       [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles         AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2         [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         81173       chromosome inactivation) gene analysis; thull gene sequence         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         81174       chromosome inactivation) gene analysis; known familial variant         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         81176       sequence         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         81176       sequence analysis (eg, exon 12)         ATN1 (ataxin 1) (eg, dentatorubrat-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN1 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN2 (ataxin 3) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN3 (ataxin 3) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles	81170	
AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2         81172       [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         81173       chromosome inactivation) gene analysis; full gene sequence         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         81174       chromosome inactivation) gene analysis; known familial variant         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; full gene sequence         81175       sequence         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted sequence analysis (eg, exon 12)         ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN3 (ataxin 3) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN1 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles <td></td> <td></td>		
81172       [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         chromosome inactivation) gene analysis; full gene sequence         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         chromosome inactivation) gene analysis; known familial variant         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         sequence         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         sequence         ATXN1 (atdrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to         detect abnormal (eg, expanded) alleles         ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN1 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles	81171	
AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         81173       chromosome inactivation) gene analysis; full gene sequence         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         81174       chromosome inactivation) gene analysis; full gene sequence         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         81174       chromosome inactivation) gene analysis; hown familial variant         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         81175       sequence         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         81176       sequence analysis (eg, exon 12)         ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to         81177       detect abnormal (eg, expanded) alleles         ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN3 (ataxin 3) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to		
81173       chromosome inactivation) gene analysis; full gene sequence         AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         81174       chromosome inactivation) gene analysis; known familial variant         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; full gene sequence         81175       sequence         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted sequence analysis (eg, exon 12)         ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN2 (ataxin 3) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN3 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN3 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to d	81172	
AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X         81174       chromosome inactivation) gene analysis; known familial variant         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; full gene         81175       sequence         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         81176       sequence analysis (eg, exon 12)         ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to         81177       detect abnormal (eg, expanded) alleles         ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN3 (ataxin 3) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN1 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnor		
81174       chromosome inactivation gene analysis; known familial variant         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; full gene         81175       sequence         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         81176       sequence analysis (eg, exon 12)         ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to         81177       detect abnormal (eg, expanded) alleles         ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN2 (ataxin 3) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN2 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN2 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN8 (ataxin 10) (eg, spinocerebellar ataxia) gene analysi	81173	
ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; full gene sequence         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         81176       sequence analysis (eg, exon 12)         ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN80S (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         CACNA1A (calcium voltage-gated channet subunit alpha1 A) (eg, spinocerebell		
myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; full gene81175sequenceASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted81176sequence analysis (eg, exon 12)ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN8 (ataxin 3) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN1 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN11 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) g	81174	
81175       sequence         ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         81176       sequence analysis (eg, exon 12)         ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to         81177       detect abnormal (eg, expanded) alleles         ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN3 (ataxin 3) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN3 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene         81182       analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene         81182       analysis, e		
ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted         81176       sequence analysis (eg, exon 12)         ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to         81177       detect abnormal (eg, expanded) alleles         ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg,         81178       expanded) alleles         ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg,         81179       expanded) alleles         ATXN3 (ataxin 3) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg,         81180       expanded) alleles         ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis,         81180       evaluation to detect abnormal (eg, expanded) alleles         ATXN3 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg,         81181       expanded) alleles         ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene         81182       analysis, evaluation to detect abnormal (eg, expanded) alleles         ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles         CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spin		
myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted81176sequence analysis (eg, exon 12)ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to81177detect abnormal (eg, expanded) allelesATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg,81178expanded) allelesATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg,81179expanded) allelesATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis,81180evaluation to detect abnormal (eg, expanded) allelesATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg,81181expanded) allelesATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg,81181expanded) allelesATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene81182analysis, evaluation to detect abnormal (eg, expanded) allelesanalysis, eva	81175	
81176sequence analysis (eg, exon 12)ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to81177detect abnormal (eg, expanded) allelesATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg,81178expanded) allelesATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg,81179expanded) alleles81179expanded) allelesATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis,81180evaluation to detect abnormal (eg, expanded) allelesATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg,81181expanded) allelesATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg,81181expanded) allelesATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene81182analysis, evaluation to detect abnormal (eg, expanded) allelesanalysis, evaluation to detect abnormal (eg, expanded) allelesattinsi(eg, expanded) allelesB1183(eg, expanded) allelesanalysis; evaluation to detect abnormal (eg, expanded) allelesanalysis; full gene sequence<		
ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN3 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN80S (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)		
81177detect abnormal (eg, expanded) allelesATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles81178expanded) alleles81179expanded) alleles81179expanded) alleles81179expanded) alleles81180evaluation to detect abnormal (eg, expanded) alleles81181evaluation to detect abnormal (eg, expanded) alleles81181expanded) alleles81182analysis, evaluation to detect abnormal (eg, expanded) alleles81181expanded) alleles81182analysis, evaluation to detect abnormal (eg, expanded) alleles81183expanded) alleles81184analysis, evaluation to detect abnormal (eg, expanded) alleles81185analysis, evaluation to detect abnormal (eg, expanded) alleles81184analysis, evaluation to detect abnormal (eg, expanded) alleles81185analysis, evaluation to detect abnormal (eg, expanded) alleles81184(eg, expanded) alleles81185analysis; evaluation to detect abnormal (eg, expanded) alleles81184analysis; evaluation to detect abnormal (eg, expanded) alleles81185analysis; evaluation to detect abnormal (eg, expanded) alleles81184analysis; evaluation to detect abnormal (eg, expanded) alleles81185analysis; involtage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81185analysis; full gene sequence81186analysis; known familial variant6000000000000000000000000000000000000	81176	
ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN7 (ataxin 7) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)		
81178expanded) allelesATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequenceB1185analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequenceB1186analysis; full gene sequenceB1186analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)	81177	
ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)		
81179expanded) allelesATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis,81180evaluation to detect abnormal (eg, expanded) allelesATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg,81181expanded) allelesATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene81182analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal81183(eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal81184analysis; evaluation to detect abnormal (eg, expanded) allelesB1185CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81185analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81185analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81186analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81186analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)	81178	
ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)		
81180evaluation to detect abnormal (eg, expanded) allelesATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) allelesATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles81182analysis, evaluation to detect abnormal (eg, expanded) alleles81183(eg, expanded) alleles81184(eg, expanded) alleles81185(eg, expanded) alleles81184(eg, expanded) alleles81185CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles81185analysis; full gene sequence81186analysis; full gene sequence81186analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)	81179	
ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles81181expanded) allelesATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles81182analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles81183(eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles81184CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence81185CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence81186CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence81186CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)		
81181expanded) allelesATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene81182analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal81183(eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81184analysis; evaluation to detect abnormal (eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81185analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81185analysis; full gene sequence81186analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81186analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)	81180	
ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene81182analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal81183(eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81184analysis; evaluation to detect abnormal (eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81185analysis; full gene sequence81185analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81186analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)		
81182analysis, evaluation to detect abnormal (eg, expanded) allelesATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal81183(eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81184analysis; evaluation to detect abnormal (eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81185analysis; full gene sequence81185analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81186analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)	81181	
ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles81183CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles81184CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence81185analysis; full gene sequence81186CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence81186CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)		
81183(eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81184analysis; evaluation to detect abnormal (eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81185analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81186analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)	81182	
CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81184analysis; evaluation to detect abnormal (eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81185analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81185analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81186analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)		
81184analysis; evaluation to detect abnormal (eg, expanded) allelesCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81185analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81186analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)	81183	
CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81185analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81186analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)		
81185analysis; full gene sequenceCACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81186analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)	81184	
CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene81186analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)		
81186analysis; known familial variantCNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)	81185	
CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2)		
	81186	
81187 gene analysis, evaluation to detect abnormal (eg, expanded) alleles		
	81187	gene analysis, evaluation to detect abnormal (eg, expanded) alleles

	CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; evaluation to detect
81188	abnormal (eg, expanded) alleles
81189	CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; full gene sequence
81190	CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; known familial variant(s)
81191	NTRK1 (neurotrophic receptor tyrosine kinase 1) (eg, solid tumors) translocation analysis
81192	NTRK2 (neurotrophic receptor tyrosine kinase 2) (eg, solid tumors) translocation analysis
81193	NTRK3 (neurotrophic receptor tyrosine kinase 3) (eg, solid tumors) translocation analysis
	NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors)
81194	translocation analysis
81200	Aspa (Aspartoacylase) (Eg, Canavan Disease) Gene Analysis, Common Variants (Eg, E285A, Y231X)
81201	APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; full gene sequence
81202	APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants
81203	APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; duplication/deletion variants
	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X
	chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or
81204	methylation status)
	Bckdhb (Branched-Chain Keto Acid Dehydrogenase E1, Beta Polypeptide) (Eg, Maple Syrup
81205	Urine Disease) Gene Analysis, Common Variants (Eg, R183P, G278S, E422X)
81206	Bcr/Abl1 (T(9;22)) (Eg, Chronic Myelogenous Leukemia) Translocation Analysis; Major
81200	Breakpoint, Qualitative Or Quantitative Bcr/Abl1 (T(9;22)) (Eg, Chronic Myelogenous Leukemia) Translocation Analysis; Minor
81207	Breakpoint, Qualitative Or Quantitative
	Bcr/Abl1 (T(9;22)) (Eg, Chronic Myelogenous Leukemia) Translocation Analysis; Other
81208	Breakpoint, Qualitative Or Quantitative
	Blm (Bloom Syndrome, Recq Helicase-Like) (Eg, Bloom Syndrome) Gene Analysis,
81209	2281Del6Ins7 Variant
	Braf (V-Raf Murine Sarcoma Viral Oncogene Homolog B1) (Eg, Colon Cancer), Gene Analysis,
81210	V600E Variant
01010	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg,
81212	hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants
01015	BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant
81215	BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene
81216	analysis; full sequence analysis
01210	BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene
81217	analysis; known familial variant
01217	CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg, acute myeloid leukemia), gene
81218	analysis, full gene sequence
	CALR (calreticulin) (eg, myeloproliferative disorders), gene analysis, common variants in exon
81219	9
	Cftr (Cystic Fibrosis Transmembrane Conductance Regulator) (Eg, Cystic Fibrosis) Gene
81220	Analysis; Common Variants (Eg, Acmg/Acog Guidelines)

	Cftr (Cystic Fibrosis Transmembrane Conductance Regulator) (Eg, Cystic Fibrosis) Gene
81221	Analysis; Known Familial Variants
01221	Cftr (Cystic Fibrosis Transmembrane Conductance Regulator) (Eg, Cystic Fibrosis) Gene
81222	Analysis; Duplication/Deletion Variants
-	Cftr (Cystic Fibrosis Transmembrane Conductance Regulator) (Eg, Cystic Fibrosis) Gene
81223	Analysis; Full Gene Sequence
	Cftr (Cystic Fibrosis Transmembrane Conductance Regulator) (Eg, Cystic Fibrosis) Gene
81224	Analysis; Intron 8 Poly-T Analysis (Eg, Male Infertility)
	Cyp2C19 (Cytochrome P450, Family 2, Subfamily C, Polypeptide 19) (Eg, Drug Metabolism),
81225	Gene Analysis, Common Variants (Eg, *2, *3, *4, *8, *17)
	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene
	analysis, common variants (eg, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN,
81226	*2XN, *4XN)
	Cyp2C9 (Cytochrome P450, Family 2, Subfamily C, Polypeptide 9) (Eg, Drug Metabolism),
81227	Gene Analysis, Common Variants (Eg, *2, *3, *5, *6)
	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities;
	interrogation of genomic regions for copy number variants, comparative genomic hybridization
81228	[CGH] microarray analysis
	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities;
01000	interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP)
81229	variants, comparative genomic hybridization (CGH) microarray analysis
01000	CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene
81230	analysis, common variant(s) (eg, *2, *22)
81231	CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)
01231	DPYD (dihydropyrimidine dehydrogenase) (eg, 5-fluorouracil/5-FU and capecitabine drug
81232	metabolism), gene analysis, common variant(s) (eg, *2A, *4, *5, *6)
01252	BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common
81233	variants (eg, C481S, C481R, C481F)
01200	DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect
81234	abnormal (expanded) alleles
	EGFR (epidermal growth factor receptor) (eg, non-small cell lung cancer) gene analysis,
81235	common variants (eg, exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q)
	EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic
81236	syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence
	EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell
81237	lymphoma) gene analysis, common variant(s) (eg, codon 646)
	DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of
81239	alleles (eg, expanded size)
	F2 (Prothrombin, Coagulation Factor Ii) (Eg, Hereditary Hypercoagulability) Gene Analysis,
81240	20210G>A Variant
81241	F5 (Coagulation Factor V) (Eg, Hereditary Hypercoagulability) Gene Analysis, Leiden Variant
	Fancc (Fanconi Anemia, Complementation Group C) (Eg, Fanconi Anemia, Type C) Gene
81242	Analysis, Common Variant (Eg, Ivs4+4A>T)
	FMR1 (fragile X messenger ribonucleoprotein 1) (eg, fragile X syndrome, X-linked intellectual
81243	disability [XLID]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles

	FMR1 (fragile X messenger ribonucleoprotein 1) (eg, fragile X syndrome, X-linked intellectual
81244	disability [XLID]) gene analysis; characterization of alleles (eg, expanded size
	Flt3 (Fms-Related Tyrosine Kinase 3) (Eg, Acute Myeloid Leukemia), Gene Analysis, Internal
81245	Tandem Duplication (Itd) Variants (Ie, Exons 14, 15)
	FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; tyrosine
81246	kinase domain (TKD) variants (eg, D835, I836)
01047	G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis;
81247	common variant(s) (eg, A, A-) G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis;
81248	known familial variant(s)
01240	G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis;
81249	full gene sequence
	G6Pc (Glucose-6-Phosphatase, Catalytic Subunit) (Eg, Glycogen Storage Disease, Type 1A,
81250	Von Gierke Disease) Gene Analysis, Common Variants (Eg, R83C, Q347X)
	Gba (Glucosidase, Beta, Acid) (Eg, Gaucher Disease) Gene Analysis, Common Variants (Eg,
81251	N370S, 84Gg, L444P, lvs2+1G>A)
	GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene
81252	analysis; full gene sequence
04050	GJB2 (gap junction protein, beta 2, 26kDa; connexin 26) (eg, nonsyndromic hearing loss) gene
81253	analysis; known familial variants
	GJB6 (gap junction protein, beta 6, 30kDa, connexin 30) (eg, nonsyndromic hearing loss) gene
81254	analysis, common variants (eg, 309kb [del(GJB6-D13S1830)] and 232kb [del(GJB6- D13S1854)])
01254	Hexa (Hexosaminidase A [Alpha Polypeptide]) (Eg, Tay-Sachs Disease) Gene Analysis,
81255	Common Variants (Eg, 1278Instatc, 1421+1G>C, G269S)
	Hfe (Hemochromatosis) (Eg, Hereditary Hemochromatosis) Gene Analysis, Common Variants
81256	(Eg, C282Y, H63D)
	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis
	syndrome, HbH disease), gene analysis; common deletions or variant (eg, Southeast Asian,
81257	Thai, Filipino, Mediterranean, alpha3.7, alpha4.2, alpha20.5, Constant Spring)
01050	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis
81258	syndrome, HbH disease), gene analysis; known familial variant
81259	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; full gene sequence
01259	IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-
	associated protein) (eg, familial dysautonomia) gene analysis, common variants (eg,
81260	2507+6T>C, R696P)
	IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene
	rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg,
81261	polymerase chain reaction)
	IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene
	rearrangement analysis to detect abnormal clonal population(s); direct probe methodology
81262	(eg, Southern blot)
	Igh@ (Immunoglobulin Heavy Chain Locus) (Eg, Leukemia And Lymphoma, B-Cell), Variable
81263	Region Somatic Mutation Analysis
01064	Igk@ (Immunoglobulin Kappa Light Chain Locus) (Eg, Leukemia And Lymphoma, B-Cell), Gene
81264	Rearrangement Analysis, Evaluation To Detect Abnormal Clonal Population(S)

	Comparative analysis using Short Tandem Repeat (STR) markers; patient and comparative
	specimen (eg, pre-transplant recipient and donor germline testing, post-transplant non-
	hematopoietic recipient germline [eg, buccal swab or other germline tissue sample] and donor
81265	testing, twin zygosity testing, or maternal cell contamination of fetal cells)
	Comparative analysis using Short Tandem Repeat (STR) markers; each additional specimen
	(eg, additional cord blood donor, additional fetal samples from different cultures, or additional
	zygosity in multiple birth pregnancies) (List separately in addition to code for primary
81266	procedure)
	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis
81269	syndrome, HbH disease), gene analysis; duplication/deletion variants
	Jak2 (Janus Kinase 2) (Eg, Myeloproliferative Disorder) Gene Analysis, P.Val617Phe (V617F)
81270	Variant
	HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg,
81271	expanded) alleles
	KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, gastrointestinal
	stromal tumor [GIST], acute myeloid leukemia, melanoma), gene analysis, targeted sequence
81272	analysis (eg, exons 8, 11, 13, 17, 18)
	KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, mastocytosis), gene
81273	analysis, D816 variant(s)
012/0	HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg,
81274	expanded size)
01274	Kras (V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene) (Eg, Carcinoma) Gene Analysis, Variants
81275	In Codons 12 And 13
01270	KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional
81276	variant(s) (eg, codon 61, codon 146)
012/0	Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions
81277	for copy number and loss-of-heterozygosity variants for chromosomal abnormalities
012/7	IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint
81278	region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative
012/0	JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons
81279	12 and 13)
81283	IFNL3 (interferon, lambda 3) (eg, drug response), gene analysis, rs12979860 variant
01203	
81284	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles
01204	
01005	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded
81285	size)
81286	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequence
04007	MGMT (O-6-methylguanine-DNA methyltransferase) (eg, glioblastoma multiforme) promoter
81287	methylation analysis
	MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis
81288	colorectal cancer, Lynch syndrome) gene analysis; promoter methylation analysis
81289	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known familial variant(s)
	Mcoln1 (Mucolipin 1) (Eg, Mucolipidosis, Type Iv) Gene Analysis, Common Variants (Eg, Ivs3-
81290	2A>G, Del6.4Kb)
	Mthfr (5,10-Methylenetetrahydrofolate Reductase) (Eg, Hereditary Hypercoagulability) Gene
81291	Analysis, Common Variants (Eg, 677T, 1298C)

	Mlh1 (Mutl Homolog 1, Colon Cancer, Nonpolyposis Type 2) (Eg, Hereditary Non-Polyposis
81292	Colorectal Cancer, Lynch Syndrome) Gene Analysis; Full Sequence Analysis
01252	Mlh1 (Mutl Homolog 1, Colon Cancer, Nonpolyposis Type 2) (Eg, Hereditary Non-Polyposis
81293	Colorectal Cancer, Lynch Syndrome) Gene Analysis; Known Familial Variants
01233	Mlh1 (Mutl Homolog 1, Colon Cancer, Nonpolyposis Type 2) (Eg, Hereditary Non-Polyposis
81294	Colorectal Cancer, Lynch Syndrome) Gene Analysis; Duplication/Deletion Variants
01234	Msh2 (Muts Homolog 2, Colon Cancer, Nonpolyposis Type 1) (Eg, Hereditary Non-Polyposis
81295	Colorectal Cancer, Lynch Syndrome) Gene Analysis; Full Sequence Analysis
01255	Msh2 (Muts Homolog 2, Colon Cancer, Nonpolyposis Type 1) (Eg, Hereditary Non-Polyposis
81296	Colorectal Cancer, Lynch Syndrome) Gene Analysis; Known Familial Variants
01200	Msh2 (Muts Homolog 2, Colon Cancer, Nonpolyposis Type 1) (Eg, Hereditary Non-Polyposis
81297	Colorectal Cancer, Lynch Syndrome) Gene Analysis; Duplication/Deletion Variants
	Msh6 (Muts Homolog 6 [E. Coli]) (Eg, Hereditary Non-Polyposis Colorectal Cancer, Lynch
81298	Syndrome) Gene Analysis; Full Sequence Analysis
	Msh6 (Muts Homolog 6 [E. Coli]) (Eg, Hereditary Non-Polyposis Colorectal Cancer, Lynch
81299	Syndrome) Gene Analysis; Known Familial Variants
	Msh6 (Muts Homolog 6 [E. Coli]) (Eg, Hereditary Non-Polyposis Colorectal Cancer, Lynch
81300	Syndrome) Gene Analysis; Duplication/Deletion Variants
	Microsatellite instability analysis (eg, hereditary non-polyposis colorectal cancer, Lynch
	syndrome) of markers for mismatch repair deficiency (eg, BAT25, BAT26), includes
81301	comparison of neoplastic and normal tissue, if performed
	Mecp2 (Methyl Cpg Binding Protein 2) (Eg, Rett Syndrome) Gene Analysis; Full Sequence
81302	Analysis
	Mecp2 (Methyl Cpg Binding Protein 2) (Eg, Rett Syndrome) Gene Analysis; Known Familial
81303	Variant
	Mecp2 (Methyl Cpg Binding Protein 2) (Eg, Rett Syndrome) Gene Analysis;
81304	Duplication/Deletion Variants
	MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia,
81305	lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant
	NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2,
81306	*3, *4, *5, *6)
01007	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; full
81307	gene sequence
01200	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis;
81308	known familial variant PIK3CA (phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha) (eg,
81309	
	colorectal and breast cancer) gene analysis, targeted sequence analysis (eg, exons 7, 9, 20)
81310	Npm1 (Nucleophosmin) (Eg, Acute Myeloid Leukemia) Gene Analysis, Exon 12 Variants NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog) (eg, colorectal carcinoma), gene
81311	analysis, variants in exon 2 (eg, codons 12 and 13) and exon 3 (eg, codon 61)
01311	PABPN1 (poly[A] binding protein nuclear 1) (eg, oculopharyngeal muscular dystrophy) gene
81312	analysis, evaluation to detect abnormal (eg, expanded) alleles
01012	PCA3/KLK3 (prostate cancer antigen 3 [non-protein coding]/kallikrein-related peptidase 3
01010	- oververse (prostate cancel antigen o fron-broten coung) variaten-retaten behringse o
01.51.5	[prostate specific antigen]) ratio (eg. prostate cancer)
81313	[prostate specific antigen]) ratio (eg, prostate cancer) PDGERA (platelet-derived growth factor receptor, alpha polypeptide) (eg, gastrointestinal
81313	[prostate specific antigen]) ratio (eg, prostate cancer) PDGFRA (platelet-derived growth factor receptor, alpha polypeptide) (eg, gastrointestinal stromal tumor [GIST]), gene analysis, targeted sequence analysis (eg, exons 12, 18)

	PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg,
	promyelocytic leukemia) translocation analysis; common breakpoints (eg, intron 3 and intron
01015	
81315	6), qualitative or quantitative
	PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg,
01010	promyelocytic leukemia) translocation analysis; single breakpoint (eg, intron 3, intron 6 or
81316	exon 6), qualitative or quantitative
	Pms2 (Postmeiotic Segregation Increased 2 [S. Cerevisiae]) (Eg, Hereditary Non-Polyposis
81317	Colorectal Cancer, Lynch Syndrome) Gene Analysis; Full Sequence Analysis
	Pms2 (Postmeiotic Segregation Increased 2 [S. Cerevisiae]) (Eg, Hereditary Non-Polyposis
81318	Colorectal Cancer, Lynch Syndrome) Gene Analysis; Known Familial Variants
	Pms2 (Postmeiotic Segregation Increased 2 [S. Cerevisiae]) (Eg, Hereditary Non-Polyposis
81319	Colorectal Cancer, Lynch Syndrome) Gene Analysis; Duplication/Deletion Variants
	PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis,
81320	common variants (eg, R665W, S707F, L845F)
	PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor
81321	syndrome) gene analysis; full sequence analysis
	PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor
81322	syndrome) gene analysis; known familial variant
	PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor
81323	syndrome) gene analysis; duplication/deletion variant
	PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with
81324	liability to pressure palsies) gene analysis; duplication/deletion analysis
	PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with
81325	liability to pressure palsies) gene analysis; full sequence analysis
01020	PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with
81326	liability to pressure palsies) gene analysis; known familial variant
81327	SEPT9 (Septin9) (eg, colorectal cancer) promoter methylation analysis
01027	SLCO1B1 (solute carrier organic anion transporter family, member 1B1) (eg, adverse drug
81328	reaction), gene analysis, common variant(s) (eg, *5)
01320	
	SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis;
01220	dosage/deletion analysis (eg, carrier testing), includes SMN2 (survival of motor neuron 2,
81329	centromeric) analysis, if performed
01000	Smpd1(Sphingomyelin Phosphodiesterase 1, Acid Lysosomal) (Eg, Niemann-Pick Disease,
81330	Type A) Gene Analysis, Common Variants (Eg, R496L, L302P, Fsp330)
01001	Snrpn/Ube3A (Small Nuclear Ribonucleoprotein Polypeptide N And Ubiquitin Protein Ligase
81331	E3A) (Eg, Prader-Willi Syndrome And/Or Angelman Syndrome), Methylation Analysis
01000	SERPINA1 (serpin peptidase inhibitor, clade A, alpha-1 antiproteinase, antitrypsin, member 1)
81332	(eg, alpha-1-antitrypsin deficiency), gene analysis, common variants (eg, *S and *Z)
	TGFBI (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis,
81333	common variants (eg, R124H, R124C, R124L, R555W, R555Q)
	RUNX1 (runt related transcription factor 1) (eg, acute myeloid leukemia, familial platelet
	disorder with associated myeloid malignancy), gene analysis, targeted sequence analysis (eg,
81334	exons 3-8)
	TPMT (thiopurine S-methyltransferase) (eg, drug metabolism), gene analysis, common variants
81335	(eg, *2, *3)
	SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full
81336	gene sequence

81337	SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)
01007	MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene
81338	analysis; common variants (eg, W515A, W515K, W515L, W515R)
	MPL (MPL proto-oncogene, thrombopoietin receptor) (eg, myeloproliferative disorder) gene
81339	analysis; sequence analysis, exon 10
	TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement
	analysis to detect abnormal clonal population(s); using amplification methodology (eg,
81340	polymerase chain reaction)
	TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement
	analysis to detect abnormal clonal population(s); using direct probe methodology (eg,
81341	Southern blot)
04040	Trg@ (T Cell Antigen Receptor, Gamma) (Eg, Leukemia And Lymphoma), Gene Rearrangement
81342	Analysis, Evaluation To Detect Abnormal Clonal Population(S)
01040	PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene
81343	analysis, evaluation to detect abnormal (eg, expanded) alleles TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect
81344	abnormal (eg, expanded) alleles
01044	TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme)
81345	gene analysis, targeted sequence analysis (eg, promoter region)
	TYMS (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drug metabolism), gene analysis,
81346	common variant(s) (eg, tandem repeat variant)
	SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid
81347	leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L)
	SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute
81348	myeloid leukemia) gene analysis, common variants (eg, P95H, P95L)
	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities;
	interrogation of genomic regions for copy number and loss-of-heterozygosity variants, low-
81349	pass sequencing analysis
	UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (eg, drug metabolism,
01250	hereditary unconjugated hyperbilirubinemia [Gilbert syndrome]) gene analysis, common
81350	variants (eg, *28, *36, *37)
81351	TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; full gene sequence TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; targeted sequence analysis
81352	(eg, 4 oncology)
81353	TP53 (tumor protein 53) (eg, Li-Fraumeni syndrome) gene analysis; known familial variant
01000	Vkorc1 (Vitamin K Epoxide Reductase Complex, Subunit 1) (Eg, Warfarin Metabolism), Gene
81355	Analysis, Common Variants (Eg, -1639/3673)
	U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid
81357	leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P)
	ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg,
	myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg,
81360	E65fs, E122fs, R448fs)
	HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia,
81361	hemoglobinopathy); common variant(s) (eg, HbS, HbC, HbE)
	HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia,
81362	hemoglobinopathy); known familial variant(s)

3, -C, And -Drb1
Hla-A, -B, And -
, Hla-A, -B, Or -
Allele Group
ne by DNA
er Danlos
nel, must
3A1, MYH11,
ar Danlag
er Danlos anel, must
anet, must
, cystic fibrosis,
lisease),
, including
-
QT syndrome,
nalysis panel,
CNE1, KCNE2,
QT syndrome,
gene analysis
ence analysis ence analysis,
de for primary
actor prinary
aluation of

	Drug metabolism (og "pharmagaganamiga) genomia seguenas analysis nanol, must insluda
	Drug metabolism (eg, pharmacogenomics) genomic sequence analysis panel, must include testing of at least 6 genes, including CYP2C19, CYP2D6, and CYP2D6 duplication/deletion
81418	analysis
01410	Epilepsy genomic sequence analysis panel, must include analyses for ALDH7A1, CACNA1A,
	CDKL5, CHD2, GABRG2, GRIN2A, KCNQ2, MECP2, PCDH19, POLG, PRRT2, SCN1A, SCN1B,
81419	
	SCN2A, SCN8A, SLC2A1, SLC9A6, STXBP1, SYNGAP1, TCF4, TPP1, TSC1, TSC2, and ZEB2
81425	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis
	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence
01406	analysis, each comparator genome (eg, parents, siblings) (List separately in addition to code
81426	for primary procedure) Genome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of
81427	previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome)
01427	Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); genomic
	sequence analysis panel, must include sequencing of at least 60 genes, including CDH23,
	CLRN1, GJB2, GPR98, MTRNR1, MYO7A, MYO15A, PCDH15, OTOF, SLC26A4, TMC1,
81430	TMPRSS3, USH1C, USH1G, USH2A, and WFS1
01400	Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome);
	duplication/deletion analysis panel, must include copy number analyses for STRC and DFNB1
81431	deletions in GJB2 and GJB6 genes
	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian
	cancer, hereditary endometrial cancer, hereditary pancreatic cancer, hereditary prostate
	cancer), genomic sequence analysis panel, 5 or more genes, interrogation for sequence
81432	variants and copy number variants
	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian
	cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include
81433	analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11
	Hereditary retinal disorders (eg, retinitis pigmentosa, Leber congenital amaurosis, cone-rod
	dystrophy), genomic sequence analysis panel, must include sequencing of at least 15 genes,
	including ABCA4, CNGA1, CRB1, EYS, PDE6A, PDE6B, PRPF31, PRPH2, RDH12, RHO, RP1,
81434	RP2, RPE65, RPGR, and USH2A
	Hereditary colon cancer-related disorders (eg, Lynch syndrome, PTEN hamartoma syndrome,
01405	Cowden syndrome, familial adenomatosis polyposis), genomic sequence analysis panel, 5 or
81435	more genes, interrogation for sequence variants and copy number variants
	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden
01400	syndrome, familial adenomatosis polyposis); duplication/deletion analysis panel, must
81436	include analysis of at least 5 genes, including MLH1, MSH2, EPCAM, SMAD4, and STK11
	Hereditary neuroendocrine tumor-related disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma), genomic sequence
81437	analysis panel, 5 or more genes, interrogation for sequence variants and copy number variants
01437	Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid
	carcinoma, malignant pheochromocytoma or paraganglioma); duplication/deletion analysis
81438	panel, must include analyses for SDHB, SDHC, SDHD, and VHL
01400	Hereditary cardiomyopathy (eg, hypertrophic cardiomyopathy, dilated cardiomyopathy,
	arrhythmogenic right ventricular cardiomyopathy), genomic sequence analysis panel, must
	include sequencing of at least 5 cardiomyopathy-related genes (eg, DSG2, MYBPC3, MYH7,
81439	PKP2, TTN)
	• •

	Nuclear encoded mitochondrial genes (eg, neurologic or myopathic phenotypes), genomic
	sequence panel, must include analysis of at least 100 genes, including BCS1L, C10orf2,
01440	COQ2, COX10, DGUOK, MPV17, OPA1, PDSS2, POLG, POLG2, RRM2B, SCO1, SCO2,
81440	SLC25A4, SUCLA2, SUCLG1, TAZ, TK2, and TYMP
	Inherited bone marrow failure syndromes (IBMFS) (eg, Fanconi anemia, dyskeratosis
	congenita, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, GATA2 deficiency syndrome, congenital amegakaryocytic thrombocytopenia) sequence analysis panel, must
	include sequencing of at least 30 genes, including BRCA2, BRIP1, DKC1, FANCA, FANCB,
	FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, GATA1, GATA2, MPL, NHP2,
	NOP10, PALB2, RAD51C, RPL11, RPL35A, RPL5, RPS10, RPS19, RPS24, RPS26, RPS7, SBDS,
81441	TERT, and TINF2
	Noonan spectrum disorders (eg, Noonan syndrome, cardio-facio-cutaneous syndrome,
	Costello syndrome, LEOPARD syndrome, Noonan-like syndrome), genomic sequence analysis
	panel, must include sequencing of at least 12 genes, including BRAF, CBL, HRAS, KRAS,
81442	MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SHOC2, and SOS1
	Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-
	associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C,
	mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies,
	phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing
	of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7,
81443	FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)
	Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for
81445	sequence variants and copy number variants or rearrangements, if performed; DNA analysis or combined DNA and RNA analysis
01445	Hereditary peripheral neuropathies (eg, Charcot-Marie-Tooth, spastic paraplegia), genomic
	sequence analysis panel, must include sequencing of at least 5 peripheral neuropathy-related
81448	genes (eg, BSCL2, GJB1, MFN2, MPZ, REEP1, SPAST, SPG11, SPTLC1)
	Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for
81449	sequence variants and copy number variants or rearrangements, if performed; RNA analysis
	Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes,
	interrogation for sequence variants, and copy number variants or rearrangements, or isoform
	expression or mRNA expression levels, if performed; DNA analysis or combined DNA and RNA
81450	analysis
	Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes,
01451	interrogation for sequence variants, and copy number variants or rearrangements, or isoform
81451	expression or mRNA expression levels, if performed; RNA analysis Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence
	analysis panel, interrogation for sequence variants and copy number variants or
	rearrangements, or isoform expression or mRNA expression levels, if performed; DNA analysis
81455	or combined DNA and RNA analysis
	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence
	analysis panel, interrogation for sequence variants and copy number variants or
81456	rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis
	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants;
81457	DNA analysis, microsatellite instability
	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants;
81458	DNA analysis, copy number variants and microsatellite instability

01450	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants;
81459	DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite
	Whole mitochondrial genome (eg, Leigh syndrome, mitochondrial encephalomyopathy, lactic
	acidosis, and stroke-like episodes [MELAS], myoclonic epilepsy with ragged-red fibers
	[MERFF], neuropathy, ataxia, and retinitis pigmentosa [NARP], Leber hereditary optic
	neuropathy [LHON]), genomic sequence, must include sequence analysis of entire
81460	mitochondrial genome with heteroplasmy detection
	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma),
	interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy
81462	number variants and rearrangements
	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma),
	interrogation for sequence variants; DNA analysis, copy number variants, and microsatellite
81463	instability
	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma),
	interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy
81464	number variants, microsatellite instability, tumor mutation burden, and rearrangements
	Whole mitochondrial genome large deletion analysis panel (eg, Kearns-Sayre syndrome,
	chronic progressive external ophthalmoplegia), including heteroplasmy detection, if
81465	performed
	X-linked intellectual disability (XLID) (eg, syndromic and non-syndromic XLID); genomic
	sequence analysis panel, must include sequencing of at least 60 genes, including ARX, ATRX,
	CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL,
81470	RPS6KA3, and SLC16A2
	X-linked intellectual disability (XLID) (eg, syndromic and non-syndromic XLID);
	duplication/deletion gene analysis, must include analysis of at least 60 genes, including ARX,
	ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL,
81471	RPS6KA3, and SLC16A2
81479	Unlisted molecular pathology procedure
	Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing
81490	serum, prognostic algorithm reported as a disease activity score
	Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes,
81493	utilizing whole peripheral blood, algorithm reported as a risk score
	Oncology (tissue of origin), microarray gene expression profiling of > 2000 genes, utilizing
81504	formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores
	Endocrinology, Biochemical Assays Of Seven Analytes Utilizing Serum Or Plasma, Algorithm
81506	Reporting A Risk Score
	Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal
	peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays,
	utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-
81517	related clinical events within 5 years
	Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7
	content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms
	reported as percentage risk for metastatic recurrence and likelihood of benefit from extended
81518	endocrine therapy
	Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing
81519	formalin-fixed paraffin embedded tissue, algorithm reported as recurrence score
01010	

	Oncology (breast), mRNA gene expression profiling by hybrid capture of 58 genes (50 content
	and 8 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as
81520	a recurrence risk score
	Oncology (breast), mRNA, microarray gene expression profiling of 70 content genes and 465
	housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue,
81521	algorithm reported as index related to risk of distant metastasis
	Oncology (breast), mRNA, gene expression profiling by RT-PCR of 12 genes (8 content and 4
	housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as
81522	recurrence risk score
	Oncology (breast), mRNA, next-generation sequencing gene expression profiling of 70 content
	genes and 31 housekeeping genes, utilizing formalin-fixed paraffin-embedded tissue,
81523	algorithm reported as index related to risk to distant metastasis
	Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content
	and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as
81525	a recurrence score
	Oncology (cutaneous melanoma), mRNA, gene expression profiling by real-time RT-PCR of 31
	genes (28 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded tissue,
81529	algorithm reported as recurrence risk, including likelihood of sentinel lymph node metastasis
	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain
	and morphology, predictive algorithm reported as a drug response score; first single drug or
81535	drug combination
	Oncology (lung), mass spectrometric 8-protein signature, including amyloid A, utilizing serum,
81538	prognostic and predictive algorithm reported as good versus poor overall survival
	Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of
	92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and
	subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability
81540	of a predicted main cancer type and subtype
	Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31
	content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm
81541	reported as a disease-specific mortality risk score
	Oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing
81542	formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score
	Oncology (thyroid), gene expression analysis of 142 genes, utilizing fine needle aspirate,
81545	algorithm reported as a categorical result (eg, benign or suspicious)
	Oncology (thyroid), mRNA, gene expression analysis of 10,196 genes, utilizing fine needle
81546	aspirate, algorithm reported as a categorical result (eg, benign or suspicious)
	Oncology (prostate), promoter methylation profiling by real-time PCR of 3 genes (GSTP1, APC,
	RASSF1), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a likelihood
81551	of prostate cancer detection on repeat biopsy
	Oncology (uveal melanoma), mRNA, gene expression profiling by real-time RT-PCR of 15 genes
	(12 content and 3 housekeeping), utilizing fine needle aspirate or formalin-fixed paraffin-
81552	embedded tissue, algorithm reported as risk of metastasis
	Pulmonary disease (idiopathic pulmonary fibrosis [IPF]), mRNA, gene expression analysis of
	190 genes, utilizing transbronchial biopsies, diagnostic algorithm reported as categorical
81554	result (eg, positive or negative for high probability of usual interstitial pneumonia [UIP])
	embedded tissue, algorithm reported as risk of metastasis Pulmonary disease (idiopathic pulmonary fibrosis [IPF]), mRNA, gene expression analysis of 190 genes, utilizing transbronchial biopsies, diagnostic algorithm reported as categorical

	Transplantation modicing (allograft rejection indicates liver and small howel), massivement of
	Transplantation medicine (allograft rejection, pediatric liver and small bowel), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral
81560	blood, algorithm reported as a rejection risk score
01300	Cardiology (heart transplant), mRNA, gene expression profiling by real-time quantitative PCR
	of 20 genes (11 content and 9 housekeeping), utilizing subfraction of peripheral blood,
81595	algorithm reported as a rejection risk score
	Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-
	macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum,
81596	prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver
81599	Unlisted Multianalyte Assay With Algorithmic Analysis
82787	Gammaglobulin (immunoglobulin); immunoglobulin subclasses (eg, lgG1, 2, 3, or 4), each
	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen;
83516	qualitative or semiquantitative, multiple step method
	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen;
83520	quantitative, not otherwise specified
86001	Allergen Specific Igg Quantitative/Semiquantitative, Ea Allergen
86343	Leukocyte Histamine Release Test (Lhr)
	Cellular function assay involving stimulation (eg, mitogen or antigen) and detection of
86352	biomarker (eg, ATP)
86357	Natural killer (NK) cells, total count
88356	Morphometric Analysis; Nerve
89250	Culture, Oocyte(S)
89251	Culture & Fertilization, Oocyte(S); W/Co-Culture
89253	Assisted Embryo Hatching, Microtechniques (Any Method)
89254	Oocyte Identification, Follicular Fluid
89255	Preparation, Embryo, Transfer (Any Method)
89268	Insemination of Oocytes
89272	Extended Culture of Oocyte(s)/Embryo(s), 4-7 Days
89329	Sperm Evaluation; Hamster Penetration Test
89330	Sperm Evaluation; Cervical Mucus Penetration Test, W/Wo Spinnbarkeit Test
89344	Storage, (Per Year); Reproductive Tissue, Testicular/Ovarian
89346	Storage, (Per Year); Oocyte
89354	Thawing of Cryopreserved; Reproductive Tissue, Testicular/Ovarian
89356	Thawing of Cryopreserved; Oocytes, Each Aliquot
90281	Immune Globulin (Ig), Human, Im Use
90283	Immune Globulin (Igiv), Human, Iv Use
90284	Immune globulin (SCIg), human, for use in subcutaneous infusions, 100mg, each
	Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg,
90378	each
	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for
90380	intramuscular use
00201	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use
90381	Intramuscular use Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including
90867	cortical mapping, motor threshold determination, delivery and management
30007	Control mapping, motor unconota determination, detivery and indiagement

	The range utic repetitive transcrapial magnetic stimulation (TMS) treatment: subsequent delivery
90868	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session
90869	Therapeutic Repetitive Transcranial Magnetic Stimulation (Tms) Treatment; Subsequent Motor Threshold Re-Determination With Delivery And Management
90875	Individual psychophysiological therapy incorporating biofeedback training by any modality (face-to-face with the patient), with psychotherapy (eg, insight oriented, behavior modifying or supportive psychotherapy); 30 minutes
90876	Individual psychophysiological therapy incorporating biofeedback training by any modality (face-to-face with the patient), with psychotherapy (eg, insight oriented, behavior modifying or supportive psychotherapy); 45 minutes
90901	Biofeedback Training, Any Modality
90912	Biofeedback training, perineal muscles, anorectal or urethral sphincter, including EMG and/or manometry, when performed; initial 15 minutes of one-on-one physician or other qualified health care professional contact with the patient
90913	Biofeedback training, perineal muscles, anorectal or urethral sphincter, including EMG and/or manometry, when performed; each additional 15 minutes of one-on-one physician or other qualified health care professional contact with the patient (List separately in addition to code for primary procedure)
91112	Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule, with interpretation and report
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual
92508	Treatment of speech, language, voice, communication, and/or auditory processing disorder; group, 2 or more individuals
92521	Evaluation of speech fluency (eg, stuttering, cluttering)
92522	Evaluation of speech sound production (eg, articulation, phonological process, apraxia, dysarthria)
92523	Evaluation of speech sound production (eg, articulation, phonological process, apraxia, dysarthria); with evaluation of language comprehension and expression (eg, receptive and expressive language)
92524	Behavioral and qualitative analysis of voice and resonance
92526	Treatment, Swallowing Dysfunction &/Or Oral Function, Feeding
92605	Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; first hour
92606	Therapeutic Service(S), Use Non-Speech Generatiing Device, W/Programming & Modification
92607	Eval, Prescription, Speech-Generating Augmentative & Alternative Communication Device; 1st Hr
92608	Eval, Prescrip, Speech-Generating Augmentative & Alternative Communication Device; Ea Add'l 30 Min
92609	Therapeutic Services, Non-Speech Generative Device Use, W/Programming & Modification
92610	Eval, Oral & Pharyngeal Swallow Function
92611	Motion Fluoroscopic Eval, Swallow Function, Cine/Video Record
	Evaluation for prescription of non-speech-generating augmentative and alternative
92618	communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure)

	Evolution of qualitary function for quartically implemented doubles (a) condidance or postor pratice
92626	Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative
92020	status of a surgically implanted device(s); first hour
	Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); each additional 15 minutes (List separately in
92627	
	addition to code for primary procedure)
92630	Auditory rehabilitation; pre-lingual hearing loss
92633	Auditory rehabilitation; post-lingual hearing loss
92920	Percutaneous transluminal coronary angioplasty; single major coronary artery or branch
	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed;
92924	single major coronary artery or branch
	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty
92928	when performed; single major coronary artery or branch
00000	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary
92933	angioplasty when performed; single major coronary artery or branch
	Percutaneous transluminal revascularization of or through coronary artery bypass graft
02027	(internal mammary, free arterial, venous), any combination of intracoronary stent,
92937	atherectomy and angioplasty, including distal protection when performed; single vessel Percutaneous transluminal revascularization of chronic total occlusion, coronary artery,
	coronary artery branch, or coronary artery bypass graft, any combination of intracoronary
92943	stent, atherectomy and angioplasty; single vessel
92943	Percutaneous transluminal coronary lithotripsy (List separately in addition to code for primary
92972	procedure)
52572	Therapy activation of implanted phrenic nerve stimulator system, including all interrogation
93150	and programming
00100	Interrogation and programming (minimum one parameter) of implanted phrenic nerve
93151	stimulator system
	Interrogation and programming of implanted phrenic nerve stimulator system during
93152	polysomnography
93153	Interrogation without programming of implanted phrenic nerve stimulator system
	External mobile cardiovascular telemetry with electrocardiographic recording, concurrent
93228	computerized real time data analysis and greater than 24 hours of accessible ECG data
	External mobile cardiovascular telemetry with electrocardiographic recording, concurrent
93229	computerized real time data analysis and greater than 24 hours of accessible ECG data
	Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including
93264	at least weekly downloads of pulmonary artery pressure recordings, interpretation
93303	Transthoracic Echocardiography, Congenital Cardiac Anomalies; Complete
93304	Transthoracic Echocardiography, Congenital Cardiac Anomalies; Follow-Up/Limited Study
	Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode
	recording, when performed, complete, with spectral Doppler echocardiography, and with color
93306	flow Doppler echocardiography
	Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode
93307	recording, when performed, complete, without spectral or color Doppler echocardiography
93308	Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode
	recording, when performed, follow-up or limited study
00040	Echocardiography, transesophageal, real-time with image documentation (2D) (with or without
93312	M-mode recording); including probe placement, image acquisition, interpretation and report

	Echopordiography transpoonhogoal real time with image decumentation (OD) (with equilibrium
93313	Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); placement of transesophageal probe only
93314	Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); image acquisition, interpretation and report only
	Echocardiography, Transesophageal, Congenital Anomalies; W/Probe, Image, Intepretation &
93315	Report
93316	Echocardiography, Transesophageal, Congenital Anomalies; Transesophageal Probe Placement Only
93317	Echocardiography, Transesophageal, Congenital Anomalies; Image, Interpretation & Report
	Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode
	recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle
93350	exercise and/or pharmacologically induced stress, with interpretation and report;
	Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode
	recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle
	exercise and/or pharmacologically induced stress, with interpretation and report; including
00054	performance of continuous electrocardiographic monitoring, with supervision by a physician or
93351	other qualified health care professional
93454	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation;
33434	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural
	injection(s) for coronary angiography, imaging supervision and interpretation; with catheter
	placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including
93455	intraprocedural injection(s) for bypass graft angiography
	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural
	injection(s) for coronary angiography, imaging supervision and interpretation; with right heart
93456	catheterization
	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural
	injection(s) for coronary angiography, imaging supervision and interpretation; with catheter
00457	placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including
93457	intraprocedural injection(s) for bypass graft angiography and right heart catheterization
	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural
	injection(s) for coronary angiography, imaging supervision and interpretation; with left heart catheterization including intraprocedural injection(s) for left ventriculography, when
93458	performed
00400	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural
	injection(s) for coronary angiography, imaging supervision and interpretation; with left heart
	catheterization including intraprocedural injection(s) for left ventriculography, when
	performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous
93459	grafts) with bypass graft angiography
	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural
	injection(s) for coronary angiography, imaging supervision and interpretation; with right and
	left heart catheterization including intraprocedural injection(s) for left ventriculography, when
93460	performed
	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural
02404	injection(s) for coronary angiography, imaging supervision and interpretation; with right and
93461	left heart catheterization including intraprocedural injection(s) for left ventriculography, when

	performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous
	grafts) with bypass graft angiography
93580	Perc Transcatheter Closure, Congenital Interatrial Communication W/Implant
93600	Bundle Of His Recording
93602	Intra-Atrial Recording
93603	Right Ventricular Recording
93609	Intraventricular &/Or Intra-Atrial Mapping, Tachycardia Site(S) W/Catheter Manipulation
93613	Intracardiac Electrophysiologic 3-Dimensional Mapping
33013	Electrophys Eval, W/Right Atrial/Ventricular Pace/Recording, Insertion Cath, W/O Arrhyth
93619	Induction
93620	Electrophys Eval, Insert Cath, W/Arrhyth Induction; W/Right Atrial/Ventricular Pace/Record
93621	Electrophys Eval, Insert Cath, W/Arrhyth Induction; W/Lt Atrial Pace/Record
93622	Electrophys Eval, Insert Cath, W/Arrythmia Induction; W/Lt Vent Pace/Record
93624	Electrophys, Follow-Up Study W/Pacing & Recording W/Arrhyth Induction
93640	Electrophys Eval, Single/Dual Pacing Cardio/Defib Leads, Initial Implant/Replace
55040	Electrophys Eval, Single/Dual Pacing Cardio/Defib Leads, Initial Implant/Replace; W/Pulse
93641	Generator
93650	Intracardiac Catheter Ablation, Atrioventricular Node Function/Conduction
	Comprehensive electrophysiologic evaluation with insertion and repositioning of multiple
	electrode catheters, induction or attempted induction of an arrhythmia with right atrial pacing
	and recording and catheter ablation of arrhythmogenic focus, including intracardiac
	electrophysiologic 3-dimensional mapping, right ventricular pacing and recording, left atrial
	pacing and recording from coronary sinus or left atrium, and His bundle recording, when
	performed; with treatment of supraventricular tachycardia by ablation of fast or slow
	atrioventricular pathway, accessory atrioventricular connection, cavo-tricuspid isthmus or
93653	other single atrial focus or source of atrial re-entry
	Comprehensive electrophysiologic evaluation with insertion and repositioning of multiple
	electrode catheters, induction or attempted induction of an arrhythmia with right atrial pacing
	and recording and catheter ablation of arrhythmogenic focus, including intracardiac
	electrophysiologic 3-dimensional mapping, right ventricular pacing and recording, left atrial pacing and recording from coronary sinus or left atrium, and His bundle recording, when
	performed; with treatment of ventricular tachycardia or focus of ventricular ectopy including
93654	left ventricular pacing and recording, when performed
00004	Intracardiac catheter ablation of a discrete mechanism of arrhythmia which is distinct from the
	primary ablated mechanism, including repeat diagnostic maneuvers, to treat a spontaneous or
93655	induced arrhythmia (List separately in addition to code for primary procedure)
	Comprehensive electrophysiologic evaluation with transseptal catheterizations, insertion and
	repositioning of multiple electrode catheters, induction or attempted induction of an
	arrhythmia including left or right atrial pacing/recording, and intracardiac catheter ablation of
	atrial fibrillation by pulmonary vein isolation, including intracardiac electrophysiologic 3-
	dimensional mapping, intracardiac echocardiography with imaging supervision and
93656	interpretation, right ventricular pacing/recording, and His bundle recording, when performed
	Additional linear or focal intracardiac catheter ablation of the left or right atrium for treatment
00057	of atrial fibrillation remaining after completion of pulmonary vein isolation (List separately in
93657	addition to code for primary procedure)
93702	Bioimpedance spectroscopy (BIS), extracellular fluid analysis for lymphedema assessment(s)

	Initial act up and programming by a physician or other gualified health acro professional of
	Initial set-up and programming by a physician or other qualified health care professional of
	wearable cardioverter-defibrillator includes initial programming of system, establishing
02745	baseline electronic ECG, transmission of data to data repository, patient instruction in wearing
93745	system and patient reporting of problems or events
93880	Duplex Scan, Extracranial Arteries; Complete Bilat Study
93882	Duplex Scan, Extracranial Arteries; Unilat/Limited Study
93922	Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior
	Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or
93923	more levels (eg, for lower extremity: ankle/brachial indices at distal posterior
	Noninvasive physiologic studies of lower extremity arteries, at rest and following treadmill
	stress testing, (ie, bidirectional Doppler waveform or volume plethysmography recording and
	analysis at rest with ankle/brachial indices immediately after and at timed intervals following
	performance of a standardized protocol on a motorized treadmill plus recording of time of
	onset of claudication or other symptoms, maximal walking time, and time to recovery)
93924	complete bilateral study
93925	Duplex Scan, Lower Extremity Arteries/Arterial Bypass Grafts; Complete Bilat Study
93926	Duplex Scan, Lower Extremity Arteries/Arterial Bypass Grafts; Unilat/Limited Study
93930	Duplex Scan, Upper Extremity Arteries/Arterial Bypass Grafts; Complete Bilat Study
93931	Duplex Scan, Upper Extremity Arteries/Arterial Bypass Grafts; Unilat/Limited Study
93978	Duplex Scan, Aorta, Inferior Vena Cava, Iliac Vasculature/Bypass Grafts; Complete Study
93979	Duplex Scan, Aorta, Inferior Vena Cava, Iliac Vasculature/Bypass Grafts; Unilat/Limited
94667	Chest Wall Manipulation, Facilitate Lung Function; Initial Demo &/Or Eval
94668	Chest Wall Manipulation, Facilitate Lung Function; Subsequent
	Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of
95782	sleep, attended by a technologist
	Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of
95783	sleep, with initiation of continuous positive airway pressure therapy or bi-level
	Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory
95800	analysis (eg, by airflow or peripheral arterial tone), and sleep time
	Sleep study, unattended, simultaneous recording; minimum of heart rate, oxygen saturation,
95801	
	Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14
95803	consecutive days of recording)
95805	Multiple Sleep Latency Test, Multiple Trails
	Sleep study, unattended, simultaneous recording of, heart rate, oxygen saturation, respiratory
95806	airflow, and respiratory
95807	Sleep Study, Attended
	Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by
95808	a technologist
	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of
95810	sleep, attended by a technologist
	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of
	sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation,
95811	attended by a technologist

	Motor and/or sensory nerve conduction, using preconfigured electrode array(s), amplitude and
	latency/velocity study, each limb, includes F-wave study when performed, with interpretation
95905	and report
95965	Magnetoencephalography (Meg), Record & Analysis; For Spontaneous Brain Magnetic Activity
	Magnetoencephalography (Meg), Record & Analysis; For Evoked Magnetic Fields, Single
95966	Modality
	Magnetoencephalography (Meg), Record & Analysis; For Evoked Magnetic Fields, Ea Add'l
95967	Modality
	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact
	group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection
	algorithms, closed loop parameters, and passive parameters) by physician or other qualified
	health care professional; with simple cranial nerve neurostimulator pulse
95976	generator/transmitter programming by physician or other qualified health care professional
	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact
	group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet
	mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection
	algorithms, closed loop parameters, and passive parameters) by physician or other qualified
05077	health care professional; with complex cranial nerve neurostimulator pulse
95977	generator/transmitter programming by physician or other qualified health care professional
96001	Comprehensive computer-based motion analysis by video-taping and 3D kinematics; with dynamic plantar pressure measurements during walking
90001	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial,
96365	up to 1 hour
	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous
96372	or intramuscular
	Whole body integumentary photography, for monitoring of high risk patients with dysplastic
	nevus syndrome or a history of dysplastic nevi, or patients with a personal or familial history of
96904	melanoma
00001	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image
96931	acquisition and interpretation and report, first lesion
96932	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition only, first lesion
30332	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin;
96933	interpretation and report only, first lesion
97010	Application of a modality to 1 or more areas; hot or cold packs
97012	Application of a modality to 1 or more areas; traction, mechanical
97014	Application of a modality to 1 or more areas; electrical stimulation (unattended)
97016	Application of a modality to 1 or more areas; vasopneumatic devices
97018	Application of a modality to 1 or more areas; paraffin bath
97022	Application of a modality to 1 or more areas; whirlpool
97024	Application of a modality to 1 or more areas; diathermy (eg, microwave)
97026	Application of a modality to 1 or more areas; infrared
97028	Application of a modality to 1 or more areas; ultraviolet
97032	Application, Modality 1+ Areas; Electrical Stimulation (Manual), Each 15 Min
97033	Application of a modality to 1 or more areas; iontophoresis, each 15 minutes

97034	Application, Modality To 1+ Areas; Contrast Baths, Each 15 Min
97035	Application, Modality To 1+ Areas; Ultrasound, Each 15 Min
97036	Application, Modality To 1+ Areas; Hubbard Tank, Each 15 Min
97110	Therapeutic Proc, 1+ Areas, Each 15 Min; Therapeutic Exercises
97112	Therapeutic Proc, 1+ Areas, Each 15 Min; Neuromuscular Reeducation
97113	Therapeutic Proc, 1+ Areas, Each 15 Min; Aquatic Therapy W/Exercises
97116	Therapeutic Proc, 1+ Areas, Each 15 Min; Gait Training (W/Stair Climbing)
97124	Therapeutic Proc, 1+ Areas, Each 15 Min; Massage
	Therapeutic interventions that focus on cognitive function (eg, attention, memory, reasoning,
	executive function, problem solving, and/or pragmatic functioning) and compensatory
	strategies to manage the performance of an activity (eg, managing time or schedules,
	initiating, organizing, and sequencing tasks), direct (one-on-one) patient contact; initial 15
97129	minutes
	Therapeutic interventions that focus on cognitive function (eg, attention, memory, reasoning,
	executive function, problem solving, and/or pragmatic functioning) and compensatory
	strategies to manage the performance of an activity (eg, managing time or schedules,
97130	initiating, organizing, and sequencing tasks), direct (one-on-one) patient contact; each additional 15 minutes (List separately in addition to code for primary procedure)
97130	Manual Therapy Techniques, 1+ Regions, Each 15 Min
97140	Therapeutic Proc(S), Group, (2+ Individuals)
97130	Behavior identification assessment, administered by a physician or other qualified health care
	professional, each 15 minutes of the physician's or other qualified health care professional's
	time face-to-face with patient and/or guardian(s)/caregiver(s) administering assessments and
	discussing findings and recommendations, and non-face-to-face analyzing past data,
97151	scoring/interpreting the assessment, and preparing the report/treatment plan
	Behavior identification-supporting assessment, administered by one technician under the
	direction of a physician or other qualified health care professional, face-to-face with the
97152	patient, each 15 minutes
	Adaptive behavior treatment by protocol, administered by technician under the direction of a
07150	physician or other qualified health care professional, face-to-face with one patient, each 15
97153	minutes
	Group adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with two or
97154	more patients, each 15 minutes
07101	Adaptive behavior treatment with protocol modification, administered by physician or other
	qualified health care professional, which may include simultaneous direction of technician,
97155	face-to-face with one patient, each 15 minutes
	Family adaptive behavior treatment guidance, administered by physician or other qualified
	health care professional (with or without the patient present), face-to-face with
97156	guardian(s)/caregiver(s), each 15 minutes
	Multiple-family group adaptive behavior treatment guidance, administered by physician or
07455	other qualified health care professional (without the patient present), face-to-face with
97157	multiple sets of guardians/caregivers, each 15 minutes
07150	Group adaptive behavior treatment with protocol modification, administered by physician or
97158	other qualified health care professional, face-to-face with multiple patients, each 15 minutes
97161	Physical therapy evaluation; low complexity, requiring components

97162	Physical therapy evaluation; moderate complexity requiring components
97163	Physical therapy evaluation; high complexity requiring components
97164	Reevaluation of physical therapy established plan of care requiring components
97165	Occupational therapy evaluation; low complexity requiring components
97166	Occupational therapy evaluation; moderate complexity requiring components
97167	Occupational therapy evaluation; high complexity requiring components
97168	Reevaluation of occupational therapy care/established plan of care requiring components
0,100	Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to
97530	improve functional performance), each 15 minutes
	Sensory integrative techniques to enhance sensory processing and promote adaptive
97533	responses to environmental demands, direct (one-on-one) patient contact, each 15 minutes
	Self-care/home management training (eg, activities of daily living (ADL) and compensatory
	training, meal preparation, safety procedures, and instructions in use of assistive technology
97535	devices/adaptive equipment) direct one-on-one contact, each 15 minutes
	Community/work reintegration training (eg, shopping, transportation, money management,
	avocational activities and/or work environment/modification analysis, work task analysis, use
07507	of assistive technology device/adaptive equipment), direct one-on-one contact, each 15
97537	minutes
97542	Wheelchair management (eg, assessment, fitting, training), each 15 minutes
97545	Work Hardening/Conditioning; Initial 2 Hours
97546	Work Hardening/Conditioning; Add'l Hr
07040	Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when
97610	performed, wound assessment, and instruction(s) for ongoing care, per day
97750	Physical Performance Test, W/Written Report, Each 15 Min
	Assistive technology assessment (eg, to restore, augment or compensate for existing function,
97755	optimize functional tasks and/or maximize environmental accessibility), direct one-on-one contact, with written report, each 15 minutes
37733	Orthotic(s) management and training (including assessment and fitting when not otherwise
	reported), upper extremity(ies), lower extremity(ies) and/or trunk, initial orthotic(s) encounter,
97760	each 15 minutes
	Prosthetic(s) training, upper and/or lower extremity(ies), initial prosthetic(s) encounter, each
97761	15 minutes
	Orthotic(s)/prosthetic(s) management and/or training, upper extremity(ies), lower
97763	extremity(ies), and/or trunk, subsequent orthotic(s)/prosthetic(s) encounter, each 15 minutes
	Physician or other qualified health care professional attendance and supervision of hyperbaric
99183	oxygen therapy, per session
	Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-
000114	macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum,
0001M	prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver
0001U	Red blood cell antigen typing, DNA, human erythrocyte antigen gene analysis of 35 antigens from 11 blood groups, utilizing whole blood, common RBC alleles reported
00010	Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total
	bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum,
	prognostic algorithm reported as quantitative scores for fibrosis, steatosis and alcoholic
0002M	steatohepatitis (ASH)

	Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total
	bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum,
	prognostic algorithm reported as quantitative scores for fibrosis, steatosis and nonalcoholic
0003M	steatohepatitis (NASH)
	Oncology (prostate) gene expression profile by real-time RT-PCR of 3 genes (ERG, PCA3, and
0005U	SPDEF), urine, algorithm reported as risk score
	Oncology (hepatic), mRNA expression levels of 161 genes, utilizing fresh hepatocellular
0006M	carcinoma tumor tissue, with alpha-fetoprotein level, algorithm reported as a risk classifier
	Oncology (gastrointestinal neuroendocrine tumors), real-time PCR expression analysis of 51
0007M	genes, utilizing whole peripheral blood, algorithm reported as a nomogram of tumor disease
0007M	index
	Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, includes specimen verification including DNA authentication in comparison to
0007U	buccal DNA, per date of service
00070	Fetal aneuploidy (trisomy 21, and 18) DNA sequence analysis of selected regions using
0009M	maternal plasma, algorithm reported as a risk score for each trisomy
000011	Oncology, prostate cancer, mRNA expression assay of 12 genes (10 content and 2
	housekeeping), RT-PCR test utilizing blood plasma and urine, algorithms to predict high-grade
0011M	prostate cancer risk
	Oncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of five
	genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm reported
0012M	as a risk score for having urothelial carcinoma
	Oncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of five
	genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm reported
0013M	as a risk score for having recurrent urothelial carcinoma
	Oncology (bladder), mRNA, microarray gene expression profiling of 219 genes, utilizing
	formalin-fixed paraffin-embedded tissue, algorithm reported as molecular subtype (luminal,
0016M	luminal infiltrated, basal, basal claudin-low, neuroendocrine-like)
	Oncology (hematolymphoid neoplasia), RNA, BCR/ABL1 major and minor breakpoint fusion
004011	transcripts, quantitative PCR amplification, blood or bone marrow, report of fusion not
0016U	detected or detected with quantitation
	Oncology (diffuse large B-cell lymphoma [DLBCL]), mRNA, gene expression profiling by
0017M	fluorescent probe hybridization of 20 genes, formalin-fixed paraffin-embedded tissue, algorithm reported as cell of origin
001714	Oncology (hematolymphoid neoplasia), JAK2 mutation, DNA, PCR amplification of exons 12-14
	and sequence analysis, blood or bone marrow, report of JAK2 mutation not detected or
0017U	detected
001/0	Transplantation medicine (allograft rejection, renal), measurement of donor and third-party-
	induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported
0018M	as a rejection risk score
	Oncology (thyroid), microRNA profiling by RT-PCR of 10 microRNA sequences, utilizing fine
	needle aspirate, algorithm reported as a positive or negative result for moderate to high risk of
0018U	malignancy
	Extracorporeal shock wave involving musculoskeletal system, not otherwise specified, low
0019T	energy

embedded tissue or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agentsTargeted genomic sequence analysis panel, non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as 0022Upresence or absence of variants and associated therapy(ies) to considerOncology (acute myelogenous leukemia), DNA, genotyping of internal tandem duplication, p.D835, p.1836, using mononuclear cells, reported as detection or non-detection of FLT30023Umutation and indication for or against the use of midostaurinOncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high optication of the transmitted isorder) gene analysis, targeted sequence analysis exons 12-150028Uanalysis exons 12-150028U0028Uanalysis exons 12-150028Uanalysis, cory number variants, common variants with reflex to targeted sequence analysis (er, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and 12:12770029U0191Uanalysis, common variants (ie, *1F, *1K, *6, *7)0031U0031Uanalysis, common variants (ie, *1F, *1K, *6, *7)0047 (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variant00320variant003312111>C1, HT22 (S3813929 [c759C>T1] and rs1414334 [c.551-3008C>G])TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common va		Oncology, RNA, gene expression by whole transcriptome sequencing, formalin-fixed paraffin
0019U       therapeutic agents         Targeted genomic sequence analysis panel, non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as         0022U       presence or absence of variants and associated therapy(ies) to consider         0010000000000000000000000000000000000		
Targeted genomic sequence analysis panel, non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as 0022U presence or absence of variants and associated therapy(ies) to consider Oncology (acute myelogenous leukemia), DNA, genotyping of internal tandem duplication, p.D835, p.I836, using mononuclear cells, reported as detection or non-detection of FLT3 0023U mutation and indication for or against the use of midostaurin Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high probability of malignancy" or "Negative, low probability of malignancy") JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15 CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and 0029U rs1277 Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7) COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) 0032U variant HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs797012 [c.614- 0031U 2211T>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G]) TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; 0034U NUDT15 *3, *4, *5) Exome (ie, somatic mutations), paired formalin-	001011	
analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as0022Upresence or absence of variants and associated therapy(ies) to consider0ncology (acute myelogenous leukemia), DNA, genotyping of internal tandem duplication, p.D835, p.1836, using mononuclear cells, reported as detection or non-detection of FLT30023Umutation and indication for or against the use of midostaurin0ncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high probability of malignancy" or "Negative, low probability of malignancy")1AK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15028Uanalysis, copy number variants, common variants with reflex to targeted sequence analysis (ie, CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and 0020U0030UVKORC1, rs12777823)0031Uanalysis, common variants (ie, +T, *1K, *6, *7)0032Uvariant0032Uvariant0032U2211T>CJ, HTR2C rs3813929 [c759C>T] and rs141334 [c.551-3008C>G])0032U2211T>CJ, HTR2C rs3813929 [c759C>T] and rs141334 [c.551-3008C>G])0032U2211T>CJ, HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])0032U2211T>CJ, HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])0032U2211T>CJ, HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])003	00130	
0022U         presence or absence of variants and associated therapy(ies) to consider           0ncology (acute myelogenous leukemia), DNA, genotyping of internal tandem duplication, p.D835, p.I836, using mononuclear cells, reported as detection or non-detection of FLT3           0023U         mutation and indication for or against the use of midostaurin           0ncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high 0026U           0027U         analysis exons 12-15           0028U         CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLC01B1, VKORC1 and 029U           0029U         rs1277           01010         analysis, common variants (regeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2C9, CYP3A4, CYP3A5, CYP4F2, SLC01B1, VKORC1 and 029U           0110         nalysis, common variants (regeted sequence analysis (ie, CYP2C9, CYP4F2, VKORC1, rs12777823)           0110         analysis, common variants (ie, *1F, *1K, *6, *7)           0111         analysis, common variants (ie, *1F, *1K, *6, *7)           0111         analysis, common variants (ie, repetor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614- 0031U           003201         22111r>CJ, HTR2C rs3813929 [c759C>		
Oncology (acute myelogenous leukemia), DNA, genotyping of internal tandem duplication, p.D835, p.1836, using mononuclear cells, reported as detection or non-detection of FLT3 mutation and indication for or against the use of midostaurin           Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high probability of malignancy" or "Negative, low probability of malignancy")           JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15           CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and 0029U           rs1277         Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)           COMU (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variant           HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, TR2A rs7997012 [c.614- 2033U           2034U         NUDT15 *3, *4, *5)           Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifi	000011	
p.D835, p.1836, using mononuclear cells, reported as detection or non-detection of FLT30023Umutation and indication for or against the use of midostaurin0ncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high probability of malignancy" or "Negative, low probability of malignancy")JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysisDrug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C9, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and 0029Urs1277Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP1A2, CYP2C9, CYP2C9, CYP2C9, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and 0029Urs1277O030UVKORC1, rs12777823)CVP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variantU330UVariantHTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, THR2A rs7997012 [c.614-U033U2211T>CJ, HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, co	00220	
0023U       mutation and indication for or against the use of midostaurin         0ncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high probability of malignancy" or "Negative, low probability of malignancy")         JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15         0028U       analysis exons 12-15         0128U       Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C6), CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and rs1277         0029U       rs1277         0030U       VKORC1, rs12777823)         0031U       analysis, common variants (ie, *1F, *1K, *6, *7)         COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variant         0032U       variant         HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; 0034U         0031U       Z11T>CJ, HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])         TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; 0034U         0034U       NUDT15 *3, *4, *5)         Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor t		
Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high probability of malignancy" or "Negative, low probability of malignancy")           JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15           CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis           Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C9, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and rs1277           Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP1A2, CYP2C9, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and rs1277           O300U         VKORC1, rs12777823           CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)           COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variant           HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614- 22117>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])           TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; 0034U           NUDT15 *3, *4, *5)         Exorme (ie, somatic mutations), paired formalin-fixed para	000011	
aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high probability of malignancy" or "Negative, low probability of malignancy")JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and 0029U0029U rs1277Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and 0029U0030U vKORC1, rs12777823)CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)0031U analysis, common variants (ie, *1F, *1K, *6, *7)COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variant0032U variantHTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; 0034U0034U v035U v035UTPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence analyses035U v037U microsatellite instability and tumor mutational burden037U wriat microsatellite instability and tumor mutational burden037U wriat microsatellite instability and tumor mu	00230	
0026Uprobability of malignancy" or "Negative, low probability of malignancy")JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence0027Uanalysis exons 12-15CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene0028Uanalysis, copy number variants, common variants with reflex to targeted sequence analysisDrug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie,CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and0029Urs1277Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene0031Uanalysis, common variants (ie, *1F, *1K, *6, *7)COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680)0032UvariantHTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614-0033U2211T>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12;0034UNUDT15 *3, *4, *5)Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses7Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, interrogation for sequence		
JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15         0027U       analysis exons 12-15         0028U       analysis, copy number variants, common variants with reflex to targeted sequence analysis         0028U       analysis, copy number variants, common variants with reflex to targeted sequence analysis         0028U       matysis, copy number variants, common variants with reflex to targeted sequence analysis         0128U       metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and         0029U       rs1277         030U       VKORC1, rs12777823)         CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)         COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680)         0032U       variant         HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614- 0033U         22111>CJ, HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])         TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; 0034U         NUDT15 *3, *4, *5)       Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal		
0027Uanalysis exons 12-15028UCYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis0028UDrug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and 0029U0029Urs12770030UVKORC1, rs12777823)CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680)0032UvariantHTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614- 0033U0034UNUDT15 'C, HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; 0034U0036Unormal specimen, sequence analysesTargeted genomic sequence analysesTargeted genomic sequence analysesTargeted genomic sequence analysesTargeted genomic sequence analyses037Umicrosatellite instability and tumor mutational burdenBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative	00260	
CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis0028Uanalysis, copy number variants, common variants with reflex to targeted sequence analysisDrug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and 0029U0029Urs1277Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP2C9, CYP4F2, VKORC1, rs12777823)CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variantHTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614- 0231U22117>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, cold organ neoplasm, DNA analysis of 324 genes, interrogation for sequence analysesTargeted genomic sequence analysesTargeted genomic sequence analyses, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden0037UBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative		
0028Uanalysis, copy number variants, common variants with reflex to targeted sequence analysisDrug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and rs12770029Urs1277Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP2C9, CYP4F2, VKORC1, rs12777823)0030UVKORC1, rs12777823)CMT (catechol-Orme P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)0031UCOMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variant0032UvariantHTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614- 0033U0033U22117>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])0034UNUDT15 *3, *4, *5)0034UNUDT15 *3, *4, *5)0034UNUDT15 *3, *4, *5)0034UTargeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, interrogation for sequence variants, gene co	0027U	
Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and 0029U0029Urs1277Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP2C9, CYP4F2, VKORC1, rs12777823)0030UVKORC1, rs12777823)CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variantHTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614- 0231U0033U2211T>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; 0034U0036Unormal specimen, sequence analysesTargeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden0040UBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative		
CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and rs12770029Urs12770030UDrug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP2C9, CYP4F2, VKORC1, rs12777823)0031UCYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)0032UCOMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variant0032Uvariant1033UHTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614- 0230U0033U2211T>CJ, HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])1154TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12;0034UNUDT15 *3, *4, *5)126Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden00370BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative	0028U	
0029Urs12770030UDrug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP2C9, CYP4F2, VKORC1, rs12777823)0030UVKORC1, rs12777823)0031Uanalysis, common variants (ie, *1F, *1K, *6, *7)0030UCOMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680)0032Uvariant0031UHTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614-0033U2211T>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])0034UNUDT15 ', At *5)0034UNUDT15 *3, *4, *5)0034UNUDT15 *3, *4, *5)0036Urargeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden0037UBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative		
Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP2C9, CYP4F2, 0030U0030UVKORC1, rs12777823)CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variantHTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614- 0230U0033U2211T>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; 0034U0036Unormal specimen, sequence analysesTargeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burdenBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative		
0030UVKORC1, rs12777823)0031UCYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)0031UCOMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variant0032UVariantHTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614- 0033U0033U2211T>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; 0034U0034UNUDT15 *3, *4, *5)Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analysesTargeted genomic sequence analyses, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burdenBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative	0029U	
CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680)0032UvariantHTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614- 0033U0032U2211T>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12;0034UNUDT15 *3, *4, *5)Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analysesTargeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, 0037U0037UBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative		
0031Uanalysis, common variants (ie, *1F, *1K, *6, *7)COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680)0032UvariantHTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614-0033U2211T>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12;0034UNUDT15 *3, *4, *5)Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analysesTargeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, 0037U0037UBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative	0030U	
COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680)0032UvariantHTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614-0033U2211T>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12;0034UNUDT15 *3, *4, *5)Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden0037UBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative		
0032Uvariant0032UHTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614- 023100033U2211T>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])0034UTPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12;0034UNUDT15 *3, *4, *5)0034UNUDT15 *3, *4, *5)0036UExome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses0037UTargeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden0040Ubreakpoint, quantitative	0031U	
HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614- 2211T>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])0033U2211T>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12;0034UNUDT15 *3, *4, *5)Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analysesTargeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden0037UBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major 0040U0040Ubreakpoint, quantitative		
citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614-0033U2211T>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12;0034UNUDT15 *3, *4, *5)Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analysesTargeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden0040UBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major	0032U	
0033U2211T>C], HTR2C rs3813929 [c759C>T] and rs1414334 [c.551-3008C>G])TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12;0034UNUDT15 *3, *4, *5)Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses0036Unormal specimen, sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden0037UBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative		
TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; 0034U0034UNUDT15 *3, *4, *5)Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses0036Unormal specimen, sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden0037UBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major 0040U		
metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12;0034UNUDT15 *3, *4, *5)Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and0036Unormal specimen, sequence analysesTargeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden0037UBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative	0033U	
0034UNUDT15 *3, *4, *5)Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses0036Unormal specimen, sequence analysesTargeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden0037UBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative		
Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses0036Unormal specimen, sequence analysesTargeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden0037UBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative		
0036Unormal specimen, sequence analysesTargeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden0037UBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major0040Ubreakpoint, quantitative	0034U	
Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden0037UBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative		
interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden0037UBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major0040Ubreakpoint, quantitative	00360	
0037Umicrosatellite instability and tumor mutational burdenBCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major0040Ubreakpoint, quantitative		
BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major0040Ubreakpoint, quantitative		
0040U breakpoint, quantitative	0037U	
	0.0.10/1	
Cerebral Perfusion Anaysis Ct W/Contrst Postprocess Determ Cerebral Blood Flow/Vol &	0040U	
		Cerebral Perfusion Anaysis, Ct W/Contrst, Postprocess, Determ Cerebral Blood Flow/Vol &
0042T Mean	0042T	
Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-		
PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded		
0045U tissue, algorithm reported as recurrence score	0045U	
FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication		
0046U (ITD) variants, quantitative	0046U	(ITD) variants, quantitative

	Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12
	content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm
0047U	reported as a risk score
	Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468
	cancer-associated genes, including interrogation for somatic mutations and microsatellite
	instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor
0048U	tissue, report of clinically significant mutation(s)
0049U	NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative
	Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194
0050U	genes, interrogation for sequence variants, copy number variants or rearrangements
0051T	Implantation of a total replacement heart system (artificial heart) with recipient cardiectomy
0052T	Replacement/repair of thoracic unit of a total replacement heart system (artificial heart)
00530	Anesthesia, Permanent Transvenous Pacemaker Insertion
	Replacement/repair of implantable component(s) of total replacement heart system (artificial
0053T	heart) excl thoracic unit
	Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN),
0053U	needle biopsy specimen, algorithm reported as probability of higher tumor grade
	Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single
0055U	nucleotide polymorphism targets and two control targets), plasma
00580	Anesthesia, Heart Transplant/Heart & Lung Transplant
0058T	Cryopreservation; reproductive tissue, ovarian
0059T	Cryopreservation; oocyte(s)
	Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing
0062U	serum, algorithm reported with a risk score
	Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed
0069U	paraffin-embedded tissue, algorithm reported as an expression score
	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene
007011	analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11,
0070U	*12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68, *83, *xN)
0071T	Ultrasound Ablation of Uterine Leioomyomata inc MR Guidance
007111	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene
0071U	analysis, full gene sequence (List separately in addition to code for primary procedure)
0072T	Ultrasound Ablation of Uterine Leioomyomata inc MR Guidance; Vol>=200 CC
	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition
0072U	to code for primary procedure)
00720	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene
	analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition
0073U	to code for primary procedure)
	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene
	analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication
0074U	is trans) (List separately in addition to code for primary procedure)
	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene
	analysis, targeted sequence analysis (ie, 5' gene duplication/multiplication) (List separately in
0075U	addition to code for primary procedure)

	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene
	analysis, targeted sequence analysis (ie, 3' gene duplication/multiplication) (List separately in
0076U	addition to code for primary procedure)
00700	Endovascular repair using prosthesis of abdominal aortic aneurysm, pseudoaneurysm or
	dissection, abdominal aorta involving visceral branches (superior mesenteric, celiac and/or
0078T	renal artery[s])
00701	Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1,
	COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR,
	OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positive
0078U	or negative risk of opioid-use disorder
00796	Anesthesia, Intraperitoneal Proc, Upper Abdomen, W/Laparoscopy; Liver Transplant, Recipient
	Comparative DNA analysis using multiple selected single-nucleotide polymorphisms(SNPs),
0079U	urine and buccal DNA, for specimen identity verification
	Endovascular repair using prosthesis of abdominal aortic aneurysm, pseudoaneurysm or
	dissection, abdominal aorta involving visceral vessels (superior mesenteric, celiac and/or
0080T	renal artery[s]), radiological supervision and interpretation
	Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger
	receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status,
	nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm
0080U	reported as a categorical probability of malignancy
0085T	Breath test for heart transplant rejection
	Anesthesia, Extraperitoneal Proc, Lower Abdomen, W/Urinary Tract; Renal Transplant,
00868	Recipient
	Cardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes,
0087U	transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score
	Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of
0088U	1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection
00000	Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518,
0089U	superficial collection using adhesive patch(es)
00000	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare
0090T	interspace (other than for decompression) cervical; single interspace
	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14
	content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue,
0090U	algorithm reported as a categorical result (ie, benign, intermediate, malignant)
	Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor
0092U	technology, plasma, algorithm reported as risk score for likelihood of malignancy
	Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence
0094U	analysis
	Removal of total disc arthroplasty (artificial disc), anterior approach, each additional
0095T	interspace, cervical (List separately in addition to code for primary procedure)
	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach,
0098T	each additional interspace, cervical (List separately in addition to code for primary procedure)
0099T	Implantation of intrastromal corneal ring segments
0.4.5.5	Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and
0100T	implantation of intra-ocular retinal electrode array, with vitrectomy
0101T	Extracorporeal shock wave involving musculoskeletal system, not otherwise specified

	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden
	syndrome, familial adenomatosis polyposis), genomic sequence analysis panel utilizing a
	combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of
	unknown significance when indicated (15 genes [sequencing and deletion/duplication],
0101U	EPCAM and GREM1 [deletion/duplication only])
	Extracorporeal shock wave performed by a physician, requiring anesthesia other than local,
0102T	and involving the lateral humeral epicondyle
	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian
	cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a
	combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of
0102U	unknown significance when indicated (17 genes [sequencing and deletion/duplication])
	Hereditary ovarian cancer (eg, hereditary ovarian cancer, hereditary endometrial cancer),
	genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array
010011	CGH, with mRNA analytics to resolve variants of unknown significance when indicated (24
0103U	genes [sequencing and deletion/duplication], EPCAM [deletion/duplication only])
	Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), genomic sequence analysis panel utilizing a
	combination of NGS, Sanger, MLPA, and array CGH, with MRNA analytics to resolve variants of
	unknown significance when indicated (32 genes [sequencing and deletion/duplication],
0104U	EPCAM and GREM1 [deletion/duplication only])
	Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay
	(ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and
	kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1
	genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability
0105U	score for rapid kidney function decline (RKFD)
	Quantitative sensory testing (QST), testing and interpretation per extremity; using touch
0106T	pressure stimuli to assess large diameter sensation
04077	Quantitative sensory testing (QST), testing and interpretation per extremity; using vibration
0107T	stimuli to assess large diameter fiber sensation
0108T	Quantitative sensory testing (QST), testing and interpretation per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia
01001	Quantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain
0109T	stimuli to assess small nerve fiber sensation and hyperalgesia
01001	Quantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli
0110T	to assess sensation
	Oncology (colon cancer), targeted KRAS (codons 12, 13, and 61) and NRAS (codons 12, 13,
0111U	and 61) gene analysis utilizing formalin-fixed paraffin-embedded tissue
	Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA
0112U	genes) with drug-resistance gene
	Oncology (prostate), measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum
	following prostatic massage, by RNA amplification and fluorescence-based detection,
0113U	algorithm reported as risk score
	Pain management, analysis of 11 endogenous analytes (methylmalonic acid, xanthurenic acid,
	homocysteine, pyroglutamic acid, vanilmandelate, 5-hydroxyindoleacetic acid,
	hydroxymethylglutarate, ethylmalonate, 3-hydroxypropyl mercapturic acid (3-HPMA),
011711	quinolinic acid, kynurenic acid), LC-MS/MS, urine, algorithm reported as a pain-index score
0117U	with likelihood of atypical biochemical function associated with pain

	Transplantation medicine, quantification of donor-derived cell-free DNA using whole genome
	next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA in
0118U	the total cell-free DNA
01100	Oncology (B-cell lymphoma classification), mRNA, gene expression profiling by fluorescent
	probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed
	paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal B-cell
010011	lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) with cell of origin subtyping in
0120U	the latter
0 4 0 4 <b>T</b>	Conjunctival incision with posterior extrascleral placement of pharmacological agent (does
0124T	not include supply of medication)
	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian
	cancer, hereditary endometrial cancer), genomic sequence analysis and deletion/duplication
0129U	analysis panel (ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, and TP53)
	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden
	syndrome, familial adenomatosis polyposis), targeted mRNA sequence analysis panel (APC,
	CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, and TP53) (List separately in
0130U	addition to code for primary procedure)
	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian
	cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (13 genes)
0131U	(List separately in addition to code for primary procedure)
	Hereditary ovarian cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian
	cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (17 genes)
0132U	(List separately in addition to code for primary procedure)
	Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial
	cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (18 genes) (List
0134U	separately in addition to code for primary procedure)
	Hereditary gynecological cancer (eg, hereditary breast and ovarian cancer, hereditary
	endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel
0135U	(12 genes) (List separately in addition to code for primary procedure)
	ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia) mRNA sequence analysis (List
0136U	separately in addition to code for primary procedure)
	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg,
	hereditary breast and ovarian cancer) mRNA sequence analysis (List separately in addition to
0138U	code for primary procedure)
	Infectious disease (bacteria and fungi), gram-positive organism identification and drug
	resistance element detection, DNA (20 gram-positive bacterial targets, 4 resistance genes, 1
	pan gram-negative bacterial target, 1 pan Candida target), blood culture, amplified probe
0141U	technique, each target reported as detected or not detected
	Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug
	resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, 1
	pan gram-positive bacterial target, 1 pan Candida target), amplified probe technique, each
0142U	target reported as detected or not detected
	Infectious disease (bacteria, fungi, parasites, and DNA viruses), microbial cell-free DNA,
0152U	plasma, untargeted next-generation sequencing, report for significant positive pathogens
	Oncology (breast), mRNA, gene expression profiling by next-generation sequencing of 101
	genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a triple
0153U	negative breast cancer clinical subtype(s) with information on immune cell involvement
01000	nogene store cancel cancel cancel and the and the manual of the manual o

	Oncology (urothelial cancer), RNA, analysis by real-time RT-PCR of the FGFR3 (fibroblast
	growth factor receptor 3) gene analysis (ie, p.R248C [c.742C>T], p.S249C [c.746C>G],
	p.G370C [c.1108G>T], p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3-TACC3v3) utilizing
	formalin-fixed paraffin-embedded urothelial cancer tumor tissue, reported as FGFR gene
0154U	alteration status
	Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase,
	catalytic subunit alpha) (eg, breast cancer) gene analysis (ie, p.C420R, p.E542K, p.E545A,
	p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R,
	p.H1047Y), utilizing formalin-fixed paraffin-embedded breast tumor tissue, reported as PIK3CA
0155U	gene mutation status
0156U	Copy number (eg, intellectual disability, dysmorphology), sequence analysis
	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare
	interspace (other than for decompression), each additional interspace, lumbar (List separately
0163T	in addition to code for primary procedure)
	Removal of total disc arthroplasty, (artificial disc), anterior approach, each additional
0164T	interspace, lumbar (List separately in addition to code for primary procedure)
	Gastroenterology (irritable bowel syndrome [IBS]), immunoassay for anti-CdtB and anti-
0164U	vinculin antibodies, utilizing plasma, algorithm for elevated or not elevated qualitative results
	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach,
0165T	each additional interspace, lumbar (List separately in addition to code for primary procedure)
01001	Liver disease, 10 biochemical assays (a2-macroglobulin, haptoglobin, apolipoprotein A1,
	bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and
	demographic data, utilizing serum, algorithm reported as scores for fibrosis,
0166U	necroinflammatory activity, and steatosis with a summary interpretation
01000	Stereotactic placement of infusion catheter(s) in the brain for delivery of therapeutic agent(s),
0169T	including computerized stereotactic planning and burr hole(s)
01001	NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug
0169U	metabolism) gene analysis, common variants
01000	Neurology (autism spectrum disorder [ASD]), RNA, next-generation sequencing, saliva,
0170U	algorithmic analysis, and results reported as predictive probability of ASD diagnosis
01/00	Insertion of posterior spinous process distraction device (including necessary removal of bone
0171T	or ligament for insertion and imaging guidance), lumbar; single level
01/11	
	Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for
	sequence variants, rearrangements and minimal residual disease, reported as
0171U	presence/absence
01/10	Oncology (solid tumor as indicated by the label), somatic mutation analysis of BRCA1 (BRCA1,
	DNA repair associated), BRCA2 (BRCA2, DNA repair associated) and analysis of homologous
	recombination deficiency pathways, DNA, formalin-fixed paraffin-embedded tissue, algorithm
0172U	
01/20	quantifying tumor genomic instability score
017211	Psychiatry (ie, depression, anxiety), genomic analysis panel, includes variant analysis of 14
0173U	gene
	Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-
017411	embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain
0174U	benefit of 39 chemotherapy and targeted therapeutic oncology agents
0175U	Psychiatry (eg, depression, anxiety), genomic analysis panel, variant analysis of 15 genes
0176U	Cytolethal distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (ie, ELISA)

	Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase
	catalytic subunit alpha) gene analysis of 11 gene variants utilizing plasma, reported as PIK3CA
0177U	gene mutation status
	Oncology (non-small cell lung cancer), cell-free DNA, targeted sequence analysis of 23 genes
	(single nucleotide variations, insertions and deletions, fusions without prior knowledge of
0179U	partner/breakpoint, copy number variations), with report of significant mutation(s)
0182T	High dose rate electronic brachytherapy, per fraction
	Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when
0183T	performed, wound assessment, and instruction(s) for ongoing care, per day
0186T	Suprachoroidal delivery of pharmacologic agent (does not include supply of medication)
	Insertion of anterior segment aqueous drainage device, without extraocular reservoir; internal
0191T	approach, into the trabecular meshwork
	Insertion of anterior segment aqueous drainage device, without extraocular reservoir; external
0192T	approach
	Anesthesia for percutaneous image-guided injection, drainage or aspiration procedures on the
01937	spine or spinal cord; cervical or thoracic
	Anesthesia for percutaneous image-guided injection, drainage or aspiration procedures on the
01938	spine or spinal cord; lumbar or sacral
	Anesthesia for percutaneous image-guided destruction procedures by neurolytic agent on the
01939	spine or spinal cord; cervical or thoracic
	Anesthesia for percutaneous image-guided destruction procedures by neurolytic agent on the
01940	spine or spinal cord; lumbar or sacral
	Anesthesia for percutaneous image-guided neuromodulation or intravertebral procedures (eg,
01941	kyphoplasty, vertebroplasty) on the spine or spinal cord; cervical or thoracic
01040	Anesthesia for percutaneous image-guided neuromodulation or intravertebral procedures (eg,
01942	kyphoplasty, vertebroplasty) on the spine or spinal cord; lumbar or sacral
0195T	Arthrodesis, pre-sacral interbody technique, disc space preparation, discectomy, without
01951	instrumentation, with image guidance, includes bone graft when performed; L5-S1 interspace Intra-fraction localization and tracking of target or patient motion during delivery of radiation
0197T	therapy (eg, 3D positional tracking, gating, 3D surface tracking), each fraction of treatment
01371	Anesthesia for diagnostic or therapeutic nerve blocks and injections (when block or injection is
01991	performed by a different physician or other qualified health care professional
01001	Anesthesia for diagnostic or therapeutic nerve blocks and injections (when block or injection is
01992	performed by a different physician or other qualified health care professional
	Physiologic recording of tremor using accelerometer(s) and/or gyroscope(s) (including
0199T	frequency and amplitude), including interpretation and report
	Percutaneous sacral augmentation (sacroplasty), unilateral injection(s), including the use of a
0200T	balloon or mechanical device, when used, 1 or more needles
	Percutaneous sacral augmentation (sacroplasty), bilateral injections, including the use of a
0201T	balloon or mechanical device, when used, 2 or more needles
	Posterior vertebral joint(s) arthroplasty (e.g., facet joint[s] replacement) including
0202T	facetectomy, laminectomy, foramin
	Autoimmune (inflammatory bowel disease), mRNA, gene expression profiling by quantitative
	RT-PCR, 17 genes (15 target and 2 reference genes), whole blood, reported as a continuous
0203U	risk score and classification of inflammatory bowel disease aggressiveness

	Oncology (thuraid) mDNA gang everyonian analysis of EQ2 gange (including PDAE, DAE, DET
	Oncology (thyroid), mRNA, gene expression analysis of 593 genes (including BRAF, RAS, RET,
0204U	PAX8, and NTRK) for sequence variants and rearrangements, utilizing fine needle aspirate,
02040	reported as detected or not detected Ophthalmology (age-related macular degeneration), analysis of 3 gene variants (2 CFH gene, 1
0205U	ARMS2 gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for
02030	neovascular age-related macular-degeneration risk associated with zinc supplements
	Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA,
020611	
0206U	cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease
0207T	Evacuation of meibomian glands, automated, using heat and intermittent pressure, unilateral
	Neurology (Alzheimer disease); quantitative imaging of phosphorylated ERK1 and ERK2 in
	response to bradykinin treatment by in situ immunofluorescence, using cultured skin
000711	fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to
0207U	code for primary procedure)
	Oncology (medullary thyroid carcinoma), mRNA, gene expression analysis of 108 genes,
0208U	utilizing fine needle aspirate, algorithm reported as positive or negative for medullary thyroid carcinoma
02080	Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy
0209U	number, structural changes and areas of homozygosity for chromosomal abnormalities
02030	Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed
0211U	paraffin-embedded tissue, interpretative report for single nucleotide variants, copy
02110	Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA
	sequence analysis, including small sequence changes, deletions, duplications, short tandem
	repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva,
0212U	identification and categorization of genetic variants, proband
02120	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or
0213T	nerves innervating that joint) with ultrasound guidance, cervical or thoracic; single level
	Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA
0213U	sequence analysis, including small sequence changes, deletions, duplications, short tand
	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or
	nerves innervating that joint) with ultrasound guidance, cervical or thoracic; second level (List
0214T	separately in addition to code for primary procedure)
	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA
	sequence analysis, including small sequence changes, deletions, duplications, short tandem
	repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva,
0214U	identification and categorization of genetic variants, proband
	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or
	nerves innervating that joint) with ultrasound guidance, cervical or thoracic; third and any
0215T	additional level(s) (List separately in addition to code for primary procedure)
	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA
	sequence analysis, including small sequence changes, deletions, duplications, short tandem
	repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva,
	identification and categorization of genetic variants, each comparator exome (eg, parent,
0215U	sibling)
	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or
0216T	nerves innervating that joint) with ultrasound guidance, lumbar or sacral; single level

	Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including
	small sequence changes, deletions, duplications, short tandem repeat gene expansions, and
001011	variants in non-uniquely mappable regions, blood or saliva, identification and categorization of
0216U	genetic variants
	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or
	nerves innervating that joint) with ultrasound guidance, lumbar or sacral; second level (List
0217T	separately in addition to code for primary procedure)
	Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small
	sequence changes, deletions, duplications, short tandem repeat gene expansions, and
	variants in non-uniquely mappable regions, blood or saliva, identification and categorization of
0217U	genetic variants
	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or
	nerves innervating that joint) with ultrasound guidance, lumbar or sacral; third and any
0218T	additional level(s) (List separately in addition to code for primary procedure)
	Neurology (muscular dystrophy), DMD gene sequence analysis, including small sequence
	changes, deletions, duplications, and variants in non-uniquely mappable regions, blood or
0218U	saliva, identification and characterization of genetic variants
	Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and
0219T	placement of bone graft(s) or synthetic device(s), single level; cervical
	Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and
0220T	placement of bone graft(s) or synthetic device(s), single level; thoracic
	Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and
0221T	placement of bone graft(s) or synthetic device(s), single level; lumbar
-	Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and
0222T	placement of bone graft(s) or synthetic device(s), single level; each additional
	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound
0228T	guidance, cervical or thoracic; single level
	Oncology (prostate), multianalyte molecular profile by photometric detection of
	macromolecules adsorbed on nanosponge array slides with machine learning, utilizing first
0228U	morning voided urine, algorithm reported as likelihood of prostate cancer
02200	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound
	guidance, cervical or thoracic; each additional level (List separately in addition to code for
0229T	primary procedure)
02201	BCAT1 (Branched chain amino acid transaminase 1) and IKZF1 (IKAROS family zinc finger 1)
0229U	(eg, colorectal cancer) promoter methylation analysis
02230	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound
0230T	guidance, lumbar or sacral; single level
02301	
	AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X
	chromosome inactivation), full sequence analysis, including small sequence changes in
000011	exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions,
0230U	mobile element insertions, and variants in non-uniquely mappable regions
	Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with ultrasound
00017	guidance, lumbar or sacral; each additional level (List separately in addition to code for
0231T	primary procedure)
	CACNA1A (calcium voltage-gated channel subunit alpha 1A) (eg, spinocerebellar ataxia), full
0231U	gene analysis, including small sequence changes in exonic and intronic regions, deletions,

	duplications, short tandem repeat (STR) gene expansions, mobile element insertions, and variants in non-uniquely mappable regions
	Injection(s), platelet rich plasma, any site, including image guidance, harvesting and
0232T	preparation when performed
02021	CSTB (cystatin B) (eg, progressive myoclonic epilepsy type 1A, Unverricht-Lundborg disease),
0232U	full gene analysis, including small sequence changes in exonic and intronic region
02020	Skin advanced glycation endproducts (AGE) measurement by multi-wavelength fluorescent
0233T	spectroscopy
02001	FXN (frataxin) (eg, Friedreich ataxia), gene analysis, including small sequence changes in
	exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions,
0233U	mobile element insertions, and variants in non-uniquely mappable regions
	MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome), full gene analysis, including small
	sequence changes in exonic and intronic regions, deletions, duplications, mobile element
0234U	insertions, and variants in non-uniquely mappable regions
	PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor
	syndrome), full gene analysis, including small sequence changes in exonic and intronic
	regions, deletions, duplications, mobile element insertions, and variants in non-uniquely
0235U	mappable regions
	SMN1 (survival of motor neuron 1, telomeric) and SMN2 (survival of motor neuron 2,
	centromeric) (eg, spinal muscular atrophy) full gene analysis, including small sequence
0236U	changes in exonic and intronic regions, duplications, deletions, and mobile element insertions
	Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome,
	catecholaminergic polymorphic ventricular tachycardia), genomic sequence analysis panel
	including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A,
	including small sequence changes in exonic and intronic regions, deletions, duplications,
0237U	mobile element insertions, and variants in non-uniquely mappable regions
	Oncology (Lynch syndrome), genomic DNA sequence analysis of MLH1, MSH2, MSH6, PMS2,
	and EPCAM, including small sequence changes in exonic and intronic regions, deletions,
0238U	duplications, mobile element insertions, and variants in non-uniquely mappable regions
	Bioimpedance spectroscopy (BIS), measuring 100 frequencies or greater, direct measurement
0239T	of extracellular fluid differences between the limbs
	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free DNA, analysis of
	311 or more genes, interrogation for sequence variants, including substitutions, insertions,
0239U	deletions, select rearrangements, and copy number variations
	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA
00.001	analysis of 55-74 genes, interrogation for sequence variants, gene copy number
0242U	amplifications, and gene rearrangements
	Obstetrics (preeclampsia), biochemical assay of placental-growth factor, time-resolved
004011	fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for
0243U	preeclampsia
	Oncology (solid organ), DNA, comprehensive genomic profiling, 257 genes, interrogation for
	single-nucleotide variants, insertions/deletions, copy number alterations, gene
024411	rearrangements, tumor-mutational burden and microsatellite instability, utilizing formalin-
0244U	fixed paraffin-embedded tumor tissue
0245T	Open treatment of rib fracture requiring internal fixation, unilateral; 1-2 ribs

	Oncology (thyroid), mutation analysis of 10 genes and 37 RNA fusions and expression of 4
	mRNA markers using next-generation sequencing, fine needle aspirate, report includes
0245U	associated risk of malignancy expressed as a percentage
0246T	Open treatment of rib fracture requiring internal fixation, unilateral; 3-4 ribs
0247T	Open treatment of rib fracture requiring internal fixation, unilateral; 5-6 ribs
	Obstetrics (preterm birth), insulin-like growth factor-binding protein 4 (IBP4), sex hormone-
	binding globulin (SHBG), quantitative measurement by LC-MS/MS, utilizing maternal serum,
004711	combined with clinical data, reported as predictive-risk stratification for spontaneous preterm
0247U	birth
0248T	Open treatment of rib fracture requiring internal fixation, unilateral; 7 or more ribs
004011	Oncology, spheroid cell culture in 3D microenvironment, 12-drug panel, brain- or brain
0248U	metastasis-response prediction for each drug
004011	Oncology (breast), semiquantitative analysis of 32 phosphoproteins and protein analytes,
0249U	includes laser capture microdissection, with algorithmic analysis and interpretative report
	Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes,
	interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-
0250U	mutation burden
02300	Insertion of anterior segment aqueous drainage device, without extraocular reservoir; internal
0253T	approach, into the suprachoroidal space
02001	Reproductive medicine (endometrial receptivity analysis), RNA gene expression profile, 238
	genes by next-generation sequencing, endometrial tissue, predictive algorithm reported as
0253U	endometrial window of implantation (eg, pre-receptive, receptive, post-receptive)
	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes
	using embryonic DNA genomic sequence analysis for aneuploidy, and a mitochondrial DNA
	score in euploid embryos, results reported as normal (euploidy), monosomy, trisomy, or partial
0254U	deletion/duplication, mosaicism, and segmental aneuploidy, per embryo tested
	Andrology (infertility), sperm-capacitation assessment of ganglioside GM1 distribution
	patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of
0255U	capacitated sperm and probability of generating a pregnancy score
	Autoimmune (psoriasis), mRNA, next-generation sequencing, gene expression profiling of 50-
	100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of
0258U	response to psoriasis biologics
	Rare diseases (constitutional/heritable disorders), identification of copy number variations,
0260U	inversions, insertions, translocations, and other structural variants by optical genome mapping
	Oncology (colorectal cancer), image analysis with artificial intelligence assessment of 4
000411	histologic and immunohistochemical features (CD3 and CD8 within tumor-stroma border and
0261U	tumor core), tissue, reported as immune response and recurrence-risk score
0262T	Implantation of catheter-delivered prosthetic pulmonary valve, endovascular approach
	Oncology (solid tumor), gene expression profiling by real-time RT-PCR of 7 gene pathways (ER,
000011	AR, PI3K, MAPK, HH, TGFB, Notch), formalin-fixed paraffin-embedded (FFPE), algorithm
0262U	reported as gene pathway activity score
	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells,
02627	multiple injections, one leg, including ultrasound guidance, if performed; complete procedure
0263T	including unilateral or bilateral bone marrow harvest

	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells,
	multiple injections, one leg, including ultrasound guidance, if performed; complete procedure
0264T	excluding bone marrow harvest
	Rare diseases (constitutional/heritable disorders), identification of copy number variations,
0264U	inversions, insertions, translocations, and other structural variants by optical genome mapping
	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells,
	multiple injections, one leg, including ultrasound guidance, if performed; unilateral or bilateral
0265T	bone marrow harvest only for intramuscular autologous bone marrow cell therapy
	Rare constitutional and other heritable disorders, whole genome and mitochondrial DNA
	sequence analysis, blood, frozen and formalin-fixed paraffin-embedded (FFPE) tissue, saliva,
0265U	buccal swabs or cell lines, identification of single nucleotide and copy number variants
	Implantation or replacement of carotid sinus baroreflex activation device; total system
	(includes generator placement, unilateral or bilateral lead placement, intra-operative
0266T	interrogation, programming, and repositioning, when performed)
	Unexplained constitutional or other heritable disorders or syndromes, tissue-specific gene
	expression by whole-transcriptome and next-generation sequencing, blood, formalin-fixed
000011	paraffin-embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of
0266U	splicing or expression changes
0267T	Implantation or replacement of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)
02071	Rare constitutional and other heritable disorders, identification of copy number variations,
	inversions, insertions, translocations, and other structural variants by optical genome mapping
0267U	and whole genome sequencing
	Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only
0268T	(includes intra-operative interrogation, programming, and repositioning, when performed)
	Hematology (atypical hemolytic uremic syndrome [aHUS]), genomic sequence analysis of 15
0268U	genes, blood, buccal swab, or amniotic fluid
	Revision or removal of carotid sinus baroreflex activation device; total system (includes
	generator placement, unilateral or bilateral lead placement, intra-operative interrogation,
0269T	programming, and repositioning, when performed)
	Hematology (autosomal dominant congenital thrombocytopenia), genomic sequence analysis
0269U	of 14 genes, blood, buccal swab, or amniotic fluid
00707	Revision or removal of carotid sinus baroreflex activation device; lead only, unilateral (includes
0270T	intra-operative interrogation, programming, and repositioning, when performed)
0270U	Hematology (congenital coagulation disorders), genomic sequence analysis of 20 genes, blood, buccal swab, or amniotic fluid
02700	Revision or removal of carotid sinus baroreflex activation device; pulse generator only
0271T	(includes intra-operative interrogation, programming, and repositioning, when performed)
02711	Hematology (congenital neutropenia), genomic sequence analysis of 23 genes, blood, buccal
0271U	swab, or amniotic fluid
	Interrogation device evaluation (in person), carotid sinus baroreflex activation system,
	including telemetric iterative communication with the implantable device to monitor device
	diagnostics and programmed therapy values, with interpretation and report (eg, battery status,
	lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst
0272T	mode, therapy start/stop times each day);
	Hematology (genetic bleeding disorders), genomic sequence analysis of 51 genes, blood,
0272U	buccal swab, or amniotic fluid, comprehensive

	Interrogetion device evolution (in person), eccetid cinus here reflex estivation evolution
	Interrogation device evaluation (in person), carotid sinus baroreflex activation system,
	including telemetric iterative communication with the implantable device to monitor device
	diagnostics and programmed therapy values, with interpretation and report (eg, battery status,
00707	lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst
0273T	mode, therapy start/stop times each day); with programming
	Hematology (genetic hyperfibrinolysis, delayed bleeding), analysis of 9 genes (F13A1, F13B,
	FGA, FGB, FGG, SERPINA1, SERPINE1, SERPINF2 by next-generation sequencing, and PLAU by
0273U	array comparative genomic hybridization), blood, buccal swab, or amniotic fluid
	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural
	elements, (with or without ligamentous resection, discectomy, facetectomy and/or
	foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or
0274T	multiple levels, unilateral or bilateral; cervical or thoracic
	Hematology (genetic platelet disorders), genomic sequence analysis of 43 genes, blood,
0274U	buccal swab, or amniotic fluid
	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural
	elements, (with or without ligamentous resection, discectomy, facetectomy and/or
	foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or
0275T	multiple levels, unilateral or bilateral; lumbar
	Hematology (inherited thrombocytopenia), genomic sequence analysis of 23 genes, blood,
0276U	buccal swab, or amniotic fluid
00771	Hematology (genetic platelet function disorder), genomic sequence analysis of 31 genes,
0277U	blood, buccal swab, or amniotic fluid
	Transcutaneous Electrical Modulation Pain Reprocessing (Eg, Scrambler Therapy), Each
0278T	Treatment Session (Includes Placement Of Electrodes)
0070	Hematology (genetic thrombosis), genomic sequence analysis of 12 genes, blood, buccal
0278U	swab, or amniotic fluid
	Percutaneous transcatheter closure of the left atrial appendage with implant, including
00047	fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial
0281T	appendage angiography, radiological supervision and interpretation
	Percutaneous or open implantation of neurostimulator electrode array(s), subcutaneous
0000T	(peripheral subcutaneous field stimulation), including imaging guidance, when performed,
0282T	cervical, thoracic or lumbar; for trial, including removal at the conclusion of trial period
	Percutaneous or open implantation of neurostimulator electrode array(s), subcutaneous
00007	(peripheral subcutaneous field stimulation), including imaging guidance, when performed,
0283T	cervical, thoracic or lumbar; permanent, with implantation of a pulse generator
	Revision or removal of pulse generator or electrodes, including imaging guidance, when
0284T	performed, including addition of new electrodes, when performed
	Electronic analysis of implanted peripheral subcutaneous field stimulation pulse generator,
0285T	with reprogramming when performed
	Oncology, response to radiation, cell-free DNA, quantitative branched chain DNA
0285U	amplification, plasma, reported as a radiation toxicity score
	CEP72 (centrosomal protein, 72-KDa), NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-
0286U	methyltransferase) (eg, drug metabolism) gene analysis, common variants
	Oncology (thyroid), DNA and mRNA, next-generation sequencing analysis of 112 genes, fine
	needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic prediction of
0287U	cancer recurrence, reported as a categorical risk result (low, intermediate, high)

	Anoscopy, with delivery of thermal energy to the muscle of the anal canal (eg, for fecal
0288T	incontinence)
	Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6,
	CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP,
	YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation
0288U	reported as a recurrence risk score
	Neurology (Alzheimer disease), mRNA, gene expression profiling by RNA sequencing of 24
0289U	genes, whole blood, algorithm reported as predictive risk score
	Pain management, mRNA, gene expression profiling by RNA sequencing of 36 genes, whole
0290U	blood, algorithm reported as predictive risk score
	Psychiatry (mood disorders), mRNA, gene expression profiling by RNA sequencing of 144
0291U	genes, whole blood, algorithm reported as predictive risk score
	Psychiatry (stress disorders), mRNA, gene expression profiling by RNA sequencing of 72 genes,
0292U	whole blood, algorithm reported as predictive risk score
	Insertion of left atrial hemodynamic monitor; complete system, includes implanted
	communication module and pressure sensor lead in left atrium including transseptal access,
	radiological supervision and interpretation, and associated injection procedures, when
0293T	performed
	Psychiatry (suicidal ideation), mRNA, gene expression profiling by RNA sequencing of 54
0293U	genes, whole blood, algorithm reported as predictive risk score
	Insertion of left atrial hemodynamic monitor; pressure sensor lead at time of insertion of
0294T	pacing cardioverter-defibrillator pulse generator including radiological supervision
	Longevity and mortality risk, mRNA, gene expression profiling by RNA sequencing of 18 genes,
0294U	whole blood, algorithm reported as predictive risk score
	Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing of
000011	at least 20 molecular features (eg, human and/or microbial mRNA), saliva, algorithm reported
0296U	as positive or negative for signature associated with malignancy
	Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA
020711	specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow,
0297U	comparative sequence analyses and variant identification Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA
	specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow,
0298U	comparative sequence analyses and expression level and chimeric transcript identification
02960	Oncology (pan tumor), whole genome optical genome mapping of paired malignant and
	normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural
0299U	variant identification
02330	Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired
	malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative
0300U	sequence analyses and variant identification
00000	Insertion or removal and replacement of intracardiac ischemia monitoring system including
	imaging supervision and interpretation when performed and intra-operative interrogation and
0302T	programming when performed; complete system (includes device and electrode)
00021	Insertion or removal and replacement of intracardiac ischemia monitoring system including
	imaging supervision and interpretation when performed and intra-operative interrogation and
0303T	programming when performed; electrode only
00001	Free or an and benefitied, electronic only

	Insertion or removal and replacement of intracordical isohomic monitoring system including
	Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and
0304T	
03041	programming when performed; device only Programming device evaluation (in person) of intracardiac ischemia monitoring system with
0305T	iterative adjustment of programmed values, with analysis, review, and report
03031	
	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis,
020011	cell-free DNA, initial (baseline) assessment to determine a patient-specific panel for future
0306U	comparisons to evaluate for MRD
	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a
0307U	patient-specific panel, cell-free DNA, subsequent assessment with comparison to previously
03070	analyzed patient specimens to evaluate for MRD
	Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 lgG
	autoantibodies and 2 cell-bound complement activation products using enzyme-linked
	immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence,
001011	serum, or plasma and whole blood, individual components reported along with an algorithmic
0312U	SLE-likelihood assessment
	Oncology (pancreas), DNA and mRNA next-generation sequencing analysis of 74 genes and
	analysis of CEA (CEACAM5) gene expression, pancreatic cyst fluid, algorithm reported as a
001011	categorical result (ie, negative, low probability of neoplasia or positive, high probability of
0313U	neoplasia)
	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32
001 411	content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue,
0314U	algorithm reported as a categorical result (ie, benign, intermediate, malignant)
	Oncology (cutaneous squamous cell carcinoma), mRNA gene expression profiling by RT-PCR
004511	of 40 genes (34 content and 6 housekeeping), utilizing formalin-fixed paraffin-embedded
0315U	(FFPE) tissue, algorithm reported as a categorical risk result (ie, Class 1, Class 2A, Class 2B)
	Oncology (lung cancer), four-probe FISH (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood,
001711	predictive algorithm-generated evaluation reported as decreased or increased risk for lung
0317U	cancer
004011	Pediatrics (congenital epigenetic disorders), whole genome methylation analysis by
0318U	microarray for 50 or more genes, blood
	Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using
0319U	pretransplant peripheral blood, algorithm reported as a risk score for early acute rejection
00001	Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using
0320U	posttransplant peripheral blood, algorithm reported as a risk score for acute cellular rejection
	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens,
	identification of 20 bacterial and fungal organisms and identification of 16 associated
0321U	antibiotic-resistance genes, multiplex amplified probe technique
	Infectious agent detection by nucleic acid (DNA and RNA), central nervous system pathogen,
	metagenomic next-generation sequencing, cerebrospinal fluid (CSF), identification of
0323U	pathogenic bacteria, viruses, parasites, or fungi
	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA
	analysis of 83 or more genes, interrogation for sequence variants, gene copy number
0326U	amplifications, gene rearrangements, microsatellite instability and tumor mutational burden
	Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants,
	gene copy number amplifications and deletions, gene rearrangements, microsatellite
0329U	instability and tumor mutational burden utilizing DNA and RNA from tumor with DNA from

	normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy
00007	associations
0330T	Tear film imaging, unilateral or bilateral, with interpretation and report
0331T	Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment;
	Oncology (hematolymphoid neoplasia), optical genome mapping for copy number alterations and gene rearrangements utilizing DNA from blood or bone marrow, report of clinically
0331U	significant alterations
00010	Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment;
0332T	with tomographic SPECT
	Oncology (pan-tumor), genetic profiling of 8 DNA-regulatory (epigenetic) markers by
	quantitative polymerase chain reaction (qPCR), whole blood, reported as a high or low
0332U	probability of responding to immune checkpoint-inhibitor therapy
	Oncology (liver), surveillance for hepatocellular carcinoma (HCC) in high-risk patients,
	analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of
	serum of AFP/AFP-L3 and oncoprotein des-gamma-carboxy-prothrombin (DCP), algorithm
0333U	reported as normal or abnormal result
	Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffin-
	embedded (FFPE) tumor tissue, DNA analysis, 84 or more genes, interrogation for sequence
0334U	variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden
03340 0335T	
03351	Insertion of sinus tarsi implant Rare diseases (constitutional/heritable disorders), whole genome sequence analysis,
	including small sequence changes, copy number variants, deletions, duplications, mobile
	element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome
	sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene
0335U	expansions, fetal sample, identification and categorization of genetic variants
	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis,
	including small sequence changes, copy number variants, deletions, duplications, mobile
	element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome
	sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene
000011	expansions, blood or saliva, identification and categorization of genetic variants, each
0336U	comparator genome (eg, parent)
	Oncology (plasma cell disorders and myeloma), circulating plasma cell immunologic selection, identification, morphological characterization, and enumeration of plasma cells
	based on differential CD138, CD38, CD19, and CD45 protein biomarker expression, peripheral
0337U	blood
	Transcatheter renal sympathetic denervation, percutaneous approach including arterial
	puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s),
	intraprocedural roadmapping and radiological supervision and interpretation, including
	pressure gradient measurements, flush aortogram and diagnostic renal angiography when
0338T	performed; unilateral
	Oncology (solid tumor), circulating tumor cell selection, identification, morphological
	characterization, detection and enumeration based on differential EpCAM, cytokeratins 8, 18,
000011	and 19, and CD45 protein biomarkers, and quantification of HER2 protein biomarker-
0338U	expressing cells, peripheral blood
0339T	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s),
03391	puncture, selective catheter placement(s) renat artery(les), https://www.contrast.mjection(s),

	intraprocedural roadmapping and radiological supervision and interpretation, including
	pressure gradient measurements, flush aortogram and diagnostic renal angiography when
	performed; bilateral
	Oncology (prostate), mRNA expression profiling of HOXC6 and DLX1, reverse transcription
	polymerase chain reaction (RT-PCR), first-void urine following digital rectal examination,
0339U	algorithm reported as probability of high-grade cancer
	Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays
	personalized to each patient based on prior next-generation sequencing of the patient's tumor
	and germline DNA, reported as absence or presence of MRD, with disease-burden correlation,
0340U	if appropriate
0342T	Therapeutic apheresis with selective HDL delipidation and plasma reinfusion
	Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B,
	osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent
	immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as
0342U	positive, negative, or borderline
	Oncology (prostate), exosome-based analysis of 442 small noncoding RNAs (sncRNAs) by
	quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as
0343U	molecular evidence of no-, low-, intermediate- or high-risk of prostate cancer
	Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid
	markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), serum,
0344U	reported as at-risk for nonalcoholic steatohepatitis (NASH) or not NASH
0345T	Transcatheter mitral valve repair percutaneous approach via the coronary sinus
	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic
0345U	analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6
	Beta amyloid, AB40 and AB42 by liquid chromatography with tandem mass spectrometry (LC-
0346U	MS/MS), ratio, plasma
0347T	Placement of interstitial device(s) in bone for radiostereometric analysis (RSA)
	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA
0347U	analysis, 16 gene report, with variant analysis and reported phenotypes
	Radiologic examination, radiostereometric analysis (RSA); spine, (includes, cervical, thoracic
0348T	and lumbosacral, when performed)
	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA
0348U	analysis, 25 gene report, with variant analysis and reported phenotypes
	Radiologic examination, radiostereometric analysis (RSA); upper extremity(ies), (includes
0349T	shoulder, elbow and wrist, when performed)
	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA
	analysis, 27 gene report, with variant analysis, including reported phenotypes and impacted
0349U	gene-drug interactions
	Radiologic examination, radiostereometric analysis (RSA); lower extremity(ies), (includes hip,
0350T	proximal femur, knee and ankle, when performed)
	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA
0350U	analysis, 27 gene report, with variant analysis and reported phenotypes
	Optical coherence tomography of breast or axillary lymph node, excised tissue, each
0351T	specimen; real time intraoperative
00011	Optical coherence tomography of breast or axillary lymph node, excised tissue, each
0352T	specimen; interpretation and report, real time or referred
0353T	Optical coherence tomography of breast, surgical cavity; real time intraoperative
03531	oplical conference tomography of breast, surgical cavity, red time initidoperative

	Optical apparance tomography of branch surgical asylty interpretation and report real time or
0354T	Optical coherence tomography of breast, surgical cavity; interpretation and report, real time or referred
0355U	APOL1 (apolipoprotein L1) (eg, chronic kidney disease), risk variants (G1, G2)
00000	Oncology (oropharyngeal or anal), evaluation of 17 DNA biomarkers using droplet digital PCR
0356U	(ddPCR), cell-free DNA, algorithm reported as a prognostic risk score for cancer recurrence
	Neurology (mild cognitive impairment), analysis of B-amyloid 1-42 and 1-40,
	chemiluminescence enzyme immunoassay, cerebral spinal fluid, reported as positive, likely
0358U	positive, or negative
	Oncology (prostate cancer), analysis of all prostate-specific antigen (PSA) structural isoforms
0359U	by phase separation and immunoassay, plasma, algorithm reports risk of cancer
	Oncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7 autoantibodies (p53, NY-
	ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and HuD), plasma, algorithm reported as a
0360U	categorical result for risk of malignancy
0361U	Neurofilament light chain, digital immunoassay, plasma, quantitative
	Behavior identification supporting assessment, each 15 minutes of technicians' time face-to-
	face with a patient, requiring the following components: administration by the physician or
	other qualified health care professional who is on site; with the assistance of two or more
0000T	technicians; for a patient who exhibits destructive behavior; completion in an environment that
0362T	is customized to the patient's behavior.
	Oncology (papillary thyroid cancer), gene-expression profiling via targeted hybrid capture- enrichment RNA sequencing of 82 content genes and 10 housekeeping genes, fine needle
	aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as one of three
0362U	molecular subtypes
00020	Oncology (urothelial), mRNA, gene-expression profiling by real-time quantitative PCR of 5
	genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm
	incorporates age, sex, smoking history, and macrohematuria frequency, reported as a risk
0363U	score for having urothelial carcinoma
	Oncology (hematolymphoid neoplasm), genomic sequence analysis using multiplex (PCR) and
	next-generation sequencing with algorithm, quantification of dominant clonal sequence(s),
	reported as presence or absence of minimal residual disease (MRD) with quantitation of
0364U	disease burden, when appropriate
	Oncology (colorectal cancer), evaluation for mutations of APC, BRAF, CTNNB1, KRAS, NRAS,
	PIK3CA, SMAD4, and TP53, and methylation markers (MYO1G, KCNQ5, C9ORF50, FLI1, CLIP4,
000011	ZNF132 and TWIST1), multiplex quantitative polymerase chain reaction (qPCR), circulating
0368U	cell-free DNA (cfDNA), plasma, report of risk score for advanced adenoma or colorectal cancer
	Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification of 21 associated antibiotic-
0369U	resistance genes, multiplex amplified probe technique
03030	Infectious agent detection by nucleic acid (DNA and RNA), surgical wound pathogens, 34
	microorganisms and identification of 21 associated antibiotic-resistance genes, multiplex
0370U	amplified probe technique, wound swab
	Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex
0372U	amplified probe technique, urine, reported as an antimicrobial stewardship risk score
	Adaptive behavior treatment with protocol modification, each 15 minutes of technicians' time
	face-to-face with a patient, requiring the following components: administration by the
0373T	physician or other qualified health care professional who is on site; with the assistance of two

	or more technicians; for a patient who exhibits destructive behavior; completion in an
	environment that is customized to the patient's behavior.
	Infectious agent detection by nucleic acid (DNA and RNA), respiratory tract infection, 17
007011	bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes, multiplex amplified probe
0373U	technique, upper or lower respiratory specimen
	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens,
	identification of 21 bacterial and fungal organisms and identification of 21 associated
0374U	antibiotic-resistance genes, multiplex amplified probe technique, urine
	Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate
	preparation (includes osteophytectomy for nerve root or spinal cord decompression and
0375T	microdissection), cervical, three or more levels
	Oncology (prostate cancer), image analysis of at least 128 histologic features and clinical
	factors, prognostic algorithm determining the risk of distant metastases, and prostate cancer-
	specific mortality, includes predictive algorithm to androgen deprivation-therapy response, if
0376U	appropriate
	Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by
	nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including
0377U	23 variables)
	Visual field assessment, with concurrent real time data analysis and accessible data storage
	with patient initiated data transmitted to a remote surveillance center for up to 30 days; review
0378T	and interpretation with report by a physician or other qualified health care professional
	RFC1 (replication factor C subunit 1), repeat expansion variant analysis by traditional and
0378U	repeat-primed PCR, blood, saliva, or buccal swab
	Visual field assessment, with concurrent real time data analysis and accessible data storage
	with patient initiated data transmitted to a remote surveillance center for up to 30 days;
	technical support and patient instructions, surveillance, analysis, and transmission of daily
	and emergent data reports as prescribed by a physician or other qualified health care
0379T	professional
	Targeted genomic sequence analysis panel, solid organ neoplasm, DNA (523 genes) and RNA
	(55 genes) by next-generation sequencing, interrogation for sequence variants, gene copy
	number amplifications, gene rearrangements, microsatellite instability, and tumor mutational
0379U	burden
00/00	Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis, 20
	gene variants and CYP2D6 deletion or duplication analysis with reported genotype and
0380U	phenotype
00000	Oncology (non-small cell lung cancer), next-generation sequencing with identification of single
	nucleotide variants, copy number variants, insertions and deletions, and structural variants in
0388U	37 cancer-related genes, plasma, with report for alteration detection
00000	Pediatric febrile illness (Kawasaki disease [KD]), interferon alpha-inducible protein 27 (IFI27)
	and mast cell-expressed membrane protein 1 (MCEMP1), RNA, using quantitative reverse
0389U	
03690	transcription polymerase chain reaction (RT-qPCR), blood, reported as a risk score for KD
020011	Obstetrics (preeclampsia), kinase insert domain receptor (KDR), Endoglin (ENG), and retinol-
0390U	binding protein 4 (RBP4), by immunoassay, serum, algorithm reported as a risk score
	Oncology (solid tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed
000411	paraffin-embedded (FFPE) tissue, 437 genes, interpretive report for single nucleotide variants,
0391U	splice-site variants, insertions/deletions, copy number alterations, gene fusions, tumor

	mutational burden, and microsatellite instability, with algorithm quantifying immunotherapy
	response score
	Drug metabolism (depression, anxiety, attention deficit hyperactivity disorder [ADHD]), gene-
	drug interactions, variant analysis of 16 genes, including deletion/duplication analysis of
0392U	CYP2D6, reported as impact of gene-drug interaction for each drug
	Obstetrics (pre-implantation genetic testing), evaluation of 300000 DNA single-nucleotide
	polymorphisms (SNPs) by microarray, embryonic tissue, algorithm reported as a probability for
0396U	single-gene germline conditions
	Magnetic resonance image guided high intensity focused ultrasound (MRgFUS), stereotactic
0398T	ablation lesion, intracranial for movement disorder including stereotactic navigation and frame placement when performed
00001	Obstetrics (expanded carrier screening), 145 genes by next-generation sequencing, fragment
	analysis and multiplex ligation-dependent probe amplification, DNA, reported as carrier
0400U	positive or negative
	Cardiology (coronary heart disease [CHD]), 9 genes (12 variants), targeted variant genotyping,
0401U	blood, saliva, or buccal swab, algorithm reported as a genetic risk score for a coronary event
	Oncology (prostate), mRNA, gene expression profiling of 18 genes, first-catch urine, algorithm
0403U	reported as percentage of likelihood of detecting clinically significant prostate cancer
	Oncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing,
0405U	plasma, reported as cancer signal detected or not detected
	Nephrology (diabetic chronic kidney disease [CKD]), multiplex electrochemiluminescent
	immunoassay (ECLIA) of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor
0407U	necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) combined with clinical data, plasma, algorithm reported as risk for progressive decline in kidney function
04070	Insertion or replacement of permanent cardiac contractility modulation system, including
	contractility evaluation when performed, and programming of sensing and therapeutic
0408T	parameters; pulse generator with transvenous electrodes
	Insertion or replacement of permanent cardiac contractility modulation system, including
	contractility evaluation when performed, and programming of sensing and therapeutic
0409T	parameters; pulse generator only
	Oncology (solid tumor), DNA (80 genes) and RNA (36 genes), by next-generation sequencing
	from plasma, including single nucleotide variants, insertions/deletions, copy number
0.40011	alterations, microsatellite instability, and fusions, report showing identified mutations with
0409U	clinical actionability Insertion or replacement of permanent cardiac contractility modulation system, including
	contractility evaluation when performed, and programming of sensing and therapeutic
0410T	parameters; atrial electrode only
04101	Oncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine
0410U	enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected
	Insertion or replacement of permanent cardiac contractility modulation system, including
	contractility evaluation when performed, and programming of sensing and therapeutic
0411T	parameters; ventricular electrode only
	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic
0411U	analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6
0412T	Removal of permanent cardiac contractility modulation system; pulse generator only
0.44.011	Beta amyloid, AB42/40 ratio, immunoprecipitation with quantitation by liquid chromatography
0412U	with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific

	proteotyping, plasma combined with age, algorithm reported as presence or absence of brain
	amyloid pathology
0413T	Removal of permanent cardiac contractility modulation system; transvenous electrode (atrial or ventricular)
	Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations,
	aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone
0413U	marrow, report of clinically significant alterations
0414T	Removal and replacement of permanent cardiac contractility modulation system pulse generator only
	Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes
	(ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1, if
041411	performed, formalin-fixed paraffin-embedded (FFPE) tissue, reported as positive or negative
0414U	for each biomarker
0415T	Repositioning of previously implanted cardiac contractility modulation transvenous electrode, (atrial or ventricular lead)
	Cardiovascular disease (acute coronary syndrome [ACS]), IL-16, FAS, FASLigand, HGF, CTACK,
	EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal
0415U	history of diabetes, blood, algorithm reported as a 5-year (deleted risk) score for ACS
0416T	Relocation of skin pocket for implanted cardiac contractility modulation pulse generator
	Programming device evaluation (in person) with iterative adjustment of the implantable device
04477	to test the function of the device and select optimal permanent programmed values with
0417T	analysis, including review and report, implantable cardiac contractility modulation system
	Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence
	with heteroplasmy detection and deletion analysis, nuclear-encoded mitochondrial gene analysis of 335 nuclear genes, including sequence changes, deletions, insertions, and copy
	number variants analysis, blood or saliva, identification and categorization of mitochondrial
0417U	disorder-associated genetic variants
	Interrogation device evaluation (in person) with analysis, review and report, includes
	connection, recording and disconnection per patient encounter, implantable cardiac
0418T	contractility modulation system
	Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis
0419U	of 13 genes, saliva or buccal swab, report of each gene phenotype
	Oncology (urothelial), mRNA expression profiling by real-time quantitative PCR of MDK,
	HOXA13, CDC2, IGFBP5, and CXCR2 in combination with droplet digital PCR (ddPCR) analysis
	of 6 single-nucleotide polymorphisms (SNPs) genes TERT and FGFR3, urine, algorithm reported
0420U	as a risk score for urothelial carcinoma
	Oncology (pan-solid tumor), analysis of DNA biomarker response to anti-cancer therapy using
	cell-free circulating DNA, biomarker comparison to a previous baseline pre-treatment cell-free
042211	circulating DNA analysis using next-generation sequencing, algorithm reported as a
0422U	quantitative change from baseline, including specific alterations, if appropriate Psychiatry (eg, depression, anxiety), genomic analysis panel, including variant analysis of 26
0423U	genes, buccal swab, report including metabolizer status and risk of drug toxicity by condition
04230	Insertion or replacement of neurostimulator system for treatment of central sleep apnea;
	complete system (transvenous placement of right or left stimulation lead, sensing lead,
0424T	implantable pulse generator)
04241	implantable pulse generatory

	Oncology (prostate), exosome-based analysis of 53 small noncoding RNAs (sncRNAs) by
	quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as no
0424U	molecular evidence, low-, moderate- or elevated-risk of prostate cancer
04240	Insertion or replacement of neurostimulator system for treatment of central sleep apnea;
0425T	sensing lead only
04251	
040511	Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence
0425U	analysis, each comparator genome (eg, parents, siblings)
04007	Insertion or replacement of neurostimulator system for treatment of central sleep apnea;
0426T	stimulation lead only
040011	Genome (eg, unexplained constitutional or heritable disorder or syndrome), ultra-rapid
0426U	sequence analysis
04077	Insertion or replacement of neurostimulator system for treatment of central sleep apnea;
0427T	pulse generator only
0428T	Removal of neurostimulator system for treatment of central sleep apnea; pulse generator only
	Oncology (breast), targeted hybrid-capture genomic sequence analysis panel, circulating
	tumor DNA (ctDNA) analysis of 56 or more genes, interrogation for sequence variants, gene
0.40011	copy number amplifications, gene rearrangements, microsatellite instability, and tumor
0428U	mutation burden
0429T	Removal of neurostimulator system for treatment of central sleep apnea; sensing lead only
0430T	Removal of neurostimulator system for treatment of central sleep apnea; stimulation lead only
	Gastroenterology, malabsorption evaluation of alpha-1-antitrypsin, calprotectin, pancreatic
0430U	elastase and reducing substances, feces, quantitative
	Removal and replacement of neurostimulator system for treatment of central sleep apnea,
0431T	pulse generator only
	Repositioning of neurostimulator system for treatment of central sleep apnea; stimulation lead
0432T	only
	Repositioning of neurostimulator system for treatment of central sleep apnea; sensing lead
0433T	only
	Oncology (prostate), 5 DNA regulatory markers by quantitative PCR, whole blood, algorithm,
0433U	including prostate-specific antigen, reported as likelihood of cancer
	Interrogation device evaluation implanted neurostimulator pulse generator system for central
0434T	sleep apnea
	Drug metabolism (adverse drug reactions and drug response), genomic analysis panel, variant
0434U	analysis of 25 genes with reported phenotypes
	Programming device evaluation of implanted neurostimulator pulse generator system for
0435T	central sleep apnea; single session
	Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from
	cultured CSCs and primary tumor cells, categorical drug response reported based on
0435U	cytotoxicity percentage observed, minimum of 14 drugs or drug combinations
	Programming device evaluation of implanted neurostimulator pulse generator system for
0436T	central sleep apnea; during sleep study
	Psychiatry (anxiety disorders), mRNA, gene expression profiling by RNA sequencing of 15
0437U	biomarkers, whole blood, algorithm reported as predictive risk score
	Drug metabolism (adverse drug reactions and drug response), buccal specimen, gene-drug
	interactions, variant analysis of 33 genes, including deletion/duplication analysis of CYP2D6,
0438U	including reported phenotypes and impacted gene-drug interactions

	B-amyloid (Abeta42) and phospho tau (181P) (pTau181), electrochemiluminescent
	immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid
0445U	pathology
	Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the
0449T	subconjunctival space; initial device
	Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the
	subconjunctival space; each additional device (List separately in addition to code for primary
0450T	procedure)
	Device evaluation, interrogation, and initial programming of intraocular retinal electrode array
	(eg, retinal prosthesis), in person, with iterative adjustment of the implantable device to test
	functionality, select optimal permanent programmed values with analysis, including visual
0472T	training, with review and report by a qualified health care professional
-	Device evaluation and interrogation of intraocular retinal electrode array (eg, retinal
	prosthesis), in person, including reprogramming and visual training, when performed, with
0473T	review and report by a qualified health care professional
	Insertion of anterior segment aqueous drainage device, with creation of intraocular reservoir,
0474T	internal approach, into the supraciliary space
	Injection(s), autologous white blood cell concentrate (autologous protein solution), any site,
0481T	including image guidance, harvesting and preparation, when performed
	Transcatheter mitral valve implantation/replacement (TMVI) with prosthetic valve;
0483T	percutaneous approach, including transseptal puncture, when performed
	Transcatheter mitral valve implantation/replacement (TMVI) with prosthetic valve;
0484T	transthoracic exposure (eg, thoracotomy, transapical)
	Autologous adipose-derived regenerative cell therapy for scleroderma in the hands; adipose
	tissue harvesting, isolation and preparation of harvested cells including incubation with cell
	dissociation enzymes, removal of non-viable cells and debris, determination of concentration
0489T	and dilution of regenerative cells
	Autologous adipose-derived regenerative cell therapy for scleroderma in the hands; multiple
0490T	injections in one or both hands
	Surgical preparation and cannulation of marginal (extended) cadaver donor lung(s) to ex vivo
	organ perfusion system, including decannulation, separation from the perfusion system, and
0494T	cold preservation of the allograft prior to implantation, when performed
	Initiation and monitoring marginal (extended) cadaver donor lung(s) organ perfusion system by
	physician or qualified health care professional, including physiological and laboratory
	assessment (eg, pulmonary artery flow, pulmonary artery pressure, left atrial pressure,
	pulmonary vascular resistance, mean/peak and plateau airway pressure, dynamic compliance
	and perfusate gas analysis), including bronchoscopy and X ray when performed; first two hours
0495T	in sterile field
	Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of
	intravascular stent graft(s) and closure by any method, including percutaneous or open
	vascular access, ultrasound guidance for vascular access when performed, all
	catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to
OFOFT	complete the intervention, all associated radiological supervision and interpretation, when
0505T	performed, with crossing of the occlusive lesion in an extraluminal fashion
0510T	Removal of sinus tarsi implant
0511T	Removal and reinsertion of sinus tarsi implant

0512T	Extracorporeal shock wave for integumentary wound healing, including topical application and dressing care; initial wound
	Insertion of wireless cardiac stimulator for left ventricular pacing, including device
	interrogation and programming, and imaging supervision and interpretation, when performed;
0515T	complete system (includes electrode and generator [transmitter and battery])
	Insertion of wireless cardiac stimulator for left ventricular pacing, including device
	interrogation and programming, and imaging supervision and interpretation, when performed;
0516T	electrode only
	Insertion of wireless cardiac stimulator for left ventricular pacing, including device
	interrogation and programming, and imaging supervision and interpretation, when performed;
0517T	both components of pulse generator (battery and transmitter) only
	Removal of pulse generator for wireless cardiac stimulator for left ventricular pacing; battery
0518T	component only
	Removal and replacement of pulse generator for wireless cardiac stimulator for left ventricular
	pacing, including device interrogation and programming; both components (battery and
0519T	transmitter)
	Removal and replacement of pulse generator for wireless cardiac stimulator for left ventricular
0520T	pacing, including device interrogation and programming; battery component only
	Interrogation device evaluation (in person) with analysis, review and report, includes
	connection, recording, and disconnection per patient encounter, wireless cardiac stimulator
0521T	for left ventricular pacing
	Programming device evaluation (in person) with iterative adjustment of the implantable device
	to test the function of the device and select optimal permanent programmed values with
0522T	analysis, including review and report, wireless cardiac stimulator for left ventricular pacing
	Endovenous catheter directed chemical ablation with balloon isolation of incompetent
	extremity vein, open or percutaneous, including all vascular access, catheter manipulation,
0524T	diagnostic imaging, imaging guidance and monitoring
	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the
	lead and monitor, initial system programming, and imaging supervision and interpretation;
0525T	complete system (electrode and implantable monitor)
	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the
0500T	lead and monitor, initial system programming, and imaging supervision and interpretation;
0526T	electrode only
	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the
05077	lead and monitor, initial system programming, and imaging supervision and interpretation;
0527T	implantable monitor only
OFOOT	Programming device evaluation (in person) of intracardiac ischemia monitoring system with
0528T	iterative adjustment of programmed values, with analysis, review, and report
0529T	Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with
05291	analysis, review, and report Removal of intracardiac ischemia monitoring system, including all imaging supervision and
0530T	interpretation; complete system (electrode and implantable monitor)
03301	Removal of intracardiac ischemia monitoring system, including all imaging supervision and
0531T	interpretation; electrode only
00011	Removal of intracardiac ischemia monitoring system, including all imaging supervision and
0532T	interpretation; implantable monitor only
00021	

0537T	Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes
05371	for development of genetically modified autologous CAR-T cells, per day
0538T	Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)
00001	Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells for
0539T	administration
05301 0540T	Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous
03401	Transcatheter mitral valve annulus reconstruction, with implantation of adjustable annulus
0544T	reconstruction device, percutaneous approach including transseptal puncture
00441	Transcatheter tricuspid valve annulus reconstruction with implantation of adjustable annulus
0545T	reconstruction device, percutaneous approach
	Radiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of
0546T	partial mastectomy, with report
	Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a
0552T	physician or other qualified health care professional
	Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid
0563T	treatment devices and manual gland expression, bilateral
	Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from
	cultured CSCs and primary tumor cells, categorical drug response reported based on percent
0564T	of cytotoxicity observed, a minimum of 14 drugs or drug combinations
	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of
0565T	the knees; tissue harvesting and cellular implant creation
0.5.0.T	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of
0566T	the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral
0569T	Transcatheter tricuspid valve repair, percutaneous approach; initial prosthesis
05047	Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance
0581T	when performed, unilateral
	Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed;
0584T	percutaneous
03041	Islet cell transplant, includes portal vein catheterization and infusion, including all imaging,
	including guidance, and radiological supervision and interpretation, when performed;
0585T	laparoscopic
	Islet cell transplant, includes portal vein catheterization and infusion, including all imaging,
0586T	including guidance, and radiological supervision and interpretation, when performed; open
	Percutaneous implantation or replacement of integrated single device neurostimulation
	system for bladder dysfunction including electrode array and receiver or pulse generator,
0587T	including analysis, programming, and imaging guidance when performed, posterior tibial nerve
	Revision or removal of percutaneously placed integrated single device neurostimulation
	system for bladder dysfunction including electrode array and receiver or pulse generator,
0588T	including analysis, programming, and imaging guidance when performed, posterior tibial nerve
05005	Temporary female intraurethral valve-pump (ie, voiding prosthesis); initial insertion, including
0596T	urethral measurement
0597T	Temporary female intraurethral valve-pump (ie, voiding prosthesis); replacement
00007	Ablation, irreversible electroporation; 1 or more tumors per organ, including imaging guidance,
0600T	when performed, percutaneous

	Ablation, irreversible electroporation; 1 or more tumors per organ, including fluoroscopic and
0601T	ultrasound guidance, when performed, open
00011	Remote monitoring of an external continuous pulmonary fluid monitoring system, including
	measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate,
	activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour
0607T	attended surveillance center; set-up and patient education on use of equipment
-	Remote monitoring of an external continuous pulmonary fluid monitoring system, including
	measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate,
	activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour
	attended surveillance center; analysis of data received and transmission of reports to the
0608T	physician or other qualified health care professional
	Automated analysis of binocular eye movements without spatial calibration, including
	disconjugacy, saccades, and pupillary dynamics for the assessment of concussion, with
0615T	interpretation and report
	Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when
	performed; without removal of crystalline lens or intraocular lens, without insertion of
0616T	intraocular lens
00477	Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when
0617T	performed; with removal of crystalline lens and insertion of intraocular lens
0618T	Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; with secondary intraocular lens placement or intraocular lens exchange
00101	Endovascular venous arterialization, tibial or peroneal vein, with transcatheter placement of
	intravascular stent graft(s) and closure by any method, including percutaneous or open
	vascular access, ultrasound guidance for vascular access when performed, all
	catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to
	complete the intervention, all associated radiological supervision and interpretation, when
0620T	performed
	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc,
0627T	unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level
	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc,
0629T	unilateral or bilateral injection, with CT guidance, lumbar; first level
	Computed tomography, breast, including 3D rendering, when performed, unilateral; without
0633T	contrast material
	Computed tomography, breast, including 3D rendering, when performed, unilateral; with
0634T	contrast material(s)
	Computed tomography, breast, including 3D rendering, when performed, unilateral; without
0635T	contrast, followed by contrast material(s)
	Computed tomography, breast, including 3D rendering, when performed, bilateral; without
0636T	contrast material(s)
00077	Computed tomography, breast, including 3D rendering, when performed, bilateral; with
0637T	contrast material(s)
00007	Computed tomography, breast, including 3D rendering, when performed, bilateral; without
0638T	contrast, followed by contrast material(s)
	Transcatheter tricuspid valve implantation (TTVI)/replacement with prosthetic valve,
06467	percutaneous approach, including right heart catheterization, temporary pacemaker insertion,
0646T	and selective right ventricular or right atrial angiography, when performed

	Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water
	content), including multiparametric data acquisition, data preparation and transmission,
	interpretation and report, obtained without diagnostic MRI examination of the same anatomy
0648T	(eg, organ, gland, tissue, target structure) during the same session; single organ
	Esophagogastroduodenoscopy, flexible, transnasal; diagnostic, including collection of
0652T	specimen(s) by brushing or washing, when performed (separate procedure)
0653T	Esophagogastroduodenoscopy, flexible, transnasal; with biopsy, single or multiple
	Esophagogastroduodenoscopy, flexible, transnasal; with insertion of intraluminal tube or
0654T	catheter
	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging
0655T	guidance, with MR-fused images or other enhanced ultrasound imaging
0656T	Anterior lumbar or thoracolumbar vertebral body tethering; up to 7 vertebral segments
0657T	Anterior lumbar or thoracolumbar vertebral body tethering; 8 or more vertebral segments
	Electrical impedance spectroscopy of 1 or more skin lesions for automated melanoma risk
0658T	score
	Transcatheter intracoronary infusion of supersaturated oxygen in conjunction with
	percutaneous coronary revascularization during acute myocardial infarction, including
	catheter placement, imaging guidance (eg, fluoroscopy), angiography, and radiologic
0659T	supervision and interpretation
0664T	Donor hysterectomy (including cold preservation); open, from cadaver donor
0665T	Donor hysterectomy (including cold preservation); open, from living donor
0666T	Donor hysterectomy (including cold preservation); laparoscopic or robotic, from living donor
	Donor hysterectomy (including cold preservation); recipient uterus allograft transplantation
0667T	from cadaver or living donor
	Backbench standard preparation of cadaver or living donor uterine allograft prior to
0000T	transplantation, including dissection and removal of surrounding soft tissues and preparation
0668T	of uterine vein(s) and uterine artery(ies), as necessary
0000T	Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation;
0669T	venous anastomosis, each Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation;
0670T	arterial anastomosis, each
00701	Insertion of anterior segment aqueous drainage device into the trabecular meshwork, without
0671T	external reservoir, and without concomitant cataract removal, one or more
00711	Endovaginal cryogen-cooled, monopolar radiofrequency remodeling of the tissues surrounding
0672T	the female bladder neck and proximal urethra for urinary incontinence
0673T	Ablation, benign thyroid nodule(s), percutaneous, laser, including imaging guidance
	Treatment of amblyopia using an online digital program; device supply, educational set-up,
0687T	and initial session
	Treatment of amblyopia using an online digital program; assessment of patient performance
	and program data by physician or other qualified health care professional, with report, per
0688T	calendar month
	Quantitative ultrasound tissue characterization (non-elastographic), including interpretation
	and report, obtained without diagnostic ultrasound examination of the same anatomy (eg,
0689T	organ, gland, tissue, target structure)

	Quantitative ultrasound tissue characterization (non-elastographic), including interpretation
	and report, obtained with diagnostic ultrasound examination of the same anatomy (eg, organ,
0690T	gland, tissue, target structure) (List separately in addition to code for primary procedure)
0692T	Therapeutic ultrafiltration
0700T	Molecular fluorescent imaging of suspicious nevus; first lesion
07001	Remote treatment of amblyopia using an eye tracking device; device supply with initial set-up
0704T	and patient education on use of equipment
	Remote treatment of amblyopia using an eye tracking device; surveillance center technical
	support including data transmission with analysis, with a minimum of 18 training hours, each
0705T	30 days
07007	Remote treatment of amblyopia using an eye tracking device; interpretation and report by
0706T	physician or other qualified health care professional, per calendar month
	Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff
07475	tear; adipose tissue harvesting, isolation and preparation of harvested cells, including
0717T	incubation with cell dissociation enzymes, filtration, washing and concentration of ADRCs
07407	Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff
0718T	tear; injection into supraspinatus tendon including ultrasound guidance, unilateral
0720T	Percutaneous electrical nerve field stimulation, cranial nerves, without implantation
	Colonic lavage, 35 or more liters of water, gravity-fed, with induced defecation, including
0736T	insertion of rectal catheter
	Treatment planning for magnetic field induction ablation of malignant prostate tissue, using
0738T	data from previously performed magnetic resonance imaging (MRI) examination
	Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural,
	transperineal needle/catheter placement for nanoparticle installation and intraprocedural
	temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle
0739T	activation
	Cardiac focal ablation utilizing radiation therapy for arrhythmia; noninvasive arrhythmia
	localization and mapping of arrhythmia site (nidus), derived from anatomical image data (eg,
	CT, MRI, or myocardial perfusion scan) and electrical data (eg, 12-lead ECG data), and
0745T	identification of areas of avoidance
	Cardiac focal ablation utilizing radiation therapy for arrhythmia; conversion of arrhythmia
	localization and mapping of arrhythmia site (nidus) into a multidimensional radiation
0746T	treatment plan
	Cardiac focal ablation utilizing radiation therapy for arrhythmia; delivery of radiation therapy,
0747T	arrhythmia
	Injections of stem cell product into perianal perifistular soft tissue, including fistula
0748T	preparation (eg, removal of setons, fistula curettage, closure of internal openings)
	Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse,
	peripheral nerve, with identification and mapping of the treatment location, including
	noninvasive electroneurographic localization (nerve conduction localization), when
0766T	performed; first nerve
	Virtual reality (VR) procedural dissociation services provided by the same physician or other
	qualified health care professional performing the diagnostic or therapeutic service that the VR
	procedural dissociation supports, requiring the presence of an independent, trained observer
	to assist in the monitoring of the patient's level of dissociation or consciousness and
0771T	physiological status; initial 15 minutes of intraservice time, patient age 5 years or older

	Virtual reality (VP) procedural discontation convious provided by a physician exother suclified
	Virtual reality (VR) procedural dissociation services provided by a physician or other qualified
	health care professional other than the physician or other qualified health care professional
07707	performing the diagnostic or therapeutic service that the VR procedural dissociation supports;
0773T	initial 15 minutes of intraservice time, patient age 5 years or older
	Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit
	(IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle
0778T	function
	Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use
0783T	of equipment
	Insertion or replacement of percutaneous electrode array, sacral, with integrated
0786T	neurostimulator, including imaging guidance, when performed
0787T	Revision or removal of neurostimulator electrode array, sacral, with integrated neurostimulator
	Revision (eg, augmentation, division of tether), replacement, or removal of thoracolumbar or
0790T	lumbar vertebral body tethering, including thoracoscopy, when performed
	Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging
	guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography,
	femoral venography) and device evaluation (eg, interrogation or programming), when
0795T	performed; complete system (ie, right atrial and right ventricular pacemaker components)
	Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging
	guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography,
	femoral venography) and device evaluation (eg, interrogation or programming), when
	performed; right atrial pacemaker component (when an existing right ventricular single
0796T	leadless pacemaker exists to create a dual-chamber leadless pacemaker system)
	Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging
	guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography,
	femoral venography) and device evaluation (eg, interrogation or programming), when
	performed; right ventricular pacemaker component (when part of a dual-chamber leadless
0797T	pacemaker system)
	Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging
	guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography,
	femoral venography), when performed; complete system (ie, right atrial and right ventricular
0798T	pacemaker components)
	Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging
	guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography,
0799T	femoral venography), when performed; right atrial pacemaker component
	Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging
	guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography,
	femoral venography), when performed; right ventricular pacemaker component (when part of a
0800T	dual-chamber leadless pacemaker system)
	Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker,
	including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right
	ventriculography, femoral venography) and device evaluation (eg, interrogation or
	programming), when performed; dual-chamber system (ie, right atrial and right ventricular
0801T	pacemaker components)
00011	Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker,
0802T	
00021	including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right

	ventriculography, femoral venography) and device evaluation (eg, interrogation or
	programming), when performed; right atrial pacemaker component
	Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-
0803T	chamber leadless pacemaker system)
0804T	Programming device evaluation (in person) with iterative adjustment of implantable device to test the function of device and to select optimal permanent programmed values, with analysis, review, and report, by a physician or other qualified health care professional, leadless pacemaker system in dual cardiac chambers
0810T	Subretinal injection of a pharmacologic agent, including vitrectomy and 1 or more retinotomies
0813T	Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon
0816T	Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subcutaneous
0817T	Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subfascial
0818T	Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve; subcutaneous
0819T	Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve; subfascial
0823T	Transcatheter insertion of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography) and device evaluation (eg, interrogation or programming), when performed
0824T	Transcatheter removal of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography), when performed
0825T	Transcatheter removal and replacement of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography) and device evaluation (eg, interrogation or programming), when performed
	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional, leadless
0826T	pacemaker system in single-cardiac chamber Removal of pulse generator for wireless cardiac stimulator for left ventricular pacing; both
0861T	components (battery and transmitter)
0862T	Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; battery component only
0863T	Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; transmitter component only

0864T	Low-intensity extracorporeal shock wave therapy involving corpus cavernosum, low energy
A0430	Fixed Wing Air Transport
A0431	Rotary Wing Air Transport
A0435	Fixed Wing Air Mileage
A0436	Rotary Wing Air Mileage
A2001	InnovaMatrix AC, per sq cm
A2001	Mirragen Advanced Wound Matrix, per sq cm
A2004	XCelliStem, 1 mg
A2005	Microlyte Matrix, per sq cm
A2006	Novosorb synpath dermal matrix, per square centimeter
A2007	Restrata, per square centimeter
A2008	Theragenesis, per square centimeter
A2009	Symphony, per square centimeter
A2010	Apis, per square centimeter
A2011	Supra SDRM, per sq cm
A2012	SUPRATHEL, per sq cm
A2013	Innovamatrix FS, per sq cm
A2014	Omeza collagen matrix, per 100 mg
A2015	Phoenix Wound Matrix, per sq cm
A2016	Permeaderm b, per square centimeter
A2017	PermeaDerm Glove, each
A2018	Permeaderm c, per square centimeter
A2019	Kerecis omega3 marigen shield, per square centimeter
A2020	Ac5 advanced wound system (ac5)
A2021	Neomatrix, per square centimeter
A2022	InnovaBurn or InnovaMatrix XL, per sq cm
A2023	InnovaMatrix PD, 1 mg
A2024	Resolve matrix or xenopatch, per square centimeter
A2025	Miro3D, per cu cm
A2026	Restrata MiniMatrix, 5 mg
A4341	Indwelling intraurethral drainage device with valve, patient inserted, replacement only, each
	Accessories for patient inserted indwelling intraurethral drainage device with valve,
A4342	replacement only, each
A4438	Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each
A4468	Exsufflation belt, includes all supplies and accessories
A4540	Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm
A4542	Supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist
A404Z	Electrode/transducer for use with electrical stimulation device used for cancer treatment,
A4555	replacement only
A4575	Topical hyperbaric oxygen chamber, disposable
A4596	Cranial electrotherapy stimulation (ces) system supplies and accessories, per month
A4600	SLEEVE FOR INTERMITTENT LIMB COMPRESSION DEVICE, REPLACEMENT ONLY, EACH

A4604	Tubing with integrated heating element for use with positive airway pressure device
A7027	Combination oral/nasal mask, used with continuous positive airway pressure
A7028	Oral cushion for combination oral/nasal mask, replacement only, each
A7029	Nasal pillows for combination oral/nasal mask, replacement only, pair
A7030	Full Face Mask Used With Positive Airway Pressure Device, Each
A7031	Face Mask Interface, Replacement For Full Face Mask, Each
A7032	Cushion for use on nasal mask interface, replacement only, each
A7033	Pillow for use on nasal cannula type interface, replacement only, pair
A7034	Nasal Interface (Mask Or Cannula Type) Used With Positive Airway Press
A7035	Headgear Used With Positive Airway Pressure Device
A7036	Chinstrap Used With Positive Airway Pressure Device
A7037	Tubing Used With Positive Airway Pressure Device
A7038	Filter, Disposable, Used With Positive Airway Pressure Device
A7039	Filter, Non Disposable, Used With Positive Airway Pressure Device
A7044	Oral Interface Used With Positive Airway Pressure Device, Each
A7045	Repl exhalation port for PAP
A7046	Water chamber for humidifier, used with positive airway pressure device, replacement, each
A9268	Programmer for transient, orally ingested capsule
	Programmable, transient, orally ingested capsule, for use with external programmer, per
A9269	month
A9292	Prescription digital visual therapy, software-only, FDA cleared, per course of treatment
A9513	Lutetium Lu 177, dotatate, therapeutic, 1 mCi
A9543	Yttrium Y-90 ibritumomab tiuxetan, therapeutic, per treatment dose, up to 40 millicuries
A9582	Iodine I-123 Iobenguane, Diagnostic, Per Study Dose, Up To 15 Millicuries
A9590	lodine I-131, iobenguane, 1 mCi
A9606	Radium RA-223 dichloride, therapeutic, per UCI
A9607	Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie
	Parenteral nutrition solution: carbohydrates (dextrose), 50% or less (500 ml = 1 unit), home
B4164	mix
B4168	Parenteral nutrition solution; amino acid, 3.5%, (500 ml = 1 unit) - home mix
B4172	Parenteral nutrition solution; amino acid, 5.5% through 7%, (500 ml = 1 unit) - home mix
B4176	Parenteral nutrition solution; amino acid, 7% through 8.5%, (500 ml = 1 unit) - home mix
B4178	Parenteral nutrition solution: amino acid, greater than 8.5% (500 ml = 1 unit) - home mix
D 4400	Parenteral nutrition solution: carbohydrates (dextrose), greater than 50% (500 ml = 1 unit),
B4180	home mix
B4185	Parenteral nutrition solution, not otherwise specified, 10 grams lipids
B4187	Omegaven, 10 g lipids
B4189	Parenteral nutrition solution: compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, 10 to 51 g of protein, premix
04103	Parenteral nutrition solution: compounded amino acid and carbohydrates with electrolytes,
B4193	trace elements, and vitamins, including preparation, any strength, 52 to 73 g of protein, premix
2.200	Parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes,
	trace elements and vitamins, including preparation, any strength, 74 to 100 g of protein -
B4197	premix

B4199       tr        B4216       d         B4220       P         B4222       P         B4224       P         B4224       P         B5000       N         B5100       P         tr        tr <td< th=""><th>Parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements and vitamins, including preparation, any strength, over 100 g of protein - premix Parenteral nutrition; additives (vitamins, trace elements, Heparin, electrolytes), home mix, per day Parenteral nutrition supply kit; premix, per day Parenteral nutrition supply kit; home mix, per day Parenteral nutrition administration kit, per day Parenteral nutrition solution: compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, renal - Amirosyn RF, NephrAmine, RenAmine - premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, stress-branch chain amino acids-FreAmine-HBC-premix</th></td<>	Parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements and vitamins, including preparation, any strength, over 100 g of protein - premix Parenteral nutrition; additives (vitamins, trace elements, Heparin, electrolytes), home mix, per day Parenteral nutrition supply kit; premix, per day Parenteral nutrition supply kit; home mix, per day Parenteral nutrition administration kit, per day Parenteral nutrition solution: compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, renal - Amirosyn RF, NephrAmine, RenAmine - premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, stress-branch chain amino acids-FreAmine-HBC-premix
P           B4216         dd           B4220         P           B4222         P           B4224         P           B4224         P           b5000         N           B5000         P           tr         B5100           P         tr           b5100         P           tr         T	Parenteral nutrition; additives (vitamins, trace elements, Heparin, electrolytes), home mix, per day Parenteral nutrition supply kit; premix, per day Parenteral nutrition administration kit, per day Parenteral nutrition administration kit, per day Parenteral nutrition solution: compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, renal - Amirosyn RF, NephrAmine, RenAmine - premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix
B4216       d         B4220       P         B4222       P         B4224       P         B5000       N         B5100       P         C       P         B5100       P         C       P         C       P         B5100       P         C       P         C       P         C       P         B5100       P         C       P         C       P         C       P         C       P         D       P         D       P         D       P         D       P         D       P         D       P         D       P         D       P         D       P         D       P         D       P         D       P         D       P         D       P         D       P         D       P         D       P         D       P         D       P	day Parenteral nutrition supply kit; premix, per day Parenteral nutrition supply kit; home mix, per day Parenteral nutrition administration kit, per day Parenteral nutrition solution: compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, renal - Amirosyn RF, NephrAmine, RenAmine - premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, stress-branch chain amino
B4222         P           B4224         P           tr         F           B5000         N           B5100         P           tr         F           tr         T           B5100         P           tr         T	Parenteral nutrition supply kit; home mix, per day Parenteral nutrition administration kit, per day Parenteral nutrition solution: compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, renal - Amirosyn RF, NephrAmine, RenAmine - premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, stress-branch chain amino
B4224 P tr B5000 N E5100 P tr B5100 P tr	Parenteral nutrition administration kit, per day Parenteral nutrition solution: compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, renal - Amirosyn RF, NephrAmine, RenAmine - premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, stress-branch chain amino
P tr B5000 N P tr B5100 P tr t	Parenteral nutrition solution: compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, renal - Amirosyn RF, NephrAmine, RenAmine - premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix
1 ti B5000 N P ti B5100 P F t	trace elements, and vitamins, including preparation, any strength, renal - Amirosyn RF, NephrAmine, RenAmine - premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix
B5000 N P tr B5100 P P tr	NephrAmine, RenAmine - premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, stress-branch chain amino
ti B5100 p P ti	trace elements, and vitamins, including preparation, any strength, hepatic-HepatAmine- premix Parenteral nutrition solution compounded amino acid and carbohydrates with electrolytes, trace elements, and vitamins, including preparation, any strength, stress-branch chain amino
ti	trace elements, and vitamins, including preparation, any strength, stress-branch chain amino
B5200 a	
B9004 P	Parenteral nutrition infusion pump, portable
B9006 P	Parenteral nutrition infusion pump, stationary
P	Pacemaker, leadless, dual chamber (right atrial and right ventricular implantable
	components), rate-responsive, including all necessary components for implantation
	Cardioverter-defibrillator, dual chamber (implantable)
C1722 C	Cardioverter-defibrillator, single chamber (implantable)
C1734 C	Orthopedic/device/drug matrix for opposing bone-to-bone or soft tissue-to bone (implantable)
C1764 E	Event recorder, cardiac (implantable)
C1767 G	Generator, neurostimulator (implantable), nonrechargeable
C1777 L	Lead, cardioverter-defibrillator, endocardial single coil (implantable)
C1778 L	Lead, neurostimulator (implantable)
C1785 P	Pacemaker, dual chamber, rate-responsive (implantable)
C1786 P	Pacemaker, single chamber, rate-responsive (implantable)
C1787 P	Patient programmer, neurostimulator
C1789 P	Prosthesis, breast (implantable)
C1813 P	Prosthesis, penile, inflatable
C1815 P	Prosthesis, urinary sphincter (implantable)
C1816 R	Receiver and/or transmitter, neurostimulator (implantable)
C1820 G	Generator, neurostimulator (implantable), with rechargeable battery and charging system
C1821 Ir	Interspinous process distraction device (implantable)
	Generator, neurostimulator (implantable), high frequency, with rechargeable battery and charging system
G	Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads
	Generator, cardiac contractility modulation (implantable)
	Generator, neurostimulator (implantable), non-rechargeable with carotid sinus baroreceptor
	stimulation lead(s)
C1832 A	Autograft suspension, including cell processing and application, and all system components
	Monitor, cardiac, including intracardiac lead and all system components (implantable)

C1839	Iris prosthesis
C1878	Material for vocal cord medialization, synthetic (implantable)
C1882	Cardioverter-defibrillator, other than single or dual chamber (implantable)
C1883	Adaptor/extension, pacing lead or neurostimulator lead (implantable)
C1895	Lead, cardioverter-defibrillator, endocardial dual coil (implantable)
C1896	Lead, cardioverter-defibrillator, other than endocardial single or dual coil (implantable)
C2614	Probe, percutaneous lumbar discectomy
C2619	Pacemaker, dual chamber, nonrate-responsive (implantable)
C2620	Pacemaker, single chamber, nonrate-responsive (implantable)
C2621	Pacemaker, other than single or dual chamber (implantable)
C2622	Prosthesis, penile, noninflatable
	Implantable wireless pulmonary artery pressure sensor with delivery catheter, including all
C2624	system components
	Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area up to
C5271	100 sq cm; first 25 sq cm or less wound surface area
	Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area
	greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of
C5273	infants and children
	Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits,
05075	genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25
C5275	sq cm or less wound surface area Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits,
	genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to
C5277	100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children
002/7	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(ies),
	unilateral, with transluminal angioplasty with intravascular ultrasound (initial noncoronary
	vessel) during diagnostic evaluation and/or therapeutic intervention, including radiological
C7531	supervision and interpretation
	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(ies),
	unilateral, with atherectomy, includes angioplasty within the same vessel, when performed
07504	with intravascular ultrasound (initial noncoronary vessel) during diagnostic evaluation and/or
C7534	therapeutic intervention, including radiological supervision and interpretation
	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(ies),
	unilateral, with transluminal stent placement(s), includes angioplasty within the same vessel, when performed, with intravascular ultrasound (initial noncoronary vessel) during diagnostic
	evaluation and/or therapeutic intervention, including radiological supervision and
C7535	interpretation
	Insertion of new or replacement of permanent pacemaker with ventricular transvenous
	electrode(s), with insertion of pacing electrode, cardiac venous system, for left ventricular
	pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (e.g., for
C7538	upgrade to dual chamber system)
	Insertion of new or replacement of permanent pacemaker with atrial and ventricular
	transvenous electrode(s), with insertion of pacing electrode, cardiac venous system, for left
07500	ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse
C7539	generator (e.g., for upgrade to dual chamber system)

	Removal of permanent pacemaker pulse generator with replacement of pacemaker pulse
	generator, dual lead system, with insertion of pacing electrode, cardiac venous system, for left
	ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse
C7540	generator (e.g., for upgrade to dual chamber system)
C8903	Magnetic resonance imaging with contrast, breast; unilateral
C8905	Magnetic resonance imaging without contrast followed by with contrast, breast; unilateral
C8906	Magnetic resonance imaging with contrast, breast; bilateral
C8908	Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral
C9047	Injection, caplacizumab-yhdp, 1 mg
	Lisocabtagene maraleucel, up to 110 million autologous anti-CD19 CAR-positive viable T cells,
C9076	including leukapheresis and dose preparation procedures, per therapeutic dose
C9077	Injection, cabotegravir and rilpivirine, 2 mg/3 mg
C9079	Injection, evinacumab-dgnb, 5 mg
	Idecabtagene vicleucel, up to 460 million autologous anti-BCMA CAR-positive viable T cells,
C9081	including leukapheresis and dose preparation procedures, per therapeutic dose
C9084	Injection, loncastuximab tesirine-lpyl, 0.1 mg
C9085	Injection, avalglucosidase alfa-ngpt, 4 mg
C9086	Injection, anifrolumab-fnia, 1 mg
C9090	Injection, plasminogen, human-tvmh, 1 mg
C9091	Injection, sirolimus protein-bound particles, 1 mg
C9094	Injection, sutimlimab-jome, 10 mg
C9095	Injection, tebentafusp-tebn, 1 mcg
C9096	Injection, filgrastim-ayow, biosimilar, (Releuko), 1 mcg
C9097	Injection, faricimab-svoa, 0.1 mg
	Ciltacabtagene autoleucel, up to 100 million autologous B-cell maturation antigen (BCMA)
C9098	directed CAR-positive T cells, including leukapheresis and dose preparation procedures
C9142	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
C9146	Injection, mirvetuximab soravtansine-gynx, 1 mg
C9147	Injection, tremelimumab-actl, 1 mg
C9148	Injection, teclistamab-cqyv, 0.5 mg
C9149	Injection, teplizumab-mzwv, 5 mcg
C9151	Injection, pegcetacoplan, 1 mg
C9157	Injection, tofersen, 1 mg
C9160	Injection, daxibotulinumtoxina-lanm, 1 unit
C9161	Injection, aflibercept hd, 1 mg
C9162	Injection, avacincaptad pegol, 0.1 mg
C9166	Injection, secukinumab, IV, 1 mg
C9167	Injection, apadamtase alfa, 10 units
C9168	Injection, mirikizumab-mrkz, 1 mg
C9169	Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 mcg
C9170	Injection, tarlatamab-dlle, 1 mg
C9257	Injection, bevacizumab, 0.25 mg
C9352	Microporous collagen implantable tube (NeuraGen Nerve Guide), per cm length
C9353	Microporous collagen implantable slit tube (NeuraWrap Nerve Protector), per cm length

C9354	Acellular pericardial tissue matrix of nonhuman origin (Veritas), per sq cm
C9355	Collagen nerve cuff (NeuroMatrix), per 0.5 cm length
	Tendon, porous matrix of cross-linked collagen and glycosaminoglycan matrix (TenoGlide
C9356	Tendon Protector Sheet), per sq cm
	Dermal substitute, native, nondenatured collagen, fetal bovine origin (SurgiMend Collagen
C9358	Matrix), per 0.5 sq cm
	Porous purified collagen matrix bone void filler (Integra Mozaik Osteoconductive Scaffold
C9359	Putty, Integra OS Osteoconductive Scaffold Putty), per 0.5 cc
	Dermal substitute, native, nondenatured collagen, neonatal bovine origin (SurgiMend Collagen
C9360	Matrix), per 0.5 sq cm
C9361	Collagen matrix nerve wrap (NeuroMend Collagen Nerve Wrap), per 0.5 cm length
	Porous purified collagen matrix bone void filler (Integra Mozaik Osteoconductive Scaffold
C9362	Strip), per 0.5 cc
C9363	Skin substitute (Integra Meshed Bilayer Wound Matrix), per square cm
C9364	Porcine implant, Permacol, per sq cm
	Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary
C9600	angioplasty when performed; single major coronary artery or branch
	Percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary
	angioplasty when performed; each additional branch of a major coronary artery (list separately
C9601	in addition to code for primary procedure)
	Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with
C9602	coronary angioplasty when performed; single major coronary artery or branch
	Percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with
00000	coronary angioplasty when performed; each additional branch of a major coronary artery (list
C9603	separately in addition to code for primary procedure)
	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent,
C9604	atherectomy and angioplasty, including distal protection when performed; single vessel
03004	Percutaneous transluminal revascularization of or through coronary artery bypass graft
	(internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent,
	atherectomy and angioplasty, including distal protection when performed; each additional
	branch subtended by the bypass graft (list separately in addition to code for primary
C9605	procedure)
	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery,
	coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting
C9607	intracoronary stent, atherectomy and angioplasty; single vessel
	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery,
	coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting
	intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary
C9608	artery branch, or bypass graft (list separately in addition to code for primary procedure)
C9727	Insertion of implants into the soft palate; minimum of 3 implants
	Focused ultrasound ablation/therapeutic intervention, other than uterine leiomyomata, with
C9734	magnetic resonance (mr) guidance
	Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy,
	including fluoroscopic guidance, when performed, with computed tomography acquisition(s)
0077	and 3D rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound
C9751	(EBUS) guided transtracheal and/or transbronchial sampling (e.g., aspiration[s]/biopsy[ies])

	and all mediastinal and/or hilar lymph node stations or structures and therapeutic
	intervention(s)
	Destruction of intraosseous basivertebral nerve, first two vertebral bodies, including imaging
C9752	guidance (e.g., fluoroscopy), lumbar/sacrum
00702	Cardiac magnetic resonance imaging for morphology and function, quantification of
C9762	segmental dysfunction; with strain imaging
03702	Cardiac magnetic resonance imaging for morphology and function, quantification of
C9763	segmental dysfunction; with stress imaging
03703	Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except
	tibial/peroneal; with intravascular lithotripsy, includes angioplasty within the same vessel(s),
C9764	when performed
09704	
	Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except
00705	tibial/peroneal; with intravascular lithotripsy, and transluminal stent placement(s), includes
C9765	angioplasty within the same vessel(s), when performed
	Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except
00700	tibial/peroneal; with intravascular lithotripsy and atherectomy, includes angioplasty within the
C9766	same vessel(s), when performed
	Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except
00707	tibial/peroneal; with intravascular lithotripsy and transluminal stent placement(s), and
C9767	atherectomy, includes angioplasty within the same vessel(s), when performed
	Vitrectomy, mechanical, pars plana approach, with subretinal injection of
C9770	pharmacologic/biologic agent
C9771	Nasal/sinus endoscopy, cryoablation nasal tissue(s) and/or nerve(s), unilateral or bilateral
	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies), with
C9772	intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed
	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with
C9773	intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty
	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with
	intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s),
C9774	when performed
	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with
	intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes
C9775	angioplasty within the same vessel(s), when performed
	Gastric restrictive procedure, endoscopic sleeve gastroplasty, with
	esophagogastroduodenoscopy and intraluminal tube insertion, if performed, including all
C9784	system and tissue anchoring components
	Endoscopic outlet reduction, gastric pouch application, with endoscopy and intraluminal tube
C9785	insertion, if performed, including all system and tissue anchoring components
	Repair of enterocutaneous fistula small intestine or colon (excluding anorectal fistula) with
C9796	plug (e.g., porcine small intestine submucosa [SIS])
	Vascular embolization or occlusion procedure with use of a pressure-generating catheter (e.g.,
	one-way valve, intermittently occluding), inclusive of all radiological supervision and
	interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the
C9797	intervention; for tumors, organ ischemia, or infarction
D7810	Open Reduction Of Dislocation
D7820	Closed Reduction Of Dislocation
D7830	Manipulation Under Anesthesia

D7840	condylectomy
D7850	Surgical Discectomy, With/Without Implant
D7852	Disc Repair
D7854	Synovectomy
D7856	Myotomy
D7858	Joint Reconstruction
D7860	Arthrotomy
D7865	Arthroplasty
D7870	Arthrocentesis
D7871	Non-Arthroscopic Lysis And Lavage
D7873	arthroscopy: lavage and lysis of adhesions
D7874	arthroscopy: disc repositioning and stabilization
D7875	arthroscopy: synovectomy
D7876	arthroscopy: discectomy
D7877	arthroscopy: debridement
D7880	Occlusal Orthotic Device, By Report
D7899	Unspecified Tmd Therapy, By Report
D7940	Osteoplasty - For Orthognathic Deformities
D7941	Osteotomy - Mandibular Rami
D7943	Osteotomy - Mandibular Rami With Bone Graft; Includes Obtaining The Graft
D7944	OSTEOTOMY-SEGMENTED OR SUBAPICAL
D7945	osteotomy - body of mandible
D7946	LeFort I (maxilla - total)
D7947	Lefort I (Maxilla - Segmented)
	LeFort II or LeFort III (osteoplasty of facial bones for midface hypoplasia or retrusion) - without
D7948	bone graft
D7949	Lefort li Or Lefort lii - With Bone Graft
	Osseous, osteoperiosteal, or cartilage graft of the mandible or maxilla - autogenous or
D7950	nonautogenous, by report
D7995	Synthetic Graft - Mandible Or Facial Bones, By Report
D7996	Implant-Mandible For Augmentation Purposes (Excluding Alveolar Ridge), By Report
D9950	Occlusion Analysis - Mounted Case
D9951	Occlusal Adjustment - Limited
D9952	Occlusal Adjustment - Complete
E0217	Water Circ Heat Pad W Pump
E0218	Fluid circulating cold pad with pump, any type
E0236	Pump for water circulating pad
E0470	Respiratory assist device, bi-level pressure capability, without backup rate
E0471	Respiratory assist device, bi-level pressure capability, with back-up rate
E0481	Intrapulmonary percussive ventilation system and related accessories
	Oral device/appliance used to reduce upper airway collapsibility, adjustable or nonadjustable,
E0485	prefabricated, includes fitting and adjustment
50 100	Oral device/appliance used to reduce upper airway collapsibility, adjustable or nonadjustable,
E0486	custom fabricated, includes fitting and adjustment

	Power source and control electronics unit for oral device/appliance for neuromuscular
E0490	electrical stimulation of the tongue muscle, controlled by hardware remote
	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in
E0491	conjunction with the power source and control electronics unit, controlled by hard
	Power source and control electronics unit for oral device/appliance for neuromuscular
E0492	electrical stimulation of the tongue muscle, controlled by phone application
	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in
	conjunction with the power source and control electronics unit, controlled by phone
E0493	application, 90-day supply
	Electronic positional obstructive sleep apnea treatment, with sensor, includes all components
E0530	and accessories, any type
E0561	Humidifier, non-heated, used with positive airway pressure device
E0562	Humidifier, heated, used with positive airway pressure device
E0601	Continuous positive airway pressure (cpap) device
E0616	Cardiac Event Recorder
E0617	Automatic Ext Defibrillator
E0650	Pneuma Compresor Non-Segment
E0651	Pneum Compressor Segmental
E0652	Pneum Compres W/Cal Pressure
E0655	Pneumatic Appliance Half Arm
E0656	Segmental pneumatic appliance for use with pneumatic compressor, trunk
E0657	Segmental pneumatic appliance for use with pneumatic compressor, chest
E0660	Pneumatic Appliance Full Leg
E0665	Pneumatic Appliance Full Arm
E0666	Pneumatic Appliance Half Leg
E0667	Seg Pneumatic Appl Full Leg
E0668	Seg Pneumatic Appl Full Arm
E0669	Seg Pneumatic Appli Half Leg
	Segmental pneumatic appliance for use with pneumatic compressor, integrated, 2 full legs
E0670	and trunk
E0671	Pressure Pneum Appl Full Leg
E0672	Pressure Pneum Appl Full Arm
E0673	Pressure Pneum Appl Half Leg
	INTERMITTENT LIMB COMPRESSION DEVICE (INCLUDES ALL ACCESSORIES), NOT
E0676	OTHERWISE
E0677	Non-pneumatic sequential compression garment, trunk
E0678	Non-pneumatic sequential compression garment, full leg
E0679	Non-pneumatic sequential compression garment, half leg
E0680	Non-pneumatic compression controller with sequential calibrated gradient pressure
E0681	Non-pneumatic compression controller without calibrated gradient pressure
E0682	Non-pneumatic sequential compression garment, full arm
	Ultraviolet light therapy system, includes bulbs/lamps, timer and eye protection; treatment
E0691	area 2 sq ft or less
	Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection, 4 ft
E0692	panel

	Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection, 6 ft
E0693	panel
	Ultraviolet multidirectional light therapy system in 6 ft cabinet, includes bulbs/lamps, timer,
E0694	and eye protection
E0732	Cranial electrotherapy stimulation (ces) system, any type
E0734	External upper limb tremor stimulator of the peripheral nerves of the wrist
E0735	Non-invasive vagus nerve stimulator
E0745	Neuromuscular Stim For Shock
E0746	Electromyograph Biofeedback
E0748	Elec Osteogen Stim Spinal
E0760	Osteogen Ultrasound Stimltor
E0761	Non-Thermal Pulsed High Frequency Radiowaves, High Peak Power Electrom
E0762	Transcutaneous electrical joint stimulation device system, includes all accessories
	Functional neuromuscular stimulation, transcutaneous stimulation of sequential muscle
E0764	groups of ambulation with computer
E0766	Electrical stimulation device used for cancer treatment, includes all accessories, any type
E0769	Electrical stimulation or electromagnetic wound treatment device, not otherwise classified
	Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups,
E0770	any type, complete system, not otherwise specified
E0986	Manual wheelchair accessory, push-rim activated power assist, each
E1002	Wheelchair accessory, power seating system, tilt only
E1003	Wheelchair accessory, power seating system, recline only, without shear
E1004	Wheelchair accessory, power seating system, recline only, with mechanical shear
E1005	Wheelchair accessory, power seatng system, recline only, with power shear
	Wheelchair accessory, power seating system, combination tilt and recline, w/o shear
E1006	reduction
E1007	Wheelchair accessory, power seating system, combination tilt and recline, with manual shear reduction
	Wheelchair accessory, power seating system, combination tilt and recline, with power shear
E1008	reduction
E1230	Power Operated Vehicle
	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen
E1390	concentration at the prescribed flow rate
E1700	Jaw Motion Rehab System
E1701	Repl Cushions For Jaw Motion
E1702	Repl Measr Scales Jaw Motion
	Static progressive stretch elbow device, extension and/or flexion, with or without range of
E1801	motion adjustment, includes all components and accessories
	Static progressive stretch wrist device, flexion and/or extension, with or without range of
E1806	motion adjustment, includes all components and accessories
E1011	Static progressive stretch knee device, extension and/or flexion, with or without range of
E1811	motion adjustment, includes all components and accessories
E1016	Static progressive stretch ankle device, flexion and/or extension, with or without range of
E1816	motion adjustment, includes all components and accessories

	Static progressive stretch forearm pronation/supination device, with or without range of
E1818	motion adjustment, includes all components and accessories
E1810	Replacement soft interface material/cuffs for bi-directional static progressive stretch device
1021	Static progressive stretch toe device, extension and/or flexion, with or without range of motion
E1831	adjustment, includes all components and accessories
21001	Static progressive stretch shoulder device, with or without range of motion adjustment,
E1841	includes all components and acce
	Virtual reality cognitive behavioral therapy device (cbt), including pre-programmed therapy
E1905	software
E2298	Complex rehabilitative power wheelchair accessory, power seat elevation system, any type
G0173	Linear accelerator based stereotactic radiosurgery, complete course of therapy in one session
	Activity therapy, such as music, dance, art or play therapies not for recreation, related to the
	care and treatment of patient's disabling mental health problems, per session (45 minutes or
G0176	more)
	Linear accelerator based stereotactic radiosurgery, delivery including collimator changes and
	custom plugging, fractionated treatment, all lesions, per session, maximum 5 sessions per
G0251	course of treatment
G0255	Current perception threshold/sensory nerve conduction test, (SNCT) per limb, any nerve
	Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other
G0260	therapeutic agent, with or without arthrography
G0277	Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval
	Electrical stimulation, (unattended), to one or more areas, for chronic Stage III and Stage IV
	pressure ulcers, arterial ulcers, diabetic ulcers, and venous stasis ulcers not demonstrating
	measurable signs of healing after 30 days of conventional care, as part of a therapy plan of
G0281	care
	Electrical stimulation, (unattended), to one or more areas, for wound care other than
G0282	described in G0281
00000	Electrical stimulation (unattended), to one or more areas for indication(s) other than wound
G0283	care, as part of a therapy plan of care
	Arthroscopy, knee, surgical, for removal of loose body, foreign body, debridement/shaving of
G0289	articular cartilage (chondroplasty) at the time of other surgical knee arthroscopy in a different compartment of the same knee
60269	Electromagnetic therapy, to one or more areas, for wound care other than described in G0329
G0295	or for other uses
00200	Electromagnetic therapy, to one or more areas for chronic Stage III and Stage IV pressure
	ulcers, arterial ulcers, diabetic ulcers and venous stasis ulcers not demonstrating measurable
G0329	signs of healing after 30 days of conventional care as part of a therapy plan of care
	Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of
G0339	therapy in one session or first session of fractionated treatment
	Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including
	collimator changes and custom plugging, fractionated treatment, all lesions, per session,
G0340	second through fifth sessions, maximum five sessions per course of treatment
G0341	Percutaneous islet cell transplant, includes portal vein catheterization and infusion
G0342	Laparoscopy for islet cell transplant, includes portal vein catheterization and infusion
G0343	Laparotomy for islet cell transplant, includes portal vein catheterization and infusion

	Home sleep study test (HST) with type II portable monitor, unattended; minimum of 7
G0398	channels: EEG, EOG, EMG, ECG/heart rate, airflow, respiratory effort and oxygen saturation
00000	Home sleep test (HST) with type III portable monitor, unattended; minimum of 4 channels: 2
G0399	respiratory movement/airflow, 1 ECG/heart rate and 1 oxygen saturation
G0400	
60400	Home sleep test (HST) with type IV portable monitor, unattended; minimum of 3 channels
C0 4 2 0	Collagen Meniscus Implant procedure for filling meniscal defects (e.g., CMI, collagen scaffold,
G0428	Menaflex) Dermal Filler injection(s) for the treatment of facial lipodystrophy syndrome (LDS) (e.g., as a
G0429	result of highly active
00423	Insertion or replacement of a permanent pacing cardioverter-defibrillator system with
	transvenous lead(s), single or dual chamber with insertion of pacing electrode, cardiac venous
G0448	system, for left ventricular pacing
G0458	Low dose rate (ldr) prostate brachytherapy services, composite rate
00400	Autologous platelet rich plasma (PRP) or other blood-derived product for nondiabetic chronic
	wounds/ulcers (includes, as applicable: administration, dressings, phlebotomy, centrifugation
G0460	or mixing, and all other preparatory procedures, per treatment)
	Autologous platelet rich plasma (PRP) or other blood-derived product for diabetic chronic
	wounds/ulcers, using an FDA-cleared device for this indication, (includes, as applicable:
	administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory
G0465	procedures, per treatment)
	Office or other outpatient visit for the evaluation and management of an established patient
	that requires the supervision of a physician or other qualified health care professional and
	provision of up to 56 mg of esketamine nasal self administration, includes 2 hours post
G2082	administration observation
	Office or other outpatient visit for the evaluation and management of an established patient
	that requires the supervision of a physician or other qualified health care professional and
	provision of greater than 56 mg esketamine nasal self administration, includes 2 hours post
G2083	administration observation
G6001	Ultrasonic guidance for placement of radiation therapy fields
00000	Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation
G6002	therapy
00000	Radiation treatment delivery, single treatment area, single port or parallel opposed ports,
G6003	simple blocks or no blocks: up to 5mev
G6004	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 6-10mev
00004	Radiation treatment delivery, single treatment area, single port or parallel opposed ports,
G6005	simple blocks or no blocks: 11-19mev
00000	Radiation treatment delivery, single treatment area, single port or parallel opposed ports,
G6006	simple blocks or no blocks: 20mev or greater
00000	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment
G6007	area, use of multiple blocks: up to 5mev
	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment
G6008	area, use of multiple blocks: 6-10mev
	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment
G6009	area, use of multiple blocks: 11-19mev
	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment
G6010	area, use of multiple blocks: 20 mev or greater

	Dediction the structure of all increases a surgest a tractment surgest surgest blocking to a generic
06011	Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential
G6011	ports, wedges, rotational beam, compensators, electron beam; up to 5mev
G6012	Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10mev
60012	Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential
G6013	ports, wedges, rotational beam, compensators, electron beam; 11-19mev
00013	Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential
G6014	ports, wedges, rotational beam, compensators, electron beam; 20mev or greater
00011	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and
G6015	temporally modulated beams, binary, dynamic mlc, per treatment session
	Compensator-based beam modulation treatment delivery of inverse planned treatment using
G6016	3 or more high resolution (milled or cast) compensator, convergent beam modulated field
	Intra-fraction localization and tracking of target or patient motion during delivery of radiation
G6017	therapy (eg,3d positional tracking, gating, 3d surface tracking), each fracti
	Warfarin responsiveness testing by genetic technique using any method, any number of
G9143	specimen(s)
G9840	RAS (KRAS and NRAS) gene mutation testing performed before initiation of anti-EGFR MoAb
G9841	RAS (KRAS and NRAS) gene mutation testing not performed before initiation of anti-EGFR MoAb
H0004	Behavioral health counseling and therapy, per 15 minutes
H0006	Alcohol and/or drug services; case management
	Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3
	hours/day and at least 3 days/week and is based on an individualized treatment plan),
H0015	including assessment, counseling; crisis intervention, and activity therapies or education
	Behavioral health; residential (hospital residential treatment program), without room and
H0017	board, per diem
	Behavioral health; long-term residential (nonmedical, nonacute care in a residential treatment
H0019	program where stay is typically longer than 30 days), without room and board, per diem
H0023	Behavioral health outreach service (planned approach to reach a targeted population)
H0035	Mental health partial hospitalization, treatment, less than 24 hours
H0038	Self-help/peer services, per 15 minutes
H0039	Assertive community treatment, face-to-face, per 15 minutes
H0040	Assertive community treatment program, per diem
H2014	Skills training and development, per 15 minutes
H2021	Community-based wrap-around services, per 15 minutes
	Injection, abatacept, 10 mg (code may be used for Medicare when drug administered under
J0129	the direct supervision of a physician, not for use when drug is self-administered)
J0135	Adalimumab injection
J0172	Injection, aducanumab-avwa, 2 mg
J0174	Injection, lecanemab-irmb, 1 mg
J0177	Injection, aflibercept HD, 1 mg
J0178	Injection, aflibercept, 1 mg
J0179	Injection, brolucizumab-dbll, 1 mg
J0180	Agalsidase beta injection
J0202	Injection, alemtuzumab, 1 mg
J0207	Amifostine
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	

J0208	Injection, sodium thiosulfate (Pedmark), 100 mg
J0200	Injection, solitan thiosattate (realitatic), 100 mg
J0217	Injection, ventilatase atta-tycv, 1 mg
J0210	Injection, avalglucosidase alfa-ngpt, 4 mg
J0213	Injection, avaigueesidase alfa, (Lumizyme), 10 mg
J0221	Injection, Patisiran, 0.1 mg
J0222	Injection, ratisfian, 0.1 mg
J0223	Injection, gives and 0.5 m
J0224	Injection, turnasiran, 0.5 m
J0225	Injection, vutrishan, 1 mg
J0250 J0257	Injection, alpha 1-proteinase inhibitor (human), not otherwise specified, 10 mg
J0257 J0456	
J0456 J0485	Azithromycin
	Injection, belatacept, 1 mg
J0490	Injection, belimumab, 10 mg
J0491	Injection, anifrolumab-fnia, 1 mg
J0517	Injection, benralizumab, 1 mg
J0558	Injection, penicilling benzathine and penicilling procaine, 100,000 units
J0561	Injection, penicillin g benzathine, 100,000 units
J0565	Injection, bezlotoxumab, 10 mg
J0567	Injection, cerliponase alfa, 1 mg
J0584	Injection, burosumab-twza 1 mg
J0585	Injection, Onabotulinumtoxina, 1 Unit
J0586	Injection, Abobotulinumtoxina, 5 Units
J0587	Injection, Rimabotulinumtoxinb, 100 Units
J0588	Injection, incobotulinumtoxinA, 1 unit
J0589	Injection, daxibotulinumtoxina-lanm, 1 unit
10500	Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered
J0593	under direct supervision of a physician, not for use when drug is self-administered)
J0596	Injection, c1 esterase inhibitor (recombinant), ruconest, 10 units
J0597	Injection, c-1 esterase inhibitor (human), berinert, 10 units
J0598	Injection, c-1 esterase inhibitor (human), cinryze, 10 units
J0599	Injection, C-1 esterase inhibitor (human), (Haegarda), 10 units
J0638	Injection, canakinumab, 1 mg
J0641	Injection, levoleucovorin, not otherwise specified, 0.5 mg
J0642	Injection, levoleucovorin (khapzory), 0.5 mg
J0690	Cefazolin Sodium Injection
J0696	Ceftriaxone Sodium Injection
J0698	Cefotaxime Sodium Injection
10747	Injection, certolizumab pegol, 1 mg (code may be used for Medicare when drug administered
J0717	under the direct supervision of a physician, not for use when drug is self-administered)
J0741	Injection, cabotegravir and rilpivirine, 2 mg/3 mg
J0743	Cilastatin Sodium Injection
J0775	Injection, collagenase, clostridium histolyticum, 0.01 mg

J0791	Injection, crizanlizumab-tmca, 5 mg
J0800	Injection, corticotropin, up to 40 units
J0801	Injection, corticotropin (Acthar Gel), up to 40 units
J0802	Injection, corticotropin (ANI), up to 40 units
J0881	Injection, darbepoetin alfa, 1 mcg (non-ESRD use)
J0882	Injection, darbepoetin alfa, 1 mcg (for ESRD on dialysis)
J0885	Injection, epoetin alfa, (for non-ESRD use), 1000 units
J0887	Injection, epoetin beta, 1 microgram, (for esrd on dialysis)
J0888	Injectin, epoetin beta, 1 microgram, (for non esrd use)
J0896	Injection, luspatercept-aamt, 0.25 mg
J0897	Injection, denosumab, 1 mg
J1203	Injection, cipaglucosidase alfa-atga, 5 mg
J1267	Injection, doripenem, 10 mg
J1290	Injection, ecallantide, 1 mg
J1300	Injection, eculizumab, 10 mg
J1301	Injection, edaravone, 1 mg
J1302	Injection, sutimlimab-jome, 10 mg
J1303	Injection, ravulizumab-cwvz, 10 mg
J1304	Injection, tofersen, 1 mg
J1305	Injection, evinacumab-dgnb, 5 mg
J1306	Injection, inclisiran, 1 mg
J1322	Injection, elosulfase alfa, 1mg
J1323	Injection, elranatamab-bcmm, 1 mg
J1325	Epoprostenol Injection
J1335	Injection, ertapenem sodium, 500 mg
J1411	Injection, etranacogene dezaparvovec-drlb, per therapeutic dose
	Injection, valoctocogene roxaparvovec-rvox, per ml, containing nominal 2 x 10^13 vector
J1412	genomes
J1413	Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose
J1426	Injection, casimersen, 10 mg
J1427	Injection, viltolarsen, 10 mg
J1428	Injection, eteplirsen, 10 mg
J1429	Injection, golodirsen, 10 mg
J1437	Injection, ferric derisomaltose, 10 mg
J1438	Etanercept Injection
J1439	Injection, ferric carboxymaltose, 1mg
J1440	Fecal microbiota, live - jslm, 1 ml
J1442	5G-CSFexcludes biosimilars, 1 microgram
J1447	Injection, tbo-filgrastim, 1 microgram
J1448	Injection, trilaciclib, 1 mg
J1449	Injection, eflapegrastim-xnst, 0.1 mg
J1450	Fluconazole
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg

J1458	INJECTION, GALSULFASE, 1 MG
J1459	Injection, immune globulin (Privigen), intravenous, nonlyophilized (e.g., liquid), 500 mg
J1460	Gamma Globulin 1 Cc Inj
J1551	Injection, immune globulin (cutaquig), 100 mg
J1554	Injection, immune globulin (asceniv), 500 mg
J1555	Injection, immune globulin (Cuvitru), 100 mg
J1556	Injection, immune globulin (bivigam), 500 mg
J1557	Injection, immune globulin, (Gammaplex), intravenous, nonlyophilized (e.g., liquid), 500 mg
J1558	Injection, immune globulin (xembify), 100 mg
J1559	Injection, immune globulin (hizentra), 100 mg
J1560	Gamma Globulin > 10 Cc Inj
,1000	Injection, immune globulin, (Gamunex/Gamunex-C/Gammaked), nonlyophilized (e.g., liquid),
J1561	500 mg
J1566	Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g.
J1569	Injection, immune globulin, (Gammagard liquid), nonlyophilized, (e.g., liquid), 500 mg
J1572	Injection, immune globulin, (Flebogamma/Flebogamma Dif), intravenous, nonlyophilized (e.g., liquid), 500 mg
J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin
J1576	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1595	Injection, glatiramer acetate, 20 mg
J1599	Injection, immune globulin, intravenous, non-lyophilized (e.g. liquid), not otherwise specified, 500 mg
J1602	Injection, golimumab, 1 mg, for intravenous use
J1628	Injection, guselkumab, 1 mg
J1632	Injection, brexanolone, 1 mg
J1675	Injection, histrelin acetate, 10 mcg
J1729	Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg
J1743	Injection, idursulfase, 1 mg
J1744	Injection, icatibant, 1 mg
J1745	Injection, infliximab, excludes biosimilar, 10 mg
J1746	Injection, ibalizumab-uiyk, 10 mg
J1747	Injection, spesolimab-sbzo, 1 mg
J1748	Injection, infliximab-dyyb (Zymfentra), 10 mg
J1750	Injection, Iron Dextran, 50mg
J1756	Injection, Iron Sucrose, 1 Mg
J1786	Injection, imiglucerase, 10 units
J1815	Injection, Insulin, Per 5 Units
J1817	Insulin For Administration Through Dme (I.E., Insulin Pump) Per 50 U
J1823	Injection, inebilizumab-cdon, 1 mg
J1826	Injection, interferon beta-1a, 30 mcg
J1830	Interferon Beta-1b / .25 Mg

J1931	Laronidase injection
J1932	Injection, lanreotide, (cipla), 1 mg
J1951	Injection, leuprolide acetate for depot suspension (fensolvi), 0.25 m
J1954	Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg
J1956	Levofloxacin Injection
J1961	Injection, lenacapavir, 1 mg
J2170	INJECTION, MECASERMIN, 1 MG
J2182	Injection, mepolizumab, 1 mg
J2185	Injection, meropenem, 100 mg
J2267	Injection, mirikizumab-mrkz, 1 mg
J2277	Injection, motixafortide, 0.25 mg
J2278	Injection, ziconotide, 1 mcg
J2280	Injection, moxifloxacin, 100 mg
J2323	Imjection, natalizumab, 1 mg
J2326	Injection, nusinersen, 0.1 mg
J2327	Injection, risankizumab-rzaa, intravenous, 1 mg
J2329	Injection, ublituximab-xiiy, 1mg
J2350	Injection, ocrelizumab, 1 mg
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg
J2354	Injection, octreotide, non-depot form for subcutaneous or intravenous
J2356	Injection, tezepelumab-ekko, 1 mg
J2357	Omalizumab injection
J2502	Injection, pasireotide long acting, 1 mg
J2503	Injection, pegaptanib sodium, 0.3 mg
J2505	Injection, pegfilgrastim, 6 mg
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg
J2507	Injection, pegloticase, 1 mg
J2508	Injection, pegunigalsidase alfa-iwxj, 1 mg
J2510	Penicillin G Procaine Inj
J2540	Penicillin G Potassium Inj
J2562	Injection, Plerixafor, 1 Mg
J2777	Injection, faricimab-svoa, 0.1 mg
J2778	Injection, ranibizumab, 0.1 mg
J2779	Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg
J2781	Injection, pegcetacoplan, intravitreal, 1 mg
J2782	Injection, avacincaptad pegol, 0.1 mg
J2786	Injection, reslizumab, 1 mg
J2793	Injection, Rilonacept, 1 Mg
J2796	Injection, Romiplostim, 10 Micrograms
J2820	Sargramostim Injection
J2840	Injection, sebelipase alfa, 1 mg
J2860	Injection, siltuximab, 10 mg
J2916	Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg

J2940	Injection, somatrem, 1 mg
J2941	Injection, somatropin, 1 mg
J2998	Injection, plasminogen, human-tvmh, 1 mg
J3032	Injection, eptinezumab-jjmr, 1 mg
J3055	Injection, talquetamab-tgvs, 0.25 mg
J3060	Injection, taliglucerace alfa, 10 units
J3111	Injection, romosozumab-aqqg, 1 mg
J3241	Injection, teprotumumab-trbw, 10 mg
J3245	Injection, tildrakizumab, 1 mg
J3247	Injection, secukinumab, IV, 1 mg
J3262	Injection, tocilizumab, 1 mg
J3263	Injection, toripalimab-tpzi, 1 mg
J3285	Injection, treprostinil, 1 mg
J3299	Injection, triamcinolone acetonide (xipere), 1 mg
	Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere
J3304	formulation, 1 mg
J3315	Injection, Triptorelin Pamoate, 3.75 Mg
J3316	Injection, triptorelin, extended-release, 3.75 mg
J3357	Ustekinumab, for subcutaneous injection, 1 mg
J3358	Ustekinumab, for intravenous injection, 1 mg
J3380	Injection, vedolizumab, IV, 1 mg
J3385	Injection, velaglucerase alfa, 100 units
J3393	Injection, betibeglogene autotemcel, per treatment
J3394	Injection, lovotibeglogene autotemcel, per treatment
J3397	Injection, vestronidase alfa-vjbk, 1 mg
J3398	Injection, voretigene neparvovec-rzyl, 1 billion vector genomes
J3399	Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes
	Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml
J3401	vector genomes, per 0.1 ml
J3489	Injection, zoledronic acid, 1 mg
J3590	UNCLASSIFIED BIOLOGICS
J7170	Injection, emicizumab-kxwh, 0.5 mg
J7171	Injection, ADAMTS13, recombinant-krhn, 10 IU
J7175	Injection, factor x, (human), 1 i.u.
J7177	Injection, human fibrinogen concentrate (Fibryga), 1 mg
J7178	Injection, human fibrinogen concentrate, not otherwise specified, 1 mg
J7179	Injection, von willebrand factor (recombinant), (vonvendi), 1 i.u. vwf:rco
J7180	Injection, factor XIII (antihemophilic factor, human), 1 IU
J7181	Injection, factor xiii a-subunit, (recombinant), per iu
J7182	Injection, factor viii, (antihemophilic factor, recombinant), (novoeight), per iu
J7183	Injection, von Willebrand factor complex (human), Wilate, 1 IU vWF:RCo
J7185	Injection, Factor Viii (Antihemophilic Factor, Recombinant) (Xyntha), Per I.U.
J7186	Injection, antihemophilic factor VIII/von Willebrand factor complex (human), per factor VIII i.u.

J7187	Injection, von Willebrand factor complex (Humate-P), per IU vWF-RC0
J7188	Injection, factor viii (antihemophilic factor, recombinant), (obizur), per i.u.
J7189	Factor VIIa (antihemophilic Factor, recombinant), per 1 mcg
J7190	Factor Viii
J7191	Factor Viii (Porcine)
J7192	Factor Viii (Antihemophilic Factor, Recombinant) Per I.U., Not Otherwise Specified
J7193	Factor IX (antihemophilic factor, purified, non-recombinant) per IU
J7194	Factor Ix Complex
J7195	Factor IX (antihemophilic factor, recombinant) per IU
J7198	Anti-Inhibitor
J7200	Injection, factor ix, (antihemophilic factor, recombinant), rixubis, per iu
J7201	Injection, factor IX, Fc fusion protein, (recombinant), Alprolix, 1 IU
J7202	Injection, factor ix, albumin fusion protein, (recombinant), idelvion, 1 i.u.
J7203	Injection Factor IX, (antihemophilic factor, recombinant), glycopegylated, (Rebinyn), 1 IU
	Injection, Factor VIII, antihemophilic factor (recombinant), (Esperoct), glycopegylated-exei,
J7204	per IU
J7205	Injection, factor viii fc fusion (recombinant), per iu
J7207	Injection, factor viii, (antihemophilic factor, recombinant), pegylated, 1 i.u.
J7208	Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl, (jivi), 1 i.u.
J7209	Injection, factor viii, (antihemophilic factor, recombinant), (nuwiq), 1 i.u.
J7210	Injection, Factor VIII, (antihemophilic factor, recombinant), (Afstyla), 1 IU
J7211	Injection, Factor VIII, (antihemophilic factor, recombinant), (Kovaltry), 1 IU
J7212	Factor viia (antihemophilic factor, recombinant)-jncw (sevenfact), 1 microgram
J7213	Injection, coagulation factor ix (recombinant), ixinity, 1 i.u.
J7214	Injection, Factor VIII/von Willebrand factor complex, recombinant (Altuviiio), per Factor VIII IU
J7311	Injection, fluocinolone acetonide, intravitreal implant (Retisert), 0.01 mg
J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg
J7313	Injection, fluocinolone acetonide, intravitreal implant (Iluvien), 0.01 mg
J7314	Injection, fluocinolone acetonide, intravitreal implant (Yutiq), 0.01 mg
J7330	Cultured Chondrocytes Implnt
J7340	Carbidopa 5 mg/levodopa 20 mg enteral suspension, 100 ml
J7351	Injection, bimatoprost, intracameral implant, 1 microgram
J7352	Afamelanotide implant, 1 mg
J7353	Anacaulase-bcdb, 8.8% gel, 1 gm
J7354	Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)
J7355	Injection, travoprost, intracameral implant, 1 mcg
J7402	Mometasone furoate sinus implant, (sinuva), 10 micrograms
17000	Treprostinil, inhalation solution, fda-approved final product, non-compounded, administered
J7686	through dme, unit dose form, 1.74 mg
J9015	Injection, aldesleukin, per single use vial
J9019	Injection, asparaginase (erwinaze), 1,000 iu
J9021	Injection, asparaginase, recombinant, (rylaze), 0.1 mg
J9022	Injection, atezolizumab, 10 mg

J9023	Injection, avelumab, 10 mg
J9029	Intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose
J9032	Injection, belinostat, 10 mg
J9033	Injection, bendamustine hydrochloride, 1 mg
J9034	Injection, bendamustine hcl (bendeka), 1 mg
J9035	Bevacizumab injection
J9036	Injection, bendamustine hydrochloride, (Belrapzo), 1 mg
J9039	Injection, blinatumomab, 1 microgram
J9042	Injection, brentuximab vedotin, 1 mg
J9043	Injection, cabazitaxel, 1 mg
J9047	Injection, carfilzomib, 1 mg
J9055	Cetuximab injection
J9056	Injection, bendamustine hydrochloride (vivimusta), 1 mg
J9057	Injection, copanlisib, 1 mg
J9058	Injection, bendamustine hydrochloride (apotex), 1 mg
J9059	Injection, bendamustine hydrochloride (baxter), 1 mg
J9061	Injection, amivantamab-vmjw, 2 mg
J9063	Injection, mirvetuximab soravtansine-gynx, 1 mg
J9064	Injection, cabazitaxel (Sandoz), not therapeutically equivalent to J9043, 1 mg
J9118	Injection, calaspargase pegol-mknl, 10 units
J9119	Injection, cemiplimab-rwlc, 1 mg
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9145	Injection, daratumumab, 10 mg
J9173	Injection, durvalumab, 10 mg
J9176	Injection, elotuzumab, 1 mg
J9177	Injection, enfortumab vedotin-ejfv, 0.25 mg
J9179	Injection, eribulin mesylate, 0.1 mg
J9202	Goserelin Acetate Implant
J9203	Injection, gemtuzumab ozogamicin, 0.1 mg
J9207	Injection, ixabepilone, 1 mg
J9210	Injection, emapalumab-lzsg, 1 mg
J9216	Injection, interferon, gamma-1B, 3 million units
J9217	Leuprolide Acetate Suspnsion
J9223	Injection, lurbinectedin, 0.1 mg
J9225	Histrelin implant (Vantas), 50 mg
J9226	Histrelin implant (supprelin LA), 50 mg
J9227	Injection, isatuximab-irfc, 10 mg
J9228	Injection, ipilimumab, 1 mg
J9229	Injection, inotuzumab ozogamicin, 0.1 mg
J9247	Injection, melphalan flufenamide, 1 mg
J9258	Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to j9264, 1 mg

	Injection, paclitaxel protein-bound particles (American Regent), not therapeutically equivalent
J9259	to J9264, 1 mg
J9262	Injection, omacetaxine mepesuccinate, 0.01 mg
J9264	Injection, paclitaxel protein-bound particles, 1 mg
J9266	Injection, pegaspargase, per single dose vial
J9269	Injection, tagraxofusp-erzs, 10 micrograms
J9271	Injection, pembrolizumab, 1 mg
J9272	Injection, dostarlimab-gxly, 10 mg
J9273	Injection, tisotumab vedotin-tftv, 1 mg
J9274	Injection, tebentafusp-tebn, 1 microgram
J9281	Mitomycin pyelocalyceal instillation, 1 mg
J9286	Injection, glofitamab-gxbm, 2.5 mg
J9294	Injection, pemetrexed (Hospira), not therapeutically equivalent to J9305, 10 mg
J9296	Injection, pemetrexed (Accord), not therapeutically equivalent to J9305, 10 mg
J9297	Injection, pemetrexed (sandoz), not therapeutically equivalent to j9305, 10 mg
J9298	Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg
J9299	Injection, nivolumab, 1 mg
J9301	Injection, obinutuzumab, 10 mg
J9302	Injection, ofatumumab, 10 mg
J9303	Injection, panitumumab, 10 mg
J9304	Injection, pemetrexed (pemfexy), 10 mg
J9305	Injection, pemetrexed, NOS,10 mg
J9306	Injection, pertuzumab, 1 mg
J9308	Injection, ramucirumab, 5 mg
J9309	Injection, polatuzumab vedotin-piiq, 1 mg
J9312	Injection, rituximab, 10 mg
J9313	Injection, moxetumomab pasudotox-tdfk, 0.01 mg
J9314	Injection, pemetrexed (Teva), not therapeutically equivalent to J9305, 10 mg
J9316	Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg
J9317	Injection, sacituzumab govitecan-hziy, 2.5 mg
J9318	Injection, romidepsin, nonlyophilized, 0.1 mg
J9319	Injection, romidepsin, lyophilized, 0.1 mg
J9321	Injection, epcoritamab-bysp, 0.16 mg
J9322	Injection, pemetrexed (BluePoint), not therapeutically equivalent to J9305, 10 mg
J9323	Injection, pemetrexed (hospira) not therapeutically equivalent to j9305, 10 mg
J9324	Injection, pemetrexed (pemrydi rtu), 10 mg
J9325	Injection, talimogene laherparepvec, per 1 million plaque forming units
J9329	Injection, tislelizumab-jsgr, 1mg
J9331	Injection, sirolimus protein-bound particles, 1 mg
J9332	Injection, efgartigimod alfa-fcab, 2mg
J9333	Injection, rozanolixizumab-noli, 1 mg
J9334	Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc
J9345	Injection, retifanlimab-dlwr, 1 mg

J9347	Injection, tremelimumab-actl, 1 mg
J9348	Injection, naxitamab-gqgk, 1 m
J9349	Injection, tafasitamab-cxix, 2 mg
J9350	Injection, mosunetuzumab-axgb, 1 mg
J9353	Injection, margetuximab-cmkb, 5 m
J9354	Injection, ado-trastuzumab emtansine, 1 mg
J9358	Injection, add-trastuzumab deruxtecan-nxki, 1 mg
J9359	
J9361	Injection, loncastuximab tesirine-lpyl, 0.075 mg
	Injection, efbemalenograstim alfa-vuxw, 0.5 mg
J9376	Injection, pozelimab-bbfg, 1 mg
J9380	Injection, teclistamab-cqyv, 0.5 mg
J9381	Injection, teplizumab-mzwv, 5 mcg
J9393	Injection, fulvestrant (Teva), not therapeutically equivalent to J9395, 25 mg
J9394	Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg
J9395	Injection, fulvestrant, 25 mg
J9400	Injection, ziv-aflibercept, 1 mg
K0010	Standard-weight frame motorized/power wheelchair
	Standard-weight frame motorized/power wheelchair with programmable control parameters
K0011	for speed adjustment, tremor dampening, acceleration control and braking
K0012	Lightweight portable motorized/power wheelchair
K0013	Custom motorized/power wheelchair base
K0014	Other motorized/power wheelchair base
K0455	Pump Uninterrupted Infusion
K0606	Automatic external defibrillator, with integrated electrocardiogram analysis, garment type
K0800	POWER OPERATED VEHICLE, GROUP 1 STANDARD, PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 300 POUNDS
K0801	POWER OPERATED VEHICLE, GROUP 1 HEAVY DUTY, PATIENT WEIGHT CAPACITY, 301 TO 450 POUNDS
K0802	POWER OPERATED VEHICLE, GROUP 1 VERY HEAVY DUTY, PATIENT WEIGHT CAPACITY 451 TO 600 POUNDS
K0806	POWER OPERATED VEHICLE, GROUP 2 STANDARD, PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 300 POUNDS
K0807	POWER OPERATED VEHICLE, GROUP 2 HEAVY DUTY, PATIENT WEIGHT CAPACITY 301 TO 450 POUNDS
K0808	POWER OPERATED VEHICLE, GROUP 2 VERY HEAVY DUTY, PATIENT WEIGHT CAPACITY 451 TO 600 POUNDS
K0812	POWER OPERATED VEHICLE, NOT OTHERWISE CLASSIFIED
	POWER WHEELCHAIR, GROUP 1 STANDARD, PORTABLE, SLING/SOLID SEAT AND BACK,
K0813	PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 300
	POWER WHEELCHAIR, GROUP 1 STANDARD, PORTABLE, CAPTAINS CHAIR, PATIENT WEIGHT
K0814	CAPACITY UP TO AND INCLUDING 300 POUNDS
	POWER WHEELCHAIR, GROUP 1 STANDARD, SLING/SOLID SEAT AND BACK, PATIENT WEIGHT
K0815	CAPACITY UP TO AND INCLUDING 300 POUNDS
K0816	POWER WHEELCHAIR, GROUP 1 STANDARD, CAPTAINS CHAIR, PATIENT WEIGHT CAPACTIY UP TO AND INCLUDING 300 POUNDS

K0820	POWER WHEELCHAIR, GROUP 2 STANDARD, PORTABLE, SLING/SOLID SEAT/BACK, PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 300 POUNDS
10020	POWER WHEELCHAIR, GROUP 2 STANDARD, PORTABLE, CAPTAINS CHAIR, PATIENT WEIGHT
K0821	CAPACITY UP TO AND INCLUDING 300 POUNDS
K0021	POWER WHEELCHAIR, GROUP 2 STANDARD, SLING/SOLID SEAT/BACK, PATIENT WEIGHT
K0822	CAPACITY UP TO AND INCLUDING 300 POUNDS
RUUZZ	POWER WHEELCHAIR, GROUP 2 STANDARD, CAPTAINS CHAIR, PATIENT WEIGHT CAPACITY
K0823	UP TO AND INCLUDING 300 POUNDS
10020	POWER WHEELCHAIR, GROUP 2 HEAVY DUTY, SLING/SOLID SEAT/BACK, PATIENT WEIGHT
K0824	CAPACITY 301 TO 450 POUNDS
	POWER WHEELCHAIR, GROUP 2 HEAVY DUTY, CAPTAINS CHAIR, PATIENT WEIGHT CAPACITY
K0825	301 TO 450 POUNDS
	POWER WHEELCHAIR, GROUP 2 VERY HEAVY DUTY, SLING/SOLID SEAT/BACK, PATIENT
K0826	WEIGHT CAPACITY 451 TO 600 POUNDS
	POWER WHEELCHAIR, GROUP 2 VERY HEAVY DUTY, CAPTAINS CHAIR, PATIENT WEIGHT
K0827	CAPACITY 451 TO 600 POUNDS
	POWER WHEELCHAIR, GROUP 2 EXTRA HEAVY DUTY, SLING/SOLID SEAT/BACK, PATIENT
K0828	WEIGHT CAPACITY 601 POUNDS OR MORE
	POWER WHEELCHAIR, GROUP 2 EXTRA HEAVY DUTY, CAPTAINS CHAIR, PATIENT WEIGHT
K0829	CAPACITY 601 POUNDS OR MORE
	POWER WHEELCHAIR, GROUP 2 STANDARD, SEAT ELEVATOR, SLING/SOLID SEAT/BACK,
K0830	PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 300 POUNDS
	POWER WHEELCHAIR, GROUP 2 STANDARD, SEAT ELEVATOR, CAPTAINS CHAIR, PATIENT
K0831	WEIGHT CAPACITY UP TO AND INCLUDING 300 POUNDS
	POWER WHEELCHAIR, GROUP 2 STANDARD, SINGLE POWER OPTION, SLING/SOLID
K0835	SEAT/BACK, PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 300 POUNDS
1/0000	POWER WHEELCHAIR, GROUP 2 STANDARD, SINGLE POWER OPTION, CAPTAINS CHAIR,
K0836	PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 300 POUNDS
1/0007	POWER WHEELCHAIR, GROUP 2 HEAVY DUTY, SINGLE POWER OPTION, SLING/SOLID
K0837	SEAT/BACK, PATIENT WEIGHT CAPACITY 301 TO 450 POUNDS
K0838	POWER WHEELCHAIR, GROUP 2 HEAVY DUTY, SINGLE POWER OPTION, CAPTAINS CHAIR, PATIENT WEIGHT CAPACITY 301 TO 450 POUNDS
10030	POWER WHEELCHAIR, GROUP 2 VERY HEAVY DUTY, SINGLE POWER OPTION, SLING/SOLID
K0839	SEAT/BACK, PATIENT WEIGHT CAPACITY 451 TO 600 POUNDS
10003	POWER WHEELCHAIR, GROUP 2 EXTRA HEAVY DUTY, SINGLE POWER OPTION, SLING/SOLID
K0840	SEAT/BACK, PATIENT WEIGHT CAPACITY 601 POUNDS OR MORE
100-0	POWER WHEELCHAIR, GROUP 2 STANDARD, MULTIPLE POWER OPTION, SLING/SOLID
K0841	SEAT/BACK, PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 300 POUNDS
110011	POWER WHEELCHAIR, GROUP 2 STANDARD, MULTIPLE POWER OPTION, CAPTAINS CHAIR,
K0842	PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 300 POUNDS
	POWER WHEELCHAIR, GROUP 2 HEAVY DUTY, MULTIPLE POWER OPTION, SLING/SOLID
K0843	SEAT/BACK, PATIENT WEIGHT CAPACITY 301 TO 450 POUNDS
	POWER WHEELCHAIR, GROUP 3 STANDARD, SLING/SOLID SEAT/BACK, PATIENT WEIGHT
K0848	CAPACITY UP TO AND INCLUDING 300 POUNDS
	POWER WHEELCHAIR, GROUP 3 STANDARD, CAPTAINS CHAIR, PATIENT WEIGHT CAPACITY
K0849	UP TO AND INCLUDING 300 POUNDS

	POWER WHEELCHAIR, GROUP 3 HEAVY DUTY, SLING/SOLID SEAT/BACK, PATIENT WEIGHT
K0850	CAPACITY 301 TO 450 POUNDS
	POWER WHEELCHAIR, GROUP 3 HEAVY DUTY, CAPTAINS CHAIR, PATIENT WEIGHT CAPACITY
K0851	301 TO 450 POUNDS
10001	POWER WHEELCHAIR, GROUP 3 VERY HEAVY DUTY, SLING/SOLID SEAT/BACK, PATIENT
K0852	WEIGHT CAPACITY 451 TO 600 POUNDS
	POWER WHEELCHAIR, GROUP 3 VERY HEAVY DUTY, CAPTAINS CHAIR, PATIENT WEIGHT
K0853	CAPACITY, 451 TO 600 POUNDS
	POWER WHEELCHAIR, GROUP 3 EXTRA HEAVY DUTY, SLING/SOLID SEAT/BACK, PATIENT
K0854	WEIGHT CAPACITY 601 POUNDS OR MORE
	POWER WHEELCHAIR, GROUP 3 EXTRA HEAVY DUTY, CAPTAINS CHAIR, PATIENT WEIGHT
K0855	CAPACITY 601 POUNDS OR MORE
	POWER WHEELCHAIR, GROUP 3 STANDARD, SINGLE POWER OPTION, SLING/SOLID
K0856	SEAT/BACK, PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 300 POUNDS
	POWER WHEELCHAIR, GROUP 3 STANDARD, SINGLE POWER OPTION, CAPTAINS CHAIR,
K0857	PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 300 POUNDS
	POWER WHEELCHAIR, GROUP 3 HEAVY DUTY, SINGLE POWER OPTION, SLING/SOLID
K0858	SEAT/BACK, PATIENT WEIGHT CAPACITY 301 TO 450 POUNDS
	POWER WHEELCHAIR, GROUP 3 HEAVY DUTY, SINGLE POWER OPTION, CAPTAINS CHAIR,
K0859	PATIENT WEIGHT CAPACITY 301 TO 450 POUNDS
	POWER WHEELCHAIR, GROUP 3 VERY HEAVY DUTY, SINGLE POWER OPTION, SLING/SOLID
K0860	SEAT/BACK, PATIENT WEIGHT CAPACITY 451 TO 600 POUNDS
	POWER WHEELCHAIR, GROUP 3 STANDARD, MULTIPLE POWER OPTION, SLING/SOLID
K0861	SEAT/BACK, PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 300 POUNDS
	POWER WHEELCHAIR, GROUP 3 HEAVY DUTY, MULTIPLE POWER OPTION, SLING/SOLID
K0862	SEAT/BACK, PATIENT WEIGHT CAPACITY 301 TO 450 POUNDS
	POWER WHEELCHAIR, GROUP 3 VERY HEAVY DUTY, MULTIPLE POWER OPTION, SLING/SOLID
K0863	SEAT/BACK, PATIENT WEIGHT CAPACITY 451 TO 600 POUNDS
	POWER WHEELCHAIR, GROUP 3 EXTRA HEAVY DUTY, MULTIPLE POWER OPTION,
K0864	SLING/SOLID SEAT/BACK, PATIENT WEIGHT CAPACITY 601 POUNDS OR MORE
	POWER WHEELCHAIR, GROUP 4 STANDARD, SLING/SOLID SEAT/BACK, PATIENT WEIGHT
K0868	CAPACITY UP TO AND INCLUDING 300 POUNDS
1/0000	POWER WHEELCHAIR, GROUP 4 STANDARD, CAPTAINS CHAIR, PATIENT WEIGHT CAPACITY
K0869	UP TO AND INCLUDING 300 POUNDS
1/0070	POWER WHEELCHAIR, GROUP 4 HEAVY DUTY, SLING/SOLID SEAT/BACK, PATIENT WEIGHT
K0870	CAPACITY 301 TO 450 POUNDS
K0074	POWER WHEELCHAIR, GROUP 4 VERY HEAVY DUTY, SLING/SOLID SEAT/BACK, PATIENT
K0871	WEIGHT CAPACITY 451 TO 600 POUNDS
	POWER WHEELCHAIR, GROUP 4 STANDARD, SINGLE POWER OPTION, SLING/SOLID
K0877	SEAT/BACK, PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 300 POUNDS
K0878	POWER WHEELCHAIR, GROUP 4 STANDARD, SINGLE POWER OPTION, CAPTAINS CHAIR, PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 300 POUNDS
10070	POWER WHEELCHAIR, GROUP 4 HEAVY DUTY, SINGLE POWER OPTION, SLING/SOLID
K0879	SEAT/BACK, PATIENT WEIGHT CAPACITY 301 TO 450 POUNDS
10073	POWER WHEELCHAIR, GROUP 4 VERY HEAVY DUTY, SINGLE POWER OPTION, SLING/SOLID
K0880	SEAT/BACK, PATIENT WEIGHT 451 TO 600 POUNDS
10000	

	POWER WHEELCHAIR, GROUP 4 STANDARD, MULTIPLE POWER OPTION, SLING/SOLID
K0884	SEAT/BACK, PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 300 POUNDS
10004	POWER WHEELCHAIR, GROUP 4 STANDARD, MULTIPLE POWER OPTION, CAPTAINS CHAIR,
K0885	WEIGHT CAPACITY UP TO AND INCLUDING 300 POUNDS
	POWER WHEELCHAIR, GROUP 4 HEAVY DUTY, MULTIPLE POWER OPTION, SLING/SOLID
K0886	SEAT/BACK, PATIENT WEIGHT CAPACITY 301 TO 450 POUNDS
	POWER WHEELCHAIR, GROUP 5 PEDIATRIC, SINGLE POWER OPTION, SLING/SOLID
K0890	SEAT/BACK, PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 125 POUNDS
	POWER WHEELCHAIR, GROUP 5 PEDIATRIC, MULTIPLE POWER OPTION, SLING/SOLID
K0891	SEAT/BACK, PATIENT WEIGHT CAPACITY UP TO AND INCLUDING 125 POUNDS
	Electronic positional obstructive sleep apnea treatment, with sensor, includes all components
K1001	and accessories, any type
	Low frequency ultrasonic diathermy treatment device for home use, includes all components
K1004	and accessories
	Bilateral hip, knee, ankle, foot (HKAFO) device, powered, includes pelvic component, single or
	double upright(s), knee joints any type, with or without ankle joints any type, includes all
K1007	components and accessories, motors, microprocessors, sensors
K1018	External upper limb tremor stimulator of the peripheral nerves of the wrist
	Supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of
K1019	the wrist
K1020	Non-invasive vagus nerve stimulator
K1024	Nonpneumatic compression controller with sequential calibrated gradient pressure
K1025	Nonpneumatic sequential compression garment, full arm
	External recharging system for battery (internal) for use with implanted cardiac contractility
K1030	modulation generator, replacement only
K1031	Nonpneumatic compression controller without calibrated gradient pressure
K1032	Nonpneumatic sequential compression garment, full leg
K1033	Nonpneumatic sequential compression garment, half leg
	Supplies and accessories (e.g., transducer) for low frequency ultrasonic diathermy treatment
K1036	device, per month
L5991	Addition to lower extremity prostheses, osseointegrated external prosthetic connector
	Transcarpal/metacarpal or partial hand disarticulation prosthesis, external power, self-
	suspended, inner socket with removable forearm section, electrodes and cables, 2 batteries,
L6025	charger, myoelectric control of terminal device
	Transcarpal/metacarpal or partial hand disarticulation prosthesis, external power, self-
10000	suspended, inner socket with removable forearm section, electrodes and cables, two
L6026	batteries, charger, myoelectric control of terminal device, excludes terminal device(s)
L6611	ADDITION TO UPPER EXTREMITY PROSTHESIS, EXTERNAL POWERED, ADDITIONAL SWITCH,
16677	Upper extremity addition, harness, triple control, simultaneous operation of terminal device and elbow
L6677	
L6715	Terminal device, multiple articulating digit, includes motor(s), initial issue or replacement
L6880	Electric hand, switch or myolelectric controlled, independently articulating digits, any grasp patterns, includes motor(s)
	AUTOMATIC GRASP FEATURE, ADDITION TO UPPER LIMB ELECTRIC PROSTHETIC TERMINAL
L6881	
L6882	Microprocessor control feature, addition to upper limb prosthesis terminal device

	Wrist disarticulation, external power, self-suspended inner socket, removable forearm shell,
	Otto Bock or equal electrodes, cables, two batteries and one charger, myoelectronic control of
L6925	terminal device
20020	Below elbow, external power, self-suspended inner socket, removable forearm shell, Otto
	Bock or equal electrodes, cables, two batteries and one charger, myoelectronic control of
L6935	terminal device
	Elbow disarticulation, external power, molded inner socket, removable humeral shell, outside
	locking hinges, forearm, Otto Bock or equal electrodes, cables, two batteries and one charger,
L6945	myoelectronic control of terminal device
	Above elbow, external power, molded inner socket, removable humeral shell, internal locking
	elbow, forearm, Otto Bock or equal electrodes, cables, two batteries and one charger,
L6955	myoelectronic control of terminal device
	Shoulder disarticulation, external power, molded inner socket, removable shoulder shell,
	shoulder bulkhead, humeral section, mechanical elbow, forearm, Otto Bock or equal
L6965	electrodes, cables, two batteries and one charger, myoelectronic control of terminal device
	Interscapular-thoracic, external power, molded inner socket, removable shoulder shell,
	shoulder bulkhead, humeral section, mechanical elbow, forearm, Otto Bock or equal
L6975	electrodes, cables, two batteries and one charger, myoelectronic control of terminal device
L7190	Electronic elbow, adolescent, Variety Village or equal, myoelectronically controlled
L7191	Electronic elbow, child, Variety Village or equal, myoelectronically controlled
L7510	Repair of prosthetic device, repair or replace minor parts
L7520	Repair prosthetic device, labor component, per 15 minutes
L8045	Auricular prosthesis, provided by a nonphysician
L8600	Implantable breast prosthesis, silicone or equal
L8607	Injectable bulking agent for vocal cord medialization, 0.1 ml, includes shipping and necessary supplies
L8614	COCHLEAR DEVICE, INCLUDES ALL INTERNAL AND EXTERNAL COMPONENTS
L8619	Cochlear Implant, External Speech Processor And Controller, Integrated System, Replacement
L8627	Cochlear Implant, External Speech Processor, Component, Replacement
L8628	Cochlear Implant, External Controller Component, Replacement
L8678	Electrical stimulator supplies (external) for use with implantable neurostimulator, per month
L8679	Implantable neurostimulator, pulse generator, any type
L8680	Implantable neurostimulator electrode, each
	Patient programmer (external) for use with implantable programmable neurostimulator pulse
L8681	generator, replacement only
L8682	Implantable neurostimulator radiofrequency receiver
	Radiofrequency transmitter (external) for use with implantable neurostimulator
L8683	radiofrequency receiver
	Radiofrequency transmitter (external) for use with implantable sacral root neurostimulator
L8684	receiver for bowel and bladder management, replacement
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension
	Implantable neurostimulator pulse generator, single array, non-rechargeable, includes
L8686	extension
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension
	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes
L8688	extension

	AUDITORY OSSEOINTEGRATED DEVICE, INCLUDES ALL INTERNAL AND EXTERNAL
L8690	COMPONENTS
	Auditory osseointegrated device, external sound processor, excludes transducer/actuator,
L8691	replacement only, each
	Auditory osseointegrated device, external sound processor, used without osseointegration,
L8692	body worn, includes headband or other means of external attachment
L8693	Auditory osseointegrated device abutment, any length, replacement only
	Powered upper extremity range of motion assist device, elbow, wrist, hand with single or
	double upright(s), includes microprocessor, sensors, all components and accessories,
L8701	custom fabricated
	Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or
	double upright(s), includes microprocessor, sensors, all components and accessories,
L8702	custom fabricated
M0075	Cellular Therapy
Q0138	Injection, Ferumoxytol, For Treatment Of Iron Deficiency Anemia, 1 Mg (Non-Esrd Use)
Q2026	Injection, Radiesse, 0.1ml
Q2028	Injection, sculptra, 0.5 mg
00044	Axicabtagene ciloleucel, up to 200 million autologous anti-CD19 CAR positive T cells,
Q2041	including leukapheresis and dose preparation procedures, per therapeutic dose
00040	Tisagenlecleucel, up to 600 million CAR-positive viable T cells, including leukapheresis and
Q2042	dose preparation procedures, per therapeutic dose
Q2043	Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion
Q2043 Q2049	Injection, doxorubicin hydrochloride, liposomal, imported Lipodox, 10 mg
Q2049 Q2050	Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
Q2050	Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells,
Q2053	including leukapheresis and dose preparation procedures, per therapeutic dose
Q2000	Lisocabtagene maraleucel, up to 110 million autologous anti-CD19 CAR-positive viable T cells,
Q2054	including leukapheresis and dose preparation procedures, per therapeutic dose
	Idecabtagene vicleucel, up to 510 million autologous B-cell maturation antigen (BCMA)
	directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per
Q2055	therapeutic dose
	Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma)
Q2056	directed car-positive t cells, including leukapheresis and dose preparation procedures
Q3001	Brachytherapy Radioelements
Q3027	Injection, interferon beta-1a, 1 mcg for intramuscular use
Q3028	Injection, interferon beta-1a, 1 mcg for subcutaneous use
	lloprost, inhalation solution, FDA-approved final product, noncompounded, administered
Q4074	through DME, unit dose form, up to 20 mcg
Q4081	INJECTION, EPOETIN ALFA, 100 UNITS (FOR ESRD ON DIALYSIS)
Q4100	Skin substitute, not otherwise specified
Q4101	Apligraf, per square centimeter
Q4102	Oasis wound matrix, per square centimeter
Q4103	Oasis burn matrix, per square centimeter
Q4104	Integra bilayer matrix wound dressing (bmwd), per square centimeter

	Integra dermal regeneration template (DRT) or Integra Omnigraft dermal regeneration matrix,
Q4105	per sq cm
Q4106	Dermagraft, per square centimeter
Q4107	Graftjacket, per square centimeter
Q4108	Integra matrix, per square centimeter
Q4110	Primatrix, per square centimeter
Q4111	Gammagraft, per square centimeter
Q4112	Cymetra, injectable, 1cc
Q4113	GRAFTJACKET XPRESS, injectable, 1cc
Q4114	Integra flowable wound matrix, injectable, 1 cc
Q4115	Alloskin, per square centimeter
Q4116	Alloderm, per square centimeter
Q4117	Hyalomatrix, per square centimeter
Q4118	Matristem micromatrix, 1 mg
Q4121	Theraskin, per square centimeter
Q4122	Dermacell, per square centimeter
Q4123	AlloSkin RT, per sq cm
Q4124	OASIS ultra tri-layer wound matrix, per sq cm
Q4125	Arthroflex, per sq cm
Q4126	MemoDerm, DermaSpan, TranZgraft or InteguPly, per sq cm
Q4127	Talymed, per sq cm
Q4128	FlexHD, or AllopatchHD, per sq cm
Q4130	Strattice TM, per sq cm
Q4132	Grafix Core and GrafixPL Core, per sq cm
Q4133	Grafix PRIME, GrafixPL PRIME, Stravix and StravixPL, per sq cm
Q4134	Hmatrix, per square centimeter
Q4135	Mediskin, per square centimeter
Q4136	Ez-derm, per square centimeter
Q4137	AmnioExcel, AmnioExcel Plus or BioDExcel, per sq cm
Q4138	Biodfence dryflex, per square centimeter
Q4139	Amniomatrix or biodmatrix, injectable, 1 cc
Q4140	Biodfence, per square centimeter
Q4141	Alloskin ac, per square centimeter
Q4142	Xcm biologic tissue matrix, per square centimeter
Q4143	Repriza, per square centimeter
Q4145	Epifix, injectable, 1 mg
Q4146	Tensix, per square centimeter
Q4147	Architect extracellular matrix, per square centimeter
Q4148	Neox Cord 1K, Neox Cord RT, or Clarix Cord 1K, per sq cm
Q4149	Excellagen, 0.1 cc
Q4150	Allowrap ds or dry, per square centimeter
Q4151	Amnioband or guardian, per square centimeter
Q4152	Dermapure, per square centimeter

Q4153	Dermavest, per square centimeter
Q4154	Biovance, per square centimeter
Q4155	Neoxflo or clarixflo, 1 mg
Q4156	Neox 100 or Clarix 100, per sq cm
Q4157	Revitalon, per square centimeter
Q4158	Kerecis Omega3, per sq cm
Q4159	Affinity, per square centimeter
Q4160	Nushield, per square centimeter
Q4161	Bio-connekt wound matrix, per square centimeter
Q4162	WoundEx Flow, BioSkin Flow, 0.5 cc
Q4163	WoundEx, BioSkin, per sq cm
Q4164	Helicoll, per square centimeter
Q4165	Keramatrix, per square centimeter
Q4166	Cytal, per square centimeter
Q4167	Truskin, per square centimeter
Q4168	Amnioband, 1 mg
Q4169	Artacent wound, per square centimeter
Q4170	Cygnus, per square centimeter
Q4171	Interfyl, 1 mg
Q4173	Palingen or palingen xplus, per square centimeter
Q4174	Palingen or promatrx, 0.36 mg per 0.25 cc
Q4175	Miroderm, per square centimeter
Q4176	Neopatch or Therion, per sq cm
Q4177	FlowerAmnioFlo, 0.1 cc
Q4178	FlowerAmnioPatch, per sq cm
Q4179	FlowerDerm, per sq cm
Q4180	Revita, per sq cm
Q4181	Amnio Wound, per sq cm
Q4183	Surgigraft, per sq cm
Q4184	Cellesta, per sq cm
Q4185	Cellesta Flowable Amnion (25 mg per cc); per 0.5 cc
Q4186	Epifix, per sq cm
Q4187	Epicord, per sq cm
Q4188	AmnioArmor, per sq cm
Q4189	Artacent AC, 1 mg
Q4190	Artacent AC, per sq cm
Q4191	Restorigin, per sq cm
Q4192	Restorigin, 1 cc
Q4193	Coll-e-Derm, per sq cm
Q4194	Novachor, per sq cm
Q4195	PuraPly, per sq cm
Q4196	PuraPly AM, per sq cm
Q4197	PuraPly XT, per sq cm

Q4198	Genesis Amniotic Membrane, per sq cm
Q4199	Cygnus matrix, per square centimeter
Q4200	SkinTE, per sq cm
Q4201	Matrion, per sq cm
Q4202	Keroxx (2.5g/cc), 1cc
Q4203	Derma-Gide, per sq cm
Q4204	XWRAP, per sq cm
Q4205	Membrane graft or membrane wrap, per square centimeter
Q4206	Fluid flow or fluid GF, 1 cc
Q4208	Novafix, per square cenitmeter
Q4209	Surgraft, per square centimeter
Q4210	Axolotl graft or axolotl dualgraft, per square centimeter
Q4211	Amnion bio or Axobiomembrane, per square centimeter
Q4212	Allogen, per cc
Q4213	Ascent, 0.5 mg
Q4214	Cellesta cord, per square centimeter
Q4215	Axolotl ambient or axolotl cryo, 0.1 mg
Q4216	Artacent cord, per square centimeter
	Woundfix, BioWound, Woundfix Plus, BioWound Plus, Woundfix Xplus or BioWound Xplus, per
Q4217	square centimeter
Q4218	Surgicord, per square centimeter
Q4219	Surgigraft-dual, per square centimeter
Q4220	BellaCell HD or Surederm, per square centimeter
Q4221	Amniowrap2, per square centimeter
Q4222	Progenamatrix, per square centimeter
Q4224	Human Health Factor 10 Amniotic Patch (HHF10-P), per sq cm
Q4225	Amniobind or dermabind tl, per square centimeter
Q4226	MyOwn skin, includes harvesting and preparation procedures, per square centimeter
Q4227	AmnioCoreTM, per sq cm
Q4229	Cogenex Amniotic Membrane, per sq cm
Q4230	Cogenex Flowable Amnion, per 0.5 cc
Q4231	Corplex P, per cc
Q4232	Corplex, per sq cm
Q4233	SurFactor or NuDyn, per 0.5 cc
Q4234	XCellerate, per sq cm
Q4235	AMNIOREPAIR or AltiPly, per sq cm
Q4236	carePATCH, per sq cm
Q4237	Cryo-Cord, per sq cm
Q4238	Derm-Maxx, per sq cm
Q4239	Amnio-Maxx or Amnio-Maxx Lite, per sq cm
Q4240	CoreCyte, for topical use only, per 0.5 cc
Q4241	PolyCyte, for topical use only, per 0.5 cc
Q4242	AmnioCyte Plus, per 0.5 cc

Q4244	Procenta, per 200 mg
Q4245	AmnioText, per cc
Q4246	CoreText or ProText, per cc
Q4247	Amniotext patch, per sq cm
Q4248	Dermacyte Amniotic Membrane Allograft, per sq cm
Q4249	Amniply, for topical use only, per square centimeter
Q4250	Amnioamp-mp, per square centimeter
Q4251	Vim, per sq cm
Q4252	Vendaje, per sq cm
Q4253	Zenith Amniotic Membrane, per sq cm
Q4254	Novafix DL, per sq c
Q4255	Reguard, for topical use only, per square centimeter
Q4256	MLG-Complete, per sq cm
Q4257	Relese, per sq cm
Q4258	Enverse, per sq cm
Q4259	Celera dual layer or celera dual membrane, per square centimeter
Q4260	Signature apatch, per square centimeter
Q4261	Tag, per square centimeter
Q4262	Dual layer impax membrane, per square centimeter
Q4263	Surgraft tl, per square centimeter
Q4264	Cocoon membrane, per square centimeter
Q4265	Neostim tl, per square centimeter
Q4266	Neostim membrane, per square centimeter
Q4267	Neostim dl, per square centimeter
Q4268	Surgraft ft, per square centimeter
Q4269	Surgraft xt, per square centimeter
Q4270	Complete sl, per square centimeter
Q4271	Complete ft, per square centimeter
Q4272	Esano a, per square centimeter
Q4273	Esano aaa, per square centimeter
Q4274	Esano ac, per square centimeter
Q4275	Esano aca, per square centimeter
Q4276	Orion, per square centimeter
Q4277	Woundplus membrane or e-graft, per square centimeter
Q4278	Epieffect, per square centimeter
Q4279	Vendaje ac, per square centimeter
Q4280	Xcell amnio matrix, per square centimeter
Q4281	Barrera sl or barrera dl, per square centimeter
Q4282	Cygnus dual, per square centimeter
Q4283	Biovance tri-layer or biovance 3l, per square centimeter
Q4284	Dermabind sl, per square centimeter
Q4285	NuDYN DL or NuDYN DL MESH, per sq cm
Q4286	NuDYN SL or NuDYN SLW, per sq cm

Q4287	Dermabind dl, per square centimeter
Q4288	Dermabind ch, per square centimeter
Q4289	Revoshield + amniotic barrier, per square centimeter
Q4290	Membrane Wrap-Hydro, per sq cm
Q4291	Lamellas xt, per square centimeter
Q4292	Lamellas, per square centimeter
Q4293	Acesso dl, per square centimeter
Q4294	Amnio quad-core, per square centimeter
Q4295	Amnio tri-core amniotic, per square centimeter
Q4296	Rebound matrix, per square centimeter
Q4297	Emerge matrix, per square centimeter
Q4298	Amnicore pro, per square centimeter
Q4299	Amnicore pro+, per square centimeter
Q4300	Acesso tl, per square centimeter
Q4301	Activate matrix, per square centimeter
Q4302	Complete aca, per square centimeter
Q4303	Complete aa, per square centimeter
Q4304	Grafix plus, per square centimeter
Q4305	American Amnion AC Tri-Layer, per sq cm
Q4306	American Amnion AC, per sq cm
Q4307	American Amnion, per sq cm
Q4308	Sanopellis, per sq cm
Q4309	VIA Matrix, per sq cm
Q4310	Procenta, per 100 mg
Q5101	Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
Q5103	Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
Q5105	Injection, epoetin alfa-epbx, biosimilar, (Retacrit) (for ESRD on dialysis), 100 units
Q5106	Injection, epoetin alfa-epbx, biosimilar, (Retacrit) (for non-ESRD use), 1000 units
Q5107	Injection, bevacizumab-awwb, biosimilar, (Mvasi), 10 mg
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
Q5109	Injection, infliximab-qbtx, biosimilar, (Ixifi), 10 mg
Q5110	Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
Q5112	Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg
Q5113	Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg
Q5114	Injection, trastuzumab-dkst, biosimilar, (Ogivri), 10 mg
Q5115	Injection, rituximab-abbs, biosimilar, 10 mg
Q5116	Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg
Q5118	Injection, bevacizumab-bvzr, biosimilar, (Zirabev), 10 mg
Q5119	Injection, rituximab-pvvr, biosimilar, (RUXIENCE), 10 mg
Q5120	Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg
Q5121	Injection, infliximab-axxq, biosimilar, (AVSOLA), 10 mg

Q5123         Injection, rituximab-arx, biosimilar, (riabni), 10 m           Q5124         Injection, ranibizumab-nuna, biosimilar, (releuko), 1 microgram           Q5125         Injection, pervaizumab-may, biosimilar, (alymsys), 10 mg           Q5126         Injection, pervaizumab-may, biosimilar, 0.5 mg           Q5127         Injection, nanibizumab-eqrn (cimerli), biosimilar, 0.5 mg           Q5128         Injection, nanibizumab-eqrn (cimerli), biosimilar, 0.5 mg           Q5131         Injection, adalimumab-aacf (idacio), biosimilar, 0.5 mg           Q5133         Injection, adalimumab-aacf (idacio), biosimilar, 0.7 mg           Q5134         Injection, colitzumab-bad (fordence), biosimilar, 10 mg           Q5135         Injection, colitzumab-bad (fordence), biosimilar, 10 mg           Q5136         Injection, colitzumab-bad (fordence), biosimilar, 10 mg           Q5137         Injection, ustekinumab-auub (Wezlana), biosimilar, 10 mg           Q5138         Injection, ustekinumab-auub (Wezlana), biosimilar, 0.7 mg           Q5139         Injection, ustekinumab-auub (Wezlana), biosimilar, 0.1 mg           Q5131         Injection, ustekinumab-auub (Wezlana), biosimilar, 0.1 mg           Q5135         Injection, ustekinumab-auub (Wezlana), biosimilar, 0.1 mg           Q5135         Injection, ustekinumab-auub (Wezlana), biosimilar, 0.1 mg           Q5135         Injection, ustekinumab-auub (Wezl	Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg
Q5124         Injection, ranibizumab-nuna, biosimilar, (Byooviz), 0.1 mg           Q5125         Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram           Q5126         Injection, pegfilgrastim-figk (stimufend), biosimilar, 0.5 mg           Q5127         Injection, bevacizumab-adcd (vegzetma), biosimilar, 0.5 mg           Q5130         Injection, pegfilgrastim-pbk (tylnetra), biosimilar, 0.5 mg           Q5131         Injection, adalimumab-adcd (vegzetma), biosimilar, 0.5 mg           Q5132         Injection, adalimumab-adcb (vegzetma), biosimilar, 10 mg           Q5133         Injection, natalizumab-bav (Tofidence), biosimilar, 10 mg           Q5134         Injection, notalizumab-bav (Tofidence), biosimilar, 1 mg           Q5135         Injection, notalizumab-azg (tyenne), biosimilar, 1 mg           Q5136         Injection, ustekinumab-auub (Wezlana), biosimilar, Nr, 1 mg           Q5137         Injection, ustekinumab-auub (Wezlana), biosimilar, Nr, 1 mg           Q5135         Injection, ustekinumab-auub (Wezlana), biosimilar, Nr, 1 mg           Q5135         Injection, nor-cornary, temporary, with delivery system (propel)           S7         Transplantation Of Small Int           S2055         Harvesting Of Donor Multivisc           S2064         Transplantation Of Multivisc           S2065         Simultaneous pancreas kidney transplantation <td< td=""><td>-</td><td></td></td<>	-	
Q5125         Injection, filgrastim-ayow, biosimilar, (reteuko), 1 microgram           Q5126         Injection, bevacizumab-maly, biosimilar, 0.1 mg           Q5127         Injection, pegfilgrastim-fpgk (stimulend), biosimilar, 0.5 mg           Q5128         Injection, anbizumab-eque (cimerly), biosimilar, 0.1 mg           Q5129         Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg           Q5131         Injection, adalimumab-aacf (idacio), biosimilar, 0.6 mg           Q5132         Injection, adalimumab-aacf (idacio), biosimilar, 10 mg           Q5133         Injection, natalizumab-savi (Toridence), biosimilar, 1 mg           Q5134         Injection, natelizumab-savi (Tyruko), biosimilar, 1 mg           Q5135         Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mg           Q5136         Injection, ustekinumab-auub (Wezlana), biosimilar, IV, 1 mg           S0313         Treatment planning and care coordination management for cancer initial treatment           Treatment planning and care coordination management for cancer established patient with a           S0353         Treatment planning and care coordination management for cancer established patient with a           S0354         change of regimen           S1091         Stent, non-coronary, temporary, with delivery system (propel)           S2055         Harvesting Of Donor Muttivisc           S2056         Simultaneous pa	-	
Q5126         Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg           Q5127         Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg           Q5128         Injection, anabizumab-eqm (cimerli), biosimilar, 0.0 mg           Q5130         Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.0 mg           Q5131         Injection, adalimumab-aacf (idacio), biosimilar, 20 mg           Q5132         Injection, adalimumab-aatz (idacio), biosimilar, 10 mg           Q5133         Injection, natalizumab-satx (Tyruko), biosimilar, 1 mg           Q5134         Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg           Q5135         Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mg           Q5136         Injection, ustekinumab-auub (Wezlana), biosimilar, IV, 1 mg           S0013         Esketamine, nasal spray, 1 mg           S0353         Treatment planning and care coordination management for cancer established patient with a change of regimen           S1091         Stent, non-coronary, temporary, with delivery system (propel)           S2055         Harvesting Of Donor Multivis           S2061         Lobar Lung Transplantation           S2065         Simultaneous pancreas kidney transplantation           S2066         Breast reconstruction of a single breast with "stacked" deep inferior epigastric artery (SIEA) ftap, including harvesting of the ftap, microvascular transfer, closure of donor si		
Q5127         Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg           Q5128         Injection, ranibizumab-eqm (cimerli), biosimilar, 0.1 mg           Q5130         Injection, pedfilgrastim-pbk (fyhtera), biosimilar, 0.5 mg           Q5131         Injection, adalimumab-acf (idacio), biosimilar, 20 mg           Q5132         Injection, adalimumab-acf (idacio), biosimilar, 10 mg           Q5133         Injection, adalimumab-atvi (Tofidence), biosimilar, 10 mg           Q5134         Injection, natalizumab-sztn (Tyruko), biosimilar, 1 mg           Q5135         Injection, natalizumab-sztn (Tyruko), biosimilar, 1 mg           Q5136         Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mg           Q5137         Injection, ustekinumab-auub (Wezlana), biosimilar, N, 1 mg           S0013         Esketamine, nasal spray, 1 mg           S0353         Treatment planning and care coordination management for cancer established patient with a change of regimen           S1091         Stent, non-coronary, temporary, with delivery system (propel)           S2053         Transplantation Of Small Int           S2064         Larvesting Of Donor Multivisc           S2065         Simultaneous pancreas kidney transplantation           S2066         Breast reconstruction with guteat artery perforator (GAP) flap, including           S2067         Breast reconstruction with guteat artery p	-	
Q5128Injection, ranibizumab-eqm (cimerli), biosimilar, 0.1 mgQ5130Injection, pegfigrastim-pbbk (fytnera), biosimilar, 10 mgQ5131Injection, adaiimumab-adcf (dacio), biosimilar, 20 mgQ5132Injection, adaiimumab-adcf (dacio), biosimilar, 10 mgQ5133Injection, natalizumab-bavi (Tofidence), biosimilar, 1 mgQ5134Injection, not collizumab-bavi (Tofidence), biosimilar, 1 mgQ5135Injection, not collizumab-bavi (Tofidence), biosimilar, 1 mgQ5136Injection, not collizumab-aub (Wezlana), biosimilar, 1 mgQ5137Injection, ustekinumab-aub (Wezlana), biosimilar, N, 1 mgS0013Esketamine, nasal spray, 1 mgS0013Esketamine, nasal spray, 1 mgS0013Esketamine, nasal spray, 1 mgS014Treatment planning and care coordination management for cancer initial treatmentTreatment planning and care coordination management for cancer established patient with aS0191Stent, non-coronary, temporary, with delivery system (propel)S2053Transplantation Of MultiviscS2064Transplantation Of MultiviscS2065Simultaneous pancreas kidney transplantationS2066Breast reconstruction with gluteal arery perforator (GAP) flap, includingS2067Breast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferior epigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateralS2068Laser-assisted uvulopatoplasty (LAUP)S2102Islet Cell Tissue TransplantS2103 <t< td=""><td></td><td></td></t<>		
Q5129         Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg           Q5130         Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 20 mg           Q5131         Injection, adalimumab-adzi (dabrilada), biosimilar, 20 mg           Q5132         Injection, notelizumab-bavi (Tofidence), biosimilar, 1 mg           Q5133         Injection, notelizumab-azgi (tyenne), biosimilar, 1 mg           Q5135         Injection, notelizumab-azgi (tyenne), biosimilar, 1 mg           Q5135         Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mg           Q5138         Injection, ustekinumab-auub (Wezlana), biosimilar, N, 1 mg           S0013         Esketamine, nasal spray, 1 mg           S0353         Treatment planning and care coordination management for cancer initial treatment           Treatment planning and care coordination management for cancer established patient with a           S0353         Transplantation Of Small Int           S2054         Transplantation Of Multivisc           S2055         Harvesting Of Donor Multivis           S2066         Simultaneous pancreas kidney transplantation           S2066         Simultaneous pancreas kidney transplantation           S2067         Breast reconstruction with gluteal artery perforator (GAP) flap, including           S2088         Tansplantation of a single breast with "stacked" deep inferior           gisar		
Q5130         Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 20 mg           Q5131         Injection, adalimumab-aacf (idacio), biosimilar, 20 mg           Q5132         Injection, adalimumab-atzb (abrilada), biosimilar, 10 mg           Q5133         Injection, nccilizumab-bavi (Tofidence), biosimilar, 1 mg           Q5134         Injection, nccilizumab-azzg (tyenne), biosimilar, 1 mg           Q5135         Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mg           Q5136         Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mg           Q5137         Injection, ustekinumab-auub (Wezlana), biosimilar, N, 1 mg           S0013         Esketamine, nasal spray, 1 mg           S0131         Esketamine, nasal spray, 1 mg           S0253         Treatment planning and care coordination management for cancer initial treatment           Treatment planning and care coordination management for cancer established patient with a           S0353         Transplantation Of Small Int           S2053         Transplantation Of Multivisc           S2054         Transplantation           S2065         Bireast reconstruction with gluteal artery perforator (GAP) flap, including           S2066         Doon Lobectomy (Lung)           S2067         Breast reconstruction with gluteal artery perforator (GAP) flap, including           S2068         Goron site and shap	-	
Q5131Injection, adalimumab-aacf (idacio), biosimilar, 20 mgQ5132Injection, adalimumab-atzb (abrilada), biosimilar, 10 mgQ5133Injection, tocilizumab-bavi (Tofidence), biosimilar, 1 mgQ5134Injection, natalizumab-sztn (Tyruko), biosimilar, 1 mgQ5135Injection, nocilizumab-aazg (tyenne), biosimilar, 1 mgQ5137Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mgQ5138Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mgQ5138Injection, ustekinumab-auub (Wezlana), biosimilar, IV, 1 mgS0013Esketamine, nasal spray, 1 mgS0013Esketamine, nasal spray, 1 mgS014change of regimenS1091Stent, non-coronary, temporary, with delivery system (propel)S2053Transplantation Of Small IntS2064Transplantation Of Small IntS2065Simultaneous pancreas kidney transplantationS2066Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2067Breast reconstruction of a single breast with "stacked" deep inferiorS2068Breast reconstruction of a single breast with "stacked" deep inferiorS2069Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantAdoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor- infiltrating lymphocyte therapy) per course of treatmentS2107Arthroseries, subtalarS2108Meta-on-metal total hip resurfacing including acetabular and femoral componentsS2109Laser-assisted uvulopatoplasty (LAUP)S2109Sate Cell T		
Q5132Injection, adalimumab-afzb (abrilada), biosimilar, 1 mgQ5133Injection, tocilizumab-bavi (Tofidence), biosimilar, 1 mgQ5134Injection, ntacilizumab-satr (Tyruko), biosimilar, 1 mgQ5135Injection, ntocilizumab-aazg (tyenne), biosimilar, 1 mgQ5137Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mgQ5138Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mgS0013Esketamine, nasal spray, 1 mgS0034Esketamine, nasal spray, 1 mgS0353Treatment planning and care coordination management for cancer initial treatmentTreatment planning and care coordination management for cancer established patient with a change of regimenS1091Stent, non-coronary, temporary, with delivery system (propel)S2053Transplantation Of Small IntS2064Lavesting Of Donor MultiviscS2065Simultaneous pancreas kidney transplantationS2066Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2067Breast reconstruction of a single breast with "stacked" deep inferior epigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateralS2068Laser-assisted uvulopalatoplasty (LAUP)S2109Laser-assisted uvulopalatoplasty (LAUP)S2101Saftenal Transplant Adoptive immuncherapy i.e. development of specific antitumor reactivity (e.g., tumor- infiltrating lymphocyte therapy) per course of treatmentS2107Arthroseeis, sublalarS2108Laser-assisted uvulopalatoplasty (LAUP)S2102	-	
Q5133Injection, tocilizumab-bavi (Tofidence), biosimilar, 1 mgQ5134Injection, natalizumab-sztn (Tyruko), biosimilar, 1 mgQ5135Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mgQ5137Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mgQ5138Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mgQ5135Treatment planning and care coordination management for cancer initial treatmentTreatment planning and care coordination management for cancer established patient with aChange of regimenS1091Stent, non-coronary, temporary, with delivery system (propel)S2053Transplantation Of Small IntS2054Harvesting Of Donor MultiviscS2055Harvesting Of Donor MultivisS2066Simultaneous pancreas kidney transplantationS2067Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2068Breast reconstruction of a single breast with "stacked" deep inferiorS2080Laser-assisted uvulopalatoplasty (LAUP)S2081Laser-assisted uvulopalatoplasty (LAUP)S2082Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantS2103Adrenal Tissue TransplantS2104Adrenal Tissue TransplantS2105Harvesting of cartilage (chondrocyte cells)S2112Arthroscepis, kuee, surgical for harvesting of cartilage (chondrocyte cells)S212Laser-assisted uvulopalatoplasty (LAUP)S212Lobert Court Tissue TransplantS213Adrenal Tissue TransplantS214Arthro	-	
Q5134Injection, natalizumab-sztn (Tyruko), biosimilar, 1 mgQ5135Injection, tocilizumab-aaug (tyenne), biosimilar, 1 mgQ5137Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mgQ5138Injection, ustekinumab-auub (Wezlana), biosimilar, IV, 1 mgS0013Esketamine, nasal spray, 1 mgS0353Treatment planning and care coordination management for cancer initial treatmentTreatment planning and care coordination management for cancer established patient with aS0354change of regimenS1091Stent, non-coronary, temporary, with delivery system (propel)S2053Transplantation Of Small IntS2054Transplantation Of MultiviscS2055Harvesting Of Donor MultivisS2066Lobar Lung TransplantationS2067Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2068Breast reconstruction of a single breast with "stacked" deep inferiorS2068donor site and shaping the flap, including harvesting of the flap, microvascular transfer, closure ofS2068choare Larer (SIEA) flap, including harvesting of the flap, microvascular transfer, closure ofS2069Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantS2103Adrenal Tissue TransplantS2104Adrenal Tissue TransplantS2105Adrenal Tissue TransplantS2106Karenal SubtarS2107Islet Cell Tissue TransplantS2108Laser-assisted uvulopalatoplasty (LAUP)S2109Laser-assisted uvulopalatoplasty (LAUP)	Q5133	
Q5137Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mgQ5138Injection, ustekinumab-auub (Wezlana), biosimilar, IV, 1 mgS0013Esketamine, nasal spray, 1 mgS0353Treatment planning and care coordination management for cancer initial treatmentTreatment planning and care coordination management for cancer established patient with aS0354change of regimenS1091Stent, non-coronary, temporary, with delivery system (propel)S2053Transplantation Of Small IntS2054Transplantation Of Small IntS2055Harvesting Of Donor MultiviscS2061Donor Lobectomy (Lung)S2065Simultaneous pancreas kidney transplantationS2066Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2067Breast reconstruction of a single breast with "stacked" deep inferiorBreast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferiorBreast reconstruction of a single breast, unilateralS2080Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantS2013Adrenal Tissue TransplantS2014Adoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor- infiltrating lymphocyte therapy) per course of treatmentS2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2114Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting	Q5134	
Q5137Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mgQ5138Injection, ustekinumab-auub (Wezlana), biosimilar, IV, 1 mgS0013Esketamine, nasal spray, 1 mgS0353Treatment planning and care coordination management for cancer initial treatmentTreatment planning and care coordination management for cancer established patient with aS0354change of regimenS1091Stent, non-coronary, temporary, with delivery system (propel)S2053Transplantation Of Small IntS2054Transplantation Of Small IntS2055Harvesting Of Donor MultiviscS2060Lobar Lung TransplantationS2061Donor Lobectomy (Lung)S2062Simultaneous pancreas kidney transplantationS2063Simultaneous pancreas kidney transplantationS2066Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2067Breast reconstruction of a single breast with "stacked" deep inferiorBreast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferiorS2068donor site and shaping the flap into a breast, unilateralS2080Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantAdoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor- infiltrating lymphocyte therapy) per course of treatmentS2117Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2114Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl) <t< td=""><td>Q5135</td><td></td></t<>	Q5135	
S0013Esketamine, nasal spray, 1 mgS0353Treatment planning and care coordination management for cancer initial treatmentTreatment planning and care coordination management for cancer established patient with aS0354change of regimenS1091Stent, non-coronary, temporary, with delivery system (propel)S2053Transplantation Of Small IntS2054Transplantation Of MultiviscS2055Harvesting Of Donor MultivisS2060Lobar Lung TransplantationS2061Donor Lobectomy (Lung)S2062Simultaneous pancreas kidney transplantationS2063Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2064Breast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferiors2065Bireast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferiors2068donor site and shaping the flap into a breast, unilateralS2080Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantS2103Adrenal Tissue TransplantS2104Adrenal Tissue TransplantS2115Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2117Arthroereisis, subtalarS2118Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(LdI)S2140Cord Blood Harvesting	-	Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mg
S0353Treatment planning and care coordination management for cancer initial treatmentTreatment planning and care coordination management for cancer established patient with a change of regimenS1091Stent, non-coronary, temporary, with delivery system (propel)S2053Transplantation Of Small IntS2054Transplantation Of MultiviscS2055Harvesting Of Donor MultivisS2061Lobar Lung TransplantationS2065Simultaneous pancreas kidney transplantationS2066Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2067Breast reconstruction of a single breast with "stacked" deep inferiorBreast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferior epigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateralS2060Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantAdoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor- infiltrating lymphocyte therapy) per course of treatmentS2117Arthroereisis, subtalarS2120Low Density Lipoprotein(LdI)S2140Cord Blood Harvesting	Q5138	Injection, ustekinumab-auub (Wezlana), biosimilar, IV, 1 mg
Treatment planning and care coordination management for cancer established patient with a change of regimen\$1091Stent, non-coronary, temporary, with delivery system (propel)\$2053Transplantation Of Small Int\$2054Transplantation Of Multivisc\$2055Harvesting Of Donor Multivis\$2060Lobar Lung Transplantation\$2061Donor Lobectomy (Lung)\$2065Simultaneous pancreas kidney transplantation\$2066Breast reconstruction with gluteal artery perforator (GAP) flap, including\$2067Breast reconstruction of a single breast with "stacked" deep inferior\$2068Boreast reconstruction of a single breast with "stacked" deep inferior\$2069boro site and shaping the flap, including harvesting of the flap, microvascular transfer, closure of epigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateral\$2008Laser-assisted uvulopalatoplasty (LAUP)\$2109Islet Cell Tissue Transplant\$2101Adrenal Tissue Transplant\$2102Adrenal Tissue Transplant\$2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)\$2117Arthroreisis, subtalar\$2118Metal-on-metal total hip resurfacing including acetabular and femoral components\$2120Low Density Lipoprotein(Ldl)\$2140Cord Blood Harvesting	S0013	Esketamine, nasal spray, 1 mg
S0354change of regimenS1091Stent, non-coronary, temporary, with delivery system (propel)S2053Transplantation Of Small IntS2054Transplantation Of MultiviscS2055Harvesting Of Donor MultivisS2060Lobar Lung TransplantationS2061Donor Lobectomy (Lung)S2065Simultaneous pancreas kidney transplantationS2066Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2067Breast reconstruction of a single breast with "stacked" deep inferiorS2068donor site and shaping the flap, including harvesting of the flap, microvascular transfer, closure ofS2068Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantS2103Adrenal Tissue TransplantS2104Adoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor-S2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2113Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting	S0353	Treatment planning and care coordination management for cancer initial treatment
S1091Stent, non-coronary, temporary, with delivery system (propel)S2053Transplantation Of Small IntS2054Transplantation Of MultiviscS2055Harvesting Of Donor MultivisS2060Lobar Lung TransplantationS2061Donor Lobectomy (Lung)S2065Simultaneous pancreas kidney transplantationS2066Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2067Breast reconstruction with gluteal artery perforator (DIEP) flap or superficial inferiorepigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure ofS2068Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantS2103Adrenal Tissue TransplantS2104Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2117Arthroereisis, subtalarS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting		Treatment planning and care coordination management for cancer established patient with a
S2053Transplantation Of Small IntS2054Transplantation Of MultiviscS2055Harvesting Of Donor MultivisS2060Lobar Lung TransplantationS2061Donor Lobectomy (Lung)S2065Simultaneous pancreas kidney transplantationS2066Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2067Breast reconstruction of a single breast with "stacked" deep inferiorS2068Breast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferiorepigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure ofdonor site and shaping the flap into a breast, unilateralS2080Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantS2103Adrenal Tissue TransplantS2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2117Arthroereisis, subtalarS2118Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(LdI)S2140Cord Blood Harvesting	S0354	change of regimen
S2054Transplantation Of MultiviscS2055Harvesting Of Donor MultivisS2060Lobar Lung TransplantationS2061Donor Lobectomy (Lung)S2062Simultaneous pancreas kidney transplantationS2063Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2064Breast reconstruction of a single breast with "stacked" deep inferiorS2065Breast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferiorepigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure ofdonor site and shaping the flap into a breast, unilateralS2080Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantS2103Adrenal Tissue TransplantS2104Adoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor- infiltrating lymphocyte therapy) per course of treatmentS2112Arthrocreisis, subtalarS2113Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting	S1091	Stent, non-coronary, temporary, with delivery system (propel)
S2055Harvesting Of Donor MultivisS2060Lobar Lung TransplantationS2061Donor Lobectomy (Lung)S2065Simultaneous pancreas kidney transplantationS2066Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2067Breast reconstruction of a single breast with "stacked" deep inferiorBreast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferiorepigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure ofdonor site and shaping the flap into a breast, unilateralS2008Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantS2103Adrenal Tissue TransplantS2104Adoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) per course of treatmentS2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2118Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting	S2053	
S2060Lobar Lung TransplantationS2061Donor Lobectomy (Lung)S2065Simultaneous pancreas kidney transplantationS2066Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2067Breast reconstruction of a single breast with "stacked" deep inferiorBreast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferiorepigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure ofdonor site and shaping the flap into a breast, unilateralS2080Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantS2103Adrenal Tissue TransplantS2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2113Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting	S2054	Transplantation Of Multivisc
S2061Donor Lobectomy (Lung)S2065Simultaneous pancreas kidney transplantationS2066Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2067Breast reconstruction of a single breast with "stacked" deep inferiorBreast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferiorepigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure ofS2068donor site and shaping the flap into a breast, unilateralS2080Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantS2103Adrenal Tissue TransplantS2104Adrenal Tissue TransplantS2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2113Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting	S2055	Harvesting Of Donor Multivis
S2065Simultaneous pancreas kidney transplantationS2066Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2067Breast reconstruction of a single breast with "stacked" deep inferiorBreast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferiorepigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure ofS2080Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantAdoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) per course of treatmentS2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2113Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting	S2060	Lobar Lung Transplantation
S2066Breast reconstruction with gluteal artery perforator (GAP) flap, includingS2067Breast reconstruction of a single breast with "stacked" deep inferiorBreast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferior epigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateralS2080Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue Transplant Adoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor- infiltrating lymphocyte therapy) per course of treatmentS2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2113Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting	S2061	
S2067Breast reconstruction of a single breast with "stacked" deep inferior Breast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferior epigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateralS2068Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantS2103Adrenal Tissue TransplantAdoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor- infiltrating lymphocyte therapy) per course of treatmentS2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2118Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting	S2065	Simultaneous pancreas kidney transplantation
Breast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferior epigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateralS2068Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantS203Adrenal Tissue TransplantAdoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor- infiltrating lymphocyte therapy) per course of treatmentS2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2117Arthroereisis, subtalarS218Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting	S2066	
epigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateralS2068Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantS2103Adrenal Tissue TransplantS2107infiltrating lymphocyte therapy) per course of treatmentS2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2117Arthroereisis, subtalarS2118Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2140Cord Blood Harvesting	S2067	
S2068donor site and shaping the flap into a breast, unilateralS2080Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantS2103Adrenal Tissue TransplantAdoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor-S2107infiltrating lymphocyte therapy) per course of treatmentS2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2117Arthroereisis, subtalarS2118Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting		
S2080Laser-assisted uvulopalatoplasty (LAUP)S2102Islet Cell Tissue TransplantS2103Adrenal Tissue TransplantAdoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor- infiltrating lymphocyte therapy) per course of treatmentS2107infiltrating lymphocyte therapy) per course of treatmentS2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2117Arthroereisis, subtalarS2118Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting	60000	
S2102Islet Cell Tissue TransplantS2103Adrenal Tissue TransplantS2104Adoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor- infiltrating lymphocyte therapy) per course of treatmentS2107infiltrating lymphocyte therapy) per course of treatmentS2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2117Arthroereisis, subtalarS2118Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting		
S2103Adrenal Tissue TransplantAdoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor- infiltrating lymphocyte therapy) per course of treatmentS2107infiltrating lymphocyte therapy) per course of treatmentS2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2117Arthroereisis, subtalarS2118Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting		
Adoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor- infiltrating lymphocyte therapy) per course of treatmentS2107Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2117Arthroereisis, subtalarS2118Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting		
S2107infiltrating lymphocyte therapy) per course of treatmentS2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2117Arthroereisis, subtalarS2118Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting	32103	
S2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)S2117Arthroereisis, subtalarS2118Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting	S2107	
S2117       Arthroereisis, subtalar         S2118       Metal-on-metal total hip resurfacing including acetabular and femoral components         S2120       Low Density Lipoprotein(Ldl)         S2140       Cord Blood Harvesting		
S2118Metal-on-metal total hip resurfacing including acetabular and femoral componentsS2120Low Density Lipoprotein(Ldl)S2140Cord Blood Harvesting		
S2120     Low Density Lipoprotein(Ldl)       S2140     Cord Blood Harvesting		
S2140 Cord Blood Harvesting		
	S2142	Cord Blood-Derived Stem-Cell

	Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous,
	harvesting, transplantation, and related complications; including: pheresis and cell
	preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient
	follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the
S2150	number of days of pre- and posttransplant care in the global definition
S2202	Echosclerotherapy
	Implantation of magnetic component of semi-implantable hearing device on ossicles in middle
S2230	ear
S2235	Implantation of auditory brain stem implant
S2300	Arthroscopy, shoulder, surgical; with thermally-induced capsulorrhaphy
S2340	Chemodenervation Of Abductor
S2341	Chemodenervation of adductor muscle(s) of vocal cord
S2348	Decompress disc RF lumbar
S2400	Repair, congenital hernia in the fetus, procedure performed in utero
S2401	Repair, urinary tract obstruction in the fetus, procedure performed in utero
	Repair, congenital cystic adenomatoid malformation in the fetus, procedure performed in
S2402	utero
S2403	Repair, extralobar pulmonary sequestration in the fetus, procedure performed in utero
S2404	Repair, myelomeningocele in the fetus, procedure performed in utero
S2405	Repair of sacrococcygeal teratoma in the fetus, procedure performed in utero
	Repair, congenital malformation of fetus, procedure performed in utero, not otherwise
S2409	classified
S3800	Genetic testing for amyotrophic lateral sclerosis (ALS)
S3840	DNA analysis for germline mutations of the ret proto-oncogene
S3841	Genetic testing for retinoblastoma
S3842	Genetic testing for von hippel-lindau disease
S3844	DNA analysis of the connexin 26 gene (gjb2) for susceptibility to congenital, profound deafness
S3845	Genetic testing for alpha-thalassemia
S3846	Genetic testing for hemoglobin e beta-thalassemia
S3849	Genetic testing for niemann-pick disease
S3850	Genetic testing for sickle cell anemia
S3852	DNA analysis for apoe epilson 4 allele for susceptibility to Alzheimer's disease
S3853	Genetic testing for myotonic muscular dystrophy
S3854	Gene expression profiling panel for use in the management of breast cancer treatment
	Genetic testing, sodium channel, voltage-gated, type V, alpha subunit (SCN5A) and variants for
S3861	suspected Brugada Syndrome
S3865	Comprehensive gene sequence analysis for hypertrophic cardiomyopathy
	Genetic analysis for a specific gene mutation for hypertrophic cardiomyopathy (HCM) in an
S3866	individual with a known HCM mutation in the family
00070	Comparative genomic hybridization (cgh) microarray testing for developmental delay, autism
S3870	spectrum disorder and/or intellectual disability
S3900	Surface electromyography (EMG)
	In vitro fertilization; including but not limited to identification and incubation of mature
S4011	oocytes, fertilization with sperm, incubation of embryo(s), and subsequent visualization for determination of development
34011	

S4013	Complete Cycle, Gamete Intrafallopian Transfer (Gift), Case Rate
S4014	Complete Cycle, Zygote Intrafallopian Transfer (Zift), Case Rate
S4015	Complete in vitro fertilization cycle, case rate
S4016	Frozen in vitro fertilization cycle, case rate
S4017	Incomplete Cycle, Treatment Cancelled Prior To Stimulation, Case Rate
S4018	Frozen embryo transfer procedure cancelled before transfer, case rate
S4020	In vitro fertilization procedure cancelled before aspiration, case rate
S4021	In vitro fertilization procedure cancellation after aspiration, case rate
S4022	Assisted oocyte fertilization, case rate
S4023	Donor Egg Cycle, Incomplete, Case Rate
S4025	Donor services for in vitro fertilization (sperm or embryo), case rate
S4026	Procurement of donor sperm from sperm bank
S4027	Storage of previously frozen embryos
S4028	Microsurgical epididymal sperm aspiration (mesa)
S4030	Sperm procurement and cryopreservation services; initial visit
S4031	Sperm procurement and cryopreservation services; subsequent visit
S4035	Stimulated Intrauterine Insemination (Iui), Case Rate
S4037	Cryopreserved Embryo Transfer, Case Rate
S4040	Monitoring And Storage Of Cryopreserved Embryos, Per 30 Days
S8030	Scleral application of tantalum ring(s) for localization of lesions for proton beam therapy
S8035	Magnetic Source Imaging
S8037	Magnetic resonance cholangiopancreatography (MRCP)
S8040	Topographic Brain Mapping
S8092	Electron Beam Computed Tomog
S8130	Interferential current stimulator, 2 channel
S8131	Interferential current stimulator, 4 channel
	Electrical stimulation of auricular acupuncture points; each 15 minutes of personal one-on-
S8930	one contact with patient
S8940	EQUESTRIAN/HIPPOTHERAPY PER SESSION
S8948	Application of a modality (requiring constant provider attendance) to one or
S8950	Complex Lymphedema Therapy
S8990	Physical or manipulative therapy performed for maintenance rather than restoration
	Intravaginal motion sensor system, provides biofeedback for pelvic floor muscle rehabilitation
S9002	device
S9056	Coma Stimulation Per Diem
S9090	Vertebral Axial Decompressio
00400	Nursing care, in the home; by registered nurse, per hour (use for general nursing care only, not
S9123	to be used when CPT codes 99500-99602 can be used)
S9124	Nursing care, in the home; by licensed practical nurse, per hour
S9152	Speech therapy, re-evaluation
S9347	Home infusion therapy, uninterrupted, long-term, controlled rate intravenous infusion therapy (e.g., Epoprostenol)
S9359	Home infusion therapy, anti-tumor necrosis factor intravenous therapy; (e.g., Infliximab)

Home infusion therapy, total parentaria function (PN), administative services, professional formulas, drugs other than in standard formula and nursing visits coded separately), per diem (do not use with home infusion codes 59365-59368 using daity volume scales)           S9365-59368 using daity volume scales)           Home infusion therapy, total parenteral nutrition (TPN); one liter per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem           Home infusion therapy, total parenteral nutrition (TPN); more than one liter but no more than two liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem           Home infusion therapy, total parenteral nutrition (TPN); more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem           S9860         Intensive outpatient psychiatric services, profem           Home infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem           S9840         Intensify subjecode separately), per di		Home infusion therapy, total parenteral nutrition (TDN); administrative convises, professional
standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem (do not use with home infusion codes S9365 S9368 using daily volume scales) Home infusion therapy, total parenteral nutrition (TPN); one liter per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem Home infusion therapy, total parenteral nutrition (TPN); more than one liter but no more than two liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem Home infusion therapy, total parenteral nutrition (TPN); more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem Home infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion codes for hourly dosing schedules S9497-S9504) Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 1 hours; administrative services, professional pharmacy servic		Home infusion therapy, total parenteral nutrition (TPN); administrative services, professional
formula and nursing visits coded separately), per diem (do not use with home infusion codes S9365-S9368 using daily volume scales)           S9365-S9368 using daily volume scales)           Mome infusion therapy, total parenteral nutrition (TPN); one liter per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem           Home infusion therapy, total parenteral nutrition (TPN); more than one liter but no more than two liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem           Home infusion therapy, total parenteral nutrition (TPN); more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem           S9460         Intensive outpatient psychiatric services, per diem (do not use this code with home infusion theray, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem           S9440         codes for hourly dosing schedules S947-S9504)           Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once ev		
S9365       S9365-S9368 using daily volume scales)         Home infusion therapy, total parenteral nutrition (TPN); one liter per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem         Home infusion therapy, total parenteral nutrition (TPN); more than one liter but no more than two liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded         S9366       separately), per diem         Home infusion therapy, total parenteral nutrition (TPN); more than thee liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula (lipids, specialty amino acid formulas, drugs other than in standard formula (lipids, specialty amino acid formulas, drugs other than in standard formula (lipids, specialty amino acid formulas, drugs other than in standard formula (lipids, specialty amino acid formulas, drugs other than in standard formula (lipids, specialty amino acid formulas, drugs other than in standard formula (lipids, specialty amino acid formulas, drugs other than in standard formula (lipids, specialty amino acid formulas, drugs other than in standard formula (lipids, specialty amino acid formulas, drugs other than in standard formula (lipids, specialty amino acid formulas, drugs other than in standard formula (lipids, specialty amino acid formulas, drugs other than i		
Home infusion therapy, total parenteral nutrition (TPN); one liter per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, speciality amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem           9365         Home infusion therapy, total parenteral nutrition (TPN); more than one liter but no more than two liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, speciality amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem           Home infusion therapy, total parenteral nutrition (TPN); more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid S9368           S9369         Intensive outpatient psychiatric services, per diem           Home infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion codes for hourly dosing schedules S9497-S9504)           Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem           Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 4 hours; administrative services,		
services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem           Home infusion therapy, total parenteral nutrition (TPN); more than one liter but no more than two liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded           S9366         separately), per diem           Home infusion therapy, total parenteral nutrition (TPN); more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem           S9460         Home infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion codes for hourly dosing schedules S9407-S9504)           Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem           Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 4 hours; administrative services, professional pharmacy services, care coordination, and	S9364	
equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other\$9365than in standard formula and nursing visits coded separately), per diemHome infusion therapy, total parenteral nutrition (TPN); more than one liter but no more than two liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded\$9366separately), per diemHome infusion therapy, total parenteral nutrition (TPN); more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem\$9480Intensive outpatient psychiatric services, per diem\$9480Intensive outpatient psychiatric services, per diem (do not use this code with home infusion (drugs and nursing visits coded separately), per diem (do not use this code with home infusion soft services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem\$9497supplies and equipment (drugs and nursing visits coded separately), per diem\$9501supplies and equipment (drugs and nursing visits coded separately), per diem\$9503supplies and equipment (drugs and nursing visits coded separately), per diem\$9504Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 2 hours; administrative services, professional pharmacy services, care coordination,		
S9365         than in standard formula and nursing visits coded separately), per diem           Home infusion therapy, total parenteral nutrition (TPN); more than one liter but no more than two liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded           S9366         separately), per diem           Home infusion therapy, total parenteral nutrition (TPN); more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid           S9368         formulas, drugs other than in standard formula and nursing visits coded separately), per diem           S9480         Intensive outpatient psychiatric services, per diem           Home infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary administrative services, professional pharmacy services, care coordination, and all necessary administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem           Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem           Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24		
Home infusion therapy, total parenteral nutrition (TPN); more than one liter but no more than two liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem           Home infusion therapy, total parenteral nutrition (TPN); more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem           S9480         Intensive outpatient psychiatric services, per diem           Home infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion codes for hourly dosing schedules S9497-S9504)           Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem           Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem           Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmac		equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other
two liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded\$9366separately), per diemHome infusion therapy, total parenteral nutrition (TPN); more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem\$9480Intensive outpatient psychiatric services, per diem (drugs and nursing visits coded separately), per diem (do not use this code with home infusion trays and nursing visits coded separately), per diem (do not use this code with home infusion terdes for hourly dosing schedules \$9497-\$9504)\$944Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem\$9501Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once ev	S9365	than in standard formula and nursing visits coded separately), per diem
and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded\$9366separately), per diemHome infusion therapy, total parenteral nutrition (TPN); more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid\$9368formulas, drugs other than in standard formula and nursing visits coded separately), per diem\$9480Intensive outpatient psychiatric services, per diem\$9480Home infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion\$9494codes for hourly dosing schedules \$9497-\$9504)Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem\$9500supplies and equipment (drugs and nursing visits coded separately), per diem\$9501supplies and equipment (drugs and nursing visits coded separately), per diem\$9502supplies and equipment (drugs and nursing visits coded separately), per diem\$9503Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), pe		Home infusion therapy, total parenteral nutrition (TPN); more than one liter but no more than
amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem Home infusion therapy, total parenteral nutrition (TPN); more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem S9480 Intensive outpatient psychiatric services, per diem Home infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion S9494 codes for hourly dosing schedules S9497-S9504) Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem Home infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coo		two liters per day, administrative services, professional pharmacy services, care coordination,
\$9366separately), per diemHome infusion therapy, total parenteral nutrition (TPN); more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid\$9368formulas, drugs other than in standard formula and nursing visits coded separately), per diem\$9480Intensive outpatient psychiatric services, per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion codes for hourly dosing schedules \$9497-\$9504)\$9497Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded sepa		and all necessary supplies and equipment including standard TPN formula (lipids, specialty
Home infusion therapy, total parenteral nutrition (TPN); more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem\$9480Intensive outpatient psychiatric services, per diemHome infusion therapy, antibiotic, antiviral, or antifungat therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion codes for hourly dosing schedules \$9497-\$9504)S9490Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungat therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungat therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungat therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antivira		amino acid formulas, drugs other than in standard formula and nursing visits coded
administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diemS9480Intensive outpatient psychiatric services, per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion codes for hourly dosing schedules S9497-S9504)S9494Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9407Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9500supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion t	S9366	separately), per diem
administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diemS9480Intensive outpatient psychiatric services, per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion codes for hourly dosing schedules S9497-S9504)S9494Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9407Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9500supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion t		Home infusion therapy, total parenteral nutrition (TPN); more than three liters per day,
supplies and equipment including standard TPN formula (lipids, specialty amino acid formulas, drugs other than in standard formula and nursing visits coded separately), per diem\$9480Intensive outpatient psychiatric services, per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion codes for hourly dosing schedules \$9497-\$9504)S9494Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem\$9497supplies and equipment (drugs and nursing visits coded separately), per diem\$9500supplies and equipment (drugs and nursing visits coded separately), per diem\$9501Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem\$9501Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem\$9502Home infusion therapy, antibiotic, antiviral, or antifungal; once every 8 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem <td></td> <td></td>		
S9368formulas, drugs other than in standard formula and nursing visits coded separately), per diemS9480Intensive outpatient psychiatric services, per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion codes for hourly dosing schedules S9497-S9504)Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9501supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs an		
S9480Intensive outpatient psychiatric services, per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion codes for hourly dosing schedules S9497-S9504)S9494codes for hourly dosing schedules S9497-S9504)Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9407Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9500supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9501Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary services, professional pharmacy services, care coor	S9368	formulas, drugs other than in standard formula and nursing visits coded separately), per diem
Home infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion codes for hourly dosing schedules S9497-S9504)Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy	S9480	
professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion codes for hourly dosing schedules S9497-S9504)S9494Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9500supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursi		
(drugs and nursing visits coded separately), per diem (do not use this code with home infusionS9494codes for hourly dosing schedules S9497-S9504)Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9500supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9501supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9502supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary services, professional pharmacy services, care coordination, and all necessary services, professional pharmacy services, care coordination, and all necessary services, professional ph		
S9494codes for hourly dosing schedules S9497-S9504)Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9497Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9500supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9501Supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9502supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9503Home infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative <br< td=""><td></td><td></td></br<>		
Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or	S9494	
administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9500Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9501Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, growth hormone, including administrative services, professional pharmacy services, car		
S9497supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9500supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9501supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9502supplies and equipment (drugs and nursing visits coded separately), per diemS9503eupipment (drugs and nursing visits coded separately), per diemS9504Home infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9503Home infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9504Home injectable therapy; growth hormone, including		
Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9501Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome injectable therapy; growth hormone, including administrative servic	S9497	
administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9502supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9504Home infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9504Home injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9508Home injectable therapy, interferon, in		
S9500supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessaryS9501supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessaryS9502supplies and equipment (drugs and nursing visits coded separately), per diemS9503supplies and equipment (drugs and nursing visits coded separately), per diemS9504Home infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9503equipment (drugs and nursing visits coded separately), per diemS9504equipment (drugs and nursing visits coded separately), per diemS9505Home infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9504Home injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9505Home injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessa		
Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 12 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9502supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing <td>S9500</td> <td></td>	S9500	
administrative services, professional pharmacy services, care coordination, and all necessary\$9501supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary\$9502supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem\$9503Home infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative 		
S9501supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessaryS9502supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9503equipment (drugs and nursing visits coded separately), per diemS9504Home infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9504Home infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9504Home injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9558Home injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing services, care coordination, and all necessary supplies and equipment (drugs and nursing		
Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 8 hours, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9502Home infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9503equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9504Home infusion therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9504Home injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9558nursing visits coded separately), per diemHome injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing services, care coordination, and all necessary supplies and equipment (drugs and nursing	\$9501	
administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9503equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9504equipment (drugs and nursing visits coded separately), per diemS9505Home injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9558Home injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	00001	
S9502supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9503equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9504equipment (drugs and nursing visits coded separately), per diemHome injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9558nursing visits coded separately), per diemHome injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem		
Home infusion therapy, antibiotic, antiviral, or antifungal; once every 6 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9504equipment (drugs and nursing visits coded separately), per diemHome injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9558nursing visits coded separately), per diemHome injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	\$9502	
services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9504equipment (drugs and nursing visits coded separately), per diemHome injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9558Home injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	00002	
S9503equipment (drugs and nursing visits coded separately), per diemHome infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9504equipment (drugs and nursing visits coded separately), per diemHome injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9558Home injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing services, care coordination, and all necessary supplies and equipment (drugs and nursing		
Home infusion therapy, antibiotic, antiviral, or antifungal; once every 4 hours; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9504Home injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing	\$0502	
services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9558Home injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	39303	
S9504equipment (drugs and nursing visits coded separately), per diemHome injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9558Home injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem		
Home injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemS9558Home injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing	S0504	
pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diemHome injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing	39304	
S9558nursing visits coded separately), per diemHome injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing		
Home injectable therapy, interferon, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing	00550	
services, care coordination, and all necessary supplies and equipment (drugs and nursing	59558	
S9559   visits coded separately), per diem		
	<u>S9559</u>	visits coded separately), per diem

	Home injectable therapy, palivizumab or other monoclonal antibody for RSV, including
	administrative services, professional pharmacy services, care coordination, and all necessary
S9562	supplies and equipment (drugs and nursing visits coded separately), per diem
S9960	Ambulance service, conventional air services, nonemergency transport, one way (fixed wing)
S9961	Ambulance service, conventional air service, nonemergency transport, one way (rotary wing)
T2036	Therapeutic camping, overnight, waiver; each session
T2037	Therapeutic camping, day, waiver; each session
V2787	Astigmatism correcting function of intraocular lens
V2788	Presbyopia correcting function of intraocular lens
V2790	Amniotic Membrane
V5095	Semi-Implantable Middle Ear Hearing Prosthesis
V5362	Speech Screening
V5363	Language Screening
V5364	Dysphagia Screening